# EDGAR Filing Document

**Accession Number:** 0000021665
**File Stem:** 0001308179-23-000418
**Filing Date:** 2023-3
**Character Count:** 785491
**Document Hash:** 3f8ed8395edbba27b079e496f1e3f680
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001308179-23-000418.hdr.sgml**: 20230329

**ACCESSION NUMBER**: 0001308179-23-000418

**CONFORMED SUBMISSION TYPE**: DEF 14A

**PUBLIC DOCUMENT COUNT**: 129

**FILED AS OF DATE**: 20230329

**DATE AS OF CHANGE**: 20230329

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** COLGATE PALMOLIVE CO
- **CENTRAL INDEX KEY:** 0000021665
- **STANDARD INDUSTRIAL CLASSIFICATION:** PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844]
- **IRS NUMBER:** 131815595
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEF 14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-00644
- **FILM NUMBER:** 23771872

**BUSINESS ADDRESS:**
- **STREET 1:** 300 PARK AVE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
- **BUSINESS PHONE:** 2123102000

**MAIL ADDRESS:**
- **STREET 1:** 300 PARK AVE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022

?xml version="1.0" encoding="ASCII"?

**[**Table of Contents**](#toc)** 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934 (Amendment No.)

☑ Filed by the Registrant ☐ Filed by a party other than the Registrant &nbsp;&nbsp;&nbsp;&nbsp;

---

| | |
|:---|:---|
| CHECK THE APPROPRIATE BOX: | CHECK THE APPROPRIATE BOX: |
| ☐ | Preliminary Proxy Statement |
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☑ | Definitive Proxy Statement |
| ☐ | Definitive Additional Materials |
| ☐ | Soliciting Material under §240.14a-12 |

---

![](cl4117791_def14ax3x1.jpg)

**Colgate-Palmolive Company**

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

---

| | |
|:---|:---|
| PAYMENT OF FILING FEE (CHECK ALL BOXES THAT APPLY): | PAYMENT OF FILING FEE (CHECK ALL BOXES THAT APPLY): |
| ☑ | No fee required |
| ☐ | Fee paid previously with preliminary materials |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |

---

**[**Table of Contents**](#toc)**![](cl4117791_def14ax1x1.jpg)

**[**Table of Contents**](#toc)** 

Our Priorities

![](cl4117791_def14ax2x1.jpg)

---

| |
|:---|
| &nbsp;&nbsp;&nbsp; **Driving Organic Sales Growth**<br> **•** Accelerating growth through science-led, core and premium innovation<br> **•** Pursuing higher-growth adjacent categories and segments<br> **•** Expanding in faster-growing channels and markets<br> **•** Maximizing growth in digital and eCommerce<br> **•** Investing to drive penetration in growing populations, including through our Bright Smiles, Bright Futures oral health education program |
| &nbsp;&nbsp;&nbsp; **Maximizing Efficiency in Our Income Statement**<br> **•** Generating savings as part of our ongoing funding-the-growth cost-saving initiatives and our 2022 Global Productivity Initiative<br> **•** Driving our digital transformation and operating with a digital-first mindset in all aspects of our business<br> **•** Using advanced data analytics to identify opportunities that amplify growth and efficiencies<br> **•** Investing in technology to drive simplification, efficiency and standardization |
| &nbsp;&nbsp;&nbsp; **Deploying Cash Flow Effectively**<br> **•** Capital spending to drive growth and productivity<br> **•** Making smart acquisitions that expand our categories, improve our market positions and/or add capabilities<br> **•** Continuing our record of paying cash dividends every year since 1895 and increasing dividends for 60 consecutive years<br> **•** Returning value to stockholders through ongoing share repurchases |
| &nbsp;&nbsp;&nbsp; **Demonstrating Our Purpose**<br> **•** Committed to being a caring, innovative growth company reimagining a healthier future for all people, their pets and our planet<br> **•** Focused on implementing our global sustainability and social impact strategy with three key ambitions—Preserving Our Environment, Helping Millions of Homes and Driving Social Impact<br> **•** Dedicated to fostering diversity, equity and inclusion<br> **•** Committed to acting with compassion, integrity, honesty and high ethics in all situations<br> **•** Focused on excellence in corporate governance, an ongoing and steadfast commitment shared by the Board of Directors, management and all Colgate people |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;![](cl4117791_def14ax2x2.jpg) | &nbsp;&nbsp;&nbsp; Learn more about our key priorities from the Annual Report, available in the Investors section of our website at www.colgatepalmolive.com<br> To learn about our 2025 Sustainability & Social Impact Strategy, see page 8 and the inside back cover of this Proxy Statement. Additional information about our sustainability and social impact initiatives and about our diversity, equity and inclusion initiatives is available in the Sustainability and Diversity, Equity and Inclusion sections of our website at www.colgatepalmolive.com<br> (The information on the Annual Report and Sustainability and Diversity, Equity and Inclusion web pages is not incorporated by reference into, and does not form part of, this Proxy Statement) |

---

**[**Table of Contents**](#toc)**![](cl4117791_def14ax3x1.jpg)

Message from Our Chairman, President and CEO

**March 29, 2023**

**Dear Fellow Colgate Stockholder:**

---

| | |
|:---|:---|
| You are cordially invited to attend our 2023 Annual Meeting of Stockholders on Friday, May 12, 2023 at 10:00 a.m. Eastern Daylight Time. The Annual Meeting will be a virtual meeting, conducted only via live webcast. You will be able to participate in the virtual meeting online, vote your shares electronically and submit your questions during the meeting by visiting: www.virtualshareholdermeeting.com/CL2023.<br> At the meeting, we will ask you to elect as directors the eleven nominees named in the Proxy Statement, to ratify the selection of our independent registered public accounting firm, to cast an advisory vote on executive compensation and to cast an advisory vote relating to the frequency of future stockholder advisory votes on executive compensation. In addition, two stockholder proposals will be offered for your consideration, if properly presented at the meeting. We will also review our progress during the past year and answer your questions.<br> This booklet includes the Notice of Annual Meeting and Proxy Statement. The Proxy Statement describes the business we will conduct at the meeting and provides information about Colgate that you should consider when you vote your shares.<br> The Proxy Statement includes a section highlighting our corporate governance practices. The Company and the Board of Directors have a longstanding commitment to the highest standards of corporate governance, and the Board of Directors reviews its governance practices on an ongoing basis to ensure that they promote stakeholder value. We invite you to review the governance section beginning on page 6 of the Proxy Statement to learn more about our continuing commitment to excellence in corporate governance.<br> **It is important that your stock be represented at the meeting. Whether or not you plan to attend the virtual meeting, we hope that you will vote on the matters to be considered. You may vote your proxy via the internet or by telephone. If you received a printed copy of your proxy materials, you may also vote by mail by signing, dating and returning your proxy card in the envelope provided.**<br> Very truly yours,<br> ![](cl4117791_def14ax3x2.jpg)<br> **Noel R. Wallace**<br> *Chairman, President and Chief Executive Officer* | &nbsp;&nbsp;&nbsp;&nbsp; ![](cl4117791_def14ax3x3.jpg)<br> ![](cl4117791_def14ax3x4.jpg)<br> As a stockholder you have an important role to play in Colgate's future. Please take the time to vote in advance of this year's meeting." |

---

**[**Table of Contents**](#toc)** 

Letter to Stockholders from Our Directors

**March 29, 2023**

**Dear Fellow Colgate Stockholder:**

We are honored to serve as your Board and want to thank you for placing your trust in us to oversee your Company and to represent you and your interests. We are pleased that Colgate continues to deliver strong progress against our growth strategy, even as we continued to navigate unprecedented uncertainty and difficult operating conditions during 2022 due to the effects of the war in Ukraine, the COVID-19 pandemic, inflation and rising interest rates.

We are pleased to have this opportunity to highlight for you a few key developments for Colgate in the past year.

**Board Refreshment**

Board composition and refreshment remain a priority for us. Our current Board is a diverse, distinguished group with a wide array of experience, skills and other qualifications. All of our Board members are independent, other than Noel Wallace, Colgate's Chairman, President and CEO. We appointed a new independent Lead Director earlier this year, Lorrie Norrington, who succeeded Steve Sadove in that role. Lorrie is a highly effective director who brings extensive global corporate leadership, digital, eCommerce and ESG experience to the independent Lead Director role. She also has extensive experience serving on other public company boards.

We have also added four new independent directors since 2019. Our recently added directors bring varied professional experiences that allow them to contribute to the Board's oversight of Colgate's business strategy and support the future growth of Colgate's business, with a particular focus on skills and experiences that are crucial in today's environment, such as global enterprise leadership, cybersecurity, eCommerce and digital transformation and environmental and social responsibility. In undertaking our board refreshment process, we have sought to balance fresh perspectives, expertise in new capabilities and disciplines and the valuable insights into Colgate and its operations that directors develop over time.

**Executive Compensation Program Changes**

Starting in 2021, the Personnel and Organization Committee determined that, in addition to financial goals, the annual incentive program should include a performance measure based on progress against strategic initiatives critical to the Company's growth strategy and continuing success, representing 20% of the annual bonus opportunity. In 2022, this strategic measure was tied to Colgate's performance against its enterprise-wide innovation, digital transformation and ESG goals. The Personnel and Organization Committee selected this strategic measure to further align compensation with Colgate's strategic priorities to build competitive advantage through digital and data capabilities, deliver innovation that drives category growth, foster a culture where everyone feels they belong and integrate sustainability into Colgate's business. The remaining 80% of the annual bonus opportunity continued to be determined by Colgate's achievement against organic sales growth and earnings-per-share goals.

The Personnel and Organization Committee also recently oversaw a review of our long-term incentive compensation structure and, with support from the other independent directors, determined to add an additional type of equity to the Company's long-term incentive program. Through 2022, we used two types of long-term incentives for officers, each weighted 50%: performance-based restricted stock units and stock options. Starting in 2023, performance-based restricted stock units will continue to comprise 50% of the long-term incentive program for officers, while stock options will comprise 30% and time-based restricted stock units will comprise 20%. We believe the new structure will better align with market standards and practice, while still focusing on growth and driving long-term performance.

**[**Table of Contents**](#toc)** 

Letter to Stockholders from Our Directors

**Responsiveness to Stockholders**

We are committed to the highest standards of corporate governance, continuous improvement and being responsive to our stockholders. We believe it is important to engage with investors to better understand their priorities and, each year, members of management engage with a diverse group of our stockholders on topics important to our stockholders as well as the Company. Such topics include our business strategy and initiatives, executive compensation, Board composition and governance practices, as well as environmental and social topics such as human capital management, DE&I and sustainability. The Board discusses feedback from these engagement sessions with management on a regular basis.

Prior to Colgate's 2022 Annual Meeting, representatives of management and the Board engaged with certain stockholders to better understand their views and policies relating to a stockholder proposal received for the 2022 Annual Meeting on stockholder ratification of termination pay. Following that engagement, in April 2022, we adopted a policy that Colgate will not execute any new severance agreement with an executive officer that provides for cash severance benefits exceeding 2.99 times the sum of the executive officer's base salary plus target annual bonus opportunity, without seeking stockholder ratification of the agreement. During Colgate's regular annual stockholder engagement program in late 2022 and early 2023, stockholders indicated that they appreciated that we were proactive and responsive to feedback regarding that stockholder proposal.

Together with Colgate's management team, we remain committed to creating long-term value for you and to meeting the needs of all of our stakeholders. Despite the continued challenges the world faces, we believe that, by ensuring Colgate's strategies focus on all of our stakeholders, Colgate is well positioned to deliver sustainable, profitable growth over the long term.

Thank you for your trust and support and your continued investment in Colgate.

---

| | | | |
|:---|:---|:---|:---|
| Very truly yours,<br> **The Members of Colgate's Board of Directors** | Very truly yours,<br> **The Members of Colgate's Board of Directors** | Very truly yours,<br> **The Members of Colgate's Board of Directors** | &nbsp;&nbsp;&nbsp; ![](cl4117791_def14ax3x4.jpg) <br> We are committed to the highest standards of corporate governance, continuous improvement and being responsive to our stockholders." |
| ![](cl4117791_def14ax5x1.jpg) | ![](cl4117791_def14ax5x2.jpg) | ![](cl4117791_def14ax5x3.jpg) | &nbsp;&nbsp;&nbsp; ![](cl4117791_def14ax3x4.jpg) <br> We are committed to the highest standards of corporate governance, continuous improvement and being responsive to our stockholders." |
| **John P. Bilbrey** | **John T. Cahill** | **Steve Cahillane** | &nbsp;&nbsp;&nbsp; ![](cl4117791_def14ax3x4.jpg) <br> We are committed to the highest standards of corporate governance, continuous improvement and being responsive to our stockholders." |
|  |  |  | &nbsp;&nbsp;&nbsp; ![](cl4117791_def14ax3x4.jpg) <br> We are committed to the highest standards of corporate governance, continuous improvement and being responsive to our stockholders." |
| ![](cl4117791_def14ax5x4.jpg) | ![](cl4117791_def14ax5x5.jpg) | ![](cl4117791_def14ax5x6.jpg) | &nbsp;&nbsp;&nbsp; ![](cl4117791_def14ax3x4.jpg) <br> We are committed to the highest standards of corporate governance, continuous improvement and being responsive to our stockholders." |
| **Lisa M. Edwards** | **C. Martin Harris** | **Martina Hund-Mejean** | &nbsp;&nbsp;&nbsp; ![](cl4117791_def14ax3x4.jpg) <br> We are committed to the highest standards of corporate governance, continuous improvement and being responsive to our stockholders." |
|  |  |  | &nbsp;&nbsp;&nbsp; ![](cl4117791_def14ax3x4.jpg) <br> We are committed to the highest standards of corporate governance, continuous improvement and being responsive to our stockholders." |
| ![](cl4117791_def14ax5x7.jpg) | ![](cl4117791_def14ax5x8.jpg) | ![](cl4117791_def14ax5x9.jpg) | &nbsp;&nbsp;&nbsp; ![](cl4117791_def14ax3x4.jpg) <br> We are committed to the highest standards of corporate governance, continuous improvement and being responsive to our stockholders." |
| **Kimberly A. Nelson** | **Lorrie M. Norrington** | **Michael B. Polk** | &nbsp;&nbsp;&nbsp; ![](cl4117791_def14ax3x4.jpg) <br> We are committed to the highest standards of corporate governance, continuous improvement and being responsive to our stockholders." |
|  |  |  | &nbsp;&nbsp;&nbsp; ![](cl4117791_def14ax3x4.jpg) <br> We are committed to the highest standards of corporate governance, continuous improvement and being responsive to our stockholders." |
| ![](cl4117791_def14ax5x10.jpg) | ![](cl4117791_def14ax5x11.jpg) |  | &nbsp;&nbsp;&nbsp; ![](cl4117791_def14ax3x4.jpg) <br> We are committed to the highest standards of corporate governance, continuous improvement and being responsive to our stockholders." |
| **Stephen I. Sadove** | **Noel R. Wallace** |  | &nbsp;&nbsp;&nbsp; ![](cl4117791_def14ax3x4.jpg) <br> We are committed to the highest standards of corporate governance, continuous improvement and being responsive to our stockholders." |

---

**[**Table of Contents**](#toc)** 

Notice of Annual Meeting of Stockholders

---

| |
|:---|
| &nbsp;&nbsp;**Logistics** |
| &nbsp;&nbsp; ![](cl4117791_def14ax6x1.jpg)<br> **DATE AND TIME**<br> Friday, May 12, 2023,<br> at 10:00 a.m.<br> Eastern Daylight Time |
| &nbsp;&nbsp; ![](cl4117791_def14ax6x2.jpg)<br> **LIVE WEBCAST**<br> www.virtualshareholder meeting.com/CL2023 |
| &nbsp;&nbsp; ![](cl4117791_def14ax6x3.jpg)<br> **WHO CAN VOTE**<br> Stockholders of record at<br> the close of business on<br> March 13, 2023 are entitled to vote at the Annual Meeting |

---

---

| | | |
|:---|:---|:---|
| **Items to be Voted On** | &nbsp;&nbsp;&nbsp;**Board<br> Recommendation** | &nbsp;&nbsp;&nbsp;**Board<br> Recommendation** |
| **PROPOSAL 1** Elect as directors the eleven nominees identified in the Proxy Statement | &nbsp;&nbsp;&nbsp;![](cl4117791_def14ax6x4.jpg) | **FOR each<br> director nominee** |
| **PROPOSAL 2** Ratify selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2023 | &nbsp;&nbsp;&nbsp;![](cl4117791_def14ax6x4.jpg) | **FOR** |
| **PROPOSAL 3** Advisory vote on executive compensation | &nbsp;&nbsp;&nbsp;![](cl4117791_def14ax6x4.jpg) | **FOR** |
| **PROPOSAL 4** Advisory vote on the frequency of future advisory votes on executive compensation | &nbsp;&nbsp;&nbsp;![](cl4117791_def14ax6x4.jpg) | **FOR** |
| **PROPOSALS 5-6** Stockholder proposals, if properly presented at the meeting | &nbsp;&nbsp;&nbsp;![](cl4117791_def14ax6x5.jpg) | **AGAINST** |

---

Stockholders will also consider and act upon such other business as may properly come before the meeting.

Because the Annual Meeting is virtual and being conducted only via live webcast, stockholders will not be able to physically attend the Annual Meeting. To attend the virtual meeting and vote during the meeting, go to www.virtualshareholdermeeting.com/CL2023. You will need the 16-digit control number found on your Notice of Internet Availability, your proxy card or the instructions that accompany your proxy materials to participate in the Annual Meeting.

Your vote is important. We encourage you to vote by proxy even if you plan to attend the virtual meeting. You may vote your proxy via the internet or by telephone by following the instructions included on your Notice of Internet Availability, your proxy card or the instructions that accompany your proxy materials. If you received a printed copy of your proxy materials, you may also vote by mail by signing, dating and returning your proxy card in the envelope provided. Voting now will not limit your right to change your vote or to attend the virtual meeting.

March 29, 2023

![](cl4117791_def14ax6x6.jpg)

**Jennifer M. Daniels**

*Chief Legal Officer and Secretary*

Colgate-Palmolive Company

300 Park Avenue

New York, New York 10022

**[**Table of Contents**](#toc)** 

**Table of Contents**

---

| | |
|:---|:---|
| **[Proxy Statement Summary](#a_001)** | **[2](#a_001)** |
| **[Governance of the Company](#a_002)** | **[6](#a_002)** |

---

---

| | |
|:---|:---|
| [Our Corporate Governance Commitment](#a_003) | [6](#a_003) |
| [The Board of Directors](#a_004) | [11](#a_004) |
| [Director Independence](#a_005) | [19](#a_005) |
| [Certain Relationships and Related Transactions](#a_006) | [20](#a_006) |
| [Compensation Committee Interlocks and Insider Participation](#a_007) | [20](#a_007) |

---

---

| | |
|:---|:---|
| [Board Structure and Responsibilities](#a_008) | [20](#a_008) |
| [Stockholder Engagement](#a_009) | [25](#a_009) |
| [Communications to the Board of Directors](#a_010) | [26](#a_010) |
| [Compensation of Directors](#a_011) | [27](#a_011) |

---

---

| | |
|:---|:---|
| **[Executive Compensation](#a_012)** | **[29](#a_012)** |

---

---

| | |
|:---|:---|
| [Compensation Discussion and Analysis](#a_013) | [29](#a_013) |
| [P&O Committee Report](#a_014) | [43](#a_014) |
| [Summary Compensation Table](#a_015) | [44](#a_015) |
| [Grants of Plan-Based Awards](#a_016) | [46](#a_016) |
| [Outstanding Equity Awards at Fiscal Year-End](#a_017) | [47](#a_017) |
| [Option Exercises and Stock Vested](#a_018) | [48](#a_018) |

---

---

| | |
|:---|:---|
| [Retirement Plans](#a_019) | [49](#a_019) |
| [Deferred Compensation Plan](#a_020) | [51](#a_020) |
| [Supplemental Savings & Investment Plan](#a_021) | [51](#a_021) |
| [Executive Severance and Other Termination Benefits](#a_022) | [52](#a_022) |
| [CEO Pay Ratio](#a_023) | [56](#a_023) |
| [Pay Versus Performance](#a_024) | [57](#a_024) |

---

---

| | |
|:---|:---|
| **[Stock Ownership](#a_025)** | **[60](#a_025)** |

---

---

| | |
|:---|:---|
| [Stock Ownership of Directors and <br> Executive Officers](#a_026) | [60](#a_026) |

---

---

| | |
|:---|:---|
| [Stock Ownership of Certain Beneficial Owners](#a_027) | [61](#a_027) |

---

---

| | |
|:---|:---|
| **[Proposals Requiring Your Vote](#a_028)** | **[62](#a_028)** |

---

---

| | |
|:---|:---|
| [**Proposal 1:** Election of Directors](#a_029) | [62](#a_029) |
| [**Proposal 2:** Ratification of Selection of Independent Registered Public Accounting Firm (includes Audit Committee Report)](#a_030) | [62](#a_030) |
| [**Proposal 3:** Advisory Vote on Executive Compensation](#a_031) | [65](#a_031) |

---

---

| | |
|:---|:---|
| [**Proposal 4:** Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation](#a_032) | [65](#a_032) |
| [**Proposals 5-6:** Stockholder Proposals](#a_033) | [66](#a_033) |
| [Other Matters](#a_033a) | [70](#a_033a) |

---

---

| | |
|:---|:---|
| **[Questions and Answers About Our Annual Meeting](#a_034)** | **[71](#a_034)** |
| **[Annex A—Reconciliation of Non-GAAP Financial Measures](#a_035)** | **[A-1](#a_035)** |
| **[Annex B—Countries Excluded Under CEO Pay Ratio *"De Minimis"* Exemption](#a_036)** | **[B-1](#a_036)** |

---

**[**Table of Contents**](#toc)** 

Proxy Statement Summary

This summary highlights information about Colgate-Palmolive Company (referred to in this Proxy Statement as "we," "us," "our," "Colgate" or the "Company") and our upcoming 2023 Annual Meeting of Stockholders (the "Annual Meeting") contained elsewhere in this Proxy Statement. This summary does not contain all of the information you should consider, and you should read the entire Proxy Statement carefully before voting.

**About Colgate**

**Our Purpose: We are a caring, innovative growth company reimagining a healthier future for all people, their pets and our planet.** We seek to deliver sustainable, profitable growth through science-led, core and premium innovation and superior shareholder returns, as well as to provide Colgate people with an innovative and inclusive work environment. We do this by developing and selling products globally that make people's and their pets' lives healthier and more enjoyable and by embracing our sustainability and social impact and diversity, equity and inclusion ("DE&I") strategies across our organization.

**Our Products** are marketed in over 200 countries and territories throughout the world across four core categories.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;**Oral Care** | &nbsp;&nbsp;**Personal Care** | &nbsp;&nbsp;**Personal Care** | &nbsp;&nbsp;**Home Care** | &nbsp;&nbsp;**Pet Nutrition** | **Worldwide** **2022 Net Sales** **$18.0 Billion**<br> ![](cl4117791_def14ax8x1.jpg) |
| ![](cl4117791_def14ax8x2.jpg) | ![](cl4117791_def14ax8x3.jpg) | ![](cl4117791_def14ax8x3.jpg) | ![](cl4117791_def14ax8x4.jpg) | ![](cl4117791_def14ax8x5.jpg) | **Worldwide** **2022 Net Sales** **$18.0 Billion**<br> ![](cl4117791_def14ax8x1.jpg) |
| &nbsp;&nbsp;**Key Brands** | &nbsp;&nbsp;**Key Brands** | &nbsp;&nbsp;**Key Brands** | &nbsp;&nbsp;**Key Brands** | &nbsp;&nbsp;**Key Brands** |  |
| &nbsp;&nbsp;• Colgate<br> • elmex<br> • hello<br> • meridol<br> • Sorriso<br> • Tom's of Maine | &nbsp;&nbsp;• EltaMD<br> • Filorga<br> • Irish Spring<br> • Palmolive<br> • PCA Skin | &nbsp;&nbsp;• Protex<br> • Sanex<br> • Softsoap<br> • Speed Stick | &nbsp;&nbsp;• Ajax<br> • Axion<br> • Fabuloso<br> • Palmolive<br> • Soupline<br> • Suavitel | &nbsp;&nbsp;• Hill's Science Diet<br> • Hill's Prescription Diet |  |

---

**Living Our Values:** Our approximately 33,800 employees worldwide share a commitment to our three core corporate values: caring, global teamwork and continuous improvement. These values are reflected not only in the quality of our products and reputation, but also in our dedication to serving the communities where we live and work.

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;CARING | &nbsp;&nbsp;&nbsp;GLOBAL TEAMWORK | &nbsp;&nbsp;&nbsp;CONTINUOUS IMPROVEMENT |
| &nbsp;&nbsp;&nbsp;We care about people: Colgate people, consumers, customers, stockholders, business partners and people in the communities where we live and work. We are committed to acting with compassion, integrity, honesty and high ethics in all situations and to providing Colgate people with an innovative and inclusive work environment. | &nbsp;&nbsp;&nbsp;All Colgate people are part of a global team, committed to working and collaborating together across functions and countries. Only by sharing ideas, technologies and talents can we achieve and sustain profitable growth. | &nbsp;&nbsp;&nbsp;We are committed to getting better every day in all that we do, as individuals and as teams. We continue to drive a learning culture and transform our learning strategy to better meet our evolving business needs. We continue to embed new ways of working and leadership principles to, among other things, instill a growth mindset to drive innovation with focus, empowerment, experimentation and digitalization. |

---

**Roadmap of Voting Items**

---

| | | | |
|:---|:---|:---|:---|
| **Items to be Voted On** | &nbsp;&nbsp;**Board's Voting<br> Recommendation** | &nbsp;&nbsp;**Board's Voting<br> Recommendation** | &nbsp;&nbsp;**More <br> Information** |
| **PROPOSAL 1** Elect as directors the eleven nominees identified in the Proxy Statement | &nbsp;&nbsp;![](cl4117791_def14ax6x4.jpg) | &nbsp;&nbsp;**FOR each<br> director nominee** | &nbsp;&nbsp;Page 62 |
| **PROPOSAL 2** Ratify selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2023 | &nbsp;&nbsp;![](cl4117791_def14ax6x4.jpg) | &nbsp;&nbsp;**FOR** | &nbsp;&nbsp;Page 62 |
| **PROPOSAL 3** Advisory vote on executive compensation | &nbsp;&nbsp;![](cl4117791_def14ax6x4.jpg) | &nbsp;&nbsp;**FOR** | &nbsp;&nbsp;Page 65 |
| **PROPOSAL 4** Advisory vote on the frequency of future advisory votes on executive compensation | &nbsp;&nbsp;![](cl4117791_def14ax6x4.jpg) | &nbsp;&nbsp;**FOR** | &nbsp;&nbsp;Page 65 |
| **PROPOSALS 5-6** Stockholder proposals, if properly presented at the meeting | &nbsp;&nbsp;![](cl4117791_def14ax6x5.jpg) | &nbsp;&nbsp;**AGAINST** | &nbsp;&nbsp;Page 66 |

---

**2**

**[**Table of Contents**](#toc)** 

Proxy Statement Summary

**Director Nominees**

The following table provides summary information about the eleven director nominees the Board has nominated for election at the Annual Meeting. Additional information about each nominee's background and experience can be found beginning on page 14.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| Name and Principal Occupation | Age | Years of Tenure | Committee Memberships | Committee Memberships | Committee Memberships | Committee Memberships | Other Current Public <br> Company Boards |
| Name and Principal Occupation | Age | Years of Tenure | &nbsp;&nbsp;AUD | &nbsp;&nbsp;FIN | NGCR | &nbsp;&nbsp;P&O | Other Current Public <br> Company Boards |
| **John P. Bilbrey** Independent<br> Former Chairman, President and Chief Executive Officer,<br> The Hershey Company | 66 | 8 | ![](cl4117791_def14ax9x1.jpg) | ![](cl4117791_def14ax9x2.jpg) | ![](cl4117791_def14ax9x3.jpg) | ![](cl4117791_def14ax9x1.jpg) | Campbell Soup Company<br> Elanco Animal Health Inc.<br> Tapestry, Inc. |
| **John T. Cahill** Independent<br> Vice Chairman, The Kraft Heinz Company | 65 | 18 | ![](cl4117791_def14ax9x2.jpg) | ![](cl4117791_def14ax9x1.jpg) | ![](cl4117791_def14ax9x1.jpg) | ![](cl4117791_def14ax9x3.jpg) | American Airlines Group Inc.<br> The Kraft Heinz Company |
| **Steve Cahillane<sup>1</sup>** Independent<br> Chairman, President and Chief Executive Officer, Kellogg Company | 57 | 0 | ![](cl4117791_def14ax9x1.jpg) | ![](cl4117791_def14ax9x1.jpg) | ![](cl4117791_def14ax9x1.jpg) | ![](cl4117791_def14ax9x1.jpg) | Kellogg Company |
| **Lisa M. Edwards** Independent<br> Executive Chair, Diligent Institute | 55 | 4 | ![](cl4117791_def14ax9x1.jpg) | ![](cl4117791_def14ax9x3.jpg) | ![](cl4117791_def14ax9x3.jpg) | ![](cl4117791_def14ax9x1.jpg) |  |
| **C. Martin Harris** Independent<br> Associate Vice President of the Health Enterprise and<br> Chief Business Officer, Dell Medical School | 66 | 7 | ![](cl4117791_def14ax9x1.jpg) | ![](cl4117791_def14ax9x1.jpg) | ![](cl4117791_def14ax9x3.jpg) | ![](cl4117791_def14ax9x3.jpg) | Agiliti, Inc. <br> MultiPlan Corporation <br> Thermo Fisher Scientific Inc. |
| **Martina Hund-Mejean** Independent<br> Former Chief Financial Officer, Mastercard Inc. | 62 | 3 | ![](cl4117791_def14ax9x3.jpg) | ![](cl4117791_def14ax9x3.jpg) | ![](cl4117791_def14ax9x1.jpg) | ![](cl4117791_def14ax9x1.jpg) | Prudential Financial, Inc.<br> Shell plc |
| **Kimberly A. Nelson** Independent<br> Former Senior Vice President, External Relations,<br> General Mills, Inc. | 60 | 2 | ![](cl4117791_def14ax9x1.jpg) | ![](cl4117791_def14ax9x1.jpg) | ![](cl4117791_def14ax9x3.jpg) | ![](cl4117791_def14ax9x3.jpg) | Cummins Inc.<br> Tate & Lyle PLC |
| **Lorrie M. Norrington** Independent, Lead Director<br> Operating Partner, Lead Edge Capital LLC | 63 | 8 | ![](cl4117791_def14ax9x3.jpg) | ![](cl4117791_def14ax9x1.jpg) | ![](cl4117791_def14ax9x2.jpg) | ![](cl4117791_def14ax9x1.jpg) | Asana, Inc.<br> Autodesk, Inc.<br> HubSpot, Inc. |
| **Michael B. Polk** Independent<br> Advisory Director, Berkshire Partners LLC and<br> Chief Executive Officer, Implus LLC | 62 | 9 | ![](cl4117791_def14ax9x1.jpg) | ![](cl4117791_def14ax9x3.jpg) | ![](cl4117791_def14ax9x1.jpg) | ![](cl4117791_def14ax9x2.jpg) | Logitech International S.A. |
| **Stephen I. Sadove** Independent<br> Founding Partner, JW Levin Management Partners LLC | 71 | 16 | ![](cl4117791_def14ax9x3.jpg) | ![](cl4117791_def14ax9x1.jpg) | ![](cl4117791_def14ax9x1.jpg) | ![](cl4117791_def14ax9x3.jpg) | Aramark<br> Movado Group, Inc.<br> Park Hotels & Resorts Inc. |
| **Noel R. Wallace** Chairman, President and Chief Executive Officer,<br> Colgate-Palmolive Company | 58 | 4 | ![](cl4117791_def14ax9x1.jpg) | ![](cl4117791_def14ax9x1.jpg) | ![](cl4117791_def14ax9x1.jpg) | ![](cl4117791_def14ax9x1.jpg) |  |

---

**AUD Audit FIN Finance&nbsp;&nbsp;&nbsp;&nbsp; NGCR Nominating, Governance & Corporate Responsibility&nbsp;&nbsp;&nbsp;&nbsp; P&O Personnel & Organization ![](cl4117791_def14ax9x4.jpg) Member** ![](cl4117791_def14ax9x5.jpg) **Chair**

<sup>1</sup> Mr. Cahillane, who became a director in 2023, is expected to be appointed to committees in 2023.

**Director Nominee Highlights**

**Strong Board Diversity**

---

| | | | | |
|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;**4**/11 | &nbsp;&nbsp;**3**/11 | &nbsp;&nbsp;**7.5** |  | &nbsp;&nbsp;**4**<br> new<br> independent<br> directors since<br> **2019** |
| &nbsp;&nbsp;women\* | &nbsp;&nbsp;members of underrepresented<br>communities\* | &nbsp;&nbsp;years average tenure of<br>independent nominees |  | &nbsp;&nbsp;**4**<br> new<br> independent<br> directors since<br> **2019** |
| ![](cl4117791_def14ax9x6.jpg) | ![](cl4117791_def14ax9x7.jpg) | &nbsp;&nbsp;![](cl4117791_def14ax9x8.jpg) | &nbsp;&nbsp;**62.3** <br>average age | &nbsp;&nbsp;**4**<br> new<br> independent<br> directors since<br> **2019** |

---

<sup>\*</sup> Ms. Edwards, Ms. Hund-Mejean, Ms. Nelson and Ms. Norrington are our female director nominees. Dr. Harris and Ms. Nelson identify as African-American and Ms. Norrington identifies as LGBTQ+.

**Director Nominee Diversity, Experience, Skills and Qualifications**

The Nominating, Governance and Corporate Responsibility Committee (the "NGCR Committee") seeks to compose a Board with members who have a broad range of experiences, skills, diversity and different perspectives. In addition to educational achievement and a strong moral and ethical character, the following skills and attributes were all considered by the Board in connection with this year's director nomination process:

![](cl4117791_def14ax9x9.jpg)

2023 Proxy Statement<sub>3</sub>

**[**Table of Contents**](#toc)** 

Proxy Statement Summary

**Governance Highlights**

The Board believes that excellence in corporate governance accompanies and greatly aids our long-term business success and that we have consistently been at the forefront of excellent corporate governance. Reflecting its commitment to continuous improvement, the Board reviews its governance practices on an ongoing basis to ensure that they promote stakeholder value. The governance section beginning on page 6 describes our corporate governance framework and commitment, which includes the following highlights:

---

| | |
|:---|:---|
| **BOARD FOCUSED ON KEY STRATEGIC PRIORITIES** | **BOARD FOCUSED ON KEY STRATEGIC PRIORITIES** |
| ![](cl4117791_def14ax10x1.jpg) | Board plays major role in overseeing business strategy and performance, risk management, Company culture and succession planning |
| ![](cl4117791_def14ax10x1.jpg) | Board and management focus on environmental, social and governance ("ESG") matters and cybersecurity, each of which we believe is crucial to our ongoing business success |
| **FOCUS ON BOARD PERFORMANCE** | **FOCUS ON BOARD PERFORMANCE** |
| ![](cl4117791_def14ax10x1.jpg) | Board composition defined by strong leadership and experience |
| ![](cl4117791_def14ax10x1.jpg) | Strong focus on diversity (45% of director nominees are female and/or members of underrepresented communities) |
| ![](cl4117791_def14ax10x1.jpg) | Strong record of Board refreshment with four new independent directors since 2019 |
| ![](cl4117791_def14ax10x1.jpg) | 98% average attendance of incumbent directors at Board and committee meetings in 2022 |
| ![](cl4117791_def14ax10x1.jpg) | Mandatory retirement age of 72 provides a mechanism for regular Board refreshment |
| ![](cl4117791_def14ax10x1.jpg) | Directorship limits and related policies prevent overboarding |
| ![](cl4117791_def14ax10x1.jpg) | Annual Board and committee self-evaluations |
| ![](cl4117791_def14ax10x1.jpg) | Regular independent director evaluations |
| ![](cl4117791_def14ax10x1.jpg) | Regular review of committee charters, corporate governance guidelines, director qualifications and related policies |
| **ALIGNMENT WITH STOCKHOLDER INTERESTS** | **ALIGNMENT WITH STOCKHOLDER INTERESTS** |
| ![](cl4117791_def14ax10x1.jpg) | Substantial majority of director compensation paid in Colgate equity |
| ![](cl4117791_def14ax10x1.jpg) | Robust stock ownership requirements for directors and officers |
| ![](cl4117791_def14ax10x1.jpg) | Clawback, anti-hedging and anti-pledging policies |
| ![](cl4117791_def14ax10x1.jpg) | Pay-for-performance philosophy |
| ![](cl4117791_def14ax10x1.jpg) | Robust annual stockholder engagement program |
| **BOARD INDEPENDENCE** | **BOARD INDEPENDENCE** |
| ![](cl4117791_def14ax10x1.jpg) | New independent Lead Director appointed as of March 1, 2023 |
| ![](cl4117791_def14ax10x1.jpg) | Strict director independence standards |
| ![](cl4117791_def14ax10x1.jpg) | 10 out of 11 director nominees are independent (all except for the Chief Executive Officer) |
| ![](cl4117791_def14ax10x1.jpg) | Board committees are 100% independent |
| ![](cl4117791_def14ax10x1.jpg) | Independent Lead Director duties recently enhanced |
| ![](cl4117791_def14ax10x1.jpg) | Executive sessions of independent directors are held at every regularly scheduled Board meeting |
| **STOCKHOLDER RIGHTS** | **STOCKHOLDER RIGHTS** |
| ![](cl4117791_def14ax10x1.jpg) | Annual election of all directors |
| ![](cl4117791_def14ax10x1.jpg) | Majority voting and director resignation policy for directors in uncontested elections |
| ![](cl4117791_def14ax10x1.jpg) | Stockholders have ability to call special meetings (threshold reduced to 15% in 2021) and to act by written consent |
| ![](cl4117791_def14ax10x1.jpg) | Stockholders have proxy access right |

---

**4**

**[**Table of Contents**](#toc)** 

Proxy Statement Summary

**Executive Compensation Program Highlights**

The key principles underlying our compensation philosophy are aligning pay and performance, driving strong business results and our strategic plan, focusing on long-term shareholder return, motivating and retaining critical talent and reflecting external market and competitive practices.

In 2022, the compensation of the Named Officers (as defined in the Compensation Discussion and Analysis, or "CD&A") was designed so that approximately 75% to 90% of their target direct compensation (salary and target annual and long-term incentives) would be performance-based. Annual and long-term incentive award payments vary from target levels based on our business performance, and long-term incentive award payments and the value of equity awards also vary based on the performance of our common stock ("Common Stock").

Our executive compensation program for 2021 received substantial stockholder support and was approved, on an advisory basis, by

90.8%

of stockholders voting on the proposal at the 2022 Annual Meeting of Stockholders.

**New ESG Component Added to Strategic Measure in 2022 Annual Incentive Program**

Starting in 2021, the Board's compensation committee, known as the Personnel and Organization Committee (the "P&O Committee"), determined that, in addition to financial goals, the annual incentive program should include a performance measure based on strategic initiatives, representing 20% of the annual bonus opportunity. For 2021, the strategic measure was tied to our enterprise-wide innovation and digital transformation progress in recognition of the critical importance of innovation and digital transformation to our growth strategy and continuing success and to further align compensation with our strategic priorities. In 2022, the P&O Committee determined that, in addition to performance measures tied to our enterprise-wide innovation and digital transformation progress, the strategic measure should also include performance measures tied to our sustainability and DE&I progress in recognition of the importance of ESG matters to our continuing success. See page 39 of the CD&A for further detail regarding how the P&O Committee measured achievement against the strategic measure. The remaining 80% of the annual bonus opportunity was determined by our achievement against our organic sales growth and earnings-per-share goals.

**Compensation Governance**

Our key executive compensation practices include the following:

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; ![](cl4117791_def14ax10x1.jpg)<br> High percentage of compensation is variable and is tied to annual and long-term performance<br> ![](cl4117791_def14ax10x1.jpg)<br> Programs designed to compensate at approximately the median level if paid at target<br> ![](cl4117791_def14ax10x1.jpg)<br> Multiple performance measures used<br> ![](cl4117791_def14ax10x1.jpg)<br> Robust stock ownership guidelines<br> ![](cl4117791_def14ax10x1.jpg)<br> Ability to claw back compensation<br> ![](cl4117791_def14ax10x1.jpg)<br> Only perquisite is use of car and driver for CEO | &nbsp;&nbsp;&nbsp;&nbsp; ![](cl4117791_def14ax10x1.jpg)<br> Double-trigger vesting of severance payments upon change in control<br> ![](cl4117791_def14ax10x1.jpg)<br> No executive officer employment agreements<br> ![](cl4117791_def14ax10x1.jpg)<br> No hedging or pledging of Colgate stock is permitted<br> ![](cl4117791_def14ax10x1.jpg)<br> No backdating, springloading or repricing of stock options<br> ![](cl4117791_def14ax10x1.jpg)<br> No tax gross-ups on perquisites or severance |

---

Please see the CD&A beginning on page 29 for a detailed description of our executive compensation programs.

2023 Proxy Statement<sub>5</sub>

**[**Table of Contents**](#toc)** 

Governance of the Company

**Our Corporate Governance Commitment**

We are a caring, innovative growth company reimagining a healthier future for all people, their pets and our planet. The Board believes that excellence in corporate governance accompanies and greatly aids our achievement of this purpose, as well as our long-term business success. Our key strategic business priorities are driving organic sales growth and long-term profitable growth through science-led, core and premium innovation, pursuing higher-growth adjacent categories and segments, expanding in faster-growing channels and markets and delivering margin expansion through operating leverage and efficiency. We also seek to maximize the impact of our ESG programs and lead in the development of human capital, including our sustainability and social impact and DE&I strategies. The Board has been at the center of these key priorities, helping to design and implement them across the organization, and seeing that they guide our operations.

The Board believes that we have consistently been at the forefront of excellent corporate governance. Reflecting its commitment to continuous improvement, the Board reviews its governance practices on an ongoing basis to ensure that they promote stakeholder value.

**Board Independence, Expertise and Accountability**

**Strict Director Independence Standards**

With the exception of Noel R. Wallace, our Chairman of the Board, President and Chief Executive Officer (the "CEO"), the Board is comprised entirely of independent directors. All members of the Audit Committee, the Finance Committee, the NGCR Committee and the P&O Committee are independent directors. The Board believes that an independent director should be free of any relationship with Colgate or our senior management that may in fact or in appearance impair the director's ability to make independent judgments or compromise the director's objectivity and loyalty to stockholders. Based on this principle, the Board adopted director independence standards that outline the types of relationships, both personal and professional, between directors and the Company, our senior management, other directors and third parties that, if present, would preclude a finding of independence. These standards, which are stricter than those required by the listing standards of the New York Stock Exchange (the "NYSE"), guide the Board's annual affirmative determinations of independence. A copy of the standards is available on our website. For more information regarding our independence standards and the Board's determinations of independence, see "Director Independence."

**Lead Director/Executive Sessions**

Lorrie M. Norrington is currently serving as our independent Lead Director, having succeeded Stephen I. Sadove in that role as of March 1, 2023. The independent directors of the Board meet in executive session, without any members of management present, at every regularly scheduled Board meeting. The Lead Director chairs these sessions. The Lead Director serves a three-year term and is selected by the independent directors following nomination by the NGCR Committee. For more information regarding the Board's leadership structure and the responsibilities of the Lead Director, which were recently enhanced in connection with a review of external practices and in response to stockholder feedback, see "Board Structure and Responsibilities—Board Leadership Structure."

**All Directors Elected Annually by Majority Vote**

The Board is accountable to stockholders through the annual election of all directors by majority vote. We have never had a staggered board. Under our by-laws, in uncontested elections for directors, if a nominee for director who is an incumbent director is not re-elected by a majority of the votes cast, the by-laws require the director to promptly tender their resignation to the Board. The NGCR Committee will then consider the resignation and make a recommendation to the Board.

**Director Attendance at Annual Meetings**

It is our policy that all members of the Board should attend our Annual Meeting of Stockholders, whether held virtually or in person, unless extraordinary circumstances prevent a director's attendance. All of the ten directors who were elected to the Board at the 2022 Annual Meeting were in attendance.

**Proxy Access**

Our by-laws permit a group of up to 20 stockholders who have owned at least three percent of our outstanding Common Stock continuously for at least three years to submit director nominees (up to the greater of two individuals or 20% of the Board) for inclusion in our proxy statement if the stockholder(s) and the nominee(s) satisfy the requirements specified in our by-laws.

**6**

**[**Table of Contents**](#toc)** 

Governance of the Company

**Audit Committee Independence and Financial Literacy**

All members of the Audit Committee are independent directors. The Board has also determined that all members of the Audit Committee are "audit committee financial experts," as that term is defined under the rules of the Securities and Exchange Commission (the "SEC"), and that they meet the independence and financial literacy requirements of the NYSE.

**Board Experience and Diversity**

As our present directors exemplify, we value the following attributes in Board members:

**•** enterprise leadership experience

**•** experience in one of more of the following areas: digital, technology and innovation; environmental and social responsibility; finance; our or a complementary industry; regulatory; and/or risk management and cybersecurity

**•** international experience

**•** corporate governance experience

**•** educational achievement

**•** strong moral and ethical character

A copy of our criteria for Board membership, entitled "Independent Board Candidate Qualifications," is available on our website. We are strongly focused on diversity, and 45% of director nominees are female and/or members of underrepresented communities. For more information regarding the role of diversity in the selection of nominees for Board membership, see "The Board of Directors—Director Diversity, Experience, Skills and Qualifications."

**Board Focused on Key Strategic Priorities**

**Strategic Role of Board**

The Board plays an essential role in developing, guiding and overseeing our business strategy. It was deeply involved in the development of our strategic plan and receives detailed briefings throughout the year on critical aspects of its implementation. These include reviews of the strategic choices we are making and the capabilities needed to deliver against our goals, as well as performance reviews of operating divisions, product categories and competitive and marketplace trends.

**Role of Board in Risk Management**

The Board oversees our risk management process to ensure it is properly designed, well-functioning and consistent with our overall corporate strategy. Annually, the Board or a relevant committee reviews each of the top risk areas identified by management and receives reports more regularly for certain risk areas to ensure risks are being adequately managed. See "Board Structure and Responsibilities—Board Role in Risk Oversight" for more information about our risk management process.

**Oversight of Company Culture**

The Board believes that our culture and our core corporate values of caring, global teamwork and continuous improvement are critical to our business success. It monitors the ongoing impact of those values and our culture in various ways, including by visiting our operations and reviewing the results of employee engagement surveys and related responsive actions.

**Succession Planning**

The Board has extensive involvement in succession planning and people development, with special focus on CEO succession. It discusses potential successors to key executives, regularly interacts with key executives and potential successors and examines backgrounds, capabilities and appropriate developmental assignments. Regular reviews of professional training programs, benefit programs and career development processes assist the Board in guiding our

people development initiatives.

**Cybersecurity**

The Board is particularly focused on cybersecurity. Specific responsibility for cybersecurity oversight is delegated to the Audit Committee, and four directors have considerable experience in this area. Our Chief Information Security Officer provides a report to the Audit Committee on cybersecurity quarterly, or more frequently if circumstances warrant, including on topics related to information security, data privacy and cyber risks and mitigation strategies. In addition, outside experts periodically present to the Board on cybersecurity. Our dedicated information security organization, led by our Chief Information Security Officer and overseen by our Chief Information Officer, leverages various frameworks for managing cybersecurity risks, including the National Institute of Standards and Technology (NIST) framework. The information security organization seeks to employ cybersecurity best practices, including implementing new

2023 Proxy Statement<sub>7</sub>

**[**Table of Contents**](#toc)** 

Governance of the Company

technologies to proactively identify and monitor new vulnerabilities and reduce risk, conducting due diligence of third-party vendors' information security programs, maintaining security policies and standards and regularly updating and testing our response planning and protocols. The information security organization also works in partnership with our Internal Audit function to review cybersecurity-related internal controls with our external auditors and other third parties as part of the overall internal controls process. Additionally, employees are provided mandatory cybersecurity awareness education and training, including conducting phishing simulations and testing scenarios through tabletop exercises, to help ensure compliance with our cyber policies and procedures. We also have a cybersecurity insurance policy in place.

**ESG**

ESG initiatives remain an important focus for us. As part of this focus, we have proactively engaged with investors to learn from their perspectives on ESG matters and to share our approach. Oversight of ESG issues has been and remains one of the Board's key priorities, particularly through the NGCR Committee, which was reconstituted and renamed in 2020 to heighten the Board's focus on sustainability (including climate change), social responsibility and corporate citizenship matters, and through the P&O Committee, which oversees human capital matters, including our DE&I strategy.

**Sustainability (Including Climate Change)**

Sustainability is critically important to our overall business and growth strategy. Our 2025 Sustainability & Social Impact Strategy focuses on three key ambitions—preserving our environment by accelerating action on climate change and reducing our environmental footprint; helping millions of homes by empowering people to develop healthier habits; and driving social impact with a commitment to helping to ensure the wellbeing of all people and their pets. These ambitions are supported by actionable targets consistent with our continued commitment to building environmental and social consciousness into our decision-making. As discussed further in our 2022 Climate Transition & Net Zero Action Plan, these actionable targets include science-based near-term, long-term and Net Zero 2040 emissions targets across our operations and supply chain, which were approved by The Science Based Targets initiative in 2022. Please see the inside back cover of this Proxy Statement for highlights of our progress and the Sustainability section of our website for more information regarding our 2025 Sustainability & Social Impact Strategy.

The NGCR Committee oversees our 2025 Sustainability & Social Impact Strategy and receives regular updates from management on sustainability matters, risks and opportunities, including our efforts to accelerate action on climate change, reduce our environmental footprint and achieve our sustainability targets.

Our sustainability function is overseen by our Group President, Growth and Strategy, an executive officer who reports to our CEO. The management and implementation of our 2025 Sustainability & Social Impact Strategy is led on a day-to-day basis by our Chief Sustainability Officer. Our Chief Sustainability Officer also leads our sustainability steering committee, which is composed of members of senior management. The sustainability steering committee makes strategic decisions related to sustainability and works to integrate our strategy into our broader organization and meet our sustainability targets. Networks of senior leaders in each division and local champions support on-the-ground sustainability efforts, communications and reporting. To integrate sustainability tracking and disclosures into our business strategy, operations and employee review process, our global sustainability initiatives are among the individual objectives used to determine the compensation for many of our senior managers. In addition, to further emphasize the importance of executing on our sustainability strategy, the P&O Committee included a sustainability component in the strategic measure of our annual incentive program applicable to all executives starting in 2022. Additional information about our strategy and processes for identifying, assessing and managing climate-related risks and opportunities, including governance, metrics and targets, can be found in the Sustainability section of our website, including our annual Sustainability & Social Impact Report, our 2022 Climate Transition & Net Zero Action Plan and our reports aligned with the Task Force on Climate-related Financial Disclosures (TCFD) recommendations and Sustainability Accounting Standards Board (SASB). References to these reports and our website are for informational purposes only and neither the reports nor the other information on our website is incorporated by reference into this Proxy Statement.

**Human Capital (Including DE&I)**

We believe our people are crucial to our ongoing business success and aim to recruit, develop and retain strong and diverse talent. We celebrate differences, promote an equitable and inclusive environment and value the contributions of all Colgate people. At Colgate, we are proud of our collaborative spirit – what we call The Power of WE. As a truly global company, we are working to ensure that our workforce reflects the diversity of the communities in which we live and work and that Colgate people around the world feel that Colgate is a place where they belong, can be their authentic selves, are treated with respect and have equal opportunity to impact the business and be recognized for it.

**8**

**[**Table of Contents**](#toc)** 

Governance of the Company

As part of our commitment to continuous improvement, we continue to drive a learning culture and transform our learning strategy to better meet our evolving business needs. We provide our employees with learning experiences focused on building leadership skills and offer training programs that are closely aligned with our business strategy. Specifically, we continue to embed new ways of working and leadership principles to, among other things, instill a growth mindset to drive innovation with focus, empowerment, experimentation and digitalization. Colgate people are embracing data and analytics as part of their jobs, and we are scaling new capabilities worldwide. For example, in 2022 approximately 14,000 Colgate people completed a new Data Literacy & Analytics Academy course we created with training experts. We are also committed to listening to our employees and seeing how the Company is evolving and growing through regular employee engagement surveys.

We are also committed to providing all of our employees with an equitable and inclusive work environment, learning opportunities and promotion and growth opportunities. A vital piece of our DE&I strategy has been ensuring that our succession planning process incorporates the advancement of women and people of all cultures, including underrepresented communities. Our global DE&I strategy aims to further advance our commitment to become an even more diverse, equitable and inclusive company through its four pillars of People, Community, Supplier Diversity and Communication. As part of our commitment to transparency and progress in these efforts, we publish our latest EEO-1 reports on our website and publish an annual DE&I report. To further emphasize the importance of executing on our DE&I strategy, the P&O Committee included a DE&I component in the strategic measure of our annual incentive program starting in 2022. Additionally, starting in 2021, DE&I measures were among the individual objectives used to determine the compensation for our managers. The NGCR Committee and the P&O Committee receive regular updates on the implementation of our DE&I strategy and initiatives. For more information about our DE&I commitment and initiatives, including detail on the gender and racial/ethnic diversity of our organization and our most recent EEO-1 reports, please see the Diversity, Equity and Inclusion section of our website.

**Directors are Stockholders**

**Director Compensation in Stock**

On average, 78% of a non-employee director's compensation was paid in Colgate equity in 2022. For more information regarding director compensation, see "Compensation of Directors."

**Significant Levels of Director Stock Ownership**

Board members own significant amounts of Colgate stock. Under our stock ownership guidelines, independent directors are required to own stock equal in value to at least five times their annual share grant. For more information on director stock ownership, see "Stock Ownership—Stock Ownership of Directors and Executive Officers."

**Established Policies Guide Governance and Business Integrity**

**Corporate Governance Guidelines**

The corporate governance guidelines reflect the Board's views and Company policy regarding significant corporate governance issues, which the Board believes are best practice. As part of its ongoing review of best practices in corporate governance, the Board periodically reviews and updates the guidelines. A copy of the guidelines, entitled "Board Guidelines on Significant Corporate Governance Issues," is available on our website.

**Code of Conduct**

The Board sponsors our Code of Conduct, which promotes the highest ethical standards in all of our business dealings. The Global Ethics and Compliance function, headed by a corporate officer who reports to the CEO and provides reports directly to the Audit Committee, oversees compliance with these standards and periodically reviews and updates the Code of Conduct in conjunction with our Global Legal Organization. The Code of Conduct applies to our directors and employees, including the CEO, the Chief Financial Officer and the Controller (who is our principal accounting officer), and satisfies the SEC's requirements for a code of ethics for senior financial officers. The Code of Conduct is available on our website.

**Business Integrity Initiatives**

The Board supports our efforts to effectively communicate our commitment to ethical business practices, which are led by our Global Ethics and Compliance function. To further this goal, all of our directors and employees worldwide are required to annually certify that they understand and comply with the Code of Conduct. In addition, all of our directors and employees worldwide participate in regular training programs regarding the Code of Conduct, and our salaried and clerical employees participate in additional periodic training programs regarding Colgate's values, ethical leadership and the applicable laws and regulations that govern our business practices around the world.

2023 Proxy Statement<sub>9</sub>

**[**Table of Contents**](#toc)** 

Governance of the Company

**Political Expenditures**

As set forth in our Code of Conduct and our Political Contributions Policy, we have a longstanding policy against making direct or indirect contributions to any political party or candidate. In addition, each year, we advise our U.S. trade associations of this policy to prevent the use of Company dues or contributions for any such expenditures and request that such associations that receive at least $10,000 annually from us confirm their compliance with this policy. The Political Contributions Policy is available on our website.

**Restrictions on Hiring Audit Firm Employees**

To bolster the independence of our independent registered public accounting firm and the integrity of our internal financial reporting and audit processes, we have a longstanding policy prohibiting us from hiring any partners or managers engaged in an audit of Colgate or any employees engaged in the corporate portion of an audit of Colgate from PricewaterhouseCoopers LLP, our independent registered public accounting firm, within five years of the end of their engagement without the approval of the Audit Committee.

**Hedging and Pledging Policies**

To further ensure that the interests of our directors, officers and senior managers are aligned with those of our stockholders, our hedging policy prohibits our directors, officers and employees who receive stock-based compensation from engaging in transactions to hedge against declines in the value of our stock, as further described in the CD&A. The policy also strongly discourages all other employees from entering into such transactions. Further, to prevent forced sales of Colgate stock by our directors and officers, we prohibit our directors and officers from pledging Colgate stock.

**Clawback Policies**

Our clawback policy permits us to recoup cash and equity-based incentive awards made to an officer or other executive subject to the policy if (i) the financial results on which such awards were based are subsequently restated or (ii) the officer or executive engaged in conduct that violates our Code of Conduct. In addition, our equity award agreements include non-competition, non-solicitation and non-interference restrictions in the event of an employee's departure from Colgate. Failure to comply with any of these requirements may result in forfeiture and/or cancellation of equity awards. We are monitoring regulatory developments regarding clawback requirements and will adopt any changes that may be necessary to comply with NYSE listing standards when effective.

**Direct Access to Management**

**Management Participation at Board Meetings**

Key senior managers regularly attend Board meetings. Topics are presented to the Board by the members of management who are most knowledgeable about the issue at hand irrespective of seniority. An open and informal environment allows dialogue to develop between directors and management, which often produces new ideas and areas of focus.

**Direct Access to Management**

The Board's direct access to management continues outside the boardroom in discussions and working groups with corporate officers, division presidents and other employees, often without the CEO present. Directors are invited to and do contact senior managers directly with questions and suggestions.

**Ensuring Management Accountability**

**Performance-Based Compensation**

We have linked the pay of our managers and employees at all levels to Colgate's performance. As described in greater detail in the CD&A, the P&O Committee adheres to this pay-for-performance philosophy, and stock-based incentive awards are a significant component of senior management's overall compensation.

**CEO Evaluation Process**

The Board's evaluation of the CEO is a formal annual process. The CEO is evaluated by the Board against the goals set each year, including both objective measures (such as earnings per share, organic sales growth and achievement of strategic initiatives) and subjective criteria (such as leadership and demonstration of our core values). As part of the overall evaluation process, the Board and the Lead Director meet informally with the CEO to give feedback on a regular basis.

**Board Practices Promote Effective Oversight**

**Board Size**

Designed to maximize board effectiveness, our by-laws fix the number of directors between seven and fifteen. The number of directors is currently fixed at eleven, and eleven directors have been nominated for election at the Annual Meeting.

**10**

**[**Table of Contents**](#toc)** 

Governance of the Company

**Board Retirement Age**

Our by-laws mandate that no director may stand for re-election after their 72nd birthday, which provides a mechanism for regular Board refreshment.

**Directorship Limits**

To ensure that directors are able to devote sufficient time to properly discharge their duties, our corporate governance guidelines provide that directors should not serve on more than three other public company boards. All directors are in compliance with this policy. Directors are also required to seek the approval of the NGCR Committee prior to joining any corporate board or assuming a leadership position (e.g., chair, lead director or committee chair) on a corporate board or upon a material change in their qualifications or status. In addition, the NGCR Committee conducts an annual review of director time commitments, with consideration given to public company board leadership positions and other director time commitments, to ensure they continue to have sufficient availability.

**Meeting Attendance**

On average, each incumbent director attended 98% of the meetings of the Board and the committees on which he or she served in 2022. No incumbent director attended less than 75% of these meetings.

**Continuous Improvement Through Evaluation and Education**

**Board Self-Evaluation Process**

Each year, the Board evaluates its performance against criteria that it has determined are important to its success. One or more of the following topics may be considered during such evaluations: financial oversight, risk oversight, succession planning, executive compensation, strategic planning, corporate governance, oversight of sustainability issues (including climate change), ethics and compliance and Board composition and structure. The Board then considers the results of the evaluation and identifies steps to enhance its performance.

**Board Committee Evaluations**

Self-evaluations of each of the Board's committees are also conducted annually. The results of these evaluations are reviewed with each committee, and further enhancements are agreed for each committee.

**Individual Director Evaluations**

Complementing the Board and committee self-evaluations, the Board has also developed an individual director evaluation process to be used every three years. Using director effectiveness criteria selected by the Board following a review of external best practices, directors evaluate their peers and the resulting feedback is shared with individual directors by an external facilitator. This process, which the Board intends to conduct again in 2023, enables directors to provide valuable feedback to one another and identifies areas of strength and areas of focus for enhanced effectiveness.

**Ongoing Director Education**

Outside experts periodically present to the Board on various subjects. During 2022, such subjects included cybersecurity, ESG reporting and executive compensation trends. From time to time, our directors also visit Colgate operations, deepening their understanding of our business. In 2022, they visited our Hill's business operations and science and technology center in Topeka, Kansas.

---

| | |
|:---|:---|
| **The Board of Directors** | |
| The Board oversees our strategy, business, performance, assets, affairs, culture, values and financial integrity. In accordance with our longstanding practice, the Board is independent, consisting of a substantial majority of outside directors. Currently, the Board has eleven directors, with ten independent directors and one employee director, Noel R. Wallace, who is our President and CEO and Chairman of the Board.<br> During 2022, the independent directors met in executive session without Mr. Wallace or other members of management present at every regularly scheduled Board meeting. | &nbsp;&nbsp;The Board met **twelve** times during 2022. On average, the incumbent directors attended<br> 98%<br> of the meetings of the Board and the committees on which they served in 2022. |

---

**Director Diversity, Experience, Skills and Qualifications**

The Board selects director candidates based on the recommendation of the NGCR Committee. The NGCR Committee identifies, screens and recruits potential candidates for membership on the Board of Directors, taking into account the needs of Colgate and the Board at the time as well as anticipated future needs. We have engaged a third-party international executive search firm to assist the NGCR Committee in identifying and evaluating potential director candidates.

2023 Proxy Statement<sub>11</sub>

**[**Table of Contents**](#toc)** 

Governance of the Company

The NGCR Committee seeks to compose a Board with members who have a broad range of experiences and skills and different perspectives, with a particular emphasis on enterprise leadership experience; experience in digital, technology and innovation, environmental and social responsibility, finance, our or a complementary industry, regulatory and/or risk management and cybersecurity; international experience; corporate governance experience; diversity; educational achievement; and strong moral and ethical character. This variety and depth of experience enables the Board collectively to understand our global business and our consumers around the world and the directors individually to make significant contributions to the deliberations of the Board.

The Board has adopted a written statement, known as the Independent Board Candidate Qualifications and made available on our website, outlining the qualities sought in our directors. This statement, which is refreshed periodically and was most recently updated in January 2023, is used by the NGCR Committee in evaluating individual director candidates. It highlights the following skills and experiences, among others, as being important to creating an effective, well-rounded and diverse Board:

---

| | |
|:---|:---|
| Experience, Skill or Qualification | Rationale |
| **Enterprise Leadership**—Is or has been the Chief Executive Officer, Chief Operating Officer or other high level executive at a complex public corporation or held a comparable position in the nonprofit sector or government and has experience with strategy. | Directors who have served in these roles possess exceptional leadership qualities and demonstrate a practical understanding of how large organizations operate, including strategic planning. |
| **Digital, Technology and Innovation**—Has experience with eCommerce, digital marketing, data and analytics, information technology or digital transformation, or relevant innovation experience including with new technologies, product development or scientific research. | We are focused on maximizing growth in eCommerce, using digital marketing as a way of reaching today's consumers and innovating to drive growth. Directors with experience in those fields are therefore able to provide insights that help us advance powerful commercial strategies in the rapidly evolving digital and eCommerce landscapes. In addition, directors with expertise in data and analytics, information technology or digital transformation, including enterprise software, artificial intelligence and machine learning, provide helpful oversight with respect to the use of technology to gain insights and drive efficiency of operations. |
| **Environmental and Social Responsibility**—Has experience with sustainability, social responsibility or human capital matters (including DE&I issues and initiatives). | Given the critical importance of sustainability and human capital matters to our culture, business and growth strategy, directors with experience with environmental and social responsibility issues strengthen the Board's oversight of these matters, including the risks and opportunities associated with them. They also bring important perspectives to our business, including with respect to our 2025 Sustainability & Social Impact Strategy, DE&I strategy and initiatives such as our Bright Smiles, Bright Futures oral health education program. |
| **Finance**—Has a background in finance, including an understanding of accounting and financial reporting processes, complex financial transactions and/or strategic mergers and acquisitions. | We use a variety of financial metrics to measure our performance, and accurate financial reporting and accounting are critical to our success. Therefore, directors with financial experience, including an understanding of accounting and financial reporting processes, provide an essential oversight role. In addition, directors who have experience with strategic mergers and acquisitions provide helpful perspectives and oversight as we evaluate and implement strategic transactions. |
| **Industry**—Has experience in the fast-moving consumer goods industry or other complementary field, such as public health. | Directors with experience in the fast-moving consumer goods industry have experience with manufacturing, marketing and selling products and consumer engagement and therefore can provide valuable market and consumer insights, as well as contribute a broad understanding of industry trends. Directors with experience in complementary industries, such as public health, also bring important perspectives and knowledge to our business, including with respect to engagement with dental, veterinary and skin health professionals. |
| **Regulatory**—Has experience working in a highly regulated industry, such as pharmaceutical, healthcare or insurance. | Directors with experience in highly regulated industries bring valuable insights because our business requires compliance with a variety of regulatory requirements around the world. |
| **Risk Management and Cybersecurity**—Has experience with overseeing and managing risk management processes, including with respect to cybersecurity. | Directors with experience overseeing and managing risk management processes play a critical role in the Board's oversight of our enterprise risk management process. Given our focus on digital transformation and increased use of data and analytics, experience in cybersecurity is increasingly important. |

---

**12**

**[**Table of Contents**](#toc)** 

Governance of the Company

---

| | |
|:---|:---|
| Experience, Skill or Qualification | Rationale |
| **International**—Has significant international experience, whether through managing international business operations or living and working outside the United States; an understanding of the language and culture of non-English speaking countries is also important. | Since approximately two-thirds of our net sales are generated outside the United States and we are focused on continuing to drive penetration in markets with growing populations, having directors with experience managing international operations is essential. Exposure to different cultural perspectives and practices is also important in helping us meet the needs of our global consumers in the over 200 countries and territories worldwide in which we compete. |
| **Corporate Governance**—Has sufficient applicable experience to understand and fulfill the legal and other responsibilities of an independent director of a <br> U.S.-based public company. | Excellence in corporate governance accompanies and greatly aids our long-term business success, including by promoting transparency, accountability and promotion of stakeholder value. Having directors with experience serving as directors of other U.S. public companies helps ensure the Board deeply understands its roles and duties and we remain at the forefront of excellent corporate governance. |

---

The NGCR Committee expects each of our directors to have the personal qualities necessary to make a substantial contribution to the Board, including high moral and ethical standards, strong communication and interpersonal skills, a commitment to Colgate's success and the willingness and ability to devote sufficient time to discharge their duties. Prospective directors must also satisfy our director independence standards and should not currently be, or have been within the past three years, an officer or director of a competitor.

In addition, the NGCR Committee has a policy of promoting diversity on the Board, as it believes the Board should constantly be striving to achieve the diversity of the communities in which we operate, including with respect to race, ethnicity, gender, sexual orientation, gender identity and cultural background. The NGCR Committee implements this policy through its director recruitment efforts and assesses the effectiveness of the policy regularly through Board and committee self-evaluations. The NGCR Committee strives to consider a diverse slate of candidates for every director search.

The NGCR Committee will consider director candidates recommended by stockholders and others if such candidates meet our criteria for Board membership, evaluating them in the same manner in which the committee evaluates other candidates. Such recommendations should be made in writing to the NGCR Committee or the Company Secretary and should include a description of the qualifications of the proposed candidate. Any of our stockholders may also nominate a director at a stockholders' meeting, and eligible stockholders may also nominate directors for inclusion in our proxy statement, in each case in accordance with the requirements of our by-laws relating to stockholder nominations as described in "Questions and Answers About Our Annual Meeting—Who nominates the directors?"

The table below provides a high-level summary of the particular skills and qualifications of each of the eleven director nominees approved by the NGCR Committee for election at the Annual Meeting. Biographical information and additional detail regarding the director nominees' particular skills and qualifications follows. The absence of a reference to a qualification for an individual director nominee does not mean that the nominee does not possess that qualification, but rather that it is not one of the specific qualifications for which the nominee has been proposed. All nominees except for Mr. Cahillane have been directors since last year's annual meeting. Mr. Cahillane, who joined the Board in February 2023, was recommended by a third-party international executive search firm.

![](cl4117791_def14ax19x1.jpg)

<sup>\*</sup> Ms. Edwards, Ms. Hund-Mejean, Ms. Nelson and Ms. Norrington are our female director nominees. Dr. Harris and Ms. Nelson identify as African-American and Ms. Norrington identifies as LGBTQ+.

2023 Proxy Statement<sub>13</sub>

**[**Table of Contents**](#toc)** 

Governance of the Company

---

| | |
|:---|:---|
| &nbsp;&nbsp;**John P. Bilbrey** | **Independent** |
| &nbsp;&nbsp;![](cl4117791_def14ax20x1.jpg)<br> Age: **66**<br> Director since **2015**<br> Committees:<br> **Finance (Chair), NGCR**<br> Other Public Company Directorships:<br> **Campbell Soup Company<br> (since 2019)<br> Elanco Animal Health<br> Incorporated (since 2019)<br> Tapestry, Inc.<br> (since 2020)**<br> *Former (During Past 5 Years):***<br> The Hershey Company<br> (until 2018)** | Mr. Bilbrey served as President and Chief Executive Officer of The Hershey Company ("Hershey"), a multinational consumer food company, from 2011 until his retirement in 2017. He also served as Chairman of the Board of Directors of Hershey from 2015 to 2017 and as Non-Executive Chairman from 2017 to 2018. Mr. Bilbrey joined Hershey as Senior Vice President, President Hershey International in 2003 and served as Senior Vice President, President Hershey North America from 2007 to 2010 and as Executive Vice President and Chief Operating Officer from 2010 to 2011. Prior to joining Hershey, Mr. Bilbrey held executive positions at Mission Foods and Danone Waters of North America, Inc., a division of Groupe Danone, and previously spent 22 years at The Procter & Gamble Company ("Procter & Gamble"). Mr. Bilbrey also serves on the Kansas State University Foundation Board of Directors. |
| &nbsp;&nbsp;![](cl4117791_def14ax20x1.jpg)<br> Age: **66**<br> Director since **2015**<br> Committees:<br> **Finance (Chair), NGCR**<br> Other Public Company Directorships:<br> **Campbell Soup Company<br> (since 2019)<br> Elanco Animal Health<br> Incorporated (since 2019)<br> Tapestry, Inc.<br> (since 2020)**<br> *Former (During Past 5 Years):***<br> The Hershey Company<br> (until 2018)** | **Skills and Qualifications:**<br> **Enterprise Leadership**<br> Extensive operational leadership experience through service as Chief Executive Officer and Chief Operating Officer of Hershey.<br> **Industry**<br> In-depth knowledge of fast-moving consumer goods industry through experience at Hershey and Procter & Gamble and expertise in marketing through leadership roles at consumer-focused companies.<br> **Finance**<br> Strong knowledge of business finance and financial statements through oversight of operating budgets and financial statements at Hershey and significant mergers and acquisitions and business integration experience throughout his career.<br> **International**<br> Experience managing Hershey's international operations and living and working in foreign countries.<br> **Corporate Governance**<br> Experience serving as a director of other U.S. public companies.<br>|
| &nbsp;&nbsp;**John T. Cahill** | **Independent** |
| &nbsp;&nbsp;![](cl4117791_def14ax20x2.jpg)<br> Age: **65**<br> Director since **2005**<br> Committees:<br> **Audit (Chair), P&O**<br> Other Public Company Directorships:<br> **American Airlines<br> Group Inc. (since 2013)<br> The Kraft Heinz Company<br> (since 2015)** | Mr. Cahill has served as Vice Chairman of The Kraft Heinz Company, a multinational food and beverage company, since 2015 after serving as Chairman and Chief Executive Officer of Kraft Foods Group, Inc. ("Kraft") from 2014 until its merger with H.J. Heinz Holding Corporation in 2015. Mr. Cahill previously served as Executive Chairman of Kraft from 2012, when Kraft was spun off from Kraft Foods Inc. ("Kraft Foods"), until 2014, when he was elected Non-Executive Chairman. He served as Executive Chairman of Kraft Foods North America in 2012. Mr. Cahill was an Industrial Partner at Ripplewood Holdings LLC, a private equity firm, from 2008 through 2011. He previously served The Pepsi Bottling Group, Inc. ("PBG") in a variety of leadership positions culminating in Chairman and Chief Executive Officer. He also held multiple senior financial and operating leadership positions at PepsiCo Inc. ("PepsiCo"). |
| &nbsp;&nbsp;![](cl4117791_def14ax20x2.jpg)<br> Age: **65**<br> Director since **2005**<br> Committees:<br> **Audit (Chair), P&O**<br> Other Public Company Directorships:<br> **American Airlines<br> Group Inc. (since 2013)<br> The Kraft Heinz Company<br> (since 2015)** | **Skills and Qualifications:**<br> **Finance**<br> Strong knowledge of business finance and financial statements through service as Chief Financial Officer of PBG, Kentucky Fried Chicken and Pepsi-Cola North America and as Senior Vice President and Treasurer of PepsiCo and significant mergers and acquisitions and business integration experience throughout his career.<br> **Risk Management and Cybersecurity**<br> Significant experience overseeing enterprise risk management through service as Chief Financial Officer at several companies.<br> **Enterprise Leadership**<br> Extensive operational leadership experience through service as Chairman and Chief Executive Officer of Kraft and as Chairman and Chief Executive Officer of PBG.<br> **Industry**<br> In-depth knowledge of fast-moving consumer goods industry through experience at Kraft and nearly 20-year career at PepsiCo and PBG.<br> **International**<br> Experience managing international operations for PBG.<br> **Corporate Governance**<br> Experience serving as a director of other U.S. public companies.<br>|

---

**14**

**[**Table of Contents**](#toc)** 

Governance of the Company

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Steve Cahillane** | **Independent** |
| &nbsp;&nbsp;![](cl4117791_def14ax21x1.jpg)<br> Age: **57**<br> Director since **February 2023**<br> Committees: **None**<br> Other Public Company Directorships:<br> **Kellogg Company<br> (since 2017)** | Mr. Cahillane has been President and Chief Executive Officer of Kellogg Company ("Kellogg"), a global snacks, cereal and frozen foods company, since 2017 and Chairman of the Board of Kellogg since 2018. Prior to joining Kellogg, from 2014 to 2017, Mr. Cahillane served as President and Chief Executive Officer of The Nature's Bounty Co. ("Nature's Bounty"). Mr. Cahillane previously spent seven years with The Coca-Cola Company ("Coca-Cola") culminating as Executive Vice President of Coca-Cola and President of Coca-Cola Americas. Prior to that, Mr. Cahillane served as President of various Coca-Cola operating groups. |
| &nbsp;&nbsp;![](cl4117791_def14ax21x1.jpg)<br> Age: **57**<br> Director since **February 2023**<br> Committees: **None**<br> Other Public Company Directorships:<br> **Kellogg Company<br> (since 2017)** | **Skills and Qualifications:**<br> **Enterprise Leadership**<br> Extensive operational leadership experience through service as President and Chief Executive Officer of Kellogg and Nature's Bounty and as head of various operating groups at Coca-Cola.<br> **Industry**<br> In-depth knowledge of fast-moving consumer goods and health and nutrition industries through experience at Kellogg, Nature's Bounty and Coca-Cola and expertise in marketing through leadership roles at consumer-focused companies.<br> **Finance**<br> Strong knowledge of business finance and financial statements through oversight of operating budgets at various companies and operating budgets and financial statements at Kellogg and significant mergers and acquisitions and business integration experience throughout his career.<br> **International**<br> Experience managing Kellogg's international operations.<br> **Corporate Governance**<br> Experience serving as a director of another U.S. public company.<br>|
| &nbsp;&nbsp;**Lisa M. Edwards** | **Independent** |
| &nbsp;&nbsp;![](cl4117791_def14ax21x2.jpg)<br> Age: **55**<br> Director since **2019**<br> Committees:<br> **Finance, NGCR**<br> Other Public Company Directorships:<br> **None** | Ms. Edwards has served as Executive Chair of Diligent Institute, a governance think tank owned by Diligent Corporation ("Diligent"), since November 2022. She previously served as President and Chief Operating Officer of Diligent, a governance software company, from 2020 to 2022. Prior to joining Diligent, she served as Executive Vice President, Strategic Business Operations, Customer and Partner Engagement of Salesforce.com, Inc. ("Salesforce"), an enterprise software company, from 2017 to 2020. She joined Salesforce in 2012 as Executive Vice President, Finance, Head of Global Corporate Services and Chief Procurement Officer. Ms. Edwards previously served in several senior management roles at Visa Inc. ("Visa"), including as Senior Vice President and Head of Global Business Development and IP Strategy. Prior to that, she was an entrepreneur after starting her career at Bain & Company. |
| &nbsp;&nbsp;![](cl4117791_def14ax21x2.jpg)<br> Age: **55**<br> Director since **2019**<br> Committees:<br> **Finance, NGCR**<br> Other Public Company Directorships:<br> **None** | **Skills and Qualifications:**<br> **Digital, Technology and Innovation**<br> Significant experience with information technology, including data and analytics, eCommerce and digital transformation through service at Diligent, Salesforce and other companies.<br> **Environmental and Social Responsibility**<br> Certifications in and experience with sustainability and social responsibility matters through service at Diligent Institute and Diligent.<br> **Risk Management and Cybersecurity**<br> Certifications in cybersecurity oversight and significant experience with cybersecurity through service at Diligent Institute, Diligent and other companies.<br> **Corporate Governance**<br> Strong knowledge of corporate governance practices through service as Executive Chair of Diligent Institute and President and Chief Operating Officer of Diligent.<br> **Enterprise Leadership**<br> Extensive operational leadership experience as President and Chief Operating Officer of Diligent and as head of various functions at Salesforce and Visa.<br> **Finance**<br> Strong knowledge of business finance and financial statements through oversight of operating budgets at Diligent and through service as Executive Vice President, Finance at Salesforce and significant mergers and acquisitions and business integration experience throughout her career.<br>|

---

---

| | |
|:---|:---|
| 2023 Proxy Statement | **15** |

---

**[**Table of Contents**](#toc)** 

Governance of the Company

---

| | |
|:---|:---|
| &nbsp;&nbsp;**C. Martin Harris** | **Independent** |
| &nbsp;&nbsp;![](cl4117791_def14ax22x1.jpg)<br> Age: **66**<br> Director since **2016**<br> Committees:<br> **NGCR, P&O**<br> Other Public Company Directorships:<br> **Agiliti, Inc. (since 2022)**<br> **MultiPlan Corporation<br> (since 2021)**<br> **Thermo Fisher Scientific<br> Inc. (since 2012)**<br> *Former (During Past 5 Years):* <br> **Healthstream, Inc.<br> (until 2021)<br> Invacare Corporation<br> (until 2022)** | Dr. Harris has served as Associate Vice President of the Health Enterprise and Chief Business Officer of the Dell Medical School at The University of Texas at Austin since 2016. Dr. Harris previously served as Chief Information Officer and Chairman of the Information Technology Division of The Cleveland Clinic Foundation, a non-profit academic medical center, and a Staff Physician for The Cleveland Clinic Hospital and The Cleveland Clinic Foundation Department of General Internal Medicine from 1996 to 2016. Additionally, from 2000 to 2016, he was Executive Director of e-Cleveland Clinic, a series of e-health clinical programs offered over the internet. Prior to joining the Cleveland Clinic, Dr. Harris spent 14 years with the School of Medicine at the University of Pennsylvania. |
| &nbsp;&nbsp;![](cl4117791_def14ax22x1.jpg)<br> Age: **66**<br> Director since **2016**<br> Committees:<br> **NGCR, P&O**<br> Other Public Company Directorships:<br> **Agiliti, Inc. (since 2022)**<br> **MultiPlan Corporation<br> (since 2021)**<br> **Thermo Fisher Scientific<br> Inc. (since 2012)**<br> *Former (During Past 5 Years):* <br> **Healthstream, Inc.<br> (until 2021)<br> Invacare Corporation<br> (until 2022)** | **Skills and Qualifications:**<br> **Digital, Technology and Innovation**<br> Significant experience with information technology, including data, through service at the Dell Medical School, the Cleveland Clinic and the University of Pennsylvania.<br> **Regulatory**<br> Extensive leadership experience in healthcare, a highly regulated industry, through positions at the Dell Medical School and the Cleveland Clinic.<br> **Risk Management and Cybersecurity**<br> Significant experience with cybersecurity through service at the Dell Medical School and the Cleveland Clinic.<br> **Environmental and Social Responsibility**<br> Experience with social responsibility through expertise in the public health field.<br> **Industry**<br> In-depth knowledge of and expertise in the public health field, a complementary industry.<br> **Corporate Governance**<br> Experience serving as a director of other U.S. public companies.<br>|
| &nbsp;&nbsp;**Martina Hund-Mejean** | **Independent** |
| &nbsp;&nbsp;![](cl4117791_def14ax22x2.jpg)<br> Age: **62**<br> Director since **2020**<br> Committees:<br> **Audit, Finance**<br> Other Public Company Directorships:<br> **Prudential Financial, Inc.<br> (since 2010)<br> Shell plc (since 2020)** | Ms. Hund-Mejean served as Chief Financial Officer of Mastercard Inc. ("Mastercard"), a technology company in the global payments industry, from 2007 until her retirement in 2019. Prior to joining Mastercard, Ms. Hund-Mejean served as Senior Vice President and Treasurer of Tyco International Ltd. ("Tyco") from 2002 to 2007 and Senior Vice President and Treasurer of Lucent Technologies Inc. ("Lucent") from 2000 to 2002. She previously held a series of finance positions of increasing responsibility at General Motors Company from 1988 to 2000. Ms. Hund-Mejean began her career as a credit analyst at Dow Chemical in Germany. |
| &nbsp;&nbsp;![](cl4117791_def14ax22x2.jpg)<br> Age: **62**<br> Director since **2020**<br> Committees:<br> **Audit, Finance**<br> Other Public Company Directorships:<br> **Prudential Financial, Inc.<br> (since 2010)<br> Shell plc (since 2020)** | **Skills and Qualifications:**<br> **Finance**<br> Strong knowledge of business finance and financial statements through service as Chief Financial Officer of Mastercard, Senior Vice President and Treasurer of Tyco and Lucent and various positions at General Motors Company and significant mergers and acquisitions and business integration experience throughout her career.<br> **Risk Management and Cybersecurity**<br> Significant experience overseeing enterprise risk management and with cybersecurity through service as Chief Financial Officer of Mastercard.<br> **Digital, Technology and Innovation**<br> Significant experience with information technology, including data, as Chief Financial Officer of Mastercard.<br> **International**<br> Experience managing global functions for Mastercard, Tyco and Lucent, serving as a director of Shell, a public company incorporated and headquartered outside the U.S., and living and working in foreign countries (native of Germany).<br> **Enterprise Leadership**<br> Extensive operational leadership experience as Chief Financial Officer of Mastercard.<br> **Corporate Governance**<br> Experience serving as a director of other public companies.<br>|

---

**16**

**[**Table of Contents**](#toc)** 

Governance of the Company

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Kimberly A. Nelson** | **Independent** |
| &nbsp;&nbsp;![](cl4117791_def14ax23x1.jpg)<br> Age: **60**<br> Director since **2021**<br> Committees:<br> **NGCR, P&O**<br> Other Public Company Directorships:<br> **Cummins Inc.<br> (since 2020)<br> Tate & Lyle PLC<br> (since 2019)** | Ms. Nelson served as Senior Vice President, External Relations of General Mills, Inc. ("General Mills"), a multinational food company, from 2010 until her retirement in 2018. In this global role, she led sustainability, consumer relations, corporate branding and communications, government affairs and public policy and external stakeholder relations for General Mills. Ms. Nelson also served as President of the General Mills Foundation from 2011 until 2018. Previously, she held several senior brand and general management roles during her nearly 30-year career at General Mills, including serving as President of the Snack Food Division from 2004 to 2010. |
| &nbsp;&nbsp;![](cl4117791_def14ax23x1.jpg)<br> Age: **60**<br> Director since **2021**<br> Committees:<br> **NGCR, P&O**<br> Other Public Company Directorships:<br> **Cummins Inc.<br> (since 2020)<br> Tate & Lyle PLC<br> (since 2019)** | **Skills and Qualifications:**<br> **Industry**<br> In-depth knowledge of fast-moving consumer goods industry through experience at General Mills and expertise in marketing through leadership roles at General Mills.<br> **Environmental and Social Responsibility**<br> Experience with sustainability and social responsibility through service as Senior Vice President, External Relations at General Mills and President of the General Mills Foundation.<br> **Enterprise Leadership**<br> Extensive operational leadership experience through service as President of General Mills's Snack Food Division and other management positions at General Mills.<br> **International**<br> Experience managing global functions for General Mills and serving as a director of Tate & Lyle, a public company incorporated and headquartered outside the U.S.<br> **Corporate Governance**<br> Experience serving as a director of other public companies.<br>|
| &nbsp;&nbsp;**Lorrie M. Norrington** | **Independent, Lead Director** |
| &nbsp;&nbsp;![](cl4117791_def14ax23x2.jpg)<br> Age: **63**<br> Director since **2015**<br> Committees:<br> **Audit, NGCR (Chair)**<br> Other Public Company Directorships:<br> **Asana, Inc. (since 2020)<br> Autodesk, Inc.<br> (since 2011)<br> HubSpot, Inc.<br> (since 2013)**<br> *Former (During Past 5 Years):*<br> **Eventbrite, Inc.<br> (until 2020)** | Ms. Norrington has served as an Operating Partner of Lead Edge Capital LLC, a growth equity investment firm, since 2012. Ms. Norrington previously served in several senior management roles at eBay from 2005 to 2010, including President of Global eBay Marketplaces, Chief Operating Officer of eBay Marketplaces, President of eBay International and CEO of Shopping.com. Prior to joining eBay, Ms. Norrington held senior positions at Intuit Inc. ("Intuit"). Prior to Intuit, she was a company officer and held a number of global operating roles, including CEO of GE FANUC, at General Electric Company ("General Electric") over an almost 20-year period. |
| &nbsp;&nbsp;![](cl4117791_def14ax23x2.jpg)<br> Age: **63**<br> Director since **2015**<br> Committees:<br> **Audit, NGCR (Chair)**<br> Other Public Company Directorships:<br> **Asana, Inc. (since 2020)<br> Autodesk, Inc.<br> (since 2011)<br> HubSpot, Inc.<br> (since 2013)**<br> *Former (During Past 5 Years):*<br> **Eventbrite, Inc.<br> (until 2020)** | **Skills and Qualifications:**<br> **Digital, Technology and Innovation**<br> Significant experience with information technology and software, including data and analytics, eCommerce, digital marketing and artificial intelligence through service at eBay and Intuit and Board advisory work for other technology companies.<br> **Risk Management and Cybersecurity**<br> Certifications in cybersecurity oversight and significant experience with cybersecurity through service at and Board advisory work for various technology companies.<br> **Environmental and Social Responsibility**<br> Experience with sustainability and social responsibility through chairing responsible committees at various U.S. public companies.<br> **Enterprise Leadership**<br> Extensive operational leadership experience through service as President and Chief Operating Officer of eBay Marketplaces and as head of various operating divisions at General Electric.<br> **Finance**<br> Strong knowledge of business finance and financial statements through oversight of operating budgets at various companies and significant mergers and acquisitions and business integration experience throughout her career.<br> **International**<br> Experience managing international operations for eBay and global businesses for General Electric.<br> **Corporate Governance**<br> Experience serving as a director of other U.S. public companies.<br>|

---

---

| | |
|:---|:---|
| 2023 Proxy Statement | **17** |

---

**[**Table of Contents**](#toc)** 

Governance of the Company

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Michael B. Polk** | **Independent** |
| &nbsp;&nbsp;![](cl4117791_def14ax24x1.jpg)<br> Age: **62**<br> Director since **2014**<br> Committees:<br> **Finance, P&O (Chair)**<br> Other Public Company Directorships:<br> **Logitech International S.A.<br> (since 2019)**<br> *Former (During Past 5 Years):*<br> **Newell Brands Inc.<br> (until 2019)** | Mr. Polk has been an Advisory Director to Berkshire Partners LLC ("Berkshire"), a private investment firm, since 2020. He became the Chief Executive Officer of a Berkshire portfolio company, Implus LLC ("Implus"), a fitness and outdoor accessories provider, in 2020, where he also serves on the Board of Directors. Mr. Polk previously served as President and Chief Executive Officer of Newell Brands Inc. and its predecessor, Newell Rubbermaid Inc. (together, "Newell"), a multinational consumer goods company, from 2011 until 2019. Prior to Newell, Mr. Polk held a series of executive positions at Unilever, including President, Global Foods, Home and Personal Care, and at Kraft Foods, where he served as President, Asia Pacific Region, Kraft Foods International and President, Nabisco Biscuit & Snacks, Kraft Foods North America. He started his career at Procter & Gamble. |
| &nbsp;&nbsp;![](cl4117791_def14ax24x1.jpg)<br> Age: **62**<br> Director since **2014**<br> Committees:<br> **Finance, P&O (Chair)**<br> Other Public Company Directorships:<br> **Logitech International S.A.<br> (since 2019)**<br> *Former (During Past 5 Years):*<br> **Newell Brands Inc.<br> (until 2019)** | **Skills and Qualifications:**<br> **Enterprise Leadership**<br> Extensive operational leadership experience through service as Chief Executive Officer of Newell and Implus and as head of various operating divisions of Unilever and Kraft Foods.<br> **Industry**<br> In-depth knowledge of fast-moving consumer goods industry through experience at Newell, Unilever, Kraft Foods and Procter & Gamble and expertise in marketing through leadership roles at consumer-focused companies.<br> **International**<br> Experience managing Newell's, Unilever's and Kraft Foods' international operations and serving as a director of Logitech International, a public company incorporated and headquartered outside the U.S.<br> **Finance**<br> Strong knowledge of business finance and financial statements through oversight of operating budgets at various companies and operating budgets and financial statements at Newell and significant mergers and acquisitions and business integration experience throughout his career.<br> **Corporate Governance**<br> Experience serving as a director of other public companies.<br>|
| &nbsp;&nbsp;**Stephen I. Sadove** | **Independent** |
| &nbsp;&nbsp;![](cl4117791_def14ax24x2.jpg)<br> Age: **71**<br> Director since **2007**<br> Committees:<br> **Audit, P&O**<br> Other Public Company Directorships:<br> **Aramark (since 2013)** **<br> Movado Group, Inc. (since 2018) Park Hotels & Resorts Inc. (since 2017)** | Mr. Sadove has served as a founding partner of JW Levin Management Partners LLC, a private equity firm, since 2015 and as principal of Stephen Sadove and Associates, which provides consulting services to the retail industry, since 2013. Mr. Sadove served as Chairman and Chief Executive Officer of Saks Incorporated ("Saks") from 2007 until 2013. He joined Saks as Vice Chairman in 2002, served as Chief Operating Officer from 2004 to 2006 and was named Chief Executive Officer in 2006. Previously, Mr. Sadove worked for Bristol-Myers Squibb Company ("Bristol-Myers Squibb"), which he joined in 1991 as President of Clairol in the U.S. He later gained additional responsibility for the consumer businesses in Canada, Europe, the Middle East, Africa and Latin America. In 1996, he was named President of Bristol-Myers Squibb's worldwide beauty care business and was later named a senior vice president with additional responsibility for Mead Johnson Nutritionals. Mr. Sadove also serves as Chairman Emeritus of the Board of Hamilton College. |
| &nbsp;&nbsp;![](cl4117791_def14ax24x2.jpg)<br> Age: **71**<br> Director since **2007**<br> Committees:<br> **Audit, P&O**<br> Other Public Company Directorships:<br> **Aramark (since 2013)** **<br> Movado Group, Inc. (since 2018) Park Hotels & Resorts Inc. (since 2017)** | **Skills and Qualifications:**<br> **Enterprise Leadership**<br> Extensive operational leadership experience through service as Chief Executive Officer of Saks and as head of various operating divisions at Bristol-Myers Squibb.<br> **Industry**<br> In-depth knowledge of fast-moving consumer goods industry through experience at Bristol-Myers Squibb and expertise in marketing through leadership roles at consumer-focused companies.<br> **Finance**<br> Strong knowledge of business finance and financial statements through oversight of operating budgets at various companies and operating budgets and financial statements at Saks and significant mergers and acquisitions and business integration experience throughout his career.<br> **International**<br> Experience managing Bristol-Myers Squibb's international operations.<br> **Corporate Governance**<br> Experience serving as a director of other U.S. public companies.<br>|

---

**18**

**[**Table of Contents**](#toc)** 

Governance of the Company

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Noel R. Wallace** | **Chairman** |
| &nbsp;&nbsp;![](cl4117791_def14ax25x1.jpg)<br> Age: **58**<br> Director since **2019**<br> Committees:<br> **None**<br> Other Public Company Directorships:<br> *Former (During Past 5 Years):*<br> **Kellogg Company<br> (until 2018)** | Mr. Wallace has been President and Chief Executive Officer of Colgate since 2019 and Chairman of the Board since 2020. He previously served as President and Chief Operating Officer of Colgate from 2018 until 2019, with responsibility for all of our operating units worldwide. Mr. Wallace began his career at Colgate in 1987 and progressed through a series of senior management roles around the world. Prior to being appointed President and Chief Operating Officer, he served as Chief Operating Officer, Global Innovation & Growth and Hill's Pet Nutrition from 2016 to 2018, as President, Colgate Latin America from 2013 to 2016 and as President, Colgate North America and Global Sustainability from 2010 to 2013. |
| &nbsp;&nbsp;![](cl4117791_def14ax25x1.jpg)<br> Age: **58**<br> Director since **2019**<br> Committees:<br> **None**<br> Other Public Company Directorships:<br> *Former (During Past 5 Years):*<br> **Kellogg Company<br> (until 2018)** | **Skills and Qualifications:**<br> **Enterprise Leadership**<br> Extensive operational leadership experience through service as President and Chief Executive Officer and Chief Operating Officer of Colgate.<br> **Industry**<br> In-depth knowledge of fast-moving consumer goods industry through 35-year career at Colgate and expertise in marketing through leadership roles at Colgate.<br> **International**<br> Experience managing Colgate's international operations and living and working in foreign countries.<br> **Environmental and Social Responsibility**<br> Experience with sustainability and social responsibility through service as President and Chief Executive Officer of Colgate and as President, Colgate North America and Global Sustainability.<br> **Finance**<br> Strong knowledge of business finance and financial statements through oversight of operating budgets and financial statements at Colgate and significant mergers and acquisitions and business integration experience throughout his career at Colgate.<br> **Corporate Governance**<br> Experience serving as a director of another U.S. public company.<br>|

---

**Director Independence**

As described above, the Board has adopted director independence standards that are stricter than those required by the listing standards of the NYSE. Specifically, a director is not considered independent if the director has any relationship with Colgate or our senior management or with another director or any other person that in the Board's judgment may impair the director's ability to make independent judgments. Such relationships could include voting arrangements or personal, economic or professional ties between a director and an officer of Colgate, another Colgate director or a significant stockholder of Colgate. Relationships and transactions (direct or indirect) that would preclude independence include:

---

| | |
|:---|:---|
| **●** current or former employment with Colgate;<br> **●** affiliation with Colgate's advisors;<br> **●** compensation from Colgate (other than director fees);<br> **●** material business relationships with Colgate;<br> **●** loans between directors and Colgate or our senior management;<br> **●** material investments with Colgate or our officers; | **●** joint investments with Colgate's officers or other directors;<br> **●** leadership roles in charitable organizations that receive significant support from Colgate;<br> **●** affiliation or employment with a present or former Colgate auditor; and<br> **●** service on interlocking boards of directors or compensation committees. |

---

A copy of the complete independence standards is available on our website.

In making its determination regarding the independence of each non-employee director, the Board considers any transactions, relationships or arrangements as required by our director independence standards. Based on these standards, the Board has determined that each current director, other than Mr. Wallace, who is our Chairman, President and CEO, is independent as there were no transactions, relationships or arrangements of the types described in our director independence standards.

---

| | |
|:---|:---|
| 2023 Proxy Statement | **19** |

---

**[**Table of Contents**](#toc)** 

Governance of the Company

**Certain Relationships and Related Transactions**

We have a longstanding policy prohibiting our directors, officers and employees from entering into transactions that present actual or potential conflicts of interest. This policy is reflected in our Code of Conduct, Business Practices Guidelines and Director Independence Standards. In addition, the Board has adopted a written policy regarding related person transactions which supplements these policies by establishing additional procedures for monitoring and reviewing and, if appropriate, approving, these types of transactions. The policy covers any "related person transaction," as defined under SEC rules, which generally includes any transaction, arrangement or relationship involving more than $120,000 in which we or any of our subsidiaries was, is or will be a participant and in which a "related person" had, has or will have a direct or indirect material interest. "Related persons" means directors and executive officers and their immediate family members, and stockholders owning five percent or more of our outstanding stock.

Our Corporate Legal Department, together with the Controller's Department, is responsible for monitoring compliance with these policies and procedures. In the rare instance where a related person transaction is determined to provide a material benefit to Colgate and our stockholders, the transaction must be submitted to the independent directors of the Board for their review. Only the independent directors of the Board may approve the transaction in accordance with the procedures for review and approval described in the policy. In the course of its review of related person transactions, the independent directors of the Board will consider all of the relevant facts and circumstances that are available to them, including but not limited to: (i) the benefits to Colgate; (ii) in a transaction involving a director, the impact on the director's independence; (iii) the availability of other sources for comparable products or services; (iv) the terms of the transaction; and (v) whether the transaction is proposed to be on terms more favorable to Colgate than terms that could have been reached with an unrelated third party.

Based on our review of Company transactions, there were no transactions considered to be a related person transaction during 2022.

**Compensation Committee Interlocks and Insider Participation**

During 2022, the following directors were members of the P&O Committee: Dr. Harris, Ms. Nelson and Messrs. Cahill, Polk and Sadove. None of the members of the P&O Committee has been an officer of Colgate and none was an employee of Colgate during 2022, and none had any relationship with us or any of our subsidiaries during 2022 that would be required to be disclosed as a related person transaction. None of our executive officers has served on the board of directors or compensation committee of another company at any time during which an executive officer of such other company served on our Board or the P&O Committee.

**Board Structure and Responsibilities**

**Board Leadership Structure**

The NGCR Committee regularly reviews Board leadership trends and has determined that combining the positions of Chairman and Chief Executive Officer is best for us. **Our current Board leadership structure consists of:**

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Noel R. Wallace**<br> Chairman, President and CEO | &nbsp;&nbsp;**Lorrie M. Norrington**<br> Independent Lead Director |

---

Ms. Norrington has served as the independent Lead Director since March 1, 2023, succeeding Stephen I. Sadove in that role. Ms. Norrington was appointed by the independent directors to serve a three-year term as Lead Director following nomination by the NGCR Committee.

**Our Board structure ensures robust, independent oversight.** Our active and independent Board, with our robust Lead Director role and independent committee chairs and committees, ensures that the Board, and not the Chairman alone, determines the Board's focus. The Chairman is guided by these strong independent leaders and having our CEO serve as Chairman creates a bridge to management that helps provide the Board with the management support it needs. Having a unified leadership structure is particularly beneficial at this time given the dynamic consumer and retail landscape and rapidly evolving environment in which we compete. Based on these considerations, the Board believes that this is the best leadership structure for us at this time and that, operating under this structure, the Board will continue to effectively guide Colgate and represent the interests of our stakeholders. The Board believes its programs for overseeing risk, as described under "Board Role in Risk Oversight," would be effective under a variety of leadership structures and therefore do not materially affect its choice of structure.

**20**

**[**Table of Contents**](#toc)** 

Governance of the Company

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Board Effectiveness**<br> The Board works very effectively together | &nbsp;&nbsp;**Board Committees**<br> The Board's committees are composed solely of, and chaired by, independent directors |
| &nbsp;&nbsp;**Board Independence <br>10** of 11 director nominees<br> ![](cl4117791_def14ax27x1.jpg)<br> are independent | &nbsp;&nbsp;**Executive Sessions**<br> The independent directors meet at each regularly scheduled Board meeting in separate executive sessions without any members of management present, which are chaired by the independent Lead Director |

---

**We have an independent lead director with significant authority and clear duties.** We have long been committed to having an independent lead director, having first established a lead independent director position in 2003. In 2021, the Board enhanced the duties of the Lead Director set forth in our corporate governance guidelines in connection with a review of external practices and in response to stockholder feedback. In many cases, the expanded responsibilities simply formalized activities that the Lead Director already had been performing. The Board further enhanced the Lead Director's duties in January 2023. The role of the Lead Director includes the following responsibilities:

![](cl4117791_def14ax27x2.jpg)

 ● Preside at the executive sessions of the independent directors that occur at every regularly scheduled Board meeting, any other executive session of the independent directors and any other meeting of the Board at which the Chairman is not present ● Serve as interim Chairman if the Chairman is unable to perform their duties ● Establish agendas for the executive sessions of the independent directors in consultation with the other directors ● Call meetings of the independent directors ● Authorize the retention of outside advisors and consultants who report directly to the independent directors on Board issues

 ● After each executive session of the independent directors, provide feedback to and apprise the Chairman/ CEO of the views expressed, suggestions made and decisions reached during the session ● Meet regularly with the Chairman/CEO between meetings, including acting as a sounding board to the CEO and providing strategic counsel ● Serve as primary liaison between the independent directors and the Chairman/CEO and management (although all independent directors are encouraged to communicate freely with the Chairman/CEO and other members of management at any time)

---

| | |
|:---|:---|
| 2023 Proxy Statement | **21** |

---

**[**Table of Contents**](#toc)** 

Governance of the Company

 ● Together with the Chairman, facilitate the efficient and effective functioning and performance of the Board ● Encourage and facilitate active and candid participation of all directors, including by fostering an environment of open dialogue and constructive feedback among the independent directors

 ● Review and approve information to be sent to the Board and provide feedback on quality, quantity and timeliness of information flow from management ● Participate in setting, and ultimately approve, proposed Board meeting agendas ● Solicit the other independent directors for advice on agenda items for Board meetings to help facilitate Board focus on key issues and topics of interest to the Board ● Review and approve meeting schedules to help ensure there is sufficient time for discussion of all agenda items ● Ensure Board meeting agendas provide the Board with the ability to periodically review and provide input on the Company's long-term strategy and to monitor management's execution of the long-term strategy

 ● Together with the P&O Committee, lead the annual performance evaluation of the Chairman/CEO, distinguishing as necessary between performance as Chairman and performance as CEO ● Together with the P&O Committee, lead the CEO succession planning process and participate in talent retention and development of senior management ● Provide guidance on Board succession and development ● In coordination with the NGCR Committee, interview Board candidates

 ● Be available, as deemed appropriate by the Board, for consultation and direct communication with stockholders or other key constituents

 ● Facilitate the effective functioning of Board committees, as appropriate ● Perform such other duties as the Board may specify from time to time

**22**

**[**Table of Contents**](#toc)** 

Governance of the Company

**Committees of the Board of Directors**

The Board has four standing committees: the Audit Committee, the Finance Committee, the NGCR Committee and the P&O Committee. A summary of the responsibilities of these committees is set forth below. The committee charters are available on our website.

Committee Membership

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Director** | **Audit** | **Finance** | **Nominating, <br> Governance<br> and Corporate<br> Responsibility** | **Personnel and<br> Organization** |
| **John P. Bilbrey** Independent | ![](cl4117791_def14ax29x1.jpg) | ![](cl4117791_def14ax29x2.jpg) | ![](cl4117791_def14ax29x3.jpg) | ![](cl4117791_def14ax29x1.jpg) |
| **John T. Cahill** Independent | ![](cl4117791_def14ax29x2.jpg) | ![](cl4117791_def14ax29x1.jpg) | ![](cl4117791_def14ax29x1.jpg) | ![](cl4117791_def14ax29x3.jpg) |
| **Steve Cahillane<sup>1</sup>** Independent | ![](cl4117791_def14ax29x1.jpg) | ![](cl4117791_def14ax29x1.jpg) | ![](cl4117791_def14ax29x1.jpg) | ![](cl4117791_def14ax29x1.jpg) |
| **Lisa M. Edwards** Independent | ![](cl4117791_def14ax29x1.jpg) | ![](cl4117791_def14ax29x3.jpg) | ![](cl4117791_def14ax29x3.jpg) | ![](cl4117791_def14ax29x1.jpg) |
| **C. Martin Harris** Independent | ![](cl4117791_def14ax29x1.jpg) | ![](cl4117791_def14ax29x1.jpg) | ![](cl4117791_def14ax29x3.jpg) | ![](cl4117791_def14ax29x3.jpg) |
| **Martina Hund-Mejean** Independent | ![](cl4117791_def14ax29x3.jpg) | ![](cl4117791_def14ax29x3.jpg) | ![](cl4117791_def14ax29x1.jpg) | ![](cl4117791_def14ax29x1.jpg) |
| **Kimberly A. Nelson** Independent | ![](cl4117791_def14ax29x1.jpg) | ![](cl4117791_def14ax29x1.jpg) | ![](cl4117791_def14ax29x3.jpg) | ![](cl4117791_def14ax29x3.jpg) |
| **Lorrie M. Norrington** Independent, Lead Director | ![](cl4117791_def14ax29x3.jpg) | ![](cl4117791_def14ax29x1.jpg) | ![](cl4117791_def14ax29x2.jpg) | ![](cl4117791_def14ax29x1.jpg) |
| **Michael B. Polk** Independent | ![](cl4117791_def14ax29x1.jpg) | ![](cl4117791_def14ax29x3.jpg) | ![](cl4117791_def14ax29x1.jpg) | ![](cl4117791_def14ax29x2.jpg) |
| **Stephen I. Sadove** Independent | ![](cl4117791_def14ax29x3.jpg) | ![](cl4117791_def14ax29x1.jpg) | ![](cl4117791_def14ax29x1.jpg) | ![](cl4117791_def14ax29x3.jpg) |
| **Noel R. Wallace** Chairman of the Board | ![](cl4117791_def14ax29x1.jpg) | ![](cl4117791_def14ax29x1.jpg) | ![](cl4117791_def14ax29x1.jpg) | ![](cl4117791_def14ax29x1.jpg) |
| **Number of meetings held in 2022** | **7** | **5** | **4** | **5** |

---

---

| | | | |
|:---|:---|:---|:---|
| <sup>1</sup> | Mr. Cahillane, who became a director in 2023, is expected to be appointed to committees in 2023. | &nbsp;&nbsp;&nbsp;&nbsp; **![](cl4117791_def14ax9x4.jpg) Member** | **![](cl4117791_def14ax9x5.jpg) Chair** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Audit Committee** | **Audit Committee** | **Audit Committee** | **Audit Committee** | **Audit Committee** |
| 7 | <br> **MEETINGS** <br> in 2022 | **Members** <br> John T. Cahill (Chair)<br> Martina Hund-Mejean | <br> Lorrie M. Norrington<br> Stephen I. Sadove | **All members of the Audit Committee are independent directors and audit committee financial experts.** |
| **Role and Responsibilities**<br> **●** Assists the Board in its oversight of management's fulfillment of its financial reporting and disclosure responsibilities and its maintenance of an appropriate internal control system.<br> **●** Appoints the independent registered public accounting firm and oversees the activities of our Internal Audit function and the Global Ethics and Compliance function.<br> **●** Assists the Board in its oversight of our enterprise risk management process, including cybersecurity.<br> **●** The Board has determined that all members of the Audit Committee are "independent," as required by the Securities Exchange Act of 1934, as amended (the "Exchange Act"), the listing standards of the NYSE and our own, stricter director independence standards, and are "audit committee financial experts" as that term is defined under SEC rules. | **Role and Responsibilities**<br> **●** Assists the Board in its oversight of management's fulfillment of its financial reporting and disclosure responsibilities and its maintenance of an appropriate internal control system.<br> **●** Appoints the independent registered public accounting firm and oversees the activities of our Internal Audit function and the Global Ethics and Compliance function.<br> **●** Assists the Board in its oversight of our enterprise risk management process, including cybersecurity.<br> **●** The Board has determined that all members of the Audit Committee are "independent," as required by the Securities Exchange Act of 1934, as amended (the "Exchange Act"), the listing standards of the NYSE and our own, stricter director independence standards, and are "audit committee financial experts" as that term is defined under SEC rules. | **Role and Responsibilities**<br> **●** Assists the Board in its oversight of management's fulfillment of its financial reporting and disclosure responsibilities and its maintenance of an appropriate internal control system.<br> **●** Appoints the independent registered public accounting firm and oversees the activities of our Internal Audit function and the Global Ethics and Compliance function.<br> **●** Assists the Board in its oversight of our enterprise risk management process, including cybersecurity.<br> **●** The Board has determined that all members of the Audit Committee are "independent," as required by the Securities Exchange Act of 1934, as amended (the "Exchange Act"), the listing standards of the NYSE and our own, stricter director independence standards, and are "audit committee financial experts" as that term is defined under SEC rules. | **Role and Responsibilities**<br> **●** Assists the Board in its oversight of management's fulfillment of its financial reporting and disclosure responsibilities and its maintenance of an appropriate internal control system.<br> **●** Appoints the independent registered public accounting firm and oversees the activities of our Internal Audit function and the Global Ethics and Compliance function.<br> **●** Assists the Board in its oversight of our enterprise risk management process, including cybersecurity.<br> **●** The Board has determined that all members of the Audit Committee are "independent," as required by the Securities Exchange Act of 1934, as amended (the "Exchange Act"), the listing standards of the NYSE and our own, stricter director independence standards, and are "audit committee financial experts" as that term is defined under SEC rules. | **Role and Responsibilities**<br> **●** Assists the Board in its oversight of management's fulfillment of its financial reporting and disclosure responsibilities and its maintenance of an appropriate internal control system.<br> **●** Appoints the independent registered public accounting firm and oversees the activities of our Internal Audit function and the Global Ethics and Compliance function.<br> **●** Assists the Board in its oversight of our enterprise risk management process, including cybersecurity.<br> **●** The Board has determined that all members of the Audit Committee are "independent," as required by the Securities Exchange Act of 1934, as amended (the "Exchange Act"), the listing standards of the NYSE and our own, stricter director independence standards, and are "audit committee financial experts" as that term is defined under SEC rules. |
| **Finance Committee** | **Finance Committee** | **Finance Committee** | **Finance Committee** | **Finance Committee** |
| 5 | <br> **MEETINGS** <br> in 2022 | **Members** <br> John P. Bilbrey (Chair)<br> Lisa M. Edwards | <br> Martina Hund-Mejean<br> Michael B. Polk | **All members of the Finance Committee are independent directors.** |
| **Role and Responsibilities**<br> **●** Oversees our financial policies and practices, reviews our budgets and makes recommendations to the Board on financial and strategic matters, including major strategic investments, acquisitions, divestitures and other transactions.<br> **●** Oversees our capital structure, our productivity initiatives and our Finance, Treasury, Tax and related functions. | **Role and Responsibilities**<br> **●** Oversees our financial policies and practices, reviews our budgets and makes recommendations to the Board on financial and strategic matters, including major strategic investments, acquisitions, divestitures and other transactions.<br> **●** Oversees our capital structure, our productivity initiatives and our Finance, Treasury, Tax and related functions. | **Role and Responsibilities**<br> **●** Oversees our financial policies and practices, reviews our budgets and makes recommendations to the Board on financial and strategic matters, including major strategic investments, acquisitions, divestitures and other transactions.<br> **●** Oversees our capital structure, our productivity initiatives and our Finance, Treasury, Tax and related functions. | **Role and Responsibilities**<br> **●** Oversees our financial policies and practices, reviews our budgets and makes recommendations to the Board on financial and strategic matters, including major strategic investments, acquisitions, divestitures and other transactions.<br> **●** Oversees our capital structure, our productivity initiatives and our Finance, Treasury, Tax and related functions. | **Role and Responsibilities**<br> **●** Oversees our financial policies and practices, reviews our budgets and makes recommendations to the Board on financial and strategic matters, including major strategic investments, acquisitions, divestitures and other transactions.<br> **●** Oversees our capital structure, our productivity initiatives and our Finance, Treasury, Tax and related functions. |

---

---

| | |
|:---|:---|
| 2023 Proxy Statement | **23** |

---

**[**Table of Contents**](#toc)** 

Governance of the Company

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Nominating, Governance and Corporate Responsibility Committee** | **Nominating, Governance and Corporate Responsibility Committee** | **Nominating, Governance and Corporate Responsibility Committee** | **Nominating, Governance and Corporate Responsibility Committee** | **Nominating, Governance and Corporate Responsibility Committee** |
| 4 | <br> **MEETINGS** <br> in 2022 | **Members** <br> Lorrie M. Norrington (Chair)<br> John P. Bilbrey<br> Lisa M. Edwards | <br> C. Martin Harris<br> Kimberly A. Nelson | **All members of the NGCR Committee are independent directors.** |
| **Role and Responsibilities**<br> **●** Recommends nominees for the Board, develops and implements formal Board self-evaluation procedures and oversees director education.<br> **●** Makes recommendations to the Board regarding Board and committee structure, corporate governance and director compensation.<br> **●** Oversees our sustainability (including climate change), social responsibility and corporate citizenship matters.<br> **Director Compensation**<br> The NGCR Committee's director compensation recommendation process is described in greater detail on page 27. The NGCR Committee does not delegate any of its authority in making director compensation recommendations. | **Role and Responsibilities**<br> **●** Recommends nominees for the Board, develops and implements formal Board self-evaluation procedures and oversees director education.<br> **●** Makes recommendations to the Board regarding Board and committee structure, corporate governance and director compensation.<br> **●** Oversees our sustainability (including climate change), social responsibility and corporate citizenship matters.<br> **Director Compensation**<br> The NGCR Committee's director compensation recommendation process is described in greater detail on page 27. The NGCR Committee does not delegate any of its authority in making director compensation recommendations. | **Role and Responsibilities**<br> **●** Recommends nominees for the Board, develops and implements formal Board self-evaluation procedures and oversees director education.<br> **●** Makes recommendations to the Board regarding Board and committee structure, corporate governance and director compensation.<br> **●** Oversees our sustainability (including climate change), social responsibility and corporate citizenship matters.<br> **Director Compensation**<br> The NGCR Committee's director compensation recommendation process is described in greater detail on page 27. The NGCR Committee does not delegate any of its authority in making director compensation recommendations. | **Role and Responsibilities**<br> **●** Recommends nominees for the Board, develops and implements formal Board self-evaluation procedures and oversees director education.<br> **●** Makes recommendations to the Board regarding Board and committee structure, corporate governance and director compensation.<br> **●** Oversees our sustainability (including climate change), social responsibility and corporate citizenship matters.<br> **Director Compensation**<br> The NGCR Committee's director compensation recommendation process is described in greater detail on page 27. The NGCR Committee does not delegate any of its authority in making director compensation recommendations. | **Role and Responsibilities**<br> **●** Recommends nominees for the Board, develops and implements formal Board self-evaluation procedures and oversees director education.<br> **●** Makes recommendations to the Board regarding Board and committee structure, corporate governance and director compensation.<br> **●** Oversees our sustainability (including climate change), social responsibility and corporate citizenship matters.<br> **Director Compensation**<br> The NGCR Committee's director compensation recommendation process is described in greater detail on page 27. The NGCR Committee does not delegate any of its authority in making director compensation recommendations. |
| **Personnel and Organization Committee** | **Personnel and Organization Committee** | **Personnel and Organization Committee** | **Personnel and Organization Committee** | **Personnel and Organization Committee** |
| 5 | <br> **MEETINGS** <br> in 2022 | **Members** <br> Michael B. Polk (Chair)<br> John T. Cahill<br> C. Martin Harris | <br> Kimberly A. Nelson<br> Stephen I. Sadove | **All members of the P&O Committee are independent directors.** |
| **Role and Responsibilities**<br> **●** Appointed by the Board to act on its behalf with respect to overseeing personnel and organizational matters, including the compensation of our executives, succession planning and our human capital management and DE&I initiatives.<br> **●** Recommends and approves, with the participation and concurrence of the other independent directors of the Board, the performance goals and compensation of the CEO.<br> **●** Reviews and approves the performance goals and compensation recommended by our Global Human Resources function and CEO for our other executive officers in accordance with the compensation programs described in the CD&A.<br> **Compensation Consultants**<br> The P&O Committee periodically retains the services of outside compensation consultants to provide it with objective, third-party advice on the appropriateness of our compensation of the CEO and other senior executives. The P&O Committee has adopted a written policy regarding its selection and use of outside compensation consultants, a copy of which is available on our website. The policy contains the following key principles: <br> **●** The P&O Committee selects all outside compensation consultants that provide advice to it, and directly retains and compensates such consultants, who report to and are solely responsible to the committee.<br> **●** Such consultants may not provide any other services to Colgate unless these are expressly approved by the P&O Committee in advance. The P&O Committee will approve such other services only if it concludes that providing them will not impair the ability of the consultant to provide objective and independent advice to the committee.<br> The P&O Committee has retained Frederic W. Cook & Co., Inc. ("FW Cook") to advise it with respect to the CEO's compensation and such other matters as the P&O Committee may direct. Neither FW Cook nor any of its affiliates provides any other services to Colgate. FW Cook works directly with the P&O Committee and its chair and meets with the P&O Committee in executive session. The P&O Committee conducted an assessment of whether the work of FW Cook during 2022 generated any conflict of interest, within the meaning of SEC rules, and concluded it did not.<br> **Compensation Data**<br> During 2022 and early 2023, our Global Human Resources function purchased executive compensation survey data from Mercer Human Resources Consulting, Aon, WTW and Equilar and used Aon to provide change-in-control and similar calculations for this Proxy Statement. These providers were chosen because they are the leading providers in their fields and have global capabilities and/or consumer products industry experience. | **Role and Responsibilities**<br> **●** Appointed by the Board to act on its behalf with respect to overseeing personnel and organizational matters, including the compensation of our executives, succession planning and our human capital management and DE&I initiatives.<br> **●** Recommends and approves, with the participation and concurrence of the other independent directors of the Board, the performance goals and compensation of the CEO.<br> **●** Reviews and approves the performance goals and compensation recommended by our Global Human Resources function and CEO for our other executive officers in accordance with the compensation programs described in the CD&A.<br> **Compensation Consultants**<br> The P&O Committee periodically retains the services of outside compensation consultants to provide it with objective, third-party advice on the appropriateness of our compensation of the CEO and other senior executives. The P&O Committee has adopted a written policy regarding its selection and use of outside compensation consultants, a copy of which is available on our website. The policy contains the following key principles: <br> **●** The P&O Committee selects all outside compensation consultants that provide advice to it, and directly retains and compensates such consultants, who report to and are solely responsible to the committee.<br> **●** Such consultants may not provide any other services to Colgate unless these are expressly approved by the P&O Committee in advance. The P&O Committee will approve such other services only if it concludes that providing them will not impair the ability of the consultant to provide objective and independent advice to the committee.<br> The P&O Committee has retained Frederic W. Cook & Co., Inc. ("FW Cook") to advise it with respect to the CEO's compensation and such other matters as the P&O Committee may direct. Neither FW Cook nor any of its affiliates provides any other services to Colgate. FW Cook works directly with the P&O Committee and its chair and meets with the P&O Committee in executive session. The P&O Committee conducted an assessment of whether the work of FW Cook during 2022 generated any conflict of interest, within the meaning of SEC rules, and concluded it did not.<br> **Compensation Data**<br> During 2022 and early 2023, our Global Human Resources function purchased executive compensation survey data from Mercer Human Resources Consulting, Aon, WTW and Equilar and used Aon to provide change-in-control and similar calculations for this Proxy Statement. These providers were chosen because they are the leading providers in their fields and have global capabilities and/or consumer products industry experience. | **Role and Responsibilities**<br> **●** Appointed by the Board to act on its behalf with respect to overseeing personnel and organizational matters, including the compensation of our executives, succession planning and our human capital management and DE&I initiatives.<br> **●** Recommends and approves, with the participation and concurrence of the other independent directors of the Board, the performance goals and compensation of the CEO.<br> **●** Reviews and approves the performance goals and compensation recommended by our Global Human Resources function and CEO for our other executive officers in accordance with the compensation programs described in the CD&A.<br> **Compensation Consultants**<br> The P&O Committee periodically retains the services of outside compensation consultants to provide it with objective, third-party advice on the appropriateness of our compensation of the CEO and other senior executives. The P&O Committee has adopted a written policy regarding its selection and use of outside compensation consultants, a copy of which is available on our website. The policy contains the following key principles: <br> **●** The P&O Committee selects all outside compensation consultants that provide advice to it, and directly retains and compensates such consultants, who report to and are solely responsible to the committee.<br> **●** Such consultants may not provide any other services to Colgate unless these are expressly approved by the P&O Committee in advance. The P&O Committee will approve such other services only if it concludes that providing them will not impair the ability of the consultant to provide objective and independent advice to the committee.<br> The P&O Committee has retained Frederic W. Cook & Co., Inc. ("FW Cook") to advise it with respect to the CEO's compensation and such other matters as the P&O Committee may direct. Neither FW Cook nor any of its affiliates provides any other services to Colgate. FW Cook works directly with the P&O Committee and its chair and meets with the P&O Committee in executive session. The P&O Committee conducted an assessment of whether the work of FW Cook during 2022 generated any conflict of interest, within the meaning of SEC rules, and concluded it did not.<br> **Compensation Data**<br> During 2022 and early 2023, our Global Human Resources function purchased executive compensation survey data from Mercer Human Resources Consulting, Aon, WTW and Equilar and used Aon to provide change-in-control and similar calculations for this Proxy Statement. These providers were chosen because they are the leading providers in their fields and have global capabilities and/or consumer products industry experience. | **Role and Responsibilities**<br> **●** Appointed by the Board to act on its behalf with respect to overseeing personnel and organizational matters, including the compensation of our executives, succession planning and our human capital management and DE&I initiatives.<br> **●** Recommends and approves, with the participation and concurrence of the other independent directors of the Board, the performance goals and compensation of the CEO.<br> **●** Reviews and approves the performance goals and compensation recommended by our Global Human Resources function and CEO for our other executive officers in accordance with the compensation programs described in the CD&A.<br> **Compensation Consultants**<br> The P&O Committee periodically retains the services of outside compensation consultants to provide it with objective, third-party advice on the appropriateness of our compensation of the CEO and other senior executives. The P&O Committee has adopted a written policy regarding its selection and use of outside compensation consultants, a copy of which is available on our website. The policy contains the following key principles: <br> **●** The P&O Committee selects all outside compensation consultants that provide advice to it, and directly retains and compensates such consultants, who report to and are solely responsible to the committee.<br> **●** Such consultants may not provide any other services to Colgate unless these are expressly approved by the P&O Committee in advance. The P&O Committee will approve such other services only if it concludes that providing them will not impair the ability of the consultant to provide objective and independent advice to the committee.<br> The P&O Committee has retained Frederic W. Cook & Co., Inc. ("FW Cook") to advise it with respect to the CEO's compensation and such other matters as the P&O Committee may direct. Neither FW Cook nor any of its affiliates provides any other services to Colgate. FW Cook works directly with the P&O Committee and its chair and meets with the P&O Committee in executive session. The P&O Committee conducted an assessment of whether the work of FW Cook during 2022 generated any conflict of interest, within the meaning of SEC rules, and concluded it did not.<br> **Compensation Data**<br> During 2022 and early 2023, our Global Human Resources function purchased executive compensation survey data from Mercer Human Resources Consulting, Aon, WTW and Equilar and used Aon to provide change-in-control and similar calculations for this Proxy Statement. These providers were chosen because they are the leading providers in their fields and have global capabilities and/or consumer products industry experience. | **Role and Responsibilities**<br> **●** Appointed by the Board to act on its behalf with respect to overseeing personnel and organizational matters, including the compensation of our executives, succession planning and our human capital management and DE&I initiatives.<br> **●** Recommends and approves, with the participation and concurrence of the other independent directors of the Board, the performance goals and compensation of the CEO.<br> **●** Reviews and approves the performance goals and compensation recommended by our Global Human Resources function and CEO for our other executive officers in accordance with the compensation programs described in the CD&A.<br> **Compensation Consultants**<br> The P&O Committee periodically retains the services of outside compensation consultants to provide it with objective, third-party advice on the appropriateness of our compensation of the CEO and other senior executives. The P&O Committee has adopted a written policy regarding its selection and use of outside compensation consultants, a copy of which is available on our website. The policy contains the following key principles: <br> **●** The P&O Committee selects all outside compensation consultants that provide advice to it, and directly retains and compensates such consultants, who report to and are solely responsible to the committee.<br> **●** Such consultants may not provide any other services to Colgate unless these are expressly approved by the P&O Committee in advance. The P&O Committee will approve such other services only if it concludes that providing them will not impair the ability of the consultant to provide objective and independent advice to the committee.<br> The P&O Committee has retained Frederic W. Cook & Co., Inc. ("FW Cook") to advise it with respect to the CEO's compensation and such other matters as the P&O Committee may direct. Neither FW Cook nor any of its affiliates provides any other services to Colgate. FW Cook works directly with the P&O Committee and its chair and meets with the P&O Committee in executive session. The P&O Committee conducted an assessment of whether the work of FW Cook during 2022 generated any conflict of interest, within the meaning of SEC rules, and concluded it did not.<br> **Compensation Data**<br> During 2022 and early 2023, our Global Human Resources function purchased executive compensation survey data from Mercer Human Resources Consulting, Aon, WTW and Equilar and used Aon to provide change-in-control and similar calculations for this Proxy Statement. These providers were chosen because they are the leading providers in their fields and have global capabilities and/or consumer products industry experience. |

---

**24**

**[**Table of Contents**](#toc)** 

Governance of the Company

**Board Role in Risk Oversight**

We have established a systematic and thorough risk management process, which is designed to identify, assess, prioritize and mitigate risks that threaten achievement of our strategic and operating objectives.

---

| | | |
|:---|:---|:---|
| **Role of the Board**<br> **●** The Board is responsible for overseeing the risk management process to ensure that it is properly designed, well-functioning and consistent with our overall corporate strategy.<br> **●** The full Board or an appropriate committee thereof oversees the top individual risk areas, with presentations to the Board and relevant committees made throughout the year.<br> **● Key risk areas overseen by the full Board include strategic, supply chain and regulatory risks.** | **Role of the Board**<br> **●** The Board is responsible for overseeing the risk management process to ensure that it is properly designed, well-functioning and consistent with our overall corporate strategy.<br> **●** The full Board or an appropriate committee thereof oversees the top individual risk areas, with presentations to the Board and relevant committees made throughout the year.<br> **● Key risk areas overseen by the full Board include strategic, supply chain and regulatory risks.** | **Role of the Board**<br> **●** The Board is responsible for overseeing the risk management process to ensure that it is properly designed, well-functioning and consistent with our overall corporate strategy.<br> **●** The full Board or an appropriate committee thereof oversees the top individual risk areas, with presentations to the Board and relevant committees made throughout the year.<br> **● Key risk areas overseen by the full Board include strategic, supply chain and regulatory risks.** |
| **Role of the Board**<br> **●** The Board is responsible for overseeing the risk management process to ensure that it is properly designed, well-functioning and consistent with our overall corporate strategy.<br> **●** The full Board or an appropriate committee thereof oversees the top individual risk areas, with presentations to the Board and relevant committees made throughout the year.<br> **● Key risk areas overseen by the full Board include strategic, supply chain and regulatory risks.** | **Role of the Board**<br> **●** The Board is responsible for overseeing the risk management process to ensure that it is properly designed, well-functioning and consistent with our overall corporate strategy.<br> **●** The full Board or an appropriate committee thereof oversees the top individual risk areas, with presentations to the Board and relevant committees made throughout the year.<br> **● Key risk areas overseen by the full Board include strategic, supply chain and regulatory risks.** | **Role of the Board**<br> **●** The Board is responsible for overseeing the risk management process to ensure that it is properly designed, well-functioning and consistent with our overall corporate strategy.<br> **●** The full Board or an appropriate committee thereof oversees the top individual risk areas, with presentations to the Board and relevant committees made throughout the year.<br> **● Key risk areas overseen by the full Board include strategic, supply chain and regulatory risks.** |
| **Key Responsibilities of Board Committees** | **Key Responsibilities of Board Committees** | **Key Responsibilities of Board Committees** |
| **Audit Committee**<br> **●** Responsible for overall risk oversight, though all Board members attend Audit Committee meetings and participate in risk management discussions.<br> **●** Oversees the enterprise risk management process and the implementation of appropriate risk monitoring and management systems.<br> **●** Oversees risks associated with cybersecurity, financial reporting and legal matters (including data privacy, competition law, litigation and ethics and compliance). | &nbsp;&nbsp;**Finance Committee**<br> **●** Oversees risks associated with foreign exchange, natural disasters and commodities.<br>**NGCR Committee**<br> **●** Oversees risks related to sustainability (including climate change and plastic waste), social responsibility and corporate governance practices. | &nbsp;&nbsp;**P&O Committee**<br> **●** Oversees risks related to succession planning.<br> **●** Oversees an annual risk assessment of our compensation policies and practices, which is conducted by our Global Human Resources executives and our Chief Financial Officer and reviewed by the Board's independent compensation consultant and focuses primarily on the design of the incentive compensation programs and the degree to which such programs appropriately balance enterprise risk and compensation. |
| **Role of Management**<br> **●** The responsibility for the day-to-day management of risk lies with Colgate's management. Each year, our Enterprise Risk Management Committee, which is comprised of a cross-functional group of our most senior executives, identifies what it believes are the top individual risks facing Colgate, as well as emerging risks, and assigns risk owners. These risks are then reviewed with the Board on an annual basis.<br> **●** The Enterprise Risk Management Committee meets at least quarterly to review the prioritization of identified risks.<br> **●** Our chief risk officer (the Chief Financial Officer) and other members of senior management responsible for the day-to-day management of the top individual risk areas present directly to the Board and its committees regularly throughout the year. | **Role of Management**<br> **●** The responsibility for the day-to-day management of risk lies with Colgate's management. Each year, our Enterprise Risk Management Committee, which is comprised of a cross-functional group of our most senior executives, identifies what it believes are the top individual risks facing Colgate, as well as emerging risks, and assigns risk owners. These risks are then reviewed with the Board on an annual basis.<br> **●** The Enterprise Risk Management Committee meets at least quarterly to review the prioritization of identified risks.<br> **●** Our chief risk officer (the Chief Financial Officer) and other members of senior management responsible for the day-to-day management of the top individual risk areas present directly to the Board and its committees regularly throughout the year. | **Role of Management**<br> **●** The responsibility for the day-to-day management of risk lies with Colgate's management. Each year, our Enterprise Risk Management Committee, which is comprised of a cross-functional group of our most senior executives, identifies what it believes are the top individual risks facing Colgate, as well as emerging risks, and assigns risk owners. These risks are then reviewed with the Board on an annual basis.<br> **●** The Enterprise Risk Management Committee meets at least quarterly to review the prioritization of identified risks.<br> **●** Our chief risk officer (the Chief Financial Officer) and other members of senior management responsible for the day-to-day management of the top individual risk areas present directly to the Board and its committees regularly throughout the year. |
| **Role of Management**<br> **●** The responsibility for the day-to-day management of risk lies with Colgate's management. Each year, our Enterprise Risk Management Committee, which is comprised of a cross-functional group of our most senior executives, identifies what it believes are the top individual risks facing Colgate, as well as emerging risks, and assigns risk owners. These risks are then reviewed with the Board on an annual basis.<br> **●** The Enterprise Risk Management Committee meets at least quarterly to review the prioritization of identified risks.<br> **●** Our chief risk officer (the Chief Financial Officer) and other members of senior management responsible for the day-to-day management of the top individual risk areas present directly to the Board and its committees regularly throughout the year. | **Role of Management**<br> **●** The responsibility for the day-to-day management of risk lies with Colgate's management. Each year, our Enterprise Risk Management Committee, which is comprised of a cross-functional group of our most senior executives, identifies what it believes are the top individual risks facing Colgate, as well as emerging risks, and assigns risk owners. These risks are then reviewed with the Board on an annual basis.<br> **●** The Enterprise Risk Management Committee meets at least quarterly to review the prioritization of identified risks.<br> **●** Our chief risk officer (the Chief Financial Officer) and other members of senior management responsible for the day-to-day management of the top individual risk areas present directly to the Board and its committees regularly throughout the year. | **Role of Management**<br> **●** The responsibility for the day-to-day management of risk lies with Colgate's management. Each year, our Enterprise Risk Management Committee, which is comprised of a cross-functional group of our most senior executives, identifies what it believes are the top individual risks facing Colgate, as well as emerging risks, and assigns risk owners. These risks are then reviewed with the Board on an annual basis.<br> **●** The Enterprise Risk Management Committee meets at least quarterly to review the prioritization of identified risks.<br> **●** Our chief risk officer (the Chief Financial Officer) and other members of senior management responsible for the day-to-day management of the top individual risk areas present directly to the Board and its committees regularly throughout the year. |

---

**Stockholder Engagement**

We believe it is important to engage with investors to better understand their priorities and therefore have developed a robust annual stockholder engagement program. Each year, we engage with a significant and diverse group of our stockholders on topics important to our stockholders as well as the Company. Such topics may include our business strategy and initiatives, executive compensation, Board composition and governance practices, as well as environmental and social topics such as human capital management, DE&I and sustainability. To the extent we receive stockholder proposals in connection with a given year's annual meeting of stockholders, we also typically include a discussion of those proposal topics in our engagements for the following year. In addition, our Investor Relations team, together with members of senior management, regularly meet with investors and participate in investor conferences and presentations.

Feedback received through management's discussions with investors, as well as engagement with proxy advisory firms that represent the interests of a wide array of stockholders, is reported to and discussed with the Board. Our Lead Director is also available, as deemed appropriate by the Board, for consultation and direct communication with stockholders, and all stockholders may contact any of our directors using the process described below under "Communications to the Board of Directors."

---

| | |
|:---|:---|
| 2023 Proxy Statement | **25** |

---

**[**Table of Contents**](#toc)** 

Governance of the Company

**Recent Engagement Highlights**

Prior to our 2022 Annual Meeting of Stockholders, representatives of management and the Board engaged with certain stockholders to better understand their views and policies relating to the stockholder proposal we received for the 2022 Annual Meeting of Stockholders on stockholder ratification of termination pay. Following that engagement, in April 2022, the Board adopted a policy that we will not execute any new severance agreement with an executive officer that provides for cash severance benefits exceeding 2.99 times the sum of the executive officer's base salary plus target annual bonus opportunity, without seeking stockholder ratification of the agreement.

In addition, since our 2022 Annual Meeting of Stockholders, representatives of our Global Human Resources, Investor Relations, Global Legal and Sustainability functions have reached out to a variety of institutional investors, including index, actively managed and public pension funds, based in and outside the United States, representing approximately 40% of our Common Stock. Discussions with those investors centered around our business strategy and our ESG focus, including our sustainability priorities and progress, driving social impact, DE&I, corporate governance and compensation. We also discussed with some of these investors their views regarding the stockholder ratification of termination pay stockholder proposal discussed in the prior paragraph and found that they appreciated that we were proactive and responsive to feedback.

**Communications to the Board of Directors**

Stockholders and other interested parties are encouraged to communicate directly with our independent directors by sending an email to directors@colpal.com or by writing to Directors, c/o Office of the Chief Legal Officer, Colgate-Palmolive Company, 300 Park Avenue, 11th Floor, New York, New York 10022. Stockholders and other interested parties may also communicate with individual independent directors and committee chairs by writing to them at the above mailing address. Such communications are handled in accordance with the procedures described on our website.

Significant concerns and questions relating to accounting, internal accounting controls or auditing matters are promptly brought to the attention of the Audit Committee chair and handled in accordance with the procedures established by the Audit Committee. Under these procedures, our Global Ethics and Compliance function, in conjunction with our Internal Audit and Corporate Legal departments, addresses these concerns in accordance with the directions of the Audit Committee chair. The Audit Committee chair approves recommendations regarding the handling of each matter, oversees any investigations and approves the disposition of each matter. The Audit Committee chair may, in their discretion, engage outside counsel and other independent advisors. The Audit Committee receives quarterly updates regarding other concerns or questions relating to accounting, internal accounting controls or auditing matters.

Concerns relating to accounting, internal accounting controls or auditing matters may also be reported to the Global Ethics and Compliance function by telephone and email as follows: 24-hour EthicsLine: (800) 778-6080 (toll-free from the United States, Canada and Puerto Rico) or (212) 310-2330 (collect from all other locations) and email: ethics@colpal.com.

We strictly prohibit retaliation against any individual who reports in good faith to the Company or the directors information concerning potential violations, or who participates in good faith in any investigation or proceeding by the Company or a government agency. Concerns may be submitted to the Company or the directors on an anonymous basis through their postal address or through the 24-hour EthicsLine numbers maintained by the Global Ethics and Compliance function. If requested, we will keep information submitted confidential, subject to the need to conduct an effective investigation and take appropriate action or as otherwise required by applicable law.

**26**

**[**Table of Contents**](#toc)** 

Governance of the Company

**Compensation of Directors**

Compensation for the non-employee directors is set by the Board at the recommendation of the NGCR Committee. The NGCR Committee seeks to set director compensation levels to ensure non-employee directors are paid competitively for their time commitment and responsibilities. A market competitive compensation package is important because it enables us to attract and retain highly qualified directors who are critical to our long-term success. The substantial majority of the compensation paid to the non-employee directors is in the form of fixed-value annual grants of Colgate equity pursuant to the stockholder-approved Colgate-Palmolive Company 2019 Incentive Compensation Plan (the "2019 Plan"), which helps foster commonality of interest between our directors and our stockholders.

In making recommendations to the Board regarding director compensation, the NGCR Committee annually reviews information provided by the Global Human Resources function regarding recent trends in director compensation and comparison data regarding peer company practices in the compensation comparison group discussed in the CD&A. The Global Human Resources function purchases subscriptions from the National Association of Corporate Directors, Aon and Equilar, from which they receive such comparison data. Based on its review of the information provided by the Global Human Resources function, the NGCR Committee determines whether to recommend to the Board any changes in the director compensation program. Based on the 2022 review, the NGCR Committee and the Board determined not to make any changes to the director compensation program.

In 2022, non-employee director compensation consisted of the following, as applicable:

---

| | |
|:---|:---|
| **Annual Share Grant** | Shares of Common Stock equal in value to $180,000 |
| **Annual Retainer** | $75000 |
| **Stock Option Grant** | Options to purchase shares of Common Stock equal in value to $45,000 |
| **Lead Director Retainer** | $20000 |
| **Committee Chair Retainers** | $10,000 for the chair of each committee |
| **Expenses and Benefits** | Reimbursement of travel and related expenses incurred in attending meetings; life and travel/accident insurance; and Charitable Matching Gifts Program available to U.S. employees as described below |

---

Mr. Wallace received no compensation for serving on the Board in 2022.

**Deferral of Compensation**

Under the 2019 Plan, directors may elect to defer all or a part of their annual stock compensation. Deferred stock compensation is credited to a stock unit account, the value of which reflects changes in the market price of our Common Stock and dividends paid. No interest is paid on deferred balances. The directors also may elect to receive cash in lieu of up to 25% of the shares of our Common Stock granted and not deferred under the 2019 Plan.

Directors may elect to defer all or a part of their cash compensation under the Colgate-Palmolive Company Restated and Amended Deferred Compensation Plan for Non-Employee Directors. As with the 2019 Plan, deferred fees are credited to a stock unit account, the value of which reflects changes in the market price of our Common Stock and dividends paid. No interest is paid on deferred balances. Under both plans, distributions are made in shares of our Common Stock in annual installments or by lump sum in accordance with the distribution election made by the director.

The tables included below under "Director Compensation" and in "Stock Ownership—Stock Ownership of Directors and Executive Officers" include information concerning directors who have elected to defer their fees.

**Director Compensation Governance Features**

Under our stock ownership guidelines, independent directors are required to own stock equal in value to at least five times their annual share grant. Directors have five years from the date of their initial election to achieve required ownership levels. Compliance with these guidelines is evaluated on an annual basis. All of the directors are in compliance with this policy. For more information on director stock ownership, see "Stock Ownership—Stock Ownership of Directors and Executive Officers." Directors are also prohibited from engaging in transactions to hedge against declines in the value of our stock and from pledging Colgate stock, as further described in the CD&A. During 2022, all of the directors were in compliance with both the anti-hedging and anti-pledging policies.

---

| | |
|:---|:---|
| 2023 Proxy Statement | **27** |

---

**[**Table of Contents**](#toc)** 

Governance of the Company

**Director Compensation**

The following table shows the compensation earned by each non-employee director in 2022.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Name** | **Fees Earned or<br> Paid in Cash<br> ($)** **<sup>(1)</sup>** | **Stock<br> Awards<br> ($)** **<sup>(2)</sup>** | **Option<br> Awards<br> ($)** | **<sup>(3)</sup>** | **All Other<br> Compensation<br> ($)** | **<sup>(4)</sup>** | **Total<br> ($)** |
| **(a)** | **(b)** | **(c)** | **(d)** |  | **(g)** |  | **(h)** |
| John P. Bilbrey | 85000<sup>(5)</sup> | 179961<sup>(5)</sup> | 44988 |  | 8715 |  | 318664 |
| John T. Cahill | 85000 | 179961 | 44988 |  | 450 |  | 310399 |
| Lisa M. Edwards | 120000<sup>(6)</sup> | 134990<sup>(6)</sup> | 44988 |  | 260 |  | 300238 |
| C. Martin Harris | 75000 | 179961<sup>(5)</sup> | 44988 |  | 715 |  | 300664 |
| Martina Hund-Mejean | 75000 | 179961<sup>(5)</sup> | 44988 |  | 8450 |  | 308399 |
| Kimberly A. Nelson | 75000 | 179961<sup>(5)</sup> | 44988 |  | 8347 |  | 308296 |
| Lorrie M. Norrington | 85000<sup>(5)</sup> | 179961<sup>(5)</sup> | 44988 |  | 450 |  | 310399 |
| Michael B. Polk | 85000 | 179961 | 44988 |  | 8450 |  | 318399 |
| Stephen I. Sadove | 95000 | 179961 | 44988 |  | 9056 |  | 329005 |

---

**NOTES TO THE DIRECTOR COMPENSATION TABLE**

<sup>(1)</sup> Consists of an annual retainer and lead director and committee chair retainers, as described above.

<sup>(2)</sup> This column reflects the aggregate grant date fair value of stock awards granted to each non-employee director in 2022. The grant date fair value of stock awards granted to each non-employee director in 2022 was $77.67 per share, based on the fair market value of our Common Stock on the date of grant.

<sup>(3)</sup> This column reflects the aggregate grant date fair value of stock option awards granted to each non-employee director in 2022. The key terms of such stock options are as follows: (i) the exercise price is equal to the closing price of our Common Stock on the date of grant; (ii) the term is eight years; and (iii) they vest in equal annual installments over three years.

The grant date fair value of stock options granted to each non-employee director in 2022 was $14.41 per option. The estimated value of options is calculated using the Black-Scholes-Merton option pricing model (the "Black-Scholes model"). For a description of the assumptions used to calculate the amounts shown in this column, see Note 8 ("Capital Stock and Stock-Based Compensation Plans") to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022.

The aggregate number of stock options outstanding for each non-employee director as of December 31, 2022 was as follows: Mr. Bilbrey—27,090; Mr. Cahill—27,090; Ms. Edwards—14,363; Dr. Harris—23,521; Ms. Hund-Mejean—10,195; Ms. Nelson—6,131; Ms. Norrington—27,090; Mr. Polk—27,090; and Mr. Sadove—27,090.

<sup>(4)</sup> The amounts shown consist of (i) the value of Company-paid life insurance premiums and (ii) matching charitable donations contributed by Colgate in the director's name pursuant to the Charitable Matching Gifts Program, which is available to all directors and to U.S. employees who are actively employed on a full-time basis. Under the Charitable Matching Gifts Program, we match an individual's contributions of up to $8,000 per year that are made to eligible institutions on a 1:1 basis. We do not match certain gifts, such as contributions to organizations that are not tax-exempt, dues to alumni or similar groups, tuition payments, contributions to school funds or associations that are not used exclusively to support educational purposes of the institution and any gift for which the donor receives a substantial benefit.

<sup>(5)</sup> Mr. Bilbrey and Ms. Norrington each elected to defer the cash retainer they earned in 2022 and Mr. Bilbrey, Dr. Harris and Mses. Hund-Mejean, Nelson and Norrington each elected to defer the share grant they earned in 2022 pursuant to the procedure described above.

<sup>(6)</sup> Ms. Edwards elected to receive 25% of her annual share grant in cash in 2022 to satisfy tax obligations pursuant to the procedure described above.

**28**

**[**Table of Contents**](#toc)** 

Executive Compensation

**Compensation Discussion and Analysis**

**Executive Summary**

**Pay for Performance Overview**

The key principles underlying our compensation philosophy are aligning pay and performance, driving strong business results and our strategic plan, focusing on long-term shareholder return, motivating and retaining critical talent and reflecting external market and competitive practices. Annual and long-term incentive award payments vary based on our business performance, and long-term incentive award payments and the value of equity awards also vary based on the performance of our common stock ("Common Stock"). Reflecting these principles, target direct compensation (salary and target annual and long-term incentives) for the executive officers listed in the Summary Compensation Table of this Proxy Statement (the "Named Officers") is designed to be weighted more heavily towards performance-based compensation than fixed compensation. For 2022, 89% of the target direct compensation of our Chairman, President and Chief Executive Officer ("CEO") and 75% of the average target direct compensation of our other Named Officers was performance-based, as the following charts demonstrate.

**TARGET PERFORMANCE-BASED COMPENSATION**<br>

---

| | |
|:---|:---|
| **CEO** | **AVERAGE NAMED OFFICER (EXCLUDING CEO)** |

---

![](cl4117791_def14ax35x1.jpg)

**2022 Performance at a Glance**

We continued to face a difficult operating environment in 2022. Global macroeconomic, geopolitical and market conditions attributable to the war in Ukraine, COVID-19, inflation, rising interest rates and foreign exchange headwinds caused significant challenges and we continued to experience significant increases in raw material and logistics costs. Despite these challenges, we remained focused on serving the needs of our customers and consumers by delivering products that make people's and their pets' lives healthier and more enjoyable and on sustaining growth through science-led, core and premium innovation, revenue growth management, digital transformation and investing behind our strategic priorities.

The strong resilience, dedication, creativity and agility of our people and our ability to execute on our business strategy in the difficult environment are positively reflected in our 2022 results. We delivered strong organic sales growth (a non-GAAP financial measure, defined as net sales excluding foreign exchange, acquisitions and divestments) and solid performance on adjusted earnings per share (a non-GAAP financial measure, referred to herein as "Base Business Earnings Per Share") in 2022 and Free Cash Flow Productivity (a non-GAAP financial measure, defined below) over a three-year period, as demonstrated below.

**OPERATING RESULTS<sup>1</sup>**<br>

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**2022 ORGANIC SALES GROWTH** | &nbsp;&nbsp;**2022 BASE BUSINESS**<br> **EARNINGS PER SHARE** | &nbsp;&nbsp;**2020-2022 FREE CASH**<br> **FLOW PRODUCTIVITY<sup>2</sup>** |
| **7.0%** | **$2.97** | **94.7%** |
| &nbsp;&nbsp;vs. 2022 Target of 5.0% | &nbsp;&nbsp;vs. 2022 Target Range of $2.92-$3.02 | &nbsp;&nbsp;vs. 2020-2022 Target of 90% |

---

<sup>1</sup> Please see Annex A for reconciliations of organic sales growth to net sales growth calculated in accordance with GAAP, of Base Business Earnings Per Share to Diluted earnings per share calculated in accordance with GAAP and of free cash flow before dividends to Net cash provided by operations calculated in accordance with GAAP.

<sup>2</sup> "Free Cash Flow Productivity" is defined as free cash flow before dividends as a percentage of net income including non-controlling interests as reported in our audited financial results, which for 2020-2022 was 109.4%. The P&O Committee (as defined below) reduced our 2020-2022 Free Cash Flow Productivity results for compensation purposes to 94.7%, as described on page 42.

Given our focus on growth, we were especially pleased with our 2022 organic sales growth, which was above our target long-term range. Our organic sales growth was broad based, as we delivered organic sales growth across all four of our categories and in nearly every division. Our Base Business Earnings Per Share for 2022 was in line with our publicly

---

| | |
|:---|:---|
| 2023 Proxy Statement | **29** |

---

**[**Table of Contents**](#toc)** 

Executive Compensation

announced goal. That goal represented a decline relative to 2021, due to the significant raw material and logistics cost inflation and foreign exchange headwinds we faced.

Our stock price was impacted by the difficult market conditions in 2022, along with the cost and foreign exchange headwinds mentioned above, which created a significant impact on the cumulative total shareholder returns on our Common Stock for the one-year, five-year and ten-year periods ended December 31, 2022. Despite these challenging conditions, we maintained our strong balance sheet and the Board of Directors authorized an increase in the quarterly cash dividend, effective in the second quarter of 2022. This was our 60th consecutive year of dividend increases and our 128th consecutive year paying a dividend, as part of our commitment to, and strong record of, returning value to shareholders.

**RETURN TO SHAREHOLDERS**<br>

![](cl4117791_def14ax36x1.jpg)

Going forward, we remain focused on delivering long-term shareholder return and building long-term business success through excellence in corporate governance and the design and implementation of our key strategic business priorities—driving organic sales growth and long-term profitable growth through science-led, core and premium innovation, pursuing higher-growth adjacent categories and segments, expanding in faster-growing channels and markets and delivering margin expansion through operating leverage and efficiency. We also continue to seek to maximize the impact of our environmental, social and governance ("ESG") programs and lead in the development of human capital, including our sustainability and social impact and diversity, equity and inclusion ("DE&I") strategies. We intend to continue our practice of tying compensation to achievement of both annual and long-term business goals to help further those priorities.

This Compensation Discussion and Analysis ("CD&A") discusses the compensation of the Named Officers, namely:

---

| | | |
|:---|:---|:---|
| **Noel R. Wallace**<br> Chairman, President and Chief Executive Officer | **Stanley J. Sutula III**<br> Chief Financial Officer | **Jennifer M. Daniels**<br> Chief Legal Officer and Secretary |
| **Prabha Parameswaran**<br> Group President, Growth and Strategy | **Panagiotis Tsourapas**<br> Group President, Europe and Developing Markets |  |

---

The Personnel and Organization Committee of the Board (the "P&O Committee") annually analyzes the relationship between pay and performance for our Named Officers. The analysis includes a review of the relationship between the compensation paid to our CEO and our other Named Officers and Company performance relative to the Comparison Group (as defined below) over the past three years. The review shows a strong link between Company pay and Company performance over time in terms of various key operating measures. During the three-year period from 2020 to 2022, our adjusted net income growth, adjusted earnings-per-share growth, total shareholder return, net sales growth, organic sales growth, return on sales, operating cash flow as a percentage of sales, return on invested capital and CEO total direct compensation relative to the Comparison Group are as shown to the right.

![](cl4117791_def14ax36x2.jpg)<br> <sup>\*</sup> Adjusted net income growth, adjusted earnings-per-share growth and organic sales growth reflect the adjustments described in Annex A to Colgate's net income, earnings per share and net sales growth, respectively, and comparable adjustments to peer companies' net income, earnings per share and net sales growth. See page 32 for an explanation regarding the components of "total direct compensation" or "TDC."<br>

**30**

**[**Table of Contents**](#toc)** 

Executive Compensation

**2022 Compensation Program Highlights**

**New ESG Component Added to Strategic Measure in 2022 Annual Incentive Program**

Starting in 2021, the P&O Committee determined that, in addition to financial goals, the annual incentive program should include a performance measure based on strategic initiatives, representing 20% of the annual bonus opportunity. For 2021, the strategic measure was tied to our enterprise-wide innovation and digital transformation progress in recognition of the critical importance of innovation and digital transformation to our growth strategy and continuing success and to further align compensation with our strategic priorities. In 2022, the P&O Committee determined that, in addition to performance measures tied to our enterprise-wide innovation and digital transformation progress, the strategic measure should also include performance measures tied to our sustainability and DE&I progress in recognition of the importance of ESG matters to our continuing success. See "Compensation Components—Annual Incentives" below for further detail regarding how the P&O Committee measured achievement against the strategic measure. The remaining 80% of the annual bonus opportunity was determined by our achievement against our organic sales growth and earnings-per-share goals.

**Performance Measures**

The P&O Committee selected the following performance measures in 2022 to assess the performance of the Named Officers in 2022 and in the three-year performance period commencing in 2022:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Pay <br>Component** | **CEO 2022 Target<br> Compensation Mix** | **Other Named Officer<br> Average 2022 Target<br> Compensation Mix** | **Performance Measures** | **Performance <br>Period** | **Form of <br>Payment** |
| **Annual<br>incentive** | ![](cl4117791_def14ax37x1.jpg) | ![](cl4117791_def14ax37x2.jpg) | **•** Base Business Earnings Per Share<br> **•** Organic sales growth<br> **•** Strategic initiatives | One year <br>(2022) | Cash bonus |
| **Long-term<br>incentive\*** | ![](cl4117791_def14ax37x3.jpg) | ![](cl4117791_def14ax37x4.jpg) | **•** Organic sales growth relative to the Comparison Group<br> **•** Base Business Net Income (defined below) growth relative to the Comparison Group<br> **•** Free Cash Flow Productivity<br> **•** Total shareholder return relative to the Comparison Group (modifier) | Three years<br>(2022-2024)  | PBRSUs (vesting in 2025, if earned) |

---

<sup>\*</sup> Percentages shown include the target value of the performance-based restricted stock unit ("PBRSU") awards for the 2022-2024 performance cycle pursuant to our Growth Performance Plan and the target value of stock option awards based on salary grade guidelines.

The performance measures in the annual and long-term incentive programs were selected to drive our growth strategy and focus on sustainable value creation.

**Annual Incentive Awards**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Measure** | **Target** | **2022 Results** | **Outcome** | **Comparison vs. Comparison Group\*** |
| **Base Business Earnings** **Per Share** | $2.92–$3.02 | $2.97 | 134.7% of the assigned award opportunities for each of the Named Officers. | **•** Annual bonuses for the Named Officers (other than Mr. Wallace) were paid at approximately the 55th to the 80th percentile of annual bonuses for similar jobs in the Comparison Group.<br> **•** Mr. Wallace's award represented a payout at approximately the 55th percentile of annual bonuses for CEOs in the Comparison Group. |
| **Organic** **Sales Growth** | 5.0% | 7.0% | 134.7% of the assigned award opportunities for each of the Named Officers. | **•** Annual bonuses for the Named Officers (other than Mr. Wallace) were paid at approximately the 55th to the 80th percentile of annual bonuses for similar jobs in the Comparison Group.<br> **•** Mr. Wallace's award represented a payout at approximately the 55th percentile of annual bonuses for CEOs in the Comparison Group. |
| **Strategic Initiatives** | See below description | See below description | 134.7% of the assigned award opportunities for each of the Named Officers. | **•** Annual bonuses for the Named Officers (other than Mr. Wallace) were paid at approximately the 55th to the 80th percentile of annual bonuses for similar jobs in the Comparison Group.<br> **•** Mr. Wallace's award represented a payout at approximately the 55th percentile of annual bonuses for CEOs in the Comparison Group. |

---

<sup>\*</sup> <sup></sup>Based on the most recent data available.

In determining the extent to which the strategic measure was achieved, the P&O Committee considered achievement against our enterprise-wide innovation, digital transformation and ESG goals. Following this evaluation, the P&O Committee determined that the strategic measure should pay out at 140% of target, based on our strong performance against those goals as described under "Compensation Components—Annual Incentives" below.

---

| | |
|:---|:---|
| 2023 Proxy Statement | **31** |

---

**[**Table of Contents**](#toc)** 

Executive Compensation

**Long-Term Incentive Awards**

**2022-2024 Long-Term Incentive Awards Performance Cycle (Growth Performance Plan)**

---

| | | |
|:---|:---|:---|
| **Measure** | **Target** | **Status** |
| **Relative Organic** **Sales Growth** | Performance at the 50th percentile of the Comparison Group  | **•**If PBRSUs were to vest solely based on performance achieved through December 31, 2022, payout would be between the threshold and target levels. Performance over the remaining two years of the performance period will determine the actual number of shares earned, if any.<br> **•**PBRSUs will vest, if earned, in 2025. |
| **Relative Base Business Net** **Income Growth** | Performance at the 50th percentile of the Comparison Group | **•**If PBRSUs were to vest solely based on performance achieved through December 31, 2022, payout would be between the threshold and target levels. Performance over the remaining two years of the performance period will determine the actual number of shares earned, if any.<br> **•**PBRSUs will vest, if earned, in 2025. |
| **Free Cash** **Flow Productivity** | 95% | **•**If PBRSUs were to vest solely based on performance achieved through December 31, 2022, payout would be between the threshold and target levels. Performance over the remaining two years of the performance period will determine the actual number of shares earned, if any.<br> **•**PBRSUs will vest, if earned, in 2025. |
| **Total Shareholder** **Return Modifier** | The number of PBRSUs may increase or decrease by up to 25% based on our total shareholder return relative to the Comparison Group | **•**If PBRSUs were to vest solely based on performance achieved through December 31, 2022, payout would be between the threshold and target levels. Performance over the remaining two years of the performance period will determine the actual number of shares earned, if any.<br> **•**PBRSUs will vest, if earned, in 2025. |

---

**Stock Options**

In 2022, the P&O Committee approved annual stock option awards for the Named Officers. These awards are made based on guidelines set for each salary grade, which are established annually based on a review of market data and share usage.

---

| | |
|:---|:---|
| **CEO Total Direct Compensation\***<br> ![](cl4117791_def14ax38x1.jpg) | ![](cl4117791_def14ax38x2.jpg)&nbsp;&nbsp;&nbsp;&nbsp;9% *vs. 2021*<br> *Primarily due to increases in his annual cash bonus opportunity, stock option award and target PBRSU award, reflecting the P&O Committee's intent to maintain his target direct compensation near the median relative to the Comparison Group as described on page 35.* |

---

<sup>\*</sup> For purposes of this CD&A, Mr. Wallace's total direct compensation for each year includes his year-end salary and the amounts shown in the Summary Compensation Table in the columns "Option Awards," "Non-Equity Incentive Plan Compensation" and "All Other Compensation" and the PBRSU award granted in such year, consistent with the way the P&O Committee analyzes his compensation. The actual value of the payout from his PBRSU awards for the Growth Performance Plan's 2021-2023 and 2022-2024 performance cycles granted in 2021 and 2022, respectively, will depend upon achievement of the performance goals as well as the price of our Common Stock at the time of vesting in 2024 and 2025, respectively.

**Additional Compensation Program Highlights**

Highlighted below are compensation practices we have implemented to drive Company performance and to align the interests of our executives with our stockholders.

---

| | |
|:---|:---|
| ![](cl4117791_def14ax38x3.jpg)<br> **What We Do** | <br> **What We Don't Do** |
| ![](cl4117791_def14ax88x3.jpg) **Pay for Performance** **.** Our executive compensation is tied to performance with clearly articulated financial and other strategic goals. Each year, the P&O Committee conducts a comprehensive review of executive compensation prior to making compensation decisions to ensure pay and performance are aligned.<br> ![](cl4117791_def14ax88x3.jpg) **Competitive Compensation Programs.** We regularly benchmark our compensation programs and design the programs to compensate employees at approximately the median level, with above-median payouts for superior performance and below-median payouts for performance below expectations.<br> ![](cl4117791_def14ax88x3.jpg) **Robust Stock Ownership Guidelines.** We maintain stringent stock ownership guidelines for members of senior management, requiring the CEO to own Colgate stock equal in value to eight times his annual salary and the other Named Officers to hold Colgate stock in amounts equal to four times their annual salaries.<br> ![](cl4117791_def14ax88x3.jpg) **Ability to "Claw Back" Compensation.** Our clawback policy permits recoupment of cash and equity-based incentive awards made to an officer or other executive subject to the policy if the financial results on which such awards were based are subsequently restated or the officer or executive engaged in conduct that violates our Code of Conduct.<br> ![](cl4117791_def14ax88x3.jpg) **Perquisites are Insignificant.** Executive perquisites are limited to the use of a Company car and driver for the CEO. | × **Incentives Do Not Encourage Excessive Risk-Taking.** Our incentive programs do not contain features that may encourage excessive risk-taking, such as multi-year guaranteed bonuses or high pay opportunities relative to peer companies. In addition, we utilize multiple performance measures for annual and long-term incentives.<br> × **No Executive Officer Employment Agreements.** We do not have employment agreements with our Named Officers, meaning they are not entitled to minimum base salaries, guaranteed bonuses or guaranteed levels of equity or other incentives.<br> × **No Hedging or Pledging of Colgate Stock is Permitted.** Our hedging policy prohibits our directors, officers and employees who receive stock-based compensation from engaging in transactions that hedge against declines in the value of Colgate stock, strengthening the alignment between stockholders and directors and executives. Further, our pledging policy prohibits our directors and officers from pledging Colgate stock to prevent forced sales of Colgate stock by our directors and officers.<br> × **No Backdating, Springloading or Repricing of Stock Options.** We make annual equity awards at the same predetermined times each year. Equity awards, including stock options, are never backdated or issued with below-market exercise prices. Repricing of stock options without stockholder approval is expressly prohibited.<br> × **No Single Trigger Severance Payments Under Our Severance Plan.** Severance payments under the Colgate-Palmolive Company Executive Severance Plan (the "Severance Plan") are payable only if an executive's employment is terminated or an executive terminates their employment as a result of an "adverse change in conditions of employment" (as defined in the Severance Plan) following a change in control.<br> × **No Tax Gross-Ups on Perquisites or Severance.** Perquisites are limited to the use of a Company car and driver for the CEO, as previously noted, and any personal income taxes due as a result of that perquisite are the CEO's responsibility. In addition, the Severance Plan does not provide for tax gross-ups on severance payments. |

---

**32**

**[**Table of Contents**](#toc)** 

Executive Compensation

**Compensation Philosophy**

We believe that people are the most important driver of our business success and, accordingly, view compensation as an important tool to motivate leaders at all levels of the organization. Outlined below are the principles underlying our executive compensation programs and examples of specific program features used to implement those principles.

---

| | | | |
|:---|:---|:---|:---|
| | **Base<br>salary** | **Annual<br>incentives** | **Long-term<br>incentives** |
| **ALIGN PAY** **AND PERFORMANCE** |  |  |  |
| Multiple performance measures are used to ensure a focus on overall Company performance. |  | ![](cl4117791_def14ax39x2.jpg) | ![](cl4117791_def14ax39x3.jpg) |
| Payouts vary based upon the degree to which performance measures are achieved. |  | ![](cl4117791_def14ax39x2.jpg) | ![](cl4117791_def14ax39x3.jpg) |
| We do not guarantee minimum base salaries, bonuses or levels of equity or other incentives for our Named Officers, through employment agreements or otherwise. | ![](cl4117791_def14ax39x1.jpg) | ![](cl4117791_def14ax39x2.jpg) | ![](cl4117791_def14ax39x3.jpg) |
| **DRIVE STRONG BUSINESS RESULTS AND OUR** **STRATEGIC PLAN** |  |  |  |
| Selecting performance measures, such as organic sales growth, net income growth, earnings per share and free cash flow productivity, that are key metrics for investors fosters profitable growth and increases shareholder value. |  | ![](cl4117791_def14ax39x2.jpg) | ![](cl4117791_def14ax39x3.jpg) |
| Using performance measures tied to our annual and long-term goals, the achievement of which the Named Officers have the ability to influence, motivates the Named Officers to achieve strong and sustained business results. |  | ![](cl4117791_def14ax39x2.jpg) | ![](cl4117791_def14ax39x3.jpg) |
| Using performance measures tied to our strategy, such as innovation, digital transformation and ESG initiatives, helps align compensation with and drive our strategic growth priorities. |  | ![](cl4117791_def14ax39x2.jpg) |  |
| Using measures in the long-term incentive award program that emphasize our performance relative to peers focuses the Named Officers on achieving peer-leading performance. |  |  | ![](cl4117791_def14ax39x3.jpg) |
| **FOCUS ON LONG-TERM** **SHAREHOLDER RETURN** |  |  |  |
| Our long-term incentive award program has a three-year performance period, driving a focus on long-term results. |  |  | ![](cl4117791_def14ax39x3.jpg) |
| A significant portion of the Named Officers' total compensation is paid in equity (approximately 50-65% in 2022), aligning the interests of the Named Officers with those of stockholders. |  |  | ![](cl4117791_def14ax39x3.jpg) |
| The Named Officers' payout through the long-term incentive award program varies based on our three-year total shareholder return compared to the Comparison Group, directly tying a portion of the Named Officers' compensation opportunity to relative shareholder return. |  |  | ![](cl4117791_def14ax39x3.jpg) |
| Our use of stock options, which provide value only to the extent that our stock price appreciates, provides an effective link to changes in shareholder value that aligns the interests of stockholders and executives. |  |  | ![](cl4117791_def14ax39x3.jpg) |
| Stock ownership guidelines require that executives own significant levels of stock, further strengthening the focus on long-term shareholder return. |  |  | ![](cl4117791_def14ax39x3.jpg) |
| **MOTIVATE AND RETAIN CRITICAL TALENT AND REFLECT EXTERNAL MARKET AND** **COMPETITIVE PRACTICES** |  |  |  |
| We regularly benchmark our compensation programs and design the programs to compensate executives at the median level, with above-median payouts for superior performance and below-median payouts for performance below expectations. |  | ![](cl4117791_def14ax39x2.jpg) | ![](cl4117791_def14ax39x3.jpg) |
| Using components that measure performance against both financial results and key strategic initiatives aligns with market practice. |  | ![](cl4117791_def14ax39x2.jpg) |  |
| To promote equal pay and fairness, our policy is to compensate each individual at a level commensurate with their role, work location, individual performance and experience, irrespective of gender, race, ethnicity or any other category protected by law. | ![](cl4117791_def14ax39x1.jpg) | ![](cl4117791_def14ax39x2.jpg) | ![](cl4117791_def14ax39x3.jpg) |
| Individual performance influences salary increases and stock option awards, motivating the Named Officers to perform at the highest levels. | ![](cl4117791_def14ax39x1.jpg) |  | ![](cl4117791_def14ax39x3.jpg) |
| We reward executives for strong performance, including by increasing payouts under the long-term incentive award program when we outperform our peers and decreasing payouts when we underperform our peers. |  | ![](cl4117791_def14ax39x2.jpg) | ![](cl4117791_def14ax39x3.jpg) |

---

---

| | |
|:---|:---|
| 2023 Proxy Statement | **33** |

---

**[**Table of Contents**](#toc)** 

Executive Compensation

The P&O Committee devotes substantial time and attention throughout each year to executive compensation matters to ensure that compensation is aligned with our performance and the best interests of stockholders. Our compensation programs reflect our strategic initiatives and balance achievement of short-term results with long-term strategic objectives. As discussed in more detail below, the P&O Committee's well-balanced and disciplined approach includes regular reviews with its independent compensation consultant and careful benchmarking to ensure that our compensation is effective in motivating and retaining critical talent, is supported by underlying performance and is reasonable relative to our peers. In reviewing and approving compensation for the Named Officers, the P&O Committee considers all material components of compensation as well as comprehensive information regarding market practices. The purpose of these materials is to bring together all of the elements of actual and potential future compensation of the Named Officers, so that the P&O Committee may review individual elements of compensation, including compensation mix, as well as the aggregate amount of total compensation.

This CD&A discusses the compensation paid to the Named Officers. The compensation programs described, however, apply more broadly to our other officers and senior managers, with changes as appropriate to reflect different salary grade levels and job responsibilities. We believe that this approach helps to align Colgate people into one global team sharply focused on our performance objectives and key strategic initiatives.

**Compensation-Setting Process**

**Role of the P&O Committee**

&nbsp;&nbsp; The P&O Committee oversees our executive compensation programs. The P&O Committee does not delegate any of its responsibilities regarding the consideration and determination of executive compensation.<br>

The P&O Committee:

**●** Recommends and approves, with the participation and concurrence of the other independent directors, the CEO's performance goals and compensation; the CEO does not play any role in setting his own compensation;

**●** Reviews and approves the performance goals and compensation recommended by our Global Human Resources function and the CEO for our other executive officers;

**●** References tally sheets that summarize all material components of compensation in reviewing and approving compensation for executive officers; and

**●** Approves the peer group companies that are used as a reference point in designing our compensation programs and in setting compensation levels and that our performance is reviewed against for purposes of making awards that are based on relative performance measures.

**Role of the Independent Compensation Consultant**

&nbsp;&nbsp; The P&O Committee has engaged Frederic W. Cook & Co., Inc. ("FW Cook") as its independent compensation consultant. FW Cook is actively involved in advising the P&O Committee on compensation decisions.<br>

FW Cook, as the P&O Committee's independent compensation consultant:

**●** Regularly reviews our executive compensation programs with the P&O Committee;

**●** Advises the P&O Committee on the setting of target compensation levels, the design of our variable incentive plans and the setting of performance goals;

**●** Helps the P&O Committee ensure there is a strong positive relationship between earned compensation and performance, as measured by operating results and changes in shareholder value;

**●** Provides observations and recommendations about the peer group companies that are used as a reference point in designing our compensation programs and in setting compensation levels and that our performance is reviewed against for purposes of making awards that are based on relative performance measures; and

**●** Informs the P&O Committee of emerging trends and best practices in executive compensation design and related regulatory developments.

**34**

**[**Table of Contents**](#toc)** 

Executive Compensation

**2022 CEO Compensation Review**

In 2022, the P&O Committee worked with FW Cook to determine the appropriate target level of direct compensation for Mr. Wallace based on his individual performance, including his leadership, and overall Company performance. Following this review, which also took into account our compensation philosophy, competitive data from the Comparison Group and market trends, the P&O Committee determined in March 2022 to maintain Mr. Wallace's overall target direct compensation (salary and annual and long-term incentives) for 2022 near the median of the Comparison Group, with the potential for above-median compensation based on superior performance and below-median compensation if performance fell below expectations. The P&O Committee also continued to have the variable portion of Mr. Wallace's target direct compensation represent a larger portion of his compensation as compared with the other Named Officers, to ensure his compensation is strongly tied to Company performance. In making these determinations, the P&O Committee worked together with the other independent directors of the Board.

In light of those considerations, in March 2022 the P&O Committee determined to increase Mr. Wallace's salary, annual bonus opportunity and long-term equity incentive target. The P&O Committee determined that a salary increase of 3.7% and an increase in assigned annual bonus award opportunity from 160% to 175% of base salary were warranted as a result of Mr. Wallace's leadership, market trends and consistent with its intent to maintain his target direct compensation near the median relative to the Comparison Group. The P&O Committee also determined to increase the long-term equity incentive portion of Mr. Wallace's target direct compensation from $9,000,000 to $9,500,000 in order to maintain his target direct compensation near the median of the Comparison Group and consistent with the P&O Committee's intent to link a significant part of his compensation to the achievement of multi-year performance goals and our absolute and relative stock price performance.

**Comparison Group**

We use comparative compensation data from a group of other leading companies, referred to in this CD&A as the "Comparison Group," as a point of reference in designing our compensation programs and in setting compensation levels. The P&O Committee does not use this comparative data as the determinative factor in setting compensation levels but rather as a single component in its effort to verify that our compensation programs are reasonable and competitive in light of compensation levels at similarly situated companies. The P&O Committee also reviews our performance against the Comparison Group for purposes of making awards that are based on relative performance measures, including the long-term incentive awards granted under the Growth Performance Plan.

The Comparison Group is selected to include companies of similar size and complexity to us (including our substantial international operations) and to represent both the market for executive talent in which we compete as well as our peer companies from a performance and investment perspective. It is comprised primarily of fast-moving consumer goods companies with product portfolios consisting of globally recognized brands that are similarly situated to us in terms of overall size or performance against relevant measures. Our 2022 revenues and market capitalization as of December 31, 2022 were at the 38th and 53rd percentiles, respectively, of the Comparison Group.

The companies comprising the Comparison Group are approved by the P&O Committee after taking into account observations and recommendations of management and FW Cook.

For 2022, the P&O Committee determined not to make any changes to the Comparison Group, so it remained unchanged from 2021 and consisted of the following 15 companies:

**COMPARISON GROUP**

---

| | | |
|:---|:---|:---|
| **●**Campbell Soup Company<br> **●**The Clorox Company<br> **●**The Coca-Cola Company<br> **●**Conagra Brands, Inc.<br> **●**The Estée Lauder Companies Inc. | **●**General Mills, Inc.<br> **●**Johnson & Johnson<br> **●**Kellogg Company<br> **●** Kimberly-Clark Corporation<br> **●**The Kraft Heinz Company | **●**Mondēlez International, Inc.<br> **●**PepsiCo, Inc.<br> **●**The Procter & Gamble Company<br> **●**Reckitt Benckiser Group PLC<br> **●**Unilever PLC |

---

Compensation data are collected for these companies for all of our three primary compensation components (base salary, annual incentive pay and long-term incentive pay), both individually and in the aggregate, as well as for indirect compensation elements such as perquisites and retirement benefits.

---

| | |
|:---|:---|
| 2023 Proxy Statement | **35** |

---

**[**Table of Contents**](#toc)** 

Executive Compensation

Our adjusted net income growth, adjusted earnings-per-share growth, total shareholder return, net sales growth, organic sales growth, return on sales, operating cash flow as a percentage of sales, return on invested capital and CEO total direct compensation relative to the Comparison Group during the three-year period from 2020 to 2022 were as follows:

---

| | |
|:---|:---|
| ![](cl4117791_def14ax42x1.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;<sup>\*</sup> Adjusted net income growth, adjusted earnings-per-share growth and organic sales growth reflect the adjustments described in Annex A to Colgate's net income, earnings per share and net sales growth, respectively, and comparable adjustments to peer companies' net income, earnings per share and net sales growth. |

---

**Compensation Components**

**Compensation Mix**

Our executive compensation programs consist of the following three primary components:

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp; **Base salary** | &nbsp;&nbsp; **Annual incentives** | &nbsp;&nbsp; **Long-term incentives** |
|  | &nbsp;&nbsp; Payable in the form of cash bonuses | &nbsp;&nbsp; Payable in the form of stock options and PBRSUs |

---

In allocating target compensation among these three components, the P&O Committee seeks to provide reasonable and competitive levels of fixed compensation (i.e., salary), while emphasizing performance-based compensation that varies based on overall Company or business unit performance and/or the performance of our Common Stock. Accordingly, as the following chart illustrates, base salaries for the Named Officers other than Mr. Wallace represented approximately 25% of the three compensation components noted above, and incentive compensation, consisting of annual and long-term, represented approximately 75% at target, while the base salary for Mr. Wallace represented 11% of the three components noted above and incentive compensation represented 89% at target. The target compensation mix for Mr. Wallace reflects the P&O Committee's belief that a larger portion of his compensation should be variable and tied to our financial and stock price performance.

![](cl4117791_def14ax42x2.jpg)

**36**

**[**Table of Contents**](#toc)** 

Executive Compensation

The target mix between annual incentive pay and long-term incentives is determined based on competitive practice and our desire to focus, first, on long-term performance and shareholder value and, second, on annual performance. Within the long-term incentive category, the Named Officers are eligible to receive a mix of stock options and PBRSUs because the two types of awards serve different but complementary purposes. Stock options provide value only to the extent that our stock price appreciates, thereby providing an effective link to changes in shareholder value that aligns the interests of stockholders and executives. PBRSUs provide value based on both our long-term performance relative to our objectives and an increase in shareholder value, creating a strong link between compensation and the achievement of our long-term financial goals and our performance relative to peers. Our compensation philosophy and competitive practice also drive determinations about total target compensation levels for the Named Officers.

In addition to the three primary components of compensation discussed above, we provide Mr. Wallace with the use of a Company car and driver, the value of which is included in note 6 to the Summary Compensation Table. Any personal income taxes due as a result of this perquisite are Mr. Wallace's responsibility. We do not provide any other perquisites to our Named Officers.

The compensation and benefits payable to the Named Officers in the event of retirement, severance and change in control are described on pages 49 to 50 and 52 to 56. Our retirement programs are designed to provide our long-serving, retiring employees with competitive retirement benefits based on prevailing market practice. The Named Officers participate in the same retirement programs that are available to other U.S. employees, with supplemental benefits provided to make up for benefits under certain plans that cannot be provided as a result of the application of certain limits under the Internal Revenue Code of 1986, as amended. Ms. Parameswaran and Messrs. Tsourapas and Wallace, who participate in the Colgate-Palmolive Company Employees' Retirement Income Plan (the "Retirement Plan"), receive pension benefits determined under the PRA formula as described in "Retirement Plans." Ms. Daniels and Mr. Sutula are not participants in the Retirement Plan and instead participate only in our defined contribution plans. Our severance program is designed to provide participants with reasonable compensation if their employment is terminated in the event of a change in control or at the Company's convenience. The potential payments and benefits under these various programs did not influence the decisions discussed in the balance of this CD&A regarding the setting of salary, annual incentives and long-term incentives for the Named Officers since these programs serve very different purposes.

**Base Salary**

Base salaries for the Named Officers and all other employees are based on established salary ranges for each grade level. The CEO's salary is set independently by the P&O Committee, without the involvement of the CEO. The P&O Committee reviews salaries for the other Named Officers based on recommendations from the Global Human Resources function and the CEO in accordance with the established salary ranges and the guidelines described below.

Since base salaries are designed to provide a reasonable, competitive level of fixed compensation, the mid-point of each salary range is based on the median pay level for similar jobs at companies in the Comparison Group. Salaries above the median are available for key contributors to our success. Setting salaries in the median range or above mitigates pressure that might otherwise exist to support short-term focused or higher-risk business strategies if fixed compensation were set materially below market rates.

Decisions regarding where in the range a particular individual's salary should be and whether their salary should be increased during the year are based on the following factors:

**●** Our
 annual salary budget guidelines;

**●** Company
 or business unit performance, as applicable;

**●** Assumption
 of new responsibilities;

**●** Data
 from the Comparison Group; and

**●** Individual
 performance, elements of which include:

**●** the individual's ability to translate our key priorities into specific strategies applicable to their function, to communicate those strategies clearly and effectively and, working with their team, to deliver results against those strategies to help us achieve our performance objectives and strategic initiatives; and

**●** other performance measures, such as the successful launch of innovative new products, increases in market share of Colgate products, geographic expansion and increases in productivity.

The Named Officers are experienced executives and key contributors to our success. In 2022, salaries for the Named Officers other than Mr. Wallace ranged between approximately the 60th and 80th percentiles of salaries for similar jobs in the Comparison Group, based on the most recent data available to us. Mr. Wallace's salary is near the median for CEOs in the Comparison Group.

---

| | |
|:---|:---|
| 2023 Proxy Statement | **37** |

---

**[**Table of Contents**](#toc)** 

Executive Compensation

**Annual Incentives**

**Award Opportunities**

Annual incentive awards are awarded under a stockholder-approved plan. Cash bonuses are designed to reward performance over a one-year period against one or more pre-established performance measures set by the P&O Committee at the beginning of the year. Awards are determined by the P&O Committee based on achievement against the designated goals early in the following year when our audited financial results are available. In addition, the P&O Committee has discretion to adjust calculated awards upward or downward, subject to award limits established by the P&O Committee at the time the performance measures were set.

Executives, including the Named Officers, are each assigned a bonus award opportunity, which is based on salary grade level, expressed as a percentage of year-end base salary and generally set at or below the median of the Comparison Group. Assigned award opportunities are established for each Named Officer to ensure that the portion of annual cash compensation (i.e., salary plus cash bonus) that is based on performance increases with the level of responsibility. This ensures that the executives who are most responsible for managing Colgate and establishing our strategic plan are held most accountable to stockholders. For 2022, the Named Officers' assigned award opportunities and award maximums, which are equal to 200% of the assigned award opportunities, were as follows:

---

| | | |
|:---|:---|:---|
| | **Assigned Award Opportunity** | **Maximum Award Opportunity** |
| **Noel R. Wallace** | 175% of base salary | 350% of base salary |
| **Stanley J. Sutula III** | 100% of base salary | 200% of base salary |
| **Jennifer M. Daniels** | 80% of base salary | 160% of base salary |
| **Prabha Parameswaran** | 80% of base salary | 160% of base salary |
| **Panagiotis Tsourapas** | 80% of base salary | 160% of base salary |

---

The annual cash bonuses for 2022 for the Named Officers were subject to a 10% downward adjustment if certain key global ethics and compliance objectives were not met. These ethics and compliance objectives were achieved in 2022 and therefore no downward adjustment was applied.

**Performance Measures and Bonus Payouts**

**Financial Measures (80%)**

80% of the 2022 cash bonuses for the Named Officers were based on financial performance measures, namely Base Business Earnings Per Share and organic sales growth, in each case as reported in our 2022 financial results. The organic sales growth measure was selected to drive our growth strategy and reflect the underlying momentum of our business. The earnings-per-share measure was selected to create a strong focus on our overall profit goal and its underlying drivers of sales, cost control and financial efficiency.

The earnings-per-share measure is adjusted for the effects of the following, as applicable: restructuring charges, charges for certain litigation and tax matters, acquisition-related costs, gains and losses from certain divestitures and certain other unusual, non-recurring items. The purpose of the adjustments is to ensure that the measurement of performance reflects factors that management can directly control and that payout levels are not impacted by factors unrelated to the ongoing operation of the business. These adjustments are consistent with the presentation in our public filings in which the impact of these items is discussed separately.

The P&O Committee typically establishes annual bonus targets in March. However, in March 2022, the P&O Committee, in consultation with FW Cook, determined to delay setting the annual bonus targets in light of the uncertainty at that time regarding the impact of the war in Ukraine and the associated volatility. Significant uncertainty remained in April 2022, leading the P&O Committee to set the 2022 earnings-per-share target as a range, rather than a single number. The P&O Committee established the target range consistent with our publicly announced guidance for 2022 and based on our 2022 plan to sustain net and organic sales growth through science-led, core and premium innovation, digital transformation and investing behind our strategic priorities while continuing to manage through the cost environment. Given the economic and market conditions at the time the targets for the annual bonus award were set, the target goals were designed to be challenging but achievable, with payout levels intended to encourage strong, focused performance in a difficult operating environment characterized by significant raw material and logistics cost inflation and foreign exchange headwinds. As a result, the 2022 earnings-per-share target range was set below the 2021 earnings-per-share target and outcome, consistent with our publicly announced earnings-per-share goal for 2022, while the maximum was set at a higher level relative to target than our historical practice. We take into account the budget for our share repurchase program when setting our earnings-per-share targets, and no decisions about share repurchase plans are tied to an attempt to influence compensation results.

**38**

**[**Table of Contents**](#toc)** 

Executive Compensation

In 2022, the performance required to receive threshold, target and maximum payouts for each of the two financial components, and the payout relative to the Comparison Group that overall performance at each level would represent for the Named Officers, were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Weight** | **Threshold**<br>| &nbsp;&nbsp;&nbsp;**Target**<br>| &nbsp;&nbsp;&nbsp;&nbsp;**Maximum**<br>|
| **Base Business Earnings Per Share** | 40% | ![](cl4117791_def14ax45x1.jpg) | ![](cl4117791_def14ax45x1.jpg) | ![](cl4117791_def14ax45x1.jpg) |
| **Organic Sales Growth** | 40% | ![](cl4117791_def14ax45x2.jpg) | ![](cl4117791_def14ax45x2.jpg) | ![](cl4117791_def14ax45x2.jpg) |
| **Strategic Initiatives** | 20% | *See discussion below* | *See discussion below* | *See discussion below* |
| **Payout Relative to the Comparison Group** |  | Below 10th<br>percentile<br>| &nbsp;&nbsp;&nbsp; 21st to 58th<br>percentile<br>| 70th to above<br> 90th percentile<br>|

---

If Base Business Earnings Per Share was less than $2.62 or organic sales growth was less than 2.0%, no annual bonus would be paid with respect to that component. To the extent performance on either performance measure fell between two applicable values, the applicable payout percentage would be interpolated on a linear basis.

**Strategic Initiatives (20%)**

The remaining 20% of the 2022 annual cash bonuses for the Named Officers was determined based on our progress on certain strategic initiatives, measured by considering our performance during 2022 against our enterprise-wide innovation, digital transformation and ESG goals. The strategic measure was selected to further align compensation with our strategic priorities to build competitive advantage through digital and data capabilities, deliver innovation that drives category growth, foster a culture where everyone feels they belong and integrate sustainability into our business.

The strategic measure was payable at 25% for threshold performance, 100% for target performance and 200% for maximum performance, as determined by the P&O Committee. However, in the event our performance on either of the two financial performance measures discussed above was below the threshold level, the strategic measure would be capped at 100%.

The chart below shows the performance considered by the P&O Committee during its assessment of our 2022 performance against the strategic goals.

---

| | | |
|:---|:---|:---|
| **Goal** | **Measure** | **Assessment** |
| **Innovation** | Our revenue from new products | Exceeded our goals by 26% |
| **Innovation** | Our incremental net sales coming from innovation | Exceeded our goals by 6% |
| **Digital Transformation** | Our year-over-year growth in net sales from eCommerce | Fell below internal goals but outpaced the industry average forecasts for 2022 by double digits |
| **DE&I** | Our progress in building a culture of inclusion and belonging | Exceeded our goals, improving our internal score year over year and achieving top quartile of the market benchmark |
| **Sustainability** | Our progress towards making all our packaging recyclable, reusable or compostable | Was in line with our 2022 goal of 86.4% percent |

---

Based on our strong performance against our enterprise-wide innovation, digital transformation and ESG goals detailed above, the P&O Committee determined that the strategic measure should pay out at 140% of target.

Based on strategic measure performance of 140%, Base Business Earnings Per Share of $2.97 and organic sales growth of 7.0%, the P&O Committee approved bonus awards for the Named Officers at 134.7% of their assigned award opportunities. The annual cash bonus for Mr. Wallace equaled 236% of his year-end salary, for Mr. Sutula equaled 135% of his year-end salary and for Mses. Daniels and Parameswaran and Mr. Tsourapas equaled 108% of their respective year-end salaries.

---

| | |
|:---|:---|
| 2023 Proxy Statement | **39** |

---

**[**Table of Contents**](#toc)** 

Executive Compensation

**Long-term Incentives**

**Overview**

Our long-term incentive compensation is designed to focus the Named Officers and other Colgate executives on increasing shareholder value and to incentivize their contribution to our long-term growth and performance. We use two types of long-term incentives for the Named Officers, both granted in the form of equity: stock options and PBRSUs (weighted equally). Stock options and PBRSUs are used to balance and support the key principles discussed on page 33. Because their value is solely dependent on appreciation in stock price, stock options strongly support the objectives of ensuring that pay is aligned with changes in shareholder value and creating commonality of interest between the Named Officers and stockholders. The use of PBRSUs ensures that the amount of long-term incentive compensation granted is tied directly to both increases in shareholder value and the achievement of critically important multi-year performance objectives. Due to the multi-year earning and/or vesting requirements, all of our long-term incentives support the goal of retaining the Named Officers and other key executives.

Consistent with our longstanding practice of encouraging stock ownership throughout the organization to reward employees for the long-term value they create and to align management and stockholder interests, long-term equity grants are the largest component of target direct compensation for the Named Officers. Following a review of the practices of the Comparison Group, long-term incentives are generally targeted at the median of the Comparison Group, with above-median awards available based on superior performance and below-median awards available based on performance below expectations.

In 2022, our annual stock option and restricted stock unit utilization for all awards was 0.63% of outstanding stock, placing us at the 76th percentile of the Comparison Group based on available market data. Because we use a mix of long-term incentives that is weighted more heavily toward stock options than full-value awards as compared with the companies in the Comparison Group, our utilization rate will generally be above the median of the Comparison Group.

**Equity Grant Process and Policies**

We make annual equity awards at the same predetermined times each year, at regularly scheduled P&O Committee meetings in the first and third quarters. Equity awards for new hires or newly promoted employees or special awards for recognition or retention purposes are generally made on a monthly basis. The grant date of any award is no earlier than the date on which such award is approved, and the grant price of any award is never less than the closing price of our Common Stock on the date of grant. All awards are granted under a stockholder-approved plan.

**Stock Options**

**Overview**

The number of stock options granted to individual executives is determined based on guidelines set for each salary grade level. Established annually, the stock option guidelines are determined based on a review of market data and share usage. Actual awards may vary from such guidelines based on a qualitative assessment of factors similar to those used to determine salary, including each individual's performance, the performance of the business unit or function for which they are responsible and the assumption of new job responsibilities. (See discussion of salary on page 37.) As with other compensation decisions, in the case of the CEO, the P&O Committee makes such assessment with the participation and concurrence of the other independent directors of the Board and considering advice from its independent consultant, FW Cook. In the case of the other Named Officers, the P&O Committee reviews and approves awards taking into account the recommendations of the Global Human Resources function and the CEO.

**Stock Option Grants**

During 2022, the stock option grants to the Named Officers were at our guideline award level. See column (j) of the Grants of Plan-Based Awards Table for the number of stock options granted to the Named Officers in 2022. Mr. Wallace's award for 2022 was 322,910 options, consistent with the pre-established guideline.

**Stock Option Terms**

For all of the Named Officers, the stock options vest in equal annual installments over three years, the exercise price of the stock options is equal to the closing price of our Common Stock on the date of grant and the term of the stock options is eight years. Unvested stock options are forfeited if the recipient terminates their employment, other than through retirement, death or disability. For more information regarding the effect of various types of termination of employment on the vesting of outstanding equity awards, including stock options, see page 54.

**Performance-Based Restricted Stock Unit Awards**

**Awards**

Under our long-term incentive program, the Growth Performance Plan, executives, including the Named Officers, receive PBRSUs at the beginning of each three-year performance cycle.

**40**

**[**Table of Contents**](#toc)** 

Executive Compensation

Each year, at the beginning of a three-year performance cycle, the P&O Committee approves a set of performance goals and a target award expressed in dollars, which is converted into PBRSUs by dividing the dollar value by the closing price of our Common Stock on the grant date. The number of PBRSUs that are earned and vest at the end of the performance period will be determined based on our performance against the pre-established performance goals. The PBRSUs will vest, to the extent earned, following the conclusion of the three-year performance period when actual performance is known and certified by the P&O Committee and shares of Common Stock are delivered in respect of the earned PBRSUs following vesting. In addition, the P&O Committee has discretion to adjust earned awards upward or downward, subject to award limits established by the P&O Committee at the time the performance measures were set.

For the 2022-2024 performance cycle, Mr. Wallace's target award was 64,328 PBRSUs and the target award for each of the other Named Officers ranged from 12,459 PBRSUs to 15,066 PBRSUs. All such target awards were granted in March 2022. Depending upon performance against the pre-established measures discussed below, including the modifier based on total shareholder return relative to peers, the number of PBRSUs that can be earned ranges from zero, if performance falls below a certain level, to a maximum of 250% of the target number of PBRSUs. The actual value of the payout from the PBRSUs will be determined in 2025 and will depend upon achievement of the performance goals as well as the price of our Common Stock at the time of vesting.

**Performance Measures**

The performance measures used for the 2022-2024 performance cycle are described below.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Performance Measure** | &nbsp;&nbsp;&nbsp;**Weight** | **Threshold** | &nbsp;&nbsp;&nbsp;**Target** | **Maximum** |
| Average organic sales growth relative to the Comparison Group over the three-year performance period | &nbsp;&nbsp;&nbsp; 50% | &nbsp;&nbsp; ![](cl4117791_def14ax47x1.jpg) | &nbsp;&nbsp; ![](cl4117791_def14ax47x1.jpg) | &nbsp;&nbsp; ![](cl4117791_def14ax47x1.jpg) |
| Average Base Business Net Income growth relative to the Comparison Group over the three-year performance period\* | &nbsp;&nbsp;&nbsp; 30% | &nbsp;&nbsp; ![](cl4117791_def14ax47x2.jpg) | &nbsp;&nbsp; ![](cl4117791_def14ax47x2.jpg) | &nbsp;&nbsp; ![](cl4117791_def14ax47x2.jpg) |
| Average Free Cash Flow Productivity over the three-year performance period | &nbsp;&nbsp;&nbsp; 20% | ![](cl4117791_def14ax47x3.jpg) | ![](cl4117791_def14ax47x3.jpg) | ![](cl4117791_def14ax47x3.jpg) |

---

---

| | |
|:---|:---|
| <sup>\*</sup>  | We adjust net income in our audited financial statements for the effects of the following, as applicable: restructuring charges, charges for certain litigation and tax matters, acquisition-related costs, gains and losses from certain divestitures and certain other unusual, non-recurring items. For purposes of this Proxy Statement, this is referred to as "Base Business Net Income." Comparable adjustments are also made to net income of the companies in the Comparison Group for purposes of determining relative performance. |

---

If performance on any of the performance measures is below the threshold level, no PBRSUs would be earned with respect to that component. To the extent performance on any of the performance measures falls between two applicable values, the applicable payout percentage would be interpolated on a linear basis.

These measures were chosen based on our view that together they will drive sustainable profitable growth while reflecting the underlying momentum and strong fundamentals of our business and our ability to generate cash to satisfy current and future obligations, reinvest in business-building activities and return value to stockholders. The measures are primarily based on our performance relative to peers to ensure focus on delivering peer-leading performance, no matter the marketplace conditions.

The Growth Performance Plan also includes a total shareholder return modifier to further link awards to the shareholder experience and hold management accountable for outperforming peers. The number of PBRSUs earned following completion of the 2022-2024 performance cycle may increase or decrease by up to 25% based on our total shareholder return, defined as stock price appreciation plus dividends paid, relative to the Comparison Group over the same three-year period, as follows:

---

| | |
|:---|:---|
| **Company's TSR Relative to Comparison Group** | **Award Modifier** |
| ≥75<sup>th</sup> percentile | +25% |
| 60<sup>th</sup> percentile | +15% |
| 50<sup>th</sup> percentile | 0 |
| 40<sup>th</sup> percentile | -15% |
| ≤25<sup>th</sup> percentile | -25% |

---

---

| | |
|:---|:---|
| 2023 Proxy Statement | **41** |

---

**[**Table of Contents**](#toc)** 

Executive Compensation

To the extent our total shareholder return relative to the Comparison Group falls between two applicable values, the total shareholder return modifier would be interpolated on a linear basis. In addition, in the event our total shareholder return over the performance period is negative, no participant would be eligible to earn more than the target number of PBRSUs, even if our performance on the other performance measures would otherwise entitle them to a higher payout.

**Performance Cycles Status**

The status of our just completed and in-progress performance cycles are described below.

---

| | | | |
|:---|:---|:---|:---|
| **Performance Period and Measures** | **Performance Period and Measures** | &nbsp;&nbsp;**Performance Levels** | **Status** |
| **2020-2022** | **2020-2022** |  |  |
| ![](cl4117791_def14ax48x1.jpg) | **50%** relative organic sales growth | ![](cl4117791_def14ax48x4.jpg) | **●**Results were certified in February 2023<br> **●**Relative organic sales growth was at the 44th percentile, relative Base Business Net Income growth was at the 32nd percentile and Free Cash Flow Productivity was 94.7% (following the reduction described below)<br> **●**Total shareholder return was at the 36th percentile relative to the Comparison Group, which decreased the payout by 18% based on the total shareholder return modifier<br> **●**Based on the above performance, the PBRSUs paid out at 73.7% of target |
| ![](cl4117791_def14ax48x2.jpg) | **30%** relative Base Business <br>Net Income growth | ![](cl4117791_def14ax48x5.jpg) | **●**Results were certified in February 2023<br> **●**Relative organic sales growth was at the 44th percentile, relative Base Business Net Income growth was at the 32nd percentile and Free Cash Flow Productivity was 94.7% (following the reduction described below)<br> **●**Total shareholder return was at the 36th percentile relative to the Comparison Group, which decreased the payout by 18% based on the total shareholder return modifier<br> **●**Based on the above performance, the PBRSUs paid out at 73.7% of target |
| ![](cl4117791_def14ax48x3.jpg) | **20%** Free Cash Flow Productivity | ![](cl4117791_def14ax48x6.jpg) | **●**Results were certified in February 2023<br> **●**Relative organic sales growth was at the 44th percentile, relative Base Business Net Income growth was at the 32nd percentile and Free Cash Flow Productivity was 94.7% (following the reduction described below)<br> **●**Total shareholder return was at the 36th percentile relative to the Comparison Group, which decreased the payout by 18% based on the total shareholder return modifier<br> **●**Based on the above performance, the PBRSUs paid out at 73.7% of target |
| **2021-2023** | **2021-2023** |  |  |
| ![](cl4117791_def14ax48x1.jpg) | **50%** relative organic sales growth | ![](cl4117791_def14ax48x7.jpg) | **●**Based on performance achieved through December 31, 2022, payout would be between the threshold and target levels. Performance over the remaining year of the performance period will determine the actual number of shares earned, if any<br> **●**Results will be certified in February 2024, including applying the total shareholder return modifier |
| ![](cl4117791_def14ax48x2.jpg) | **30%** relative Base Business<br>Net Income growth | ![](cl4117791_def14ax48x8.jpg) | **●**Based on performance achieved through December 31, 2022, payout would be between the threshold and target levels. Performance over the remaining year of the performance period will determine the actual number of shares earned, if any<br> **●**Results will be certified in February 2024, including applying the total shareholder return modifier |
| ![](cl4117791_def14ax48x3.jpg) | **20%** Free Cash Flow Productivity | ![](cl4117791_def14ax48x9.jpg) | **●**Based on performance achieved through December 31, 2022, payout would be between the threshold and target levels. Performance over the remaining year of the performance period will determine the actual number of shares earned, if any<br> **●**Results will be certified in February 2024, including applying the total shareholder return modifier |
| **2022-2024** | **2022-2024** |  |  |
| ![](cl4117791_def14ax48x1.jpg) | **50%** relative organic sales growth | ![](cl4117791_def14ax48x10.jpg) | **●**Based on performance achieved through December 31, 2022, payout would be between the threshold and target levels. Performance over the remaining two years of the performance period will determine the actual number of shares earned, if any<br> **●**Results will be certified in February 2025, including applying the total shareholder return modifier |
| ![](cl4117791_def14ax48x2.jpg) | **30%** relative Base Business <br>Net Income growth | ![](cl4117791_def14ax48x11.jpg) | **●**Based on performance achieved through December 31, 2022, payout would be between the threshold and target levels. Performance over the remaining two years of the performance period will determine the actual number of shares earned, if any<br> **●**Results will be certified in February 2025, including applying the total shareholder return modifier |
| ![](cl4117791_def14ax48x3.jpg) | **20%** Free Cash Flow Productivity | ![](cl4117791_def14ax48x12.jpg) | **●**Based on performance achieved through December 31, 2022, payout would be between the threshold and target levels. Performance over the remaining two years of the performance period will determine the actual number of shares earned, if any<br> **●**Results will be certified in February 2025, including applying the total shareholder return modifier |

---

<sup>\*</sup> Free Cash Flow Productivity for 2020-2022 was 109.4%. However, in each of 2022 and 2021, our Free Cash Flow Productivity was impacted by goodwill and intangible assets impairment charges related to the Filorga skin health business. These non-cash charges had the effect of reducing the Company's 2022 and 2021 GAAP net income (the denominator used to calculate Free Cash Flow Productivity) but did not impact free cash flow before dividends (the numerator), thus resulting in higher Free Cash Flow Productivity than the Company would otherwise have achieved in 2022 and 2021. Therefore, the P&O Committee adjusted net income for the goodwill and intangible assets impairment charges related to the Filorga skin health business in order to eliminate the distortion the charges caused to the Free Cash Flow Productivity measure, resulting in Free Cash Flow Productivity for 2022 of 71.9%, for 2021 of 96.5%, and for the 2020-2022 performance period of 94.7%.

**PBRSU Terms**

To the extent earned, the PBRSUs granted under the Growth Performance Plan vest upon certification of the performance results in February of the year following completion of the performance period (in 2025 for the 2022-2024 performance cycle) and are distributed as shares of Common Stock as soon as administratively practicable thereafter. Awards are forfeited if the recipient terminates their employment, other than through retirement, death or disability, prior to the end of the performance period. If a recipient retires, dies or becomes disabled during the performance period (provided they remained employed for at least the first six months of the performance period), they are eligible to earn PBRSUs on a pro rata basis at the conclusion of the performance period reflecting the proportion of the performance period for which they were employed. For more information regarding the effect of various types of termination on the vesting of outstanding equity awards, including PBRSUs, see page 54. Recipients of PBRSUs do not have voting rights or the right to receive dividends until they are distributed as shares of Common Stock.

**42**

**[**Table of Contents**](#toc)** 

Executive Compensation

**Compensation Governance Features**

**Stock Ownership Guidelines**

To further align the interests of our officers with those of our stockholders and ensure a long-term perspective, the Board has established minimum stock ownership guidelines for members of senior management. The CEO is required to own Colgate stock equal in value to eight times his annual salary, and the other Named Officers must hold Colgate stock in amounts equal to four times their annual salaries. Other senior managers are subject to ownership requirements of one or two times their annual salaries. Executives have five years from their initial promotion into an eligible position to achieve required ownership levels and neither unexercised stock options nor unearned PBRSUs are counted for purposes of determining whether the ownership requirements have been met. Compliance with these guidelines is evaluated on an annual basis. All of the Named Officers are in compliance with this policy.

**Hedging and Pledging of Company Stock**

The Board has adopted a policy that prohibits our directors, officers and employees who receive stock-based compensation from purchasing any financial instrument that is designed to hedge against or offset any decrease in the value of Colgate's stock, such as short sales and put and call options. The policy also strongly discourages all other employees from entering into such transactions. In addition, we prohibit our directors and officers from pledging Colgate stock. During 2022, all of the Named Officers were in compliance with both the anti-hedging and anti-pledging policies.

**Clawback Policies**

The Board has adopted a policy that permits us to recoup cash and equity-based incentive awards made to an officer or other executive subject to the policy if (i) the financial results on which such awards were based are subsequently restated or (ii) the officer or executive engaged in conduct that violates our Code of Conduct. In addition, our equity award agreements include non-competition, non-solicitation and non-interference restrictions in the event of an employee's departure from Colgate. Failure to comply with any of these requirements may result in forfeiture and/or cancellation of equity awards. We are monitoring regulatory developments regarding clawback requirements and will adopt any changes that may be necessary to comply with New York Stock Exchange listing standards when effective.

&nbsp;&nbsp; **Advisory Vote on Executive Compensation**<br> Our executive compensation program received substantial stockholder support and was approved, on an advisory basis, by 90.8% of stockholders voting on the proposal at the 2022 Annual Meeting of Stockholders. The P&O Committee believes that this strong result reflects the stockholders' support for the compensation decisions made by the P&O Committee for our Named Officers. See **pages 25 to 26** for information regarding our stockholder engagement efforts on compensation and other matters.<br>

**Conclusion**

In summary, the P&O Committee believes in aligning pay and performance. Thus, its approach to executive compensation is guided by the principle that executives should have the potential for increased compensation when performance objectives are exceeded, provided that compensation decreases if performance objectives are not met.

**P&O Committee Report**

The P&O Committee has reviewed and discussed with management the foregoing Compensation Discussion and Analysis and, based on such review and discussion, recommended to the Board of Directors that the Compensation Discussion and Analysis be included in our Annual Report on Form 10-K for the year ended December 31, 2022 and this Proxy Statement.

*The foregoing P&O Committee report has been submitted by the members of the P&O Committee: Michael B. Polk (Chair), John T. Cahill, C. Martin Harris, Kimberly A. Nelson and Stephen I. Sadove.*

---

| | |
|:---|:---|
| 2023 Proxy Statement | **43** |

---

**[**Table of Contents**](#toc)** 

Executive Compensation

**Summary Compensation Table**

The following table shows the compensation of our Chief Executive Officer, Chief Financial Officer and three other most highly compensated executive officers (the "Named Officers") for 2022, 2021 and 2020, as applicable.

---

| | | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Name and Principal Position**<br> **(a)** | **Year<br>(b)** | **Salary<br>($)<br>(c)** | **Bonus<br>($)**<br> **(d)**<br> **<sup>(1)</sup>** | **Stock<br>Awards<br>($)**<br> **(e)** | **<sup>(2)</sup>** | **Option<br>Awards<br>($)**<br> **(f)** | **<sup>(3)</sup>** | **Non-Equity<br>Incentive Plan<br>Compensation<br>($)**<br> **(g)** | **<sup>(4)</sup>** | **Change in<br>Pension<br>Value and<br>Nonqualified<br>Deferred<br>Compensation<br>Earnings<br>($)**<br> **(h)** | **<sup>(5)</sup>** | **All Other<br>Compensation<br>($)**<br> **(i)** | **<sup>(6)</sup>** | **Total<br>($)<br>(j)** |
| Noel R. Wallace<br> Chairman, President <br>and Chief Executive Officer | 2022 | 1387500 |  | 4364655 |  | 4750006 |  | 3300150 |  | 31939 |  | 628156 |  | 14462406 |
| Noel R. Wallace<br> Chairman, President <br>and Chief Executive Officer | 2021 | 1337500 |  | 6403522 |  | 4500006 |  | 2613600 |  | 29102 |  | 574421 |  | 15458151 |
| Noel R. Wallace<br> Chairman, President <br>and Chief Executive Officer | 2020 | 1287500 |  | 4391284 |  | 4250008 |  | 4097600 |  | 32585 |  | 305141 |  | 14364118 |
| Stanley J. Sutula III<br> Chief Financial Officer | 2022 | 905018 | 589199<br><sup>(7)</sup> | 1022228 |  | 1112503 |  | 1232694 |  |  |  | 138685 |  | 5000327 |
| Stanley J. Sutula III<br> Chief Financial Officer | 2021 | 868488 | 877908<br><sup>(7)</sup> | 983698 |  | 1060005 |  | 952494 |  |  |  | 78717 |  | 4821310 |
|  | 2020 | 130769 | 100000<br><sup>(7)</sup> | 2254184 |  | 1179008 |  |  |  |  |  | 8500 |  | 3672461 |
| Jennifer M. Daniels<br> Chief Legal Officer <br>and Secretary | 2022 | 835748 |  | 845343 |  | 920008 |  | 910820 |  |  |  | 138252 |  | 3650171 |
| Jennifer M. Daniels<br> Chief Legal Officer <br>and Secretary | 2021 | 800475 |  | 1356976 |  | 831250 |  | 683783 |  |  |  | 139232 |  | 3811716 |
| Jennifer M. Daniels<br> Chief Legal Officer <br>and Secretary | 2020 | 766368 |  | 904184 |  | 787502 |  | 1075620 |  |  |  | 95512 |  | 3629186 |
| Prabha Parameswaran<br> Group President, <br>Growth and Strategy | 2022 | 876475 |  | 845343 |  | 920008 |  | 953999 |  | 7655 |  | 196010 |  | 3799490 |
| Prabha Parameswaran<br> Group President, <br>Growth and Strategy | 2021 | 800475 |  | 1356976 |  | 831250 |  | 683783 |  | 6790 |  | 167850 |  | 3847124 |
| Prabha Parameswaran<br> Group President, <br>Growth and Strategy | 2020 | 744117 |  | 904184 |  | 787502 |  | 1075620 |  | 8239 |  | 387724 |  | 3907386 |
| Panagiotis Tsourapas<br> Group President, Europe and Developing Markets | 2022 | 876475 |  | 845343 |  | 920008 |  | 953999 |  | 2215 |  | 196333 |  | 3794373 |
| Panagiotis Tsourapas<br> Group President, Europe and Developing Markets | 2021 | 800475 |  | 1356976 |  | 831250 |  | 683783 |  | 1964 |  | 188508 |  | 3862956 |
| Panagiotis Tsourapas<br> Group President, Europe and Developing Markets | 2020 | 751617 |  | 904184 |  | 787502 |  | 1075620 |  | 2384 |  | 126516 |  | 3647823 |

---

**NOTES TO THE SUMMARY COMPENSATION TABLE**

<sup>(1)</sup> **Bonus.** Except as described in note 7 below, cash bonuses are awarded based on specific pre-established performance measures and therefore are reported in column (g) under Non-Equity Incentive Plan Compensation.

<sup>(2)</sup> **Stock Awards.** The amounts reported in this column reflect the aggregate grant date fair value of performance-based restricted stock units ("PBRSUs") granted to each Named Officer in the years reported pursuant to our Growth Performance Plan under the stockholder-approved 2019 Plan. These PBRSUs may be earned and, if earned, will vest in shares of Common Stock to the extent the pre-established performance measures are met over the three-year performance cycle starting in the year of grant. Since these awards are subject to future performance conditions, the aggregate values at the grant date reflected in this column for those awards were based on the probable outcome of those conditions at the grant date, consistent with applicable accounting guidance. For a description of how the aggregate grant date fair value of the PBRSUs was calculated, see Note 8 ("Capital Stock and Stock-Based Compensation Plans") to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022. The below table provides the aggregate value of the PBRSUs for the 2022-2024 performance cycle at the grant date at the threshold, target and maximum performance levels. The actual value of the PBRSUs at the time of payout will depend upon achievement of the performance measures as well as the price of our Common Stock at the time of vesting. For more information regarding these awards and the program under which they were made, including the terms and conditions and applicable performance measures, see pages 40 to 42 of the CD&A and the Grants of Plan-Based Awards Table.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **2022-2024 PBRSUs** | **2022-2024 PBRSUs** | **2022-2024 PBRSUs** | **2022-2024 PBRSUs** | |
| **Named Officer** | **Value at**<br> **Threshold**<br> **Level**<br> **($)** | **<sup>(a)</sup>** | **Value at Target**<br> **Level (Reported**<br> **in Column**<br> **(e) above)**<br> **($)** | **Value at**<br> **Maximum**<br> **Level**<br> **($)** | **<sup>(a)</sup>** |
| Noel R. Wallace | 436479 |  | 4364655 | 8729310 |  |
| Stanley J. Sutula III | 102250 |  | 1022228 | 2044456 |  |
| Jennifer M. Daniels | 84541 |  | 845343 | 1690686 |  |
| Prabha Parameswaran | 84541 |  | 845343 | 1690686 |  |
| Panagiotis Tsourapas | 84541 |  | 845343 | 1690686 |  |

---

---

| | |
|:---|:---|
| <sup>(a)</sup>  | The amount of shares earned at the conclusion of the 2022-2024 performance cycle may increase or decrease by up to 25% based on our total shareholder return relative to the Comparison Group. |
| Since Mr. Sutula joined Colgate in November 2020, he did not receive PBRSUs pursuant to the Growth Performance Plan for the 2020-2022 performance cycle. The amounts reported in this column for Mr. Sutula for 2020 instead reflect the aggregate grant date fair value of restricted stock unit awards granted to him in 2020 under the stockholder-approved 2019 Plan to compensate him for awards from his former employer that he forfeited upon joining Colgate. The value of these restricted stock unit awards is based on the fair market value (which is the closing stock price) of our Common Stock on the date of grant. | Since Mr. Sutula joined Colgate in November 2020, he did not receive PBRSUs pursuant to the Growth Performance Plan for the 2020-2022 performance cycle. The amounts reported in this column for Mr. Sutula for 2020 instead reflect the aggregate grant date fair value of restricted stock unit awards granted to him in 2020 under the stockholder-approved 2019 Plan to compensate him for awards from his former employer that he forfeited upon joining Colgate. The value of these restricted stock unit awards is based on the fair market value (which is the closing stock price) of our Common Stock on the date of grant. |

---

**44**

**[**Table of Contents**](#toc)** 

Executive Compensation

---

| | |
|:---|:---|
|  | The amounts reported in this column for 2021 also reflect the aggregate grant date fair value of performance-based restricted stock unit awards made to each Named Officer (other than Mr. Sutula) pursuant to our legacy Long-Term Global Growth Program under the stockholder-approved 2019 Plan in 2021 with respect to the 2018-2020 performance cycle based on pre-established performance measures. The value of these restricted stock unit awards is based on the fair market value (which is the closing stock price) of our Common Stock on the date of grant. No amounts are shown for 2020 under the legacy Long-Term Global Growth Program for the performance cycle ending in 2019, because none were earned. 2018-2020 represented the final performance cycle under the Long-Term Global Growth Program, so there were no awards granted under that program in 2022. |
| <sup>(3)</sup>  | **Option Awards.** This column reflects the aggregate grant date fair value of stock option awards granted to each Named Officer in the years reported under the stockholder-approved 2019 Plan. The estimated value of stock options is calculated using the Black-Scholes model. For a description of the assumptions used to calculate the amounts, see Note 8 ("Capital Stock and Stock-Based Compensation Plans") to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022. For more information regarding these awards, including their terms and conditions, see page 40 of the CD&A and the Grants of Plan-Based Awards Table. |
| <sup>(4)</sup>  | **Non-Equity Incentive Plan Compensation.** This column reflects the cash bonuses earned by the Named Officers under the stockholder-approved 2019 Plan based on one or more pre-established performance measures, as discussed more fully on pages 38 to 39 of the CD&A. These bonuses were awarded and paid after audited financial results for the years for which performance was measured were known early in the following year. See the Grants of Plan-Based Awards Table for more information regarding 2022 bonuses. |
| <sup>(5)</sup>  | **Change in Pension Value.** This column reflects (i) for Ms. Parameswaran and Messrs. Tsourapas and Wallace, the aggregate change in the actuarial present value of their accumulated benefit under the Colgate-Palmolive Company Employees' Retirement Income Plan (the "Retirement Plan") and the Colgate-Palmolive Company Supplemental Salaried Employees' Retirement Plan (the "Supplemental Retirement Plan") from December 31, 2021 to December 31, 2022, December 31, 2020 to December 31, 2021 and December 31, 2019 to December 31, 2020, as applicable, reflecting additional interest credited to their plan accounts as described beginning on page 49 and (ii) for Mr. Wallace, above-market interest earned during those periods ($6,046 in 2022) under the Colgate-Palmolive Company Supplemental Savings and Investment Plan (the "Supplemental Savings & Investment Plan"), as described on page 51. None of the Named Officers except Mr. Wallace earned above-market interest under the Supplemental Savings & Investment Plan. Ms. Daniels and Mr. Sutula are not participants in the Retirement Plan or Supplemental Retirement Plan and instead participate only in our defined contribution plans so no amounts are shown for either of them in this column. |
| <sup>(6)</sup>  | **All Other Compensation.** The amounts shown in this column are paid pursuant to programs available either to all U.S. employees generally or to a broad group of management employees, except as specifically noted in the footnotes below. The dollar amounts paid under each such program and the value of perquisites and other personal benefits granted to the Named Officers in 2022 were: |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Named Officer** | **Company** <br> **Contributions** <br> **to Savings &**<br> **Investment <br>401(k) Plan <br>($)**  | <sup>**(a)**</sup> | **Company**<br> **Allocations to** <br> **Supplemental** <br> **Savings &** <br> **Investment** <br> **Plan<br>($)**  | <sup>**(b)**</sup> | **Value of** <br> **Company-**<br> **Paid Life** <br> **Insurance** <br> **Premiums<br>($)**  | **Perquisites** <br> **and Other** <br> **Personal** <br> **Benefits** <br> **($)** | <sup>**(c)**</sup> |
| **Noel R. Wallace** | 35837 |  | 491193 |  | 2754 | 98372 |  |
| **Stanley J. Sutula III** | 28213 |  | 108687 |  | 1785 |  |  |
| **Jennifer M. Daniels** | 32788 |  | 103247 |  | 2217 |  |  |
| **Prabha Parameswaran** | 35838 |  | 158272 |  | 1900 |  |  |
| **Panagiotis Tsourapas** | 35838 |  | 158272 |  | 2223 |  |  |

---

<sup>(a)</sup> This column reflects Company contributions to the Named Officers' accounts under the Colgate-Palmolive Company Employees Savings and Investment Plan (the "Savings & Investment Plan"), a broad-based employee stock ownership and 401(k) plan available generally to all U.S. employees. Profit-sharing contributions are made in the form of shares of Common Stock. Company matching contributions and retirement contributions are invested in the same form as employees' own contributions to the Savings & Investment Plan. The amounts shown represent the value of such contributions at the time of allocation to the Named Officers' accounts.

<sup>(b)</sup> This column reflects Company allocations to the Supplemental Savings & Investment Plan, a plan available to U.S. employees who are not able to receive the full Company matching or retirement contributions under the Savings & Investment Plan due to Internal Revenue Service ("IRS") or Savings & Investment Plan rules. Amounts allocated by Colgate to the Named Officers' and other employees' accounts under this plan are equal only to the amount of the Company matching and/or retirement contributions that cannot be made to the Savings & Investment Plan due to these IRS or Savings & Investment Plan rules.

<sup>(c)</sup> This column consists of the incremental cost to Colgate of the personal use of a car and driver by Mr. Wallace, valued as a proportionate amount of the cost of the annual lease, driver and related operating expenses. Any income taxes due as a result of this perquisite are the responsibility of Mr. Wallace.

<sup>(7)</sup> Mr. Sutula was appointed Chief Financial Officer effective November 9, 2020. In connection with his hiring, he received a one-time sign-on bonus of $100,000 in 2020 to compensate him for certain retirement and other benefits he relinquished upon his departure from his former employer, Pitney Bowes. In addition, in March 2021 he received cash payments of (i) $492,600, equal to the actual 2020 annual bonus he would have received from Pitney Bowes had he remained in his prior role and (ii) $385,308, equal to the value of the restricted stock units he would have received under the Pitney Bowes long-term incentive compensation program for the Pitney Bowes 2018-2020 performance cycle had he remained in his prior role, and in March 2022, he received a cash payment of $589,199, equal to the value of the restricted stock units he would have received under the Pitney Bowes long-term incentive compensation program for the Pitney Bowes 2019-2021 performance cycle had he remained in his prior role. These compensatory arrangements were negotiated at arm's length at a level appropriate to attract external talent.

---

| | |
|:---|:---|
| 2023 Proxy Statement | **45** |

---

**[**Table of Contents**](#toc)** 

Executive Compensation

**Grants of Plan-Based Awards**

The following table shows information in accordance with SEC requirements about the non-equity incentive awards, stock options and PBRSUs that are reflected in the Summary Compensation Table for 2022 and that were granted to the Named Officers either during, or with respect to services rendered in, 2022.

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  | **Estimated Possible <br> Payouts Under Non-Equity <br> Incentive Plan Awards**<sup>(1)</sup> | **Estimated Possible <br> Payouts Under Non-Equity <br> Incentive Plan Awards**<sup>(1)</sup> | **Estimated Possible <br> Payouts Under Non-Equity <br> Incentive Plan Awards**<sup>(1)</sup> | **Estimated Possible <br> Payouts Under Equity<br> Incentive Plan Awards**<sup>(2)</sup> | **Estimated Possible <br> Payouts Under Equity<br> Incentive Plan Awards**<sup>(2)</sup> | **Estimated Possible <br> Payouts Under Equity<br> Incentive Plan Awards**<sup>(2)</sup> | **All Other <br> Option <br> Awards:<br> Number of <br> Securities <br> Underlying <br> Options (#)** | <sup>(3)</sup> | **Exercise <br> or Base <br> Price of<br> Option <br> Awards <br> ($/Sh)** | **Grant <br> Date Fair <br> Value of <br> Stock and <br> Option <br> Awards <br> ($)** | <sup>(4)</sup> |
| **Name** | **Grant<br> Date** | **Threshold<br> ($)** | **Target<br> ($)** | **Maximum<br> ($)** | **Threshold<br> (#)** | **Target<br> (#)** | **Maximum<br> (#)** | **All Other <br> Option <br> Awards:<br> Number of <br> Securities <br> Underlying <br> Options (#)** | <sup>(3)</sup> | **Exercise <br> or Base <br> Price of<br> Option <br> Awards <br> ($/Sh)** | **Grant <br> Date Fair <br> Value of <br> Stock and <br> Option <br> Awards <br> ($)** | <sup>(4)</sup> |
| **(a)** | **(b)** | **(c)** | **(d)** | **(e)** | **(f)** | **(g)** | **(h)** **(i)** | **(j)** |  | **(k)** | **(l)** |  |
| Noel R. Wallace | 3/10/22 |  |  |  | 6433 | 64328 | 128656 |  |  |  | 4364655 |  |
|  | 9/9/22 |  |  |  |  |  |  | 322910 |  | 78.03 | 4750006 |  |
|  | 2/16/23 | 122500 | 2450000 | 4900000 |  |  |  |  |  |  |  |  |
| Stanley J. Sutula III | 3/10/22 |  |  |  | 1507 | 15066 | 30132 |  |  |  | 1022228 |  |
|  | 9/9/22 |  |  |  |  |  |  | 75629 |  | 78.03 | 1112503 |  |
|  | 2/16/23 | 45757 | 915140 | 1830280 |  |  |  |  |  |  |  |  |
| Jennifer M. Daniels | 3/10/22 |  |  |  | 1246 | 12459 | 24918 |  |  |  | 845343 |  |
|  | 9/9/22 |  |  |  |  |  |  | 62543 |  | 78.03 | 920008 |  |
|  | 2/16/23 | 33809 | 676184 | 1352368 |  |  |  |  |  |  |  |  |
| Prabha Parameswaran | 3/10/22 |  |  |  | 1246 | 12459 | 24918 |  |  |  | 845343 |  |
|  | 9/9/22 |  |  |  |  |  |  | 62543 |  | 78.03 | 920008 |  |
|  | 2/16/23 | 35412 | 708240 | 1416480 |  |  |  |  |  |  |  |  |
| Panagiotis Tsourapas | 3/10/22 |  |  |  | 1246 | 12459 | 24918 |  |  |  | 845343 |  |
|  | 9/9/22 |  |  |  |  |  |  | 62543 |  | 78.03 | 920008 |  |
|  | 2/16/23 | 35412 | 708240 | 1416480 |  |  |  |  |  |  |  |  |

---

**NOTES TO THE GRANTS OF PLAN-BASED AWARDS TABLE**

<sup>(1)</sup> The amounts shown represent the threshold, target and maximum payouts for annual performance-based cash bonuses under the stockholder-approved 2019 Plan with respect to services rendered in 2022. The threshold amounts represent the potential payout if performance against the pre-established performance measures is at the lowest level resulting in an award being paid, while the target and maximum amounts represent the potential payout if performance against the pre-established performance measures is at target and maximum levels, respectively. The actual amounts awarded are reported in column (g) of the Summary Compensation Table. See pages 38 to 39 of the CD&A for a description of our annual incentive program, including the above-mentioned performance measures.

<sup>(2)</sup> The amounts shown represent the number of shares the Named Officers are eligible to earn at the threshold, target and maximum levels in connection with the target PBRSUs granted to the Named Officers in March 2022 under the Growth Performance Plan pursuant to the stockholder-approved 2019 Plan for the 2022-2024 performance cycle. The threshold amounts represent the number of shares that would be earned if performance against the pre-established performance measures is at the lowest level resulting in an award being paid, while the target and maximum amounts represent the number of shares that would be earned if performance against the pre-established performance measures is at target and maximum levels, respectively. The awards are also subject to a relative total shareholder return modifier. The aggregate grant date fair value of such awards is included in column (e) of the Summary Compensation Table. As described in more detail on pages 40 to 42 of the CD&A, these PBRSUs provide the Named Officers with an opportunity to earn shares of Common Stock, the amount of which will be determined based on our performance against pre-established performance measures over the three-year performance period from January 1, 2022 to December 31, 2024. Target award opportunities were expressed in dollars and converted into the target number of PBRSUs based on the price of our Common Stock on the date of grant.

<sup>(3)</sup> The amounts shown represent annual stock option awards granted in September 2022 under the stockholder-approved 2019 Plan. The aggregate grant date fair value of such awards is included in column (f) of the Summary Compensation Table. The key terms of our stock options are as follows: (i) the exercise price is equal to the closing price of our Common Stock on the date of grant; (ii) the term is eight years; and (iii) they vest in equal annual installments over three years.

<sup>(4)</sup> This column shows the grant date fair value of: (i) the unearned PBRSUs granted to the Named Officers in March 2022 under the Growth Performance Plan for the 2022-2024 performance cycle calculated in accordance with accounting guidance and (ii) the stock option awards shown in column (j) of this table calculated using the Black-Scholes model. For a description of the assumptions used to calculate these amounts, see Note 8 ("Capital Stock and Stock-Based Compensation Plans") to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022.

**46**

**[**Table of Contents**](#toc)** 

Executive Compensation

**Outstanding Equity Awards at Fiscal Year-End**

The following table contains information about stock options and PBRSUs and other restricted stock units held by the Named Officers as of December 31, 2022.

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Option Awards<sup>(1)(2)</sup>** | **Option Awards<sup>(1)(2)</sup>** | **Option Awards<sup>(1)(2)</sup>** | **Option Awards<sup>(1)(2)</sup>** | **Option Awards<sup>(1)(2)</sup>** | **Stock Awards<sup>(1)</sup>** | **Stock Awards<sup>(1)</sup>** | **Stock Awards<sup>(1)</sup>** | **Stock Awards<sup>(1)</sup>** |
| **Name** | **Option<br> Grant** | **Number of <br> Securities <br> Underlying <br> Unexercised <br> Options <br> (#)<br> Exercisable** | **Number of <br> Securities <br> Underlying <br> Unexercised <br> Options <br> (#)<br> Unexercisable**<sup>(3)</sup> | **Option <br> Exercise <br> Price <br> ($)** | **Option <br> Expiration<br> Date** | **Number of <br> Shares or <br> Units of <br> Stock <br> That <br> Have Not <br> Vested<br> (#)**<sup>(4)(5)</sup> | **Market <br> Value <br> of Shares <br> or Units <br> of Stock <br> That Have <br> Not <br> Vested<br> ($)**<sup>(6)</sup> | **Equity <br> Incentive <br> Plan Awards: <br> Number of <br> Unearned <br> Shares, <br> Units or <br> Other Rights <br> That Have <br> Not Vested<br> (#)**<sup>(7)</sup> | **Equity <br> Incentive <br> Plan Awards: <br> Market or <br> Payout Value <br> of Unearned <br> Shares, Units or <br> Other Rights <br> That Have <br> Not Vested<br> ($)**<sup>(8)</sup> |
| **(a)** | **Date** | **(b)** | **(c)** | **(e)** | **(f)** | **(g)** | **(h)** | **(i)** | **(j)** |
| Noel R. Wallace | 9/25/17 | 98627 |  | 73.00 | 9/25/23 | 73516 | 5792326 | 124113 | 9778863 |
|  | 9/13/18 | 105486 |  | 68.16 | 9/13/24 |  |  |  |  |
|  | 9/12/19 | 322042 |  | 72.29 | 9/12/27 |  |  |  |  |
|  | 9/10/20 | 251628 | 125815 | 76.41 | 9/10/28 |  |  |  |  |
|  | 9/10/21 | 135013 | 270028 | 77.04 | 9/10/29 |  |  |  |  |
|  | 9/9/22 |  | 322910 | 78.03 | 9/9/30 |  |  |  |  |
| Stanley J. Sutula III | 11/9/20 | 65228 | 32615 | 81.78 | 11/9/28 | 21399 | 1686027 | 29149 | 2296650 |
|  | 9/10/21 | 31803 | 63607 | 77.04 | 9/10/29 |  |  |  |  |
|  | 9/9/22 |  | 75629 | 78.03 | 9/9/30 |  |  |  |  |
| Jennifer M. Daniels | 9/25/17 | 49407 |  | 73.00 | 9/25/23 | 16223 | 1278210 | 24085 | 1897657 |
|  | 9/13/18 | 65433 |  | 68.16 | 9/13/24 |  |  |  |  |
|  | 9/12/19 | 66250 |  | 72.29 | 9/12/27 |  |  |  |  |
|  | 9/10/20 | 46625 | 23313 | 76.41 | 9/10/28 |  |  |  |  |
|  | 9/10/21 | 24940 | 49880 | 77.04 | 9/10/29 |  |  |  |  |
|  | 9/9/22 |  | 62543 | 78.03 | 9/9/30 |  |  |  |  |
| Prabha Parameswaran | 9/25/17 | 64373 |  | 73.00 | 9/25/23 | 16190 | 1275610 | 24085 | 1897657 |
|  | 9/13/18 | 56836 |  | 68.16 | 9/13/24 |  |  |  |  |
|  | 9/12/19 | 66794 |  | 72.29 | 9/12/27 |  |  |  |  |
|  | 9/10/20 | 46625 | 23313 | 76.41 | 9/10/28 |  |  |  |  |
|  | 9/10/21 | 24940 | 49880 | 77.04 | 9/10/29 |  |  |  |  |
|  | 9/9/22 |  | 62543 | 78.03 | 9/9/30 |  |  |  |  |
| Panagiotis Tsourapas | 9/25/17 | 68698 |  | 73.00 | 9/25/23 | 16223 | 1278210 | 24085 | 1897657 |
|  | 9/13/18 | 65433 |  | 68.16 | 9/13/24 |  |  |  |  |
|  | 9/12/19 | 66794 |  | 72.29 | 9/12/27 |  |  |  |  |
|  | 9/10/20 | 46625 | 23313 | 76.41 | 9/10/28 |  |  |  |  |
|  | 9/10/21 | 24940 | 49880 | 77.04 | 9/10/29 |  |  |  |  |
|  | 9/9/22 |  | 62543 | 78.03 | 9/9/30 |  |  |  |  |

---

**NOTES TO THE OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END TABLE**

<sup>(1)</sup> For information regarding the treatment of these awards in the event of termination of employment under various circumstances including retirement, see "Executive Severance and Other Termination Benefits—Equity Awards."

<sup>(2)</sup> The following table contains information about the aggregate value of stock options held by each of the Named Officers as of December 31, 2022. The values shown are calculated based on the difference between the closing price of our Common Stock on December 31, 2022 and the applicable exercise prices.

---

| | | |
|:---|:---|:---|
|  | **Value of Unexercised <br> In-the-Money Options<br> at Fiscal Year-End** | **Value of Unexercised <br> In-the-Money Options<br> at Fiscal Year-End** |
| **Named Officer** | **Exercisable<br> ($)** | **Unexercisable<br> ($)** |
| Noel R. Wallace | 4620787 | 1017400 |
| Stanley J. Sutula III | 55655 | 168790 |
| Jennifer M. Daniels | 1566857 | 190308 |
| Prabha Parameswaran | 1565660 | 190308 |
| Panagiotis Tsourapas | 1682088 | 190308 |

---

<sup>(3)</sup> The stock option awards shown in this column vest as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Named Officer** | **9/9/23** | **9/10/23** | **11/9/23** | **9/9/24** | **9/10/24** | **9/9/25** |
| Noel R. Wallace | 107636 | 260829 |  | 107637 | 135014 | 107637 |
| Stanley J. Sutula III | 25209 | 31803 | 32615 | 25210 | 31804 | 25210 |
| Jennifer M. Daniels | 20847 | 48253 |  | 20848 | 24940 | 20848 |
| Prabha Parameswaran | 20847 | 48253 |  | 20848 | 24940 | 20848 |
| Panagiotis Tsourapas | 20847 | 48253 |  | 20848 | 24940 | 20848 |

---

---

| | |
|:---|:---|
| 2023 Proxy Statement | **47** |

---

**[**Table of Contents**](#toc)** 

Executive Compensation

<sup>(4)</sup> The amounts shown in this column and in note 5 below also include, where applicable, dividend equivalents in the form of additional restricted stock units that have accrued during the applicable vesting period, rounded down to the nearest whole number. Any accrued fractional restricted stock units are settled in cash and therefore are not included in the amounts shown.

<sup>(5)</sup> The earned PBRSUs and restricted stock units shown in this column will vest as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **PBRSUs** | **Restricted Stock Units** | **Restricted Stock Units** | **Restricted Stock Units** |
| <br>**Named Officer** | **2/16/23** | **2/15/23** | **11/9/23** | **2/18/24** |
| Noel R. Wallace | 45461 |  |  | 28055 |
| Stanley J. Sutula III |  | 17669 | 3730 |  |
| Jennifer M. Daniels | 9361 |  |  | 6862 |
| Prabha Parameswaran | 9361 |  |  | 6829 |
| Panagiotis Tsourapas | 9361 |  |  | 6862 |

---

<sup>(6)</sup> The market value of earned PBRSUs and restricted stock units that have not vested is calculated based on the closing price of our Common Stock on December 31, 2022.

<sup>(7)</sup> The PBRSUs shown in this column were granted under our Growth Performance Plan and will vest, subject to achievement of the applicable performance criteria, in February 2024 and February 2025, as shown in the below table. The amounts shown in this column (and in column (j)) reflect the number of shares each of the Named Officers will earn if the target level of performance is achieved.

---

| | | |
|:---|:---|:---|
|  | **Unearned PBRSUs Under the Growth<br> Performance Plan – Target Level** | **Unearned PBRSUs Under the Growth<br> Performance Plan – Target Level** |
| **Named Officer** | **2021-2023 Cycle<br> (Vesting in 2024)** | **2022-2024 Cycle<br> (Vesting in 2025)** |
| Noel R. Wallace | 59785 | 64328 |
| Stanley J. Sutula III | 14083 | 15066 |
| Jennifer M. Daniels | 11626 | 12459 |
| Prabha Parameswaran | 11626 | 12459 |
| Panagiotis Tsourapas | 11626 | 12459 |

---

<sup>(8)</sup> The market value of unearned PBRSUs that have not vested is calculated based on the closing price of our Common Stock on December 31, 2022.

**Option Exercises and Stock Vested**

The following table contains information about the number of shares acquired and value realized (including, in the case of restricted stock units, dividend equivalents in the form of additional restricted stock units that accrued during the vesting period) during 2022 upon the exercise or vesting of equity awards previously granted to each of the Named Officers.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Option Awards** | **Option Awards** | **Stock Awards** | **Stock Awards** |
| **Name** | **Number of<br> Shares Acquired<br> on Exercise (#)** | **Value<br> Realized<br> on Exercise ($)** **<sup>(1)</sup>** | **Number of<br> Shares Acquired<br> on Vesting (#)** | **Value<br> Realized<br> on Vesting ($)** **<sup>(2)</sup>** |
| **(a)** | **(b)** | **(c)** | **(d)** | **(e)** |
| Noel R. Wallace | 101665 | 745271 | 73562 | 5822432 |
| Stanley J. Sutula III |  |  | 3730 | 274106 |
| Jennifer M. Daniels | 65283 | 607161 | 16797 | 1329483 |
| Prabha Parameswaran | 48778 | 283257 | 12450 | 985418 |
| Panagiotis Tsourapas | 60976 | 530869 | 14332 | 1134378 |

---

**NOTES TO THE OPTION EXERCISES AND STOCK VESTED TABLE**

<sup>(1)</sup> The aggregate dollar amount realized upon the exercise of stock options is calculated based on the difference between the fair market value of our Common Stock on the exercise date and the exercise price of the stock option.

<sup>(2)</sup> The aggregate dollar amount realized upon the vesting of PBRSUs and restricted stock units is calculated based on the closing price of our Common Stock on the vesting date of each award. The aggregate dollar amount realized upon the vesting of PBRSUs and restricted stock units includes the value of any accrued fractional restricted stock units settled in cash.

**48**

**[**Table of Contents**](#toc)** 

Executive Compensation

**Retirement Plans**

Ms. Parameswaran and Messrs. Tsourapas and Wallace are participants in and will receive retirement benefits under the Retirement Plan, a broad-based, tax-qualified retirement plan available generally to all U.S. employees who were eligible for the plan as of August 31, 2010, and the Supplemental Retirement Plan, a non-qualified supplemental plan available to employees whose benefits under the Retirement Plan are subject to certain IRS limits. The Supplemental Retirement Plan provides for payment of the portion of the Retirement Plan benefit that exceeds IRS and Retirement Plan limits. Our retirement programs, including these plans, are generally designed to provide our long-serving, retiring employees with competitive replacement income based on prevailing market practice. Employees hired after June 1, 2010 are not eligible to participate in the Retirement Plan. Ms. Daniels and Mr. Sutula, who joined Colgate in 2014 and 2020, respectively, are not participants in either the Retirement Plan or the Supplemental Retirement Plan.

All Named Officers participate in the Savings & Investment Plan, a defined contribution plan sponsored by Colgate generally available to all U.S. employees, as well as the Supplemental Savings & Investment Plan, a plan available to U.S. employees whose benefits under the Savings & Investment Plan are otherwise limited due to IRS or Savings & Investment Plan rules.

Ms. Parameswaran's and Messrs. Tsourapas's and Wallace's Retirement Plan benefits are determined in accordance with the Personal Retirement Account ("PRA") formula. Under the PRA formula, the benefit is payable upon the employee's departure from Colgate at any age and the value is equal to the employee's vested account balance. Total annual retirement benefits payable under the Retirement Plan and the Supplemental Retirement Plan are subject to a maximum of 70% of the sum of an individual's base salary at retirement plus cash-based incentive compensation awarded for services rendered in the calendar year immediately preceding retirement. Under the standard form of retirement benefit for a married participant, the employee receives a monthly retirement benefit for life and, upon the employee's death, their spouse is entitled to receive a monthly benefit for life equal to 50% of the employee's benefit. For approximately 200 employees, including the Named Officers who participate in the Retirement Plan, the employee's spouse is entitled to receive an additional monthly amount equal to 25% of the employee's normal monthly retirement benefit for life if the employee dies during retirement or while in active service after attaining early retirement eligibility. However, this benefit is not available to the extent it would cause the total retirement benefit payable to the employee's spouse to exceed 100% of the employee's normal retirement benefit and is not available if a participant elects a lump sum form of payment under the Retirement Plan.

If the participant in question is a "specified employee" under Section 409A of the Internal Revenue Code of 1986, as amended (the "Internal Revenue Code"), there may be a six-month delay in the commencement of Supplemental Retirement Plan distributions, if triggered by the participant's termination or retirement.

Ms. Parameswaran and Messrs. Tsourapas and Wallace each accrued benefits under the PRA formula until December 31, 2013. PRA formula benefits are determined as follows: On July 1, 1989, an account was established for each eligible person employed on June 30, 1989, with an opening balance equal to the greater of (i) the value of the pension then accrued under the formula that existed prior to July 1, 1989 and (ii) an amount equal to the sum of the monthly pay-based credits that would have been made to the employee's account had the PRA formula always been in effect. For employees who were hired or became eligible to participate in the Retirement Plan between July 1, 1989 and June 1, 2010, monthly pay-based credits accumulated in a PRA account established in the employee's name. Through August 31, 2010, these credits equaled a percentage of the employee's monthly recognized earnings determined in accordance with the following schedule:

---

| | | |
|:---|:---|:---|
| **Years of Service** | **Up to 1/48 of<br> Social Security<br> Wage Base** | **Over 1/48 of<br> Social Security<br> Wage Base** |
| 0–9 | 2.50% | 3.75% |
| 10–14 | 3.00% | 4.50% |
| 15–19 | 4.00% | 6.00% |
| 20–24 | 5.35% | 8.00% |
| 25 or more | 7.50% | 11.25% |

---

"Recognized earnings" for a particular year were set on February 1 each year prior to 2022, and consisted of the higher of (i) the compensation earned by an employee during the previous year and (ii) their annual salary as of January 1 of the year in question plus the annual bonus paid to the employee in the previous year. Recognized earnings did not include the value of equity compensation.

---

| | |
|:---|:---|
| 2023 Proxy Statement | **49** |

---

**[**Table of Contents**](#toc)** 

Executive Compensation

The PRA formula was amended effective September 1, 2010 to provide for monthly pay-based credits equal to a percentage of the employee's monthly recognized earnings determined in accordance with the following schedule:

---

| | |
|:---|:---|
| **Years of Service** | **Basic Retirement<br> Contributions** |
| 0–9 | 2.00% |
| 10 or more | 2.50% |

---

In addition, eligible employees received additional allocations to their PRA accounts in September 2010 and September 2011 of 0.25% of their projected PRA balance as of August 31, 2010 for each full year of vesting service through August 31, 2010, up to a combined maximum of 15% based on 30 years of service.

The Retirement Plan was amended effective January 1, 2014 to provide that no additional pay-based credits will be made to PRA accounts after December 31, 2013. This change also applied to the Supplemental Retirement Plan.

Employees who accrued benefits under the PRA formula receive monthly credits for interest in their accounts. Interest credits continue after December 31, 2013. The interest crediting rate for 2022 was 2.82%, which was determined in accordance with the Retirement Plan rules and applicable IRS guidance.

For employees retiring under the PRA formula, benefits earned under the Supplemental Retirement Plan through December 31, 2004 will follow the form of payment elected under the Retirement Plan, and benefits earned after December 31, 2004 will be paid in a lump sum. However, employees may request to have their full retirement benefit under the Supplemental Retirement Plan paid in a lump sum. Such requests may be accepted or denied.

**Pension Benefits**

The following table shows the actuarial present value of each Named Officer's total accumulated benefit as of December 31, 2022 under the terms of the Retirement Plan and the Supplemental Retirement Plan. As described above, Ms. Daniels and Mr. Sutula are not participants in the Retirement Plan or the Supplemental Retirement Plan and therefore do not appear in the following table.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Name** | **Plan Name** | **Number of Years<br> Credited Service<br> (#)** | **<sup>(1)</sup>** | **Present Value of<br> Accumulated Benefit<br> ($)** | **<sup>(2)</sup>** | **Payments During<br> Last Fiscal Year<br> ($)** |
| **(a)** | **(b)** | **(c)** |  | **(d)** |  | **(e)** |
| Noel R. Wallace | Retirement Plan | 26.25 |  | 495442 |  |  |
|  | Supplemental Retirement Plan | 26.25 |  | 436691 |  |  |
|  |  |  |  | 932133 |  |  |
| Prabha Parameswaran | Retirement Plan | 16.17 |  | 245633 |  |  |
|  | Supplemental Retirement Plan | 16.17 |  | 29940 |  |  |
|  |  |  |  | 275573 |  |  |
| Panagiotis Tsourapas | Retirement Plan | 3.58 |  | 38571 |  |  |
| Panagiotis Tsourapas | Supplemental Retirement Plan | 3.58 |  | 41149 |  |  |
| Panagiotis Tsourapas |  |  |  | 79720 |  |  |

---

**NOTES TO THE PENSION BENEFITS TABLE**

---

| | |
|:---|:---|
| <sup>(1)</sup> | For Mr. Wallace, the years in this column represent the actual years worked by him for Colgate as of December 31, 2013. For Ms. Parameswaran and Mr. Tsourapas, the years in this column represent the years worked by them for Colgate as of December 31, 2013 during which they were eligible to participate in the Retirement Plan and Supplemental Retirement Plan described above. As noted above, the Retirement Plan and Supplemental Retirement Plan do not take into account service after December 31, 2013. |
| <sup>(2)</sup> | The amounts shown reflect the value as of December 31, 2022 of the applicable Named Officers' benefits under the PRA formula under the Retirement Plan and Supplemental Retirement Plan described above. |
|  | As noted above, Ms. Parameswaran and Messrs. Tsourapas and Wallace are eligible to receive their full benefit (including benefits under both the Retirement Plan and the Supplemental Retirement Plan) in a lump sum under the PRA formula. |

---

**50**

**[**Table of Contents**](#toc)** 

Executive Compensation

**Deferred Compensation Plan**

Prior to 2021, eligible employees, including the Named Officers, were able to elect annually to defer a portion of their salary and/or cash bonus under the Colgate-Palmolive Company Deferred Compensation Plan (the "Deferred Compensation Plan"). Under this plan, participants could defer up to 75% of their salary and/or 100% of their cash bonus payable in the following calendar year. At the option of the participant, these amounts could be deferred to a specific date, at least five years from when the compensation was otherwise payable, or until retirement. Effective October 28, 2021, the Deferred Compensation Plan was amended to prohibit new participation and freeze future deferral elections. Prior deferral elections were unaffected by the amendment.

Interest on deferred amounts is credited to the participant's account at the end of each calendar year and compounded annually. Interest accrues at a fixed rate equal to 120% of the Applicable Federal Rate ("AFR") published by the IRS for the year of deferral. Mid- or long-term AFRs are used based on the length of the deferral period elected. Once established at the time of deferral, the same rate remains in effect throughout the entire deferral period.

At the time of deferral, a participant indicated whether they wished to receive the amount deferred in either a lump sum or up to ten annual installments. If the participant in question is a "specified employee" under Section 409A of the Internal Revenue Code, there may be a six-month delay in the commencement of distributions, if triggered by the participant's termination or retirement. Changes to deferral elections and early withdrawals from deferred accounts are only permitted in extreme cases, such as unforeseen financial hardship that is demonstrated to the P&O Committee. Of the Named Officers, only Mr. Wallace had previously elected to participate in the Deferred Compensation Plan, and information about earnings on his prior deferrals is included in the Nonqualified Deferred Compensation Table.

**Supplemental Savings & Investment Plan**

Employees, including the Named Officers, whose earnings exceed IRS limitations on compensation that may be recognized under the Savings & Investment Plan or whose benefits under the Savings & Investment Plan are otherwise limited due to IRS or Savings & Investment Plan rules, are entitled to receive a supplemental contribution under the Supplemental Savings & Investment Plan. The supplemental contribution is equal to the amount of the Company's matching contributions and/or retirement contributions that cannot be made under the Savings & Investment Plan due to certain IRS or Savings & Investment Plan rules. Under the Savings & Investment Plan, we match a portion of employee contributions up to 6% of the employee's eligible earnings and provide retirement contributions based on a percentage of eligible earnings as such earnings are paid to the employee, subject to a maximum amount of eligible earnings under applicable IRS regulations ($330,000 for 2023 and $305,000 for 2022). Eligible earnings include compensation paid in cash but do not include the value of equity compensation. The supplemental contributions are allocated to the Supplemental Savings & Investment Plan.

Interest is credited under the Supplemental Savings & Investment Plan as follows:

&nbsp;&nbsp;&nbsp;&nbsp;**•** Contributions allocated to the plan through December 31, 2002 realize investment results based on the performance of our Common Stock.

**•** Contributions allocated to the plan from January 1, 2003 through December 31, 2009 for matching contributions were credited with interest at annual interest rates calculated on the same basis as under the Deferred Compensation Plan described above. Effective October 1, 2010, the interest crediting rate was adjusted so that these contributions are credited with interest at the rate of 6.01%.

**•** Contributions allocated to the plan in December 2010 for 2010 matching contributions are credited with interest at the rate of 6.01%.

**•** Contributions allocated to the plan for retirement contributions beginning on September 1, 2010, and for matching contributions beginning on January 1, 2011, are credited with the same interest rate that applies under the Retirement Plan as described on page 50.

Amounts allocated to the Supplemental Savings & Investment Plan are distributed upon the participant's departure from Colgate. If the participant in question is a "specified employee" under Section 409A of the Internal Revenue Code, there may be a six-month delay in the commencement of distributions, if triggered by the participant's termination or retirement.

---

| | |
|:---|:---|
| 2023 Proxy Statement | **51** |

---

**[**Table of Contents**](#toc)** 

Executive Compensation

**Nonqualified Deferred Compensation**

The following table shows information about the amount of contributions, earnings and balances for each Named Officer under the Supplemental Savings & Investment Plan and, in the case of Mr. Wallace, the Deferred Compensation Plan as of December 31, 2022.

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| Name | Aggregate<br> Balance at<br> Beginning of<br> Last Fiscal<br> Year | Executive<br> Contributions<br> in Last<br> Fiscal<br> Year<br> ($) | Registrant<br> Contributions<br> in Last<br> Fiscal Year<br> ($) | <sup>(1)</sup> | Aggregate<br> Earnings<br> in Last<br> Fiscal Year<br> ($) | <sup>(2)</sup> | Aggregate<br> Withdrawals/<br> Distributions<br> ($) | Aggregate<br> Balance<br> at Last Fiscal<br> Year End<br> ($) | <sup>(3)</sup> |
| (a) | ($) | (b) | (c) |  | (d) |  | (e) | (f) |  |
| Noel R. Wallace | 2232891 |  | 491193 |  | 77183 |  |  | 2801267 |  |
| Stanley J. Sutula III | 45463 |  | 108687 |  | 3176 |  |  | 157326 |  |
| Jennifer M. Daniels | 417685 |  | 103247 |  | 13607 |  |  | 534539 |  |
| Prabha Parameswaran | 700278 |  | 158272 |  | 22618 |  |  | 881168 |  |
| Panagiotis Tsourapas | 905682 |  | 158272 |  | 28485 |  |  | 1092439 |  |

---

**NOTES TO THE NONQUALIFIED DEFERRED COMPENSATION TABLE**

<sup>(1)</sup> These amounts represent Company contributions under the Supplemental Savings & Investment Plan for 2022, which were allocated to the Supplemental Savings & Investment Plan. These contributions are also included in compensation reported for each Named Officer in column (i) of the Summary Compensation Table.

<sup>(2)</sup> These amounts represent the interest credited to each Named Officer during 2022 and the impact of investment results based on the performance of our Common Stock, as applicable, for amounts allocated under the Supplemental Savings & Investment Plan and, in the case of Mr. Wallace, deferred under the Deferred Compensation Plan. For further information regarding the calculation of interest earnings on these amounts, see page 51.

<sup>(3)</sup> To the extent that an executive was a "Named Officer" for a reported year, these amounts, other than the portion attributable to accrued earnings, were reported in previous proxy statements as compensation in the year of the executive's deferral (under the Deferred Compensation Plan) or the Company's contribution (under the Supplemental Savings & Investment Plan), as applicable.

**Executive Severance and Other Termination Benefits**

The P&O Committee periodically reviews the appropriateness of the payment and benefit levels provided under the plans and programs described in this section, based on competitive market information and emerging best practices and governance trends. In particular, the Colgate-Palmolive Company Executive Severance Plan (the "Severance Plan") is subject to approval periodically by the Board. The most recent approval was in September 2018.

**Severance Plan**

The Severance Plan is designed to provide participants with reasonable compensation if their employment is terminated following a change in control of the Company. Individual employees are assigned a particular severance level up to the maximum allowed under the plan (24 months) based on grade level and years of service.

Approximately 125 senior executives participate in the Severance Program, including the Named Officers. In addition to the Severance Plan, we have incorporated other arrangements relating to a change in control into our compensation and benefit plans, as described below.

Under the Severance Plan, if at any time within two years of a "change in control" of the Company, we terminate a Named Officer's employment for any reason other than for cause, or a Named Officer terminates employment due to an adverse change in his or her conditions of employment, such as a diminution in his or her position, authority or responsibilities, or a salary reduction (each a "Qualified Termination"), such Named Officer is entitled to receive a lump sum amount equal to (i) either 18 or 24 months of compensation (defined as base salary as of the termination date plus the average of his or her last three years' annual bonus awards) plus (ii) the present value of additional retirement program benefits he or she would have received had he or she remained employed until the end of the severance period, or age 65, if earlier. The Named Officers are also entitled to receive the continuation of medical, dental and life insurance benefits during the severance period. No severance payments are required if a Named Officer is terminated for "cause," which is defined as the felony conviction of the Named Officer for a crime having a detrimental effect on our reputation, business or financial condition, the Named Officer's willful engagement in any malfeasance, dishonesty, fraud or gross misconduct having a material detrimental effect on our reputation, business or financial condition or the Named Officer's willful and deliberate failure to materially perform his or her employment duties.

**52**

**[**Table of Contents**](#toc)** 

Executive Compensation

Generally under the plan, a "change in control" is deemed to occur if: (i) any person, entity or group acquires 30% or more of the outstanding shares of our Common Stock or voting securities (other than securities acquired directly from the Company); (ii) a majority of the board of directors as of the effective date of the Severance Plan is replaced (unless any subsequent board member is approved by at least a majority of the original incumbent board, who shall thereafter be considered an incumbent board member); (iii) a reorganization, merger, consolidation or sale or other disposition of all or substantially all of the Company's assets is consummated (other than under specific circumstances); or (iv) a complete liquidation or dissolution of the Company is approved by our stockholders.

If an outside accounting firm were to determine that a payment under the Severance Plan would cause a Named Officer to exceed the statutory limit and subject him or her to the so-called "golden parachute" tax under Section 4999 of the Internal Revenue Code, then the Named Officer would either (i) receive all payments and pay the tax or (ii) receive a reduced amount such that the tax does not apply, whichever approach yields the best after-tax outcome for the Named Officer.

In addition to the foregoing severance benefit, the Severance Plan provides for a payment within 30 days after the change in control, whether or not the Named Officer remains employed, of a pro-rated bonus for the year in which the change in control occurs. The pro-rated bonus paid may be used to offset any other bonus awarded for such year.

**Other Change-in-Control Arrangements**

Other arrangements relating to a change in control in our compensation and benefit plans are as follows.

&nbsp;&nbsp;&nbsp;&nbsp;**•** **Equity Awards.** We generally have a "double
trigger" vesting policy upon a change in control, meaning that unvested equity awards only vest upon a change in control if (i)
there is also a Qualified Termination or (ii) the acquirer fails to assume or replace the outstanding awards. The following provides
further detail about the treatment of various equity awards upon a change in control (assuming that outstanding awards are assumed or
replaced by the acquirer):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**•** Stock options held by employees that are not yet exercisable become exercisable upon a change
in control and a Qualified Termination; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**•** Unvested restricted stock units are considered earned in full and non-forfeitable (i) in
the case of performance-based awards for which the performance goals have been satisfied (i.e., restricted stock units granted under
our legacy Long-Term Global Growth Program), upon a change in control and (ii) in the case of all other awards (including PBRSUs granted
under our Growth Performance Plan), upon a change in control and a Qualified Termination. Upon a change in control and a Qualified Termination,
performance-based awards for which the performance goals have not yet been satisfied are deemed earned at the greater of the target level
or the level of performance achieved to that point.

&nbsp;&nbsp;&nbsp;&nbsp;**•** **Deferred Compensation Balances.** Under the Severance
Plan, participating employees are also entitled to receive within 30 days following a change in control all amounts previously deferred
by the employee under the Deferred Compensation Plan. They are also entitled to receive amounts held in the employee's Supplemental
Savings & Investment Plan account as soon as practicable following a change in control. For more information regarding the Deferred
Compensation Plan and the Supplemental Savings & Investment Plan, see page 51.

&nbsp;&nbsp;&nbsp;&nbsp;**•** **Letter of Credit for Unfunded Retirement Plan.** With respect to the Supplemental Retirement Plan, which is an unfunded plan, we have arranged for a letter of credit that requires the
issuing bank to fund the accrued benefits payable under this plan if we refuse to pay these benefits after a change in control. Funding
would be made by payments to a trust, the assets of which would be subject to the claims of our creditors if we were to become insolvent.

**Termination for Company Convenience**

If we terminate the employment of a Named Officer at the Company's convenience, we will pay in a lump sum an amount equal to between 12 and 24 months of the Named Officer's base salary and continue to pay certain medical and dental insurance benefits for either 12 or 18 months. Mr. Sutula and Ms. Daniels are also entitled to receive the continuation of life insurance benefits for 12 months following termination, while the other Named Officers, who each have at least 10 years of service with Colgate and are at least 55 years old, are eligible to receive retiree life insurance benefits. We are not required to make these payments if we terminate a Named Officer's employment for "cause" (as defined above) or if the Named Officer voluntarily terminates his or her employment.

**Deferred Compensation and Retirement Benefits**

For information about the pension benefits payable to the Named Officers upon their retirement and deferred compensation balances, see pages 49 to 52. In addition to the post-retirement welfare benefits available to U.S. employees generally, approximately 600 employees, including the Named Officers, who have at least 10 years of service at retirement, qualify for a post-retirement life insurance benefit. Named Officers are eligible to receive a retiree life insurance benefit up to a maximum of $750,000 in lieu of our regular life insurance benefit for retirees.

---

| | |
|:---|:---|
| 2023 Proxy Statement | **53** |

---

**[**Table of Contents**](#toc)** 

Executive Compensation

**Equity Awards**

The treatment, in general, of previously granted equity awards in the case of the termination of employment under the following circumstances is as follows:

---

| | | | |
|:---|:---|:---|:---|
| Nature of Termination | Stock Options | Unearned PBRSUs | Unvested Restricted Stock Units |
| **Change in Control<sup>(1)</sup>** | Double-trigger vesting | Double-trigger vesting | Double-trigger vesting<sup>(2)</sup> |
| **Termination for Cause** | Forfeited | Forfeited | Forfeited |
| **Termination for Company Convenience** | Vested stock options (including those that vest during the severance period) are exercisable for shorter of remainder of option term or three months; remaining unvested stock options are forfeited<sup>(3)(4)</sup> | Forfeited | Normal vesting continues through the severance period; remaining unvested are forfeited<sup>(3)(4)</sup> |
| **Retirement** | Fully vest; exercisable for shorter of remainder of option term or three years<sup>(4)</sup> | Pro rata vesting at the end of the performance period with payout subject to actual performance<sup>(5)</sup> | Normal vesting continues<sup>(4)</sup> |
| **Death or Disability** | Fully vest; exercisable for shorter of remainder of option term or three years | Pro rata vesting at the end of the performance period with payout subject to actual performance<sup>(5)</sup> | Normal vesting continues |
| **Resignation** | Vested stock options are exercisable for shorter of remainder of option term or three months; unvested stock options are forfeited | Forfeited | Forfeited |

---

<sup>(1)</sup> See "Other Change-In-Control Arrangements—Equity Awards" above for a full description of the treatment of equity awards following a change in control of the Company.

<sup>(2)</sup> Except for performance-based awards granted under our legacy Long-Term Global Growth Program for which the performance goals have been satisfied.

<sup>(3)</sup> If the employee becomes retirement-eligible during the severance period, stock options and restricted stock units instead receive retirement treatment.

<sup>(4)</sup> Except for special retention awards that are subject to continued employment.

<sup>(5)</sup> As long as the recipient was employed for at least the first six months of the performance period.

The treatments described above assume that employees comply with the terms and conditions of the applicable equity award agreements, including non-competition, non-solicitation and non-interference restrictions, in each case following termination of employment. Failure to comply with any of these requirements may result in forfeiture and/or cancellation of those equity awards.

**Potential Payments Upon Termination or Change in Control**

The following table sets forth the estimated incremental payments and benefits that would be payable to each Named Officer upon termination of their employment or a change in control of the Company, assuming that the triggering event occurred at year-end 2022. These amounts would be incremental to the compensation and benefit entitlements described previously in this Proxy Statement that are not contingent upon a termination or change in control.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | Change In Control | Change In Control | Involuntary<br> Termination | Involuntary<br> Termination |  |  |  |  |
| Name | Without<br> Qualified<br> Termination<br> ($)<sup>(1)</sup> | With<br> Qualified<br> Termination<br> ($)<sup>(2)</sup> | With<br> Cause<br> ($) | Without<br> Cause<br> ($)<sup>(3)</sup> | Resignation<br> ($) | Death<br> ($)<sup>(4)</sup> | Disability<br> ($)<sup>(4)</sup> | Retirement<br> ($)<sup>(5)</sup> |
| Noel R. Wallace |  | 5057428 |  | 2872819 |  |  |  |  |
| Stanley J. Sutula III |  | 3050214 |  | 953334 |  |  |  |  |
| Jennifer M. Daniels |  | 2722348 |  | 883856 |  |  |  |  |
| Prabha Parameswaran |  | 2504589 |  | 1364188 |  |  |  |  |
| Panagiotis Tsourapas |  | 3816355 |  | 1364188 |  |  |  |  |

---

**NOTES TO THE POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE IN CONTROL TABLE**

<sup>(1)</sup> **Change in Control without Qualified Termination.** As shown in this column, if there is a change in control but there is no Qualified Termination of the Named Officer's employment, the Named Officer would not be entitled to receive any incremental payment or benefit. However, the vesting or distribution of certain existing compensation reported previously in this Proxy Statement would be accelerated as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Equity Awards.** The vesting of certain previously earned but unvested performance-based restricted stock units would be accelerated as described under "Other Change-in-Control Arrangements—Equity Awards" above. All such awards were reported as compensation in the proxy statement for the year of grant, to the extent the executive was a "Named Officer" for that year. The estimated value as of year-end 2022 of the previously granted awards that would be accelerated for the applicable Named Officers is as follows: Mr. Wallace—$2,210,453; Ms. Daniels—$540,657; Ms. Parameswaran—$538,057; and Mr. Tsourapas—$540,657. For all of the applicable Named Officers, these amounts reflect the value of previously granted and earned performance-based restricted stock units under our legacy Long-Term Global Growth Program that they were already entitled to receive in accordance with their original vesting schedule because they were eligible for retirement but would be accelerated upon a change in control. The estimated value of restricted stock units that would be accelerated was calculated based on the closing

**54**

**[**Table of Contents**](#toc)** 

Executive Compensation

---

| | |
|:---|:---|
|  | price of our Common Stock on December 31, 2022. Assuming that all other outstanding equity awards were assumed or replaced upon the change in control, no other outstanding equity awards would be accelerated. |
| • | **Cash Bonus.** If the change in control occurs at year-end, as assumed in the table above, the Named Officers would be entitled to receive their annual cash bonus for the year in which the change in control occurs (reported as of year-end 2022 in column (g) of the Summary Compensation Table). |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Deferred Compensation Balances.** The Named Officers would be entitled to receive any amounts previously deferred by or allocated
to them under the Deferred Compensation Plan or Supplemental Savings & Investment Plan (reported as of year-end 2022 in column (f)
of the Nonqualified Deferred Compensation Table).

---

| | |
|:---|:---|
| <sup>(2)</sup> | **Change in Control with Qualified Termination.** This column consists of the following benefits under the Severance Plan described beginning on page 52: (i) severance payments; (ii) the value of benefits under our retirement programs during the severance period; and (iii) the value of the continuation of medical and dental (and, for Mr. Sutula and Ms. Daniels, life) insurance benefits during the severance period. The value of retirement benefits was calculated based on the difference between the present value of additional retirement program benefits that the Named Officer would have received had he or she remained employed until the end of the severance period, or age 65, if earlier, and the present value of retirement benefits payable at the change-in-control date without assuming future service. The additional medical, dental and life insurance benefits were valued based on the aggregate premiums paid by us for the applicable severance period. |
|  | In addition to the amounts shown in this column, the vesting or distribution of certain existing compensation reported previously in this Proxy Statement would be accelerated as follows: |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Equity Awards.** The vesting of previously earned but unvested restricted stock units and unearned PBRSUs would be accelerated
as described under "Other Change-in-Control Arrangements—Equity Awards" above. All such awards were reported as compensation
in the proxy statement for the year of grant, to the extent the executive was a "Named Officer" for that year. The estimated
value as of year-end 2022 of the previously granted awards that would be accelerated for the applicable Named Officers is as follows:
Mr. Wallace—$11,989,317; Mr. Sutula—$3,982,677; Ms. Daniels—$2,438,314; Ms. Parameswaran—$2,435,714; and Mr. Tsourapas—$2,438,314.
The amounts shown in the preceding sentence include the following values of previously granted and earned restricted stock units under
our legacy Long-Term Global Growth Program that they were already entitled to receive in accordance with their original vesting schedule
because they were eligible for retirement but would be accelerated upon a Qualified Termination: Mr. Wallace—$2,210,453; Ms. Daniels—$540,657;
Ms. Parameswaran—$538,057; and Mr. Tsourapas—$540,657. For the assumptions used to calculate the value of the restricted stock
units, see note 1 above. The estimated value of PBRSUs that would be considered earned in full and accelerated was calculated based on
(i) the greater of target level and the level of performance achieved through December 31, 2022 and (ii) the closing price of our Common
Stock on December 31, 2022.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Cash Bonus and PBRSU Award.** If the triggering event occurs at year-end, as assumed in the table above, the Named Officers would
be entitled to receive their annual cash bonus for the year in which the triggering event occurs (reported as of year-end 2022 in column
(g) of the Summary Compensation Table) and their earned PBRSUs for the Growth Performance Plan three-year performance cycle ending such
year, if any (reported in note 5 to the Outstanding Equity Awards at Fiscal Year-End Table).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Retirement Accruals and Deferred Compensation Balances.** The Named Officers would be entitled to receive their accrued retirement
benefits (reported in the Pension Benefits Table) and any amounts previously deferred by or allocated to them under the Deferred Compensation
Plan or Supplemental Savings & Investment Plan (reported as of year-end 2022 in column (f) of the Nonqualified Deferred Compensation
Table). The Named Officers would also be entitled to receive the balance in their accounts under the Savings & Investment Plan, including
the Company contributions to the accounts, as further described in note 5 below.

---

| | |
|:---|:---|
| <sup>(3)</sup> | **Involuntary Termination without Cause.** This column shows the severance payment and the value of the continuation of medical and dental (and, for Mr. Sutula and Ms. Daniels, life) insurance benefits during the severance period. For the assumptions used to calculate the additional insurance benefits, see note 2 above. |
|  | In addition to the amounts shown in this column, the vesting or distribution of certain existing compensation reported previously in this Proxy Statement would continue or be accelerated as follows: |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Equity Awards.** Certain earned but unvested restricted stock units would be allowed to vest in accordance with their original
vesting schedule and certain unvested stock options would become exercisable for a period of three months or until the end of the original
term, whichever is shorter, in each case only if they would have otherwise vested before the end of the severance period. All such awards
were reported as compensation in the proxy statement for the year of grant, to the extent the executive was a "Named Officer"
for that year. For Mr. Sutula the estimated value as of year-end 2022 of previously granted restricted stock units that would continue
to vest is $1,686,027. Mr. Sutula 's stock option award received in November 2020 in connection with his hiring would also be subject
to acceleration, but no amount is included here because the award was out of the money as of year-end 2022. No other amounts are shown
for any of the Named Officers because, as employees eligible for retirement, they were already entitled to have their previously granted
and earned restricted stock units continue to vest and stock options accelerate (other than special retention awards that are subject
to continued employment). Since the Named Officers are retirement-eligible, their PBRSUs under the Growth Performance Plan would be treated
as described in note 5 below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Cash Bonus.** If the triggering event occurs at year-end, as assumed in the table above, each Named Officer would also be entitled
to receive their annual cash bonus for the year in which the triggering event occurs (reported in column (g) of the Summary Compensation
Table).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Deferred Compensation Balances.** The Named Officers would be entitled to receive any amounts previously deferred by or allocated
to them under the Deferred Compensation Plan and Supplemental Savings & Investment Plan (reported as of year-end 2022 in column (f)
of the Nonqualified Deferred Compensation Table).

<sup>(4)</sup> **Death and Disability.** As shown in these columns, the Named Officers would not be entitled to receive any incremental payment or benefit upon death or disability. However, the vesting or distribution of certain existing compensation reported previously in this Proxy Statement would continue or be accelerated as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Equity Awards.** Earned but unvested restricted stock units would continue to vest in accordance with their original vesting
schedule and all outstanding stock options would be exercisable for a period of three years or until the end of the original term, whichever
is shorter. All such awards were reported as compensation in the proxy statement for the year of grant, to the extent the executive was
a "Named Officer" for that year. For Mr. Sutula the estimated value as of year-end 2022 of previously granted restricted stock
units that would continue to vest is $1,686,027. Mr. Sutula 's stock option award received in November 2020 in connection with his
hiring would also be subject to acceleration, but no amount is included here because the award was out of the money as of year-end 2022.
No other amounts are shown for any of the Named Officers because, as employees eligible for retirement, they were already entitled to
have their previously granted and earned restricted stock units continue to vest and stock options accelerate (other than special retention
awards that are subject to continued employment). If the triggering event occurs at year-end, as assumed in the table above, each Named
Officer's earned PBRSUs for the Growth Performance Plan three-year performance cycle ending such year, if any (reported in note
5 to the Outstanding Equity Awards at Fiscal Year-End Table) would vest in accordance with their original vesting schedule. The Named
Officers would also be entitled to vest at the conclusion of each in-progress Growth Performance Plan three-year performance cycle in
a prorated amount of the PBRSUs earned reflecting the proportion of the performance period for which they were employed. No amounts are
shown for those PBRSUs because they remain subject to performance requirements even after the triggering event.

---

| | |
|:---|:---|
| 2023 Proxy Statement | **55** |

---

**[**Table of Contents**](#toc)** 

Executive Compensation

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Cash Bonus.** If the triggering event occurs at year-end, as assumed in the table above, each Named Officer would also be entitled
to receive their annual cash bonus for the year in which the triggering event occurs (reported in column (g) of the Summary Compensation
Table).

<sup>(5)</sup> **Retirement.** As shown in this column, the Named Officers would not be entitled to receive any incremental payment or benefit upon retirement. However, the vesting or distribution of certain existing compensation reported previously in this Proxy Statement would continue or be accelerated as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Equity Awards.** Earned but unvested restricted stock units, except those subject to continued employment, would continue to
vest in accordance with their original vesting schedule and all outstanding stock options, except those subject to continued employment,
would be exercisable for a period of three years or until the end of the original term, whichever is shorter. All such awards were reported
as compensation in the proxy statement for the year of grant, to the extent the executive was a "Named Officer" for that year.
If the triggering event occurs at year-end, as assumed in the table above, each Named Officer's earned PBRSUs for the Growth Performance
Plan three-year performance cycle ending such year, if any (reported in note 5 to the Outstanding Equity Awards at Fiscal Year-End Table)
would vest in accordance with their original vesting schedule. The Named Officers would also be entitled to vest at the conclusion of
each in-progress Growth Performance Plan three-year performance cycle in a prorated amount of the PBRSUs earned reflecting the proportion
of the performance period for which they were employed. No amounts are shown for those PBRSUs because they remain subject to performance
requirements even after the triggering event.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Retirement Accruals.** Each Named Officer would be entitled to receive their retirement benefits under the Retirement Plan and
Supplemental Retirement Plan, if any, as described on pages 49 to 50. Each Named Officer would also be entitled to receive the balance
in their account under the Savings & Investment Plan, including the Company contributions made pursuant to the Company match, profit-sharing
and retirement program under the Savings & Investment Plan, as well as investment gains and losses thereon. As of year-end 2022, the
balance, which remains subject to future investment gains and losses, in each Named Officer's Savings & Investment Plan account
from these sources was as follows: Mr. Wallace—$2,174,386; Mr. Sutula—$44,777; Ms. Daniels—$260,010; Ms. Parameswaran—$981,720;
and Mr. Tsourapas—$606,782. The annual contributions by the Company to these accounts are reported in note 6 to the Summary Compensation
Table.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Cash Bonus.** If the triggering event occurs at year-end, as assumed in the table above, each Named Officer would also be entitled
to receive their annual cash bonus for the year in which the triggering event occurs (reported in column (g) of the Summary Compensation
Table).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Deferred Compensation Balances.** The Named Officers would be entitled to receive any amounts previously deferred by or allocated
to them under the Deferred Compensation Plan and Supplemental Savings & Investment Plan (reported as of year-end 2022 in column (f)
of the Nonqualified Deferred Compensation Table) in accordance with the distribution schedule they elected.

**CEO Pay Ratio**

Our products are marketed in over 200 countries and territories throughout the world with approximately two-thirds of our net sales generated outside the United States and approximately 45% of net sales coming from emerging markets. Consistent with our global presence, we have a dispersed workforce, with over 85% of our employees based outside the United States in over 100 countries. To attract and retain talent, we seek to pay competitively in each jurisdiction consistent with market practice, resulting in compensation levels that vary from country to country. Our workforce also covers a broad range of functions, from manufacturing employees to management personnel, and includes both employees who are compensated on a salaried basis and those who are compensated on an hourly basis.

For 2022, the median of the annual total compensation of all employees (other than our CEO, Noel Wallace) was $39,370 and the annual total compensation of the CEO, as reported in the Summary Compensation Table on page 44, was $14,462,406. Based on this information, for 2022 the CEO's annual total compensation was 367 times that of the median of the annual total compensation of all employees. This amount is a reasonable estimate calculated in a manner consistent with Item 402(u) of Regulation S-K.

The above-referenced pay ratio may not be comparable to pay ratios disclosed by other companies, including the companies in the Comparison Group (as defined in the CD&A). Pay ratios at different companies may vary due to differences in workforce composition, including geographic breadth, types of work performed and the relative percentages of salaried versus hourly compensated workers.

**Methodology for Determining the Median Employee and Annual Total Compensation**

For purposes of calculating the above-referenced 2022 pay ratio, we used the same median employee that was identified in 2020, as we determined that there have been no changes to the employee population or employee compensation arrangements in 2022 (including the compensation arrangements of the previously identified median employee) that we believe would result in a significant change to our pay ratio.

We used the following methodology, material assumptions, adjustments and estimates to identify the median of the annual total compensation of all employees. As described above, all determinations were made in 2020 except the annual total compensation of the median employee, which was calculated for 2022 based on the median employee identified in 2020.

Determination of Employee Population in 2020

We determined that, as of October 1, 2020, we had approximately 35,300 employees (including approximately 1,500 temporary employees) working for Colgate-Palmolive Company or its consolidated subsidiaries, of which approximately 5,100 were based in the United States and the remaining approximately 30,200 were based outside the United States.

As permitted by SEC rules, we chose to exclude from this population approximately 900 employees in 55 countries, representing approximately 2.5% of our total employees. All employees from each of these countries, which are identified in

**56**

**[**Table of Contents**](#toc)** 

Executive Compensation

Annex B to this Proxy Statement along with the number of employees based in each such country, were excluded. As a result, our employee population used for determining the median employee was approximately 34,400, consisting of approximately 5,100 employees based in the United States and approximately 29,300 employees based outside the United States.

Statistical Sampling

We elected to use statistical sampling to identify the median employee and conducted a simple random sample of 2,000 employees worldwide, which was determined to be the appropriate sample size for the size and complexity of our employee population based on advice from an external consultant.

Compensation Measure

We selected base salary or comparable wages for the 12-month period ended September 30, 2020 as the measure of compensation that could be consistently applied across the sample population. In making this determination, the compensation of all permanent employees included in the sample who were hired in 2020 but were not employed for the entire measurement period was annualized, but no cost-of-living adjustments were made. Using this methodology, the median employee was identified as a full-time, salaried employee located in China.

Annual Total Compensation of Median Employee

The elements of the median employee's annual total compensation for 2022 were calculated in accordance with the requirements of Item 402(c)(2)(x) of Regulation S-K, resulting in annual total compensation of $39,370. For purposes of this disclosure, Chinese renminbi were converted to U.S. dollars using a 12-month average exchange rate from January 1, 2022 through December 31, 2022.

**Pay Versus Performance**

As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item 402(v) of Regulation S-K, we are providing the following information about the relationship between the "total compensation" and "compensation actually paid" to our Named Officers and certain financial performance of the Company. This disclosure has been prepared in accordance with Item 402(v) of Regulation S-K and does not necessarily reflect value actually realized by the Named Officers. The P&O Committee evaluates compensation decisions in light of Company or individual performance and does not use "compensation actually paid" as a basis for making compensation decisions. For information concerning our compensation philosophy and how we align executive compensation with our performance, see the CD&A.

---

| | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  |  | Average <br> Summary<br> Compensation<br> Table Total for<br> Non-CEO Named Officers<br> ($)<br> (d) |  | Average<br> Compensation<br> Actually Paid to<br> Non-CEO Named<br> Officers<br> ($)<br> (e) | Value of Initial Fixed $100<br> Investment Based On: | Value of Initial Fixed $100<br> Investment Based On: |  |  |  |  |
| Year<br> (a) | Summary<br> Compensation <br> Table<br> Total for CEO<br> ($)<br> (b)<sup>(1)</sup> | Compensation<br> Actually Paid <br> to CEO<br> ($)<br> (c)<sup>(2)</sup> | Average <br> Summary<br> Compensation<br> Table Total for<br> Non-CEO Named Officers<br> ($)<br> (d) | (3) | Average<br> Compensation<br> Actually Paid to<br> Non-CEO Named<br> Officers<br> ($)<br> (e)<sup>(</sup>4) | Total<br> Shareholder<br> Return<br> ($)<br> (f) | Peer Group<br> Total<br> Shareholder<br> Return<br> ($)<br> (g) | (5) | Net Income<br> ($ in<br> millions)<br> (h) | Company-Selected<br> Measure:<br> Organic Sales<br> Growth<br> (%)<br> (i) | (6) |
| 2022 | 14462406 | 11047446 | 4061090 |  | 3453780 | 122.8 | 126.7 |  | 1967 | 7.0 |  |
| 2021 | 15458151 | 18008793 | 4085777 |  | 4559072 | 129.8 | 125.3 |  | 2338 | 4.4 |  |
| 2020 | 14364118 | 22765213 | 4024886 |  | 5573106 | 127.2 | 110.7 |  | 2860 | 7.2 |  |

---

**NOTES TO THE PAY VERSUS PERFORMANCE TABLE**

<sup>(1)</sup> The dollar amounts reported in column (b) are the amounts of total compensation reported for Noel R. Wallace (who was our Chairman, President and Chief Executive Officer for all years presented) in the "Total" column of the Summary Compensation Table.

<sup>(2)</sup> The dollar amounts reported in column (c) represent the amount of compensation actually paid to Mr. Wallace, as computed in accordance with Item 402(v) of Regulation S-K ("CAP"). The dollar amounts do not reflect the actual amount of compensation earned by or paid to Mr. Wallace during the applicable year. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to Mr. Wallace's total compensation for each year to determine the CAP:

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| Year | Reported<br> Summary<br> Compensation<br> Table Total for<br> CEO<br> ($) | (Subtract):<br> Reported<br> Value of<br> Equity Awards<br> ($) | <sup>(a)</sup> | Add:<br> Equity<br> Award<br> Adjustments<br> ($) | <sup>(b)</sup> | (Subtract):<br> Reported<br> Change in<br> the Actuarial<br> Present Value<br> of Pension<br> Benefits<br> ($) | <sup>(c)</sup> | Add:<br> Pension <br> Benefit<br> Adjustments<br> ($) | <sup>(d)</sup> | CAP for CEO<br> ($) |
| 2022 | 14462406 | (9114661) |  | 5725594 |  | (25893) |  |  |  | 11047446 |
| 2021 | 15458151 | (10903528) |  | 13477139 |  | (22969) |  |  |  | 18008793 |
| 2020 | 14364118 | (8641292) |  | 17070257 |  | (27870) |  |  |  | 22765213 |

---

<sup>(a)</sup> The reported value of equity awards represents the grant date fair value of equity awards as reported in the "Stock Awards" and "Option Awards" columns in the Summary Compensation Table for each applicable year.

---

| | |
|:---|:---|
| 2023 Proxy Statement | **57** |

---

**[**Table of Contents**](#toc)** 

Executive Compensation

<sup>(b)</sup> The amounts added (or subtracted, as applicable) in calculating the equity award adjustments for the CEO for each applicable year are as follows:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| Year | Year End Fair<br> Value of Equity<br> Awards <br> Granted During<br> the Year<br> ($) | Year over Year<br> Change in<br> Fair Value of<br> Outstanding<br> and Unvested<br> Equity Awards<br> Granted in<br> Prior Years<br> ($) | Fair Value as of<br> Vesting Date of<br> Equity Awards<br> Granted and<br> Vested in <br> the Year<br> ($) | Year over Year<br> Change in Fair<br> Value of Equity<br> Awards Granted<br> in Prior Years<br> that Vested in<br> the Year<br> ($) | Fair Value at the <br> End of the Prior <br> Year of Equity <br> Awards that Failed <br> to Meet Vesting<br> Conditions in the<br> Year<br> ($) | Value of<br> Dividends or<br> other Earnings<br> Paid on Equity<br> Awards not<br> Otherwise<br> Reflected in Fair<br> Value or Total<br> Compensation<br> ($) | Total Equity<br> Award<br> Adjustments<br> ($) |
| 2022 | 9656022 | (1253543) |  | (2725632) |  | 48747 | 5725594 |
| 2021 | 13417733 | 296498 | 105132 | (382562) |  | 40338 | 13477139 |
| 2020 | 11443463 | 4540148 |  | 1059193 |  | 27453 | 17070257 |

---

<sup>(c)</sup> The amounts in this column represent the change in pension value amounts reported in the "Change in Pension and Nonqualified Deferred Compensation" column of the Summary Compensation Table for each applicable year.

<sup>(d)</sup> No values are shown in this column for pension benefit adjustments because (i) there are no service costs for services rendered during the applicable years because the Retirement Plan and Supplemental Retirement Plan were both frozen prior to 2020 and (ii) there are no prior service costs because no additional benefits were granted in a plan amendment during the applicable years.

<sup>(3)</sup> The dollar amounts reported in column (d) represent the average of the amounts reported for our Named Officers as a group (excluding Mr. Wallace) in the "Total" column of the Summary Compensation Table for each applicable year. The Named Officers included for purposes of calculating the average amounts in each applicable year are as follows: (i) for each of 2022 and 2021, Stanley J. Sutula III, Jennifer M. Daniels, Prabha Parameswaran and Panagiotis Tsourapas; and (ii) for 2020, Henning I. Jakobsen, Stanley J. Sutula III, Jennifer M. Daniels, Prabha Parameswaran and Panagiotis Tsourapas.

<sup>(4)</sup> The dollar amounts reported in column (e) represent the average amount of CAP for the Named Officers as a group (excluding Mr. Wallace), as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual average amount of compensation earned by or paid to the Named Officers as a group (excluding Mr. Wallace) during the applicable year. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to the average total compensation of the Named Officers as a group (excluding Mr. Wallace) for each year to determine the CAP, using the same methodology described above in note 2:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| Year | Average <br> Reported <br> Summary<br> Compensation <br> Table Total for <br> non-CEO <br> Named Officers<br> ($) | (Subtract): <br> Average <br> Reported <br> Value of <br> Equity Awards<br> ($) | Add: <br> Average <br> Equity Award <br> Adjustments <br> ($)<sup>(a)</sup> | (Subtract):<br> Average<br> Reported<br> Change in<br> the Actuarial<br> Present Value of<br> Pension Benefits<br> ($) | Add:<br> Average <br> Pension<br> Benefit <br> Adjustments<br> ($) | Average CAP <br> for non-CEO <br> Named <br> Officers<br> ($) |
| 2022 | 4061090 | (1857696) | 1252854 | (2468) |  | 3453780 |
| 2021 | 4085777 | (2152095) | 2627579 | (2189) |  | 4559072 |
| 2020 | 4024886 | (2057487) | 3607832 | (2125) |  | 5573106 |

---

<sup>(a)</sup> The amounts added (or subtracted, as applicable) in calculating the total average equity award adjustments for each applicable year are as follows:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| Year | Year End<br> Fair Value of<br> Equity <br> Awards<br> Granted<br> During the<br> Year<br> ($) | Year over Year<br> Change in<br> Fair Value of<br> Outstanding<br> and Unvested<br> Equity Awards<br> Granted in<br> Prior Years <br> ($) | Fair Value as of<br> Vesting Date of<br> Equity Awards<br> Granted and<br> Vested in <br> the Year <br> ($) | Year over Year<br> Change in<br> Fair Value of<br> Equity Awards<br> Granted in<br> Prior Years<br> that Vested in the Year <br> ($) | Fair Value at<br> the End of the<br> Prior Year of<br> Equity Awards<br> that Failed to<br> Meet Vesting<br> Conditions in<br> the Year <br> ($) | Value of Dividends<br> or other Earnings<br> Paid on Equity<br> Awards not<br> Otherwise<br> Reflected in Fair<br> Value or Total<br> Compensation<br> ($) | Total Equity<br> Award<br> Adjustments |
| 2022 | 1968034 | (285769) |  | (448213) |  | 18802 | 1252854 |
| 2021 | 2651509 | 49886 | 19907 | (114020) |  | 20297 | 2627579 |
| 2020 | 2538288 | 785601 |  | 269390 |  | 14553 | 3607832 |

---

<sup>(5)</sup> Represents the weighted peer group total shareholder return, weighted according to the respective companies' stock market capitalization at the beginning of each period for which a return is indicated. The peer company index used for this purpose, which is the peer company index used by us for purposes of Item 201(e) of Regulation S-K, is comprised of the following companies: Campbell Soup Company, The Clorox Company, The Coca-Cola Company, ConAgra Brands, Inc., The Estée Lauder Companies, Inc., General Mills, Inc., Johnson & Johnson, Kellogg Company, Kimberly-Clark Corporation, The Kraft Heinz Company, Mondēlez International, Inc., PepsiCo, Inc., The Procter & Gamble Company, Reckitt Benckiser Group plc and Unilever PLC.

<sup>(6)</sup> Organic sales growth is a non-GAAP financial measure defined as net sales excluding foreign exchange, acquisitions and divestments. Please see Annex A for a reconciliation of organic sales growth to net sales growth calculated in accordance with GAAP.

**58**

**[**Table of Contents**](#toc)** 

Executive Compensation

**Tabular List of Financial Performance Measures Used to Link CAP For the Most Recently Completed Fiscal Year To Company Performance**

The following table lists the financial performance metrics that, in our assessment, represent the most important financial performance measures we use to link CAP for our Named Officers for 2022 to Company performance.

Adjusted Earnings Per Share

Free Cash Flow Productivity

Organic Sales Growth (Company-Selected Measure)

Relative Adjusted Net Income Growth

Relative Organic Sales Growth

Relative Total Shareholder Return

**Analysis of the Information Presented in the Pay versus Performance Table**

As described in more detail in the CD&A beginning on page 29, the key principles underlying our compensation philosophy are aligning pay and performance, driving strong business results and our strategic plan, focusing on long-term shareholder return, motivating and retaining critical talent and reflecting external market and competitive practices.

In accordance with Item 402(v) of Regulation S-K, we are providing the following graphs showing the relationships over the past three years of CAP as compared to our total shareholder return, net income and organic sales growth, as well as the relationship between total shareholder return and peer group total shareholder return. Since a significant portion of the Named Officers' compensation is comprised of equity awards (71% of Mr. Wallace's target direct compensation and 54% of the average target direct compensation of our other Named Officers for 2022, as described in more detail in the CD&A), the CAP of our CEO and other Named Officers is higher when our stock price is higher, and lower when our stock price is lower, demonstrating the clear alignment of interests of our CEO and other Named Officers and our stockholders.

 **CAP vs. TSR and Peer TSR**

![](cl4117791_def14ax65x1.jpg)

**CAP vs. Net Income**

![](cl4117791_def14ax65x2.jpg)

**CAP vs. Organic Sales Growth**

![](cl4117791_def14ax65x3.jpg)

---

| | |
|:---|:---|
| 2023 Proxy Statement | **59** |

---

**[**Table of Contents**](#toc)** 

Stock Ownership

**Stock Ownership of Directors and Executive Officers**

Our directors and executive officers own significant amounts of Colgate stock. Under our stock ownership guidelines, non-employee directors are required to own stock equal in value to at least five times their annual share grant, and executive officers are required to own stock equal in value to between two and eight times their salary, depending on their position.

The following table shows the beneficial ownership of Common Stock of each director, each of the Named Officers and the directors and executive officers (including the Named Officers) as a group. "Beneficial ownership" as used here means more than "ownership" as that term is commonly used. For example, a person "beneficially" owns Common Stock not only if they hold it directly, but also if they have (or share) the power to vote or sell the stock indirectly (for example, through a relationship, a position as a director or trustee, or a contract or understanding). Beneficial ownership also includes shares a person has the right to acquire within 60 days, for example, through the exercise of a stock option.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Common Stock | Common Stock | Common Stock | Common Stock |
|  | Amount and Nature of Beneficial Ownership<sup>(1)(2)</sup> | Amount and Nature of Beneficial Ownership<sup>(1)(2)</sup> | Amount and Nature of Beneficial Ownership<sup>(1)(2)</sup> | Amount and Nature of Beneficial Ownership<sup>(1)(2)</sup> |
| Name of<br> Beneficial Owner | Directly<br> Owned | Exercisable<br> Options<sup>(3)</sup> | Common<br> Stock Units | Held by<br> Savings &<br> Investment<br> Plan Trustee<sup>(4)</sup> |
| Noel R. Wallace<sup>(5)</sup> | 270719 | 912796 |  | 50677 |
| Stanley J. Sutula III<sup>(6)</sup> | 14484 | 97031 |  | 78 |
| Jennifer M. Daniels<sup>(6)</sup> | 45822 | 252655 |  | 1070 |
| Prabha Parameswaran<sup>(6)(7)</sup> | 26252 | 259568 |  | 4685 |
| Panagiotis Tsourapas<sup>(6)(8)</sup> | 61686 | 272490 |  | 4279 |
| John P. Bilbrey<sup>(9)</sup> | 5902 | 23804 | 24782<sup>(10)</sup> |  |
| John T. Cahill<sup>(11)</sup> | 30213 | 18101 | 24384<sup>(10)</sup> |  |
| Steve Cahillane<sup>(12)(13)</sup> |  |  |  |  |
| Lisa M. Edwards<sup>(13)</sup> | 6876 | 11077 | 120<sup>(10)</sup> |  |
| C. Martin Harris | 14650 | 14532 | 2360<sup>(10)</sup> |  |
| Martina Hund-Mejean<sup>(13)</sup> | 1622 | 6909 | 4622<sup>(10)</sup> |  |
| Kimberly A. Nelson<sup>(13)(14)</sup> | 3214 | 3046 | 2360<sup>(10)</sup> |  |
| Lorrie M. Norrington | 889 | 18101 | 26780<sup>(10)</sup> |  |
| Michael B. Polk | 23583 | 18101 |  |  |
| Stephen I. Sadove<sup>(15)</sup> | 22220 | 23804 | 11866<sup>(10)</sup> |  |
| All directors and executive officers as a group (18 persons) | 541615 | 2151742 | 97274 | 86231 |

---

**NOTES TO THE STOCK OWNERSHIP OF DIRECTORS AND EXECUTIVE OFFICERS TABLE**

<sup>(1)</sup> Information about Common Stock holdings is as of March 13, 2023, the record date for the Annual Meeting. Unless stated otherwise in these notes, each person named in the table owns his or her shares directly and has sole voting and investment power over such shares.

<sup>(2)</sup> Each person named in the table beneficially owns less than 0.25% of the outstanding Common Stock. The directors and executive officers as a group beneficially own 0.35% of the outstanding Common Stock.

<sup>(3)</sup> This column consists of options that are exercisable on or before May 12, 2023, which is 60 days after March 13, 2023. As of March 13, 2023, a total of 22,662,530 options were outstanding under the 2019 Plan and the predecessors to the 2019 Plan and 22,088,403 shares were available for future grants under the 2019 Plan.

<sup>(4)</sup> Consists of Common Stock credited to or otherwise beneficially owned by executive officers under our Savings & Investment Plan. Under this plan, we issue Common Stock to a trustee acting on behalf of the plan. Employees who participate in the Savings & Investment Plan, including the Named Officers, have voting power over the shares allocated to their accounts under the plan, subject to the right of the plan trustee to vote such shares if a participant fails to do so. Participants have no investment power over such shares until they are distributed or diversified at the participant's election in accordance with the terms of the plan.

<sup>(5)</sup> Mr. Wallace's holdings include 335 shares of Common Stock owned by the Noel R. Wallace 2012 GST Trust and 52,000 shares of Common Stock owned by the N.R.W. Irrevocable Trust.

<sup>(6)</sup> Executive officers have five years from the date of their initial hiring or promotion into an eligible position to achieve required ownership levels.

<sup>(7)</sup> Ms. Parameswaran's holdings include 20,698 shares of Common Stock owned by the Prabha Parameswaran Mitra Revocable Trust.

<sup>(8)</sup> Mr. Tsourapas's holdings include 53,059 shares of Common Stock owned by the Panagiotis Tsourapas Revocable Living Trust and 3,226 shares of Common Stock owned by his spouse, 822 of which are held through our Savings & Investment Plan.

<sup>(9)</sup> Mr. Bilbrey's holdings include 4,719 shares of Common Stock owned by the John P. Bilbrey Revocable Trust.

<sup>(10)</sup> Consists of Common Stock units credited to one or more of the following accounts: (i) a deferred account for amounts granted under the 2019 Plan and any predecessor plans or (ii) a deferred account under the Restated and Amended Deferred Compensation Plan for Non-Employee Directors. In each case, the holder of Common Stock units has no voting or investment power over such units.

**60**

**[**Table of Contents**](#toc)** 

Stock Ownership

<sup>(11)</sup> Mr. Cahill's holdings include 30,213 shares of Common Stock owned by the John Tobin Cahill Revocable Trust.

<sup>(12)</sup> In accordance with the 2019 Plan, Mr. Cahillane, who was first elected to the Board effective February 1, 2023, will receive grants in 2023 of shares of Common Stock equal in value to $165,000 and options to purchase shares of Common Stock equal in value to $41,250 on May 15, 2023.

<sup>(13)</sup> Mr. Cahillane was first elected to the Board effective February 1, 2023, Ms. Edwards was first elected to the Board effective March 1, 2019, Ms. Hund-Mejean was first elected to the Board effective March 11, 2020 and Ms. Nelson was first elected to the Board effective March 11, 2021. Directors have five years from the date of their initial election to meet our stock ownership guidelines.

<sup>(14)</sup> Ms. Nelson's holdings include 1,799 shares of Common Stock owned by the Kimberly A. Nelson 2011 Revocable Trust, 215 shares of Common Stock owned by her spouse and 575 shares of Common Stock owned by the Stafford B Nelson 2015 Irrevocable Family Trust.

<sup>(15)</sup> Mr. Sadove's holdings include 9,220 shares of Common Stock owned by the Stephen I. Sadove Revocable Trust and 13,000 shares of Common Stock owned by the Sadove Family Delaware Dynasty Trust.

**Stock Ownership of Certain Beneficial Owners**

The following table sets forth information regarding persons or groups known to us to be beneficial owners of more than 5% of our outstanding Common Stock as of December 31, 2022.

---

| | | |
|:---|:---|:---|
| Name and Address of Beneficial Owner | Number of Shares <br> Beneficially Owned as of <br> December 31, 2022 | Percent of Common<br> Stock Outstanding as of<br> December 31, 2022 |
| The Vanguard Group<br> 100 Vanguard Blvd.<br> Malvern, PA 19355 | 80375011<sup>(1)</sup> | 9.6% |
| BlackRock, Inc.<br> 55 East 52nd Street<br> New York, NY 10055 | 68041416<sup>(2)</sup> | 8.1% |
| State Street Corporation<sup>(3)</sup><br> State Street Financial Center<br> One Lincoln Street<br> Boston, MA 02111 | 49899351<sup>(4)</sup> | 6.0% |

---

**NOTES TO THE STOCK OWNERSHIP OF CERTAIN BENEFICIAL OWNERS TABLE**

<sup>(1)</sup> On a Schedule 13G/A filed with the SEC by The Vanguard Group ("Vanguard") on February 9, 2023, Vanguard reported that, as of December 31, 2022, it beneficially owned 80,375,011 shares of Common Stock with shared voting power over 1,201,151 shares of Common Stock, sole dispositive power over 76,804,816 shares of Common Stock and shared dispositive power over 3,570,195 shares of Common Stock.

<sup>(2)</sup> On a Schedule 13G/A filed with the SEC by BlackRock, Inc. ("BlackRock") on February 3, 2023, BlackRock reported that, as of December 31, 2022, it beneficially owned 68,041,416 shares of Common Stock with sole voting power over 59,783,771 shares of Common Stock and sole dispositive power over 68,041,416 shares of Common Stock.

<sup>(3)</sup> State Street Bank and Trust Company, a subsidiary of State Street Corporation ("State Street"), is the trustee of the Colgate-Palmolive Company Employee Stock Ownership Trust (the "Trustee").

<sup>(4)</sup> On a Schedule 13G/A filed with the SEC by State Street on February 6, 2023, State Street reported that, as of December 31, 2022, it beneficially owned 49,899,351 shares of Common Stock with shared voting power over 45,191,754 shares of Common Stock and shared dispositive power over 49,614,512 shares of Common Stock.

For information regarding the voting of shares allocated to the Colgate-Palmolive Company Employee Stock Ownership Plan participants, please see "Questions and Answers About Our Annual Meeting—How can I vote if I am an employee participating in the Savings & Investment Plan?" The Trustee will vote unallocated shares in the same proportion in which allocated shares are voted.

---

| | |
|:---|:---|
| 2023 Proxy Statement | **61** |

---

**[**Table of Contents**](#toc)** 

Proposals Requiring Your Vote

The following six proposals will be presented at the meeting for your vote. When voting by internet or telephone, you will be instructed how to vote for or against or abstain from voting on these proposals. If you received a printed copy of your proxy materials, space is provided on the proxy card to vote for or against or abstain from voting on each of the proposals.

---

| | |
|:---|:---|
| **Proposal 1**<br> **Election of Directors** | **Proposal 1**<br> **Election of Directors** |
| The Board has nominated eleven people for election as directors at the Annual Meeting. All nominees are currently serving as Colgate directors and all nominees except for Mr. Cahillane were elected at the 2022 Annual Meeting. Mr. Cahillane was elected by the Board effective February 1, 2023. If elected, each nominee will hold office until the next Annual Meeting or until his or her successor is elected and qualified.<br> The nominees are John P. Bilbrey, John T. Cahill, Steve Cahillane, Lisa M. Edwards, C. Martin Harris, Martina Hund-Mejean, Kimberly A. Nelson, Lorrie M. Norrington, Michael B. Polk, Stephen I. Sadove and Noel R. Wallace. Biographical information regarding the nominees and information regarding the skills and qualifications of the nominees appears on pages 14 to 19 of this Proxy Statement. | The Board has nominated eleven people for election as directors at the Annual Meeting. All nominees are currently serving as Colgate directors and all nominees except for Mr. Cahillane were elected at the 2022 Annual Meeting. Mr. Cahillane was elected by the Board effective February 1, 2023. If elected, each nominee will hold office until the next Annual Meeting or until his or her successor is elected and qualified.<br> The nominees are John P. Bilbrey, John T. Cahill, Steve Cahillane, Lisa M. Edwards, C. Martin Harris, Martina Hund-Mejean, Kimberly A. Nelson, Lorrie M. Norrington, Michael B. Polk, Stephen I. Sadove and Noel R. Wallace. Biographical information regarding the nominees and information regarding the skills and qualifications of the nominees appears on pages 14 to 19 of this Proxy Statement. |
| ![](cl4117791_def14ax68x1.jpg) |  |
| ![](cl4117791_def14ax68x1.jpg) | The Board of Directors recommends a vote **FOR** each of the nominees for director listed above. |

---

---

| | |
|:---|:---|
| **Proposal 2**<br> **Ratification of Selection of Independent Registered Public Accounting Firm** | **Proposal 2**<br> **Ratification of Selection of Independent Registered Public Accounting Firm** |
| We ask that you ratify the Audit Committee's selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2023. PricewaterhouseCoopers LLP has audited the accounts of the Company since May 2002. The members of the Audit Committee and the Board believe that the continued retention of PricewaterhouseCoopers LLP as our independent registered public accounting firm is in the best interests of Colgate and our stockholders. | We ask that you ratify the Audit Committee's selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2023. PricewaterhouseCoopers LLP has audited the accounts of the Company since May 2002. The members of the Audit Committee and the Board believe that the continued retention of PricewaterhouseCoopers LLP as our independent registered public accounting firm is in the best interests of Colgate and our stockholders. |
| ![](cl4117791_def14ax68x1.jpg) |  |
| ![](cl4117791_def14ax68x1.jpg) | The Board of Directors recommends a vote **FOR** the ratification of the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2023. |

---

**Audit Committee Report**

The Audit Committee is composed of four independent directors. The Board of Directors has determined that it would be desirable for all Audit Committee members to be "audit committee financial experts" as that term is defined under SEC rules. The Board has conducted an inquiry into the qualifications and experience of each member of the Audit Committee, and has determined that they each meet the SEC's criteria for audit committee financial experts.

**Role and Responsibilities**

The Audit Committee assists the Board of Directors in its oversight of our financial statements and reporting processes, including our internal control over financial reporting and our Internal Audit function. The Audit Committee is also directly responsible for the appointment, compensation, retention and oversight of the independent registered public accounting firm, including review of their qualifications, independence and performance and approval of their fees. In addition, the Audit Committee oversees our Global Ethics and Compliance function, enterprise risk management process, including cybersecurity, and compliance with legal and regulatory requirements. For more information about oversight of the Global Ethics and Compliance function, including procedures for investigating complaints related to accounting, internal accounting controls or auditing matters, see "Governance of the Company—Communications to the Board of Directors." A copy of the charter of the Audit Committee, which describes these and other responsibilities of the committee, is available on our website at www.colgatepalmolive.com.

Management has the direct and primary responsibility for the financial statements and the reporting processes, including establishing and maintaining adequate internal control over financial reporting. The independent registered public accounting firm is responsible for auditing the annual financial statements prepared by management and expressing an opinion as to whether those financial statements present fairly, in all material respects, the financial position of the Company and our subsidiaries and the results of our operations and our cash flows in conformity with accounting principles generally accepted in the United States of America. The independent registered public accounting firm is also responsible for auditing the effectiveness of our internal control over financial reporting.

**62**

**[**Table of Contents**](#toc)** 

Proposals Requiring Your Vote

**Selection of Independent Registered Public Accounting Firm**

The Audit Committee appointed PricewaterhouseCoopers LLP ("PwC") to audit our financial statements as of and for the year ended December 31, 2022 and the effectiveness of our internal control over financial reporting as of December 31, 2022. PwC has served as our independent registered public accounting firm continuously since May 2002. The Audit Committee considered several factors in selecting PwC as our independent registered public accounting firm, including the firm's independence and internal quality controls, the qualifications and experience of the lead audit partner and overall depth of talent, their experience with our industry (including any potential conflicts arising from representation of our direct competitors) and their capability and expertise in handling the breadth and complexity of our global operations along with the firm's familiarity with our business, accounting policies and internal control over financial reporting. In determining whether to reappoint PwC as our independent registered public accounting firm for the year ending December 31, 2023, the Audit Committee again took those factors into consideration along with its evaluation of the past performance of PwC. The Audit Committee determined that the continued retention of PwC as our independent registered public accounting firm is in the Company's best interests. The Audit Committee periodically considers whether there should be a regular rotation of the independent registered public accounting firm in order to assure continuing auditor independence.

PwC's lead audit partner rotates every five years pursuant to the requirement mandated by the Sarbanes-Oxley Act of 2002. The process for selecting the new lead audit partner involves an assessment of many factors, including the candidates' independence, objectivity, broad-based business judgment, multinational and industry experience, commitment to serving the Company, ability to leverage the resources of the firm and commitment to continuous improvement and robust dialogue with the Audit Committee. The selection process also involves discussions with management and the Audit Committee regarding each of the candidates and a meeting between the Audit Committee chair and the final candidate for the role.

**Review and Recommendation Regarding Financial Statements**

The Audit Committee met seven times in 2022, including to review and discuss each quarterly earnings release prior to its announcement and each of our quarterly and annual financial statements. The Audit Committee reviewed and discussed the scope of and plans for the internal and external audits with management and the independent registered public accounting firm together and separately. The Audit Committee also met with management and the independent registered public accounting firm together and separately to review and discuss the audited financial statements, including the critical audit matter reported on by the independent registered public accounting firm, and matters related to the design and operating effectiveness of our internal control over financial reporting. These discussions and reviews included the reasonableness of significant estimates and judgments, significant accounting policies (including critical accounting policies), significant unusual transactions, the independent registered public accounting firm's assessment of the quality, not just acceptability, of our accounting principles, risk assessment and such other matters as are required to be discussed with the Audit Committee under the standards of the Public Company Accounting Oversight Board (United States) (the "PCAOB").

The Audit Committee has received the written disclosures of the independent registered public accounting firm as required by the applicable requirements of the PCAOB, and has discussed with the independent registered public accounting firm, and received a letter from them confirming, their independence from management and the Company. In addition, the Audit Committee has reviewed and approved our policy with regard to the hiring of former employees of the independent registered public accounting firm. In evaluating the independent registered public accounting firm's independence, the Audit Committee considered whether the firm's provision of any non-audit services impaired or compromised the firm's independence and the Audit Committee concluded that the provision of those services did not. Those services, along with the fees paid to the independent registered public accounting firm and the Audit Committee's pre-approval policy for services that may be performed by the independent registered public accounting firm, are described below.

Based upon the review and discussions described in this report, the Audit Committee recommended to the Board of Directors that the audited financial statements as of and for the year ended December 31, 2022 be accepted and included in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC.

*The foregoing report has been submitted by the members of the Audit Committee: John T. Cahill (Chair), Martina Hund-Mejean, Lorrie M. Norrington and Stephen I. Sadove.*

---

| | |
|:---|:---|
| 2023 Proxy Statement | **63** |

---

**[**Table of Contents**](#toc)** 

Proposals Requiring Your Vote

**Fees of Independent Accounting Firm**

The Audit Committee approves the fees billed or expected to be billed by PricewaterhouseCoopers LLP for their services. Such fees for services rendered to Colgate during 2022 and 2021 are set forth below. The Audit Committee has concluded that the provision to Colgate of the non-audit services by PricewaterhouseCoopers LLP described below did not and does not impair or compromise their independence. All such services were pre-approved by the Audit Committee in accordance with the pre-approval policy described below.

---

| |
|:---|
| **PRICEWATERHOUSECOOPERS LLP FEES** |
| (in millions) |

---

---

| | | |
|:---|:---|:---|
| | 2022<br> ($) | 2021<br> ($) |
| Audit Fees | 13.0 | 11.9 |
| Audit-Related Fees | 0.4 | 0.3 |
| Tax Fees | 1.4 | 2.5 |
| All Other Fees |  |  |
| Total | 14.8 | 14.7 |

---

Audit Fees

These amounts represent fees billed or expected to be billed by PricewaterhouseCoopers LLP for professional services rendered for the audits of our annual financial statements for the years ended December 31, 2022 and 2021 and the effectiveness of our internal control over financial reporting as of December 31, 2022 and 2021, the reviews of the financial statements included in our Quarterly Reports on Form 10-Q, and services related to statutory and regulatory filings and engagements for such fiscal years.

Audit-Related Fees

These amounts represent fees billed or expected to be billed by PricewaterhouseCoopers LLP for professional services rendered that were reasonably related to the performance of the audits or the reviews of our financial statements in 2022 and 2021 (but which are not included under "Audit Fees" above). Audit-Related fees consist primarily of certain agreed-upon-procedures engagements.

Tax Fees

These amounts represent fees billed or expected to be billed by PricewaterhouseCoopers LLP for professional services rendered relating to tax compliance, tax advice and tax planning in various tax jurisdictions around the world. Specifically, these fees were associated with assistance in tax return filings, tax audits and refund claims, as well as advice on interpretation of and compliance with tax laws and tax valuation services.

All Other Fees

None.

**Audit Committee Pre-Approval Policy**

The Audit Committee has adopted a policy for the pre-approval of all audit and permitted non-audit services that may be performed by our independent registered public accounting firm. Under this policy, each year, at the time it engages the independent registered public accounting firm, the Audit Committee pre-approves the audit engagement terms and fees and also pre-approves detailed types of audit-related and permitted tax services, subject to certain dollar limits, that may be performed during the year. All other permitted non-audit services are required to be pre-approved by the Audit Committee on an engagement-by-engagement basis. The Audit Committee may delegate its authority to pre-approve services to one or more of its members, whose activities are reported to the Audit Committee at each regularly scheduled meeting.

**Independent Accounting Firm Attendance at Annual Meeting**

Representatives of PricewaterhouseCoopers LLP are expected to attend the Annual Meeting. They will have the opportunity to make a statement if they desire to do so and will be available to respond to appropriate questions.

**64**

**[**Table of Contents**](#toc)** 

Proposals Requiring Your Vote

---

| | |
|:---|:---|
| **Proposal 3**<br> **Advisory Vote on Executive Compensation** | **Proposal 3**<br> **Advisory Vote on Executive Compensation** |
| We ask that you indicate your support for the executive compensation, as described in this Proxy Statement, of our executive officers named in the Summary Compensation Table appearing on page 44. We are providing stockholders with this vote pursuant to Section 14A of the Exchange Act.<br> The Board is asking you to cast a non-binding advisory vote on the following resolution:<br> "RESOLVED, that the compensation of our executive officers named in the Summary Compensation Table, as disclosed in the Proxy Statement, including the Compensation Discussion and Analysis, compensation tables and narrative discussion, is hereby APPROVED."<br> The Compensation Discussion and Analysis, beginning on page 29, describes our executive compensation programs and the compensation decisions made by the Personnel and Organization Committee and the Board of Directors for 2022 with respect to the Chief Executive Officer and the other officers named in the Summary Compensation Table (referred to as the "Named Officers"). As described in detail in the Compensation Discussion and Analysis and highlighted in the section captioned "Executive Summary," the key principles underlying the Personnel and Organization Committee's compensation philosophy are aligning pay and performance, driving strong business results and our strategic plan, focusing on long-term shareholder return, motivating and retaining critical talent and reflecting external market and competitive practices. Annual and long-term incentive award payments vary based on our business performance, and long-term incentive award payments and the value of equity awards also vary based on the performance of our Common Stock.<br> The Board is asking you to support this proposal. Because your vote is advisory, it will not be binding on the Board. However, the Board and the Personnel and Organization Committee will review the voting results in their entirety and take them into consideration when making future decisions regarding executive compensation. | We ask that you indicate your support for the executive compensation, as described in this Proxy Statement, of our executive officers named in the Summary Compensation Table appearing on page 44. We are providing stockholders with this vote pursuant to Section 14A of the Exchange Act.<br> The Board is asking you to cast a non-binding advisory vote on the following resolution:<br> "RESOLVED, that the compensation of our executive officers named in the Summary Compensation Table, as disclosed in the Proxy Statement, including the Compensation Discussion and Analysis, compensation tables and narrative discussion, is hereby APPROVED."<br> The Compensation Discussion and Analysis, beginning on page 29, describes our executive compensation programs and the compensation decisions made by the Personnel and Organization Committee and the Board of Directors for 2022 with respect to the Chief Executive Officer and the other officers named in the Summary Compensation Table (referred to as the "Named Officers"). As described in detail in the Compensation Discussion and Analysis and highlighted in the section captioned "Executive Summary," the key principles underlying the Personnel and Organization Committee's compensation philosophy are aligning pay and performance, driving strong business results and our strategic plan, focusing on long-term shareholder return, motivating and retaining critical talent and reflecting external market and competitive practices. Annual and long-term incentive award payments vary based on our business performance, and long-term incentive award payments and the value of equity awards also vary based on the performance of our Common Stock.<br> The Board is asking you to support this proposal. Because your vote is advisory, it will not be binding on the Board. However, the Board and the Personnel and Organization Committee will review the voting results in their entirety and take them into consideration when making future decisions regarding executive compensation. |
| ![](cl4117791_def14ax68x1.jpg) |  |
| ![](cl4117791_def14ax68x1.jpg) | The Board of Directors recommends a vote **FOR** the executive compensation of our Named Officers, as described in this Proxy Statement. |

---

---

| | |
|:---|:---|
| **Proposal 4**<br> **Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation** | **Proposal 4**<br> **Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation** |
| We ask that you indicate how frequently we should hold future stockholder advisory votes on executive compensation, such as Proposal 3. By voting on this Proposal 4, you may indicate whether you would prefer an advisory vote on named executive officer compensation once every one, two or three years. Alternatively, you may abstain from voting. Consistent with Section 14A of the Exchange Act, we intend to provide stockholders with a non-binding advisory vote on the frequency of future stockholder advisory votes on executive compensation every six years.<br> The Board has determined that an annual stockholder advisory vote on executive compensation continues to be the most appropriate for the Company and therefore recommends that stockholders vote in favor of holding a stockholder advisory vote on executive compensation every year.<br> The Company has held a stockholder advisory vote on executive compensation every year since 2010, consistent with the advisory votes of the stockholders at the Company's 2011 and 2017 Annual Meetings of Stockholders. The Board has found that such vote provides a clear and simple means for stockholders to provide direct feedback to the Company regarding its compensation philosophy, policies and practices as disclosed in the proxy statement, consistent with the Company's practice of seeking input from, and engaging in discussions with, the Company's stockholders on executive compensation and other matters.<br> While the Board is making a recommendation with respect to this proposal, stockholders are not voting to approve or disapprove the Board's recommendation. Instead, stockholders are being asked to specify one of the four choices for this proposal indicated on the proxy card: one year, two years, three years or abstain. Since you have several voting choices, it is possible that no single choice will receive a majority vote. In addition, because your vote is advisory, it will not be binding on the Board, whether or not a particular frequency receives a majority vote. However, the Board will review the voting results in their entirety and take them into consideration when making future decisions regarding the frequency of advisory votes on executive compensation. | We ask that you indicate how frequently we should hold future stockholder advisory votes on executive compensation, such as Proposal 3. By voting on this Proposal 4, you may indicate whether you would prefer an advisory vote on named executive officer compensation once every one, two or three years. Alternatively, you may abstain from voting. Consistent with Section 14A of the Exchange Act, we intend to provide stockholders with a non-binding advisory vote on the frequency of future stockholder advisory votes on executive compensation every six years.<br> The Board has determined that an annual stockholder advisory vote on executive compensation continues to be the most appropriate for the Company and therefore recommends that stockholders vote in favor of holding a stockholder advisory vote on executive compensation every year.<br> The Company has held a stockholder advisory vote on executive compensation every year since 2010, consistent with the advisory votes of the stockholders at the Company's 2011 and 2017 Annual Meetings of Stockholders. The Board has found that such vote provides a clear and simple means for stockholders to provide direct feedback to the Company regarding its compensation philosophy, policies and practices as disclosed in the proxy statement, consistent with the Company's practice of seeking input from, and engaging in discussions with, the Company's stockholders on executive compensation and other matters.<br> While the Board is making a recommendation with respect to this proposal, stockholders are not voting to approve or disapprove the Board's recommendation. Instead, stockholders are being asked to specify one of the four choices for this proposal indicated on the proxy card: one year, two years, three years or abstain. Since you have several voting choices, it is possible that no single choice will receive a majority vote. In addition, because your vote is advisory, it will not be binding on the Board, whether or not a particular frequency receives a majority vote. However, the Board will review the voting results in their entirety and take them into consideration when making future decisions regarding the frequency of advisory votes on executive compensation. |
| ![](cl4117791_def14ax68x1.jpg) |  |
| ![](cl4117791_def14ax68x1.jpg) | The Board of Directors recommends a vote **FOR** the option of once every **ONE YEAR** as the frequency with which stockholders will be provided an advisory vote on executive compensation. |

---

---

| | |
|:---|:---|
| 2023 Proxy Statement | **65** |

---

**[**Table of Contents**](#toc)** 

Proposals Requiring Your Vote

---

| |
|:---|
| **Proposal 5**<br> **Stockholder Proposal** |
| John Chevedden, 2215 Nelson Avenue, No. 205, Redondo Beach, California 90278, owner of at least 100 shares of Common Stock, has informed us that he intends to offer the following resolution for consideration at the Annual Meeting.<br> **Proposal 5—Independent Board Chairman**<br> ![](cl4117791_def14ax72x1.jpg)<br> Shareholders request that the Board of Directors adopt an enduring policy, and amend the governing documents as necessary in order that 2 separate people hold the office of the Chairman and the office of the CEO as follows:<br> Selection of the Chairman of the Board the Board requires the separation of the offices of the Chairman of the Board and the Chief Executive Officer.<br> Whenever possible, the Chairman of the Board shall be an Independent Director.<br> The Board has the discretion to select a Temporary Chairman of the Board who is not an Independent Director to serve while the Board is seeking an Independent Chairman of the Board. This policy could be phased in when there is a contract renewal for our current CEO or for the next CEO transition.<br> This proposal topic has built up momentum at Colgate-Palmolive. Year after year it has progressed form 37% to 46% to 47% support. The 47% support likely means close to 55% support form the shares that have access to independent proxy voting advice and are not forced to rely on the biased opinion of management. Colgate-Palmolive should support the vote of a majority of shareholders who have full access to the pro and con arguments.<br> Colgate-Palmolive is Exhibit A in why the Lead Director role is an empty suit compared to an independent Board Chairman. Our Lead Director, Mr. Stephen Sadove, attracts negative shareholder votes. Mr. Sadove received the most negative shareholder votes in 2020 and 2021 and the second highest negative votes in 2022.<br> Mr. Sadove's negative votes were up to 35-times the number of negative votes of other CL directors. Mr. Sadove violates the most important attribute of a Lead Director - independence. As director tenure goes up director independence goes down. Mr. Sadove has 16-years tenure. Mr. Sadove's long tenure makes him a prime candidate to retire.<br> With the current CEO serving as Chair this means giving up a substantial check and balance safeguard that can only occur with an independent Board Chairman.<br> A lead director is no substitute for an independent board chairman. A lead director cannot call a special shareholder meeting and cannot even call a special meeting of the board. A lead director can delegate most of his lead director duties to the CEO office and then simply rubber-stamp it. There is no way shareholders can be sure of what goes on.<br> This is proposal is especially important due to our lackluster stock price since 2017 when it was $76. |
| Please vote yes:<br> **Independent Board Chairman—Proposal 5**<br> **Company Response**<br> Your Board of Directors recommends a vote **AGAINST** this stockholder proposal for the following reasons:<br> **The Board is truly independent and has an experienced and highly effective independent Lead Director with significant authority and clear duties to ensure proper checks and balances.**<br> Lorrie M. Norrington has served as the independent Lead Director since March 1, 2023, succeeding Stephen I. Sadove in that role. Ms. Norrington joined the Board in 2015 and has been the Chair of the Nominating, Governance and Corporate Responsibility Committee since 2021. Ms. Norrington is a highly effective director who brings extensive global corporate leadership, digital, eCommerce and ESG experience to the independent Lead Director role. She also has extensive experience serving on other public company boards.<br> The duties of the independent Lead Director are comprehensive and are clearly delineated in our corporate governance guidelines, entitled "Board Guidelines on Significant Corporate Governance Issues." In 2021, the Board enhanced these duties in connection with a review of external practices and in response to stockholder feedback. |

---

**66**

**[**Table of Contents**](#toc)** 

Proposals Requiring Your Vote

---

| |
|:---|
| In many cases, the expanded responsibilities simply formalized activities that the independent Lead Director already had been performing. The Board further enhanced the independent Lead Director's duties in January 2023 in response to feedback from the proponent of this stockholder proposal. The role of the Lead Director includes the following responsibilities: |
| In many cases, the expanded responsibilities simply formalized activities that the independent Lead Director already had been performing. The Board further enhanced the independent Lead Director's duties in January 2023 in response to feedback from the proponent of this stockholder proposal. The role of the Lead Director includes the following responsibilities: |
| *Board Leadership*<br> **•** Preside at the executive sessions of the independent directors that occur at every regularly scheduled Board meeting, any other executive session of the independent directors and any other meeting of the Board at which the Chairman is not present<br> **•** Serve as interim Chairman if the Chairman is unable to perform their duties<br> **•** Establish agendas for the executive sessions of the independent directors in consultation with the other directors<br> **•** Call meetings of the independent directors<br> **•** Authorize the retention of outside advisors and consultants who report directly to the independent directors on Board issues |
| *Communicating with Management*<br> **•** After each executive session of the independent directors, provide feedback to and apprise the Chairman/CEO of the views expressed, suggestions made and decisions reached during the session<br> **•** Meet regularly with the Chairman/CEO between meetings, including acting as a sounding board to the CEO and providing strategic counsel<br> **•** Serve as primary liaison between the independent directors and the Chairman/CEO and management (although all independent directors are encouraged to communicate freely with the Chairman/CEO and other members of management at any time) |
| *Board Culture*<br> **•** Together with the Chairman, facilitate the efficient and effective functioning and performance of the Board<br> **•** Encourage and facilitate active and candid participation of all directors, including by fostering an environment of open dialogue and constructive feedback among the independent directors |
| *Board Information, Agendas and Schedules*<br> **•** Review and approve information to be sent to the Board and provide feedback on quality, quantity and timeliness of information flow from management<br> **•** Participate in setting, and ultimately approve, proposed Board meeting agendas<br> **•** Solicit the other independent directors for advice on agenda items for Board meetings to help facilitate Board focus on key issues and topics of interest to the Board<br> **•** Review and approve meeting schedules to help ensure there is sufficient time for discussion of all agenda items<br> **•** Ensure Board meeting agendas provide the Board with the ability to periodically review and provide input on the Company's long-term strategy and to monitor management's execution of the long-term strategy |
| *Performance Evaluations, Succession Planning, Recruitment and Development* |
| **•** Together with the Personnel and Organization Committee, lead the annual performance evaluation of the Chairman/CEO, distinguishing as necessary between performance as Chairman and performance as CEO<br> **•** Together with the Personnel and Organization Committee, lead the CEO succession planning process and participate in talent retention and development of senior management<br> **•** Provide guidance on Board succession and development<br> **•** In coordination with the Nominating, Governance and Corporate Responsibility Committee, interview Board candidates |
| *Stakeholder Engagement*<br> **•** Be available, as deemed appropriate by the Board, for consultation and direct communication with stockholders or other key constituents |
| *Other*<br> **•** Facilitate the effective functioning of Board committees, as appropriate<br> **•** Perform such other duties as the Board may specify from time to time |

---

---

| | |
|:---|:---|
| 2023 Proxy Statement | **67** |

---

**[**Table of Contents**](#toc)** 

Proposals Requiring Your Vote

---

| | |
|:---|:---|
| With the exception of Noel R. Wallace, the Chairman, President and CEO, the Board is composed entirely of independent directors, and the Board's meeting practices and leadership structure encourage independence. As described above, the independent directors meet at each regularly scheduled Board meeting in separate executive sessions without any members of management present. These sessions are chaired by the independent Lead Director. The independent Lead Director serves a three-year term and is selected by and from the independent directors following nomination by the Nominating, Governance and Corporate Responsibility Committee.<br> Further, all of the members (including the chairs) of the Audit Committee, the Finance Committee, the Nominating, Governance and Corporate Responsibility Committee and the Board's compensation committee (known as the Personnel and Organization Committee) are independent directors. This, when coupled with the independent composition of the Board as described above, ensures that independent directors guide all critical matters, such as the integrity of our financial statements, oversight of the enterprise risk management process, cybersecurity and ESG initiatives, CEO and senior management compensation, succession planning and talent development and selection of directors.<br> **The Board and Colgate are committed to the highest standards of corporate governance and are accountable and responsive to stockholders.**<br> Our corporate governance practices and policies are described in the section of this Proxy Statement entitled "Governance of the Company." As discussed in that section, we have had a longstanding commitment to the highest standards of corporate governance, including a policy requiring the annual election of all directors by majority vote. Reflecting the Board's commitment to continuous improvement, the Board reviews its governance practices on an ongoing basis to ensure that they promote stakeholder value and effective functioning of the Board. As a result of this review, the Board has made a number of enhancements over the years. For example, in 2021 the Board reduced the ownership threshold required to call a special stockholder meeting from 25% to 15% in response to stockholder feedback in connection with a stockholder proposal received on the topic. In 2016, the Board adopted proxy access, allowing eligible stockholders to nominate directors for inclusion in our proxy statement if they satisfy the requirements specified in our by-laws. These actions demonstrate the Board's accountability and responsiveness to stockholders, and the proxy access right, together with the requirement that all directors be elected annually by majority vote, helps to ensure that the Board remains accountable to stockholders.<br> **Requiring an independent Chairman and the separation of the Chairman and CEO roles is not in the best interests of stockholders.**<br> Our active and independent Board, with our robust independent Lead Director role and independent committee chairs and committees, ensures that the Board, and not the Chairman alone, determines the Board's focus. The Chairman is guided by these strong independent leaders and having our CEO serve as Chairman creates a bridge to management that helps provide the Board with the management support it needs. Having a unified leadership structure is particularly beneficial at this time given the dynamic consumer and retail landscape and rapidly evolving environment in which we compete. Under the leadership of Mr. Wallace as Chairman and CEO during the past three years, and overseen by our strong independent Board, we have delivered strong performance, as illustrated by the following chart: | With the exception of Noel R. Wallace, the Chairman, President and CEO, the Board is composed entirely of independent directors, and the Board's meeting practices and leadership structure encourage independence. As described above, the independent directors meet at each regularly scheduled Board meeting in separate executive sessions without any members of management present. These sessions are chaired by the independent Lead Director. The independent Lead Director serves a three-year term and is selected by and from the independent directors following nomination by the Nominating, Governance and Corporate Responsibility Committee.<br> Further, all of the members (including the chairs) of the Audit Committee, the Finance Committee, the Nominating, Governance and Corporate Responsibility Committee and the Board's compensation committee (known as the Personnel and Organization Committee) are independent directors. This, when coupled with the independent composition of the Board as described above, ensures that independent directors guide all critical matters, such as the integrity of our financial statements, oversight of the enterprise risk management process, cybersecurity and ESG initiatives, CEO and senior management compensation, succession planning and talent development and selection of directors.<br> **The Board and Colgate are committed to the highest standards of corporate governance and are accountable and responsive to stockholders.**<br> Our corporate governance practices and policies are described in the section of this Proxy Statement entitled "Governance of the Company." As discussed in that section, we have had a longstanding commitment to the highest standards of corporate governance, including a policy requiring the annual election of all directors by majority vote. Reflecting the Board's commitment to continuous improvement, the Board reviews its governance practices on an ongoing basis to ensure that they promote stakeholder value and effective functioning of the Board. As a result of this review, the Board has made a number of enhancements over the years. For example, in 2021 the Board reduced the ownership threshold required to call a special stockholder meeting from 25% to 15% in response to stockholder feedback in connection with a stockholder proposal received on the topic. In 2016, the Board adopted proxy access, allowing eligible stockholders to nominate directors for inclusion in our proxy statement if they satisfy the requirements specified in our by-laws. These actions demonstrate the Board's accountability and responsiveness to stockholders, and the proxy access right, together with the requirement that all directors be elected annually by majority vote, helps to ensure that the Board remains accountable to stockholders.<br> **Requiring an independent Chairman and the separation of the Chairman and CEO roles is not in the best interests of stockholders.**<br> Our active and independent Board, with our robust independent Lead Director role and independent committee chairs and committees, ensures that the Board, and not the Chairman alone, determines the Board's focus. The Chairman is guided by these strong independent leaders and having our CEO serve as Chairman creates a bridge to management that helps provide the Board with the management support it needs. Having a unified leadership structure is particularly beneficial at this time given the dynamic consumer and retail landscape and rapidly evolving environment in which we compete. Under the leadership of Mr. Wallace as Chairman and CEO during the past three years, and overseen by our strong independent Board, we have delivered strong performance, as illustrated by the following chart: |
| With the exception of Noel R. Wallace, the Chairman, President and CEO, the Board is composed entirely of independent directors, and the Board's meeting practices and leadership structure encourage independence. As described above, the independent directors meet at each regularly scheduled Board meeting in separate executive sessions without any members of management present. These sessions are chaired by the independent Lead Director. The independent Lead Director serves a three-year term and is selected by and from the independent directors following nomination by the Nominating, Governance and Corporate Responsibility Committee.<br> Further, all of the members (including the chairs) of the Audit Committee, the Finance Committee, the Nominating, Governance and Corporate Responsibility Committee and the Board's compensation committee (known as the Personnel and Organization Committee) are independent directors. This, when coupled with the independent composition of the Board as described above, ensures that independent directors guide all critical matters, such as the integrity of our financial statements, oversight of the enterprise risk management process, cybersecurity and ESG initiatives, CEO and senior management compensation, succession planning and talent development and selection of directors.<br> **The Board and Colgate are committed to the highest standards of corporate governance and are accountable and responsive to stockholders.**<br> Our corporate governance practices and policies are described in the section of this Proxy Statement entitled "Governance of the Company." As discussed in that section, we have had a longstanding commitment to the highest standards of corporate governance, including a policy requiring the annual election of all directors by majority vote. Reflecting the Board's commitment to continuous improvement, the Board reviews its governance practices on an ongoing basis to ensure that they promote stakeholder value and effective functioning of the Board. As a result of this review, the Board has made a number of enhancements over the years. For example, in 2021 the Board reduced the ownership threshold required to call a special stockholder meeting from 25% to 15% in response to stockholder feedback in connection with a stockholder proposal received on the topic. In 2016, the Board adopted proxy access, allowing eligible stockholders to nominate directors for inclusion in our proxy statement if they satisfy the requirements specified in our by-laws. These actions demonstrate the Board's accountability and responsiveness to stockholders, and the proxy access right, together with the requirement that all directors be elected annually by majority vote, helps to ensure that the Board remains accountable to stockholders.<br> **Requiring an independent Chairman and the separation of the Chairman and CEO roles is not in the best interests of stockholders.**<br> Our active and independent Board, with our robust independent Lead Director role and independent committee chairs and committees, ensures that the Board, and not the Chairman alone, determines the Board's focus. The Chairman is guided by these strong independent leaders and having our CEO serve as Chairman creates a bridge to management that helps provide the Board with the management support it needs. Having a unified leadership structure is particularly beneficial at this time given the dynamic consumer and retail landscape and rapidly evolving environment in which we compete. Under the leadership of Mr. Wallace as Chairman and CEO during the past three years, and overseen by our strong independent Board, we have delivered strong performance, as illustrated by the following chart: | With the exception of Noel R. Wallace, the Chairman, President and CEO, the Board is composed entirely of independent directors, and the Board's meeting practices and leadership structure encourage independence. As described above, the independent directors meet at each regularly scheduled Board meeting in separate executive sessions without any members of management present. These sessions are chaired by the independent Lead Director. The independent Lead Director serves a three-year term and is selected by and from the independent directors following nomination by the Nominating, Governance and Corporate Responsibility Committee.<br> Further, all of the members (including the chairs) of the Audit Committee, the Finance Committee, the Nominating, Governance and Corporate Responsibility Committee and the Board's compensation committee (known as the Personnel and Organization Committee) are independent directors. This, when coupled with the independent composition of the Board as described above, ensures that independent directors guide all critical matters, such as the integrity of our financial statements, oversight of the enterprise risk management process, cybersecurity and ESG initiatives, CEO and senior management compensation, succession planning and talent development and selection of directors.<br> **The Board and Colgate are committed to the highest standards of corporate governance and are accountable and responsive to stockholders.**<br> Our corporate governance practices and policies are described in the section of this Proxy Statement entitled "Governance of the Company." As discussed in that section, we have had a longstanding commitment to the highest standards of corporate governance, including a policy requiring the annual election of all directors by majority vote. Reflecting the Board's commitment to continuous improvement, the Board reviews its governance practices on an ongoing basis to ensure that they promote stakeholder value and effective functioning of the Board. As a result of this review, the Board has made a number of enhancements over the years. For example, in 2021 the Board reduced the ownership threshold required to call a special stockholder meeting from 25% to 15% in response to stockholder feedback in connection with a stockholder proposal received on the topic. In 2016, the Board adopted proxy access, allowing eligible stockholders to nominate directors for inclusion in our proxy statement if they satisfy the requirements specified in our by-laws. These actions demonstrate the Board's accountability and responsiveness to stockholders, and the proxy access right, together with the requirement that all directors be elected annually by majority vote, helps to ensure that the Board remains accountable to stockholders.<br> **Requiring an independent Chairman and the separation of the Chairman and CEO roles is not in the best interests of stockholders.**<br> Our active and independent Board, with our robust independent Lead Director role and independent committee chairs and committees, ensures that the Board, and not the Chairman alone, determines the Board's focus. The Chairman is guided by these strong independent leaders and having our CEO serve as Chairman creates a bridge to management that helps provide the Board with the management support it needs. Having a unified leadership structure is particularly beneficial at this time given the dynamic consumer and retail landscape and rapidly evolving environment in which we compete. Under the leadership of Mr. Wallace as Chairman and CEO during the past three years, and overseen by our strong independent Board, we have delivered strong performance, as illustrated by the following chart: |
| ![](cl4117791_def14ax74x1.jpg) | <sup>\*</sup> Adjusted earnings-per-share growth and organic sales growth reflect the adjustments described in Annex A to Colgate's earnings per share and net sales growth, respectively, and comparable adjustments to peer companies' earnings per share and net sales growth. |

---

**68**

**[**Table of Contents**](#toc)** 

Proposals Requiring Your Vote

---

| | |
|:---|:---|
| Based on these considerations, the Board believes that this is the best leadership structure for us at this time and that, operating under this structure, the Board will continue to effectively guide Colgate and represent the interests of our stakeholders. A requirement that the Chairman be an independent director, as the proposal requests, would reduce the Board's ability to act in the best interests of the Company and to respond to the changing needs of the Board and the Company.<br> Given its in-depth knowledge of Colgate's business and experience, the Board is uniquely positioned to evaluate the optimal leadership structure for the Company at any particular time, and, based on the effective governance practices described above, stockholders can be confident the Board is composed of the right people to make that determination. The Board believes that retaining the flexibility to determine the best Board leadership structure based on the circumstances in effect from time to time best protects the interests of the stockholders. | Based on these considerations, the Board believes that this is the best leadership structure for us at this time and that, operating under this structure, the Board will continue to effectively guide Colgate and represent the interests of our stakeholders. A requirement that the Chairman be an independent director, as the proposal requests, would reduce the Board's ability to act in the best interests of the Company and to respond to the changing needs of the Board and the Company.<br> Given its in-depth knowledge of Colgate's business and experience, the Board is uniquely positioned to evaluate the optimal leadership structure for the Company at any particular time, and, based on the effective governance practices described above, stockholders can be confident the Board is composed of the right people to make that determination. The Board believes that retaining the flexibility to determine the best Board leadership structure based on the circumstances in effect from time to time best protects the interests of the stockholders. |
| ![](cl4117791_def14ax75x1.jpg) |  |
| ![](cl4117791_def14ax75x1.jpg) | For these reasons, the Board of Directors recommends a vote **AGAINST** this proposal. |

---

---

| |
|:---|
| **Proposal 6**<br> **Stockholder Proposal** |
| Kenneth Steiner, 14 Stoner Avenue, 2M, Great Neck, New York 11021, owner of at least 500 shares of Common Stock, has informed us that he intends to offer the following resolution for consideration at the Annual Meeting.<br> **Proposal 6—Executives To Retain Significant Stock**<br> ![](cl4117791_def14ax72x1.jpg)<br> Shareholders urge that our executive pay committee adopt a policy requiring senior executives to retain a significant percentage of stock acquired through equity pay programs until reaching normal retirement age and to report to shareholders regarding the policy in our Company's next annual meeting proxy. For the purpose of this policy, normal retirement age would be an age of at least 60 and be determined by our executive pay committee. Shareholders recommend a share retention percentage requirement of 33% of net after-tax shares.<br> This single unified policy shall prohibit hedging transactions for shares subject to this policy which are not sales but reduce the risk of loss to the executive. Otherwise our directors might be able to avoid the impact of this proposal. This policy shall supplement any other share ownership requirements that have been established for senior executives, and should be implemented without violating current company contractual obligations or the terms of any current pay or benefit plan.<br> Requiring senior executives to hold a significant portion of stock obtained through executive pay plans would focus our executives on our company's long-term success. A Conference Board Task Force report stated that hold-to-retirement requirements give executives "an ever-growing incentive to focus on long-term stock price performance.<br> Please vote yes:<br> **Executives To Retain Significant Stock—Proposal 6**<br> **Company Response**<br> Your Board of Directors recommends a vote **AGAINST** this stockholder proposal for the following reasons:<br> **Senior executives are already required to hold significant amounts of Colgate stock.**<br> Our robust stock ownership guidelines already require members of senior management to hold significant amounts of Colgate stock. The CEO is required to own Colgate stock equal in value to eight times his annual salary, and the other Named Officers must hold Colgate stock equal in value to four times their annual salaries. Other senior managers are subject to ownership requirements of one or two times their annual salaries. Executives have five years from their initial promotion into an eligible position to achieve required ownership levels and neither unexercised stock options nor unearned performance-based restricted stock units are counted for purposes of determining whether the ownership requirements have been met. All of the executives who are subject to our rigorous stock ownership guidelines are in compliance with them and many of our senior executives own Colgate stock at levels far in excess of these requirements. For example, Noel R. Wallace, our Chairman, President and CEO, currently holds Colgate stock equal in value to 18 times his annual salary. All of the other Named Officers, each of whom have been Named Officers for less than five years, either already hold Colgate stock equal in value to more than four times their annual salary or are on track to do so within the required five-year period. We also prohibit executives from pledging Colgate stock and from purchasing any financial instrument that is designed to hedge against or offset any decrease in the value of Colgate's stock, such as short sales and put and call options. As a result, our policies already ensure that executives' interests are aligned with those of our stockholders. Our Board also believes that these policies compare favorably with those of our peer companies and that implementation of the policy requested by this proposal could have an adverse impact on our ability to recruit and retain executive talent because it is not market practice. |

---

---

| | |
|:---|:---|
| 2023 Proxy Statement | **69** |

---

**[**Table of Contents**](#toc)** 

Proposals Requiring Your Vote

---

| | |
|:---|:---|
| **The proposal is unnecessary because our executive compensation program already effectively incentivizes management to increase shareholder value.**<br> Long-term equity grants are the largest component of target direct compensation for the Named Officers. Our long-term incentive compensation is designed to focus the Named Officers and other Colgate executives on increasing shareholder value and to incentivize their contribution to our long-term growth and performance. As discussed in greater detail in the CD&A, we use two types of long-term incentives for officers, both granted in the form of equity: stock options and performance-based restricted stock units. Our stock options provide value only to the extent that our stock price appreciates, thereby providing an effective link to changes in shareholder value that aligns the interests of stockholders and executives. Our use of performance-based restricted stock units, which pay out only upon achievement of our long-term financial performance goals over a three-year period, ensures that the amount of long-term incentive compensation executives receive is tied directly to both increases in shareholder value and the achievement of critically important multi-year performance objectives. The multi-year earning and/or vesting requirements in all of our long-term incentives provides an additional mechanism to reward long-term value creation. Our Board believes that these existing compensation components already align our executive compensation to long-term shareholder value and that requiring executives to hold stock acquired through our executive compensation program until retirement, regardless of the value of their existing stock ownership, would not provide additional benefit. | **The proposal is unnecessary because our executive compensation program already effectively incentivizes management to increase shareholder value.**<br> Long-term equity grants are the largest component of target direct compensation for the Named Officers. Our long-term incentive compensation is designed to focus the Named Officers and other Colgate executives on increasing shareholder value and to incentivize their contribution to our long-term growth and performance. As discussed in greater detail in the CD&A, we use two types of long-term incentives for officers, both granted in the form of equity: stock options and performance-based restricted stock units. Our stock options provide value only to the extent that our stock price appreciates, thereby providing an effective link to changes in shareholder value that aligns the interests of stockholders and executives. Our use of performance-based restricted stock units, which pay out only upon achievement of our long-term financial performance goals over a three-year period, ensures that the amount of long-term incentive compensation executives receive is tied directly to both increases in shareholder value and the achievement of critically important multi-year performance objectives. The multi-year earning and/or vesting requirements in all of our long-term incentives provides an additional mechanism to reward long-term value creation. Our Board believes that these existing compensation components already align our executive compensation to long-term shareholder value and that requiring executives to hold stock acquired through our executive compensation program until retirement, regardless of the value of their existing stock ownership, would not provide additional benefit. |
| ![](cl4117791_def14ax75x1.jpg) |  |
| ![](cl4117791_def14ax75x1.jpg) | For these reasons, the Board of Directors recommends a vote **AGAINST** this proposal. |

---

**Other Matters**

As of the date of this Proxy Statement's printing, we do not intend to submit any matters to the meeting other than those set forth herein, and we know of no additional matters that will be presented by others. However, if any other business should come before the meeting and you have voted by proxy, the directors named on the voting website and your proxy card as the Proxy Committee (the "Proxy Committee") have discretionary authority to vote your shares with respect to such matters in accordance with their best judgment.

By order of the Board of Directors.

![](cl4117791_def14ax76x1.jpg)

**Jennifer M. Daniels** *Chief Legal Officer and Secretary*

**70**

**[**Table of Contents**](#toc)** 

Questions and Answers About Our

Annual Meeting

&nbsp;&nbsp;&nbsp;**Who receives this Proxy Statement?**

Beginning March 29, 2023, we are mailing a printed copy of this Proxy Statement, a proxy card and our 2022 Annual Report to stockholders who have requested a printed copy, and a Notice of Internet Availability to all other stockholders who have not consented to electronic delivery. The Annual Report being made available on the internet and mailed with the Proxy Statement is not part of the proxy-soliciting material.

&nbsp;&nbsp;&nbsp;**Who is entitled to vote at the Annual Meeting?**

We have one class of voting stock outstanding: Common Stock. If you were a record owner of our Common Stock on March 13, 2023, the record date for voting at the Annual Meeting, you are entitled to vote at the meeting. At the close of business on March 13, 2023, there were 832,137,632 shares of Common Stock outstanding and entitled to vote. Each share of Common Stock has one vote.

&nbsp;&nbsp;&nbsp;**How can I vote my shares?**

You can vote your shares in two ways: either by proxy or electronically during the virtual Annual Meeting. If you choose to vote by proxy, you may do so using the internet, the telephone or, if you received a printed copy of your proxy materials, the mail. Each of these procedures is more fully explained below. Even if you plan to attend the virtual meeting, the Board recommends that you vote by proxy.

&nbsp;&nbsp;&nbsp;**How can I vote my shares by proxy?**

You may vote your proxy by internet, telephone or, if you received a printed copy of your proxy materials, by mail, each as more fully explained below. In each case, the deadline for voting is 11:59 p.m. (Eastern Daylight Time) on Thursday, May 11, 2023, unless you are a Colgate employee participating in the Savings & Investment Plan or another Colgate employee stock ownership plan, in which case the deadline for voting is 11:59 p.m. (Eastern Daylight Time) on Wednesday, May 10, 2023. When you vote your proxy, you can specify whether you wish to vote "FOR" or "AGAINST" or "ABSTAIN" from voting on each nominee for director, the ratification of the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2023 and, if properly presented at the meeting, two stockholder proposals. In addition, you can cast non-binding advisory votes on executive compensation and on whether you wish to hold future advisory votes on executive compensation every year, every two years or every three years, or abstain from voting. We will vote your shares as you direct.

If any other matters are properly presented for consideration at the Annual Meeting, the Proxy Committee will have discretion to vote for you on those matters. At the time this Proxy Statement was printed, we knew of no other matters to be raised at the Annual Meeting.

---

| | |
|:---|:---|
| ![](cl4117791_def14ax77x1.jpg)<br> **VOTE BY<br> INTERNET** | To vote your shares via the internet, go to the voting website, www.proxyvote.com. Internet voting is available 24 hours a day, seven days a week. You will have the opportunity to confirm that your instructions have been properly recorded. The internet voting procedures are designed to authenticate stockholders through individual control numbers. If you received a proxy card in the mail and choose to vote via the internet, you do not need to return your proxy card. |
| ![](cl4117791_def14ax77x2.jpg)<br> **VOTE BY<br> TELEPHONE** | If you reside in the United States, Canada or Puerto Rico, you can vote your shares by telephone by calling the toll-free number provided on the voting website (www.proxyvote.com) and on the proxy card. Telephone voting is available 24 hours a day, seven days a week. Easy-to-follow voice prompts allow you to vote your shares and confirm that your instructions have been properly recorded. The telephone voting procedures are designed to authenticate stockholders through individual control numbers. If you received a proxy card in the mail and choose to vote by telephone, you do not need to return your proxy card. |
| ![](cl4117791_def14ax77x3.jpg)<br> **VOTE BY<br> MAIL** | If you received a printed copy of your proxy materials, you can vote your shares by completing and mailing the enclosed proxy card to us so that we receive it by the deadline. If you received a Notice of Internet Availability, you can request a printed copy of your proxy materials by following the instructions contained in the notice. If you sign and return your proxy card but do not specify how to vote, we will vote your shares in favor of each of the Board's nominees for director, the ratification of the selection of the independent registered public accounting firm, the advisory vote on executive compensation and the advisory vote on holding future advisory votes on executive compensation every year, and against the two stockholder proposals. |

---

---

| | |
|:---|:---|
| 2023 Proxy Statement | **71** |

---

**[**Table of Contents**](#toc)** 

Questions and Answers About Our Annual Meeting

&nbsp;&nbsp;&nbsp;**How can I vote my shares during the Annual Meeting?**

As described in more detail below under "How can I participate in the Annual Meeting?", this year's Annual Meeting will be a virtual meeting, conducted on the following website: www.virtualshareholdermeeting.com/CL2023 (the "Annual Meeting Website"). If you would like to vote at the Annual Meeting, please follow the instructions that will be available on the Annual Meeting Website during the Annual Meeting. If your shares are held in the name of a bank, broker or other holder of record, you should follow the instructions provided by your bank, broker or other holder of record to be able to vote electronically at the meeting. Voting by proxy, whether by internet, telephone or mail, will not limit your right to vote electronically at the Annual Meeting. However, if you vote by proxy and also participate in the meeting, there is no need to vote electronically at the meeting unless you would like to change your vote.

&nbsp;&nbsp;&nbsp;**How can I participate in the Annual Meeting?**

Participation in the Annual Meeting is limited to holders of Common Stock on March 13, 2023, the record date for voting at the Annual Meeting.

The Annual Meeting will be a virtual meeting, conducted only via live webcast through the Annual Meeting Website. You will have the same rights and opportunities to participate as you would have at a physical annual meeting, including voting your shares electronically and submitting questions during the meeting. To participate in the Annual Meeting, you will need the 16-digit control number found on your Notice of Internet Availability, your proxy card or the instructions that accompany your proxy materials. If you do not have your 16-digit control number, you will still be able to attend the meeting as a guest but will not be able to vote your shares electronically or submit questions during the meeting. If your shares are held in the name of a bank, broker or other holder of record, you should follow the instructions provided by your bank, broker or other holder of record to be able to participate in the meeting.

The meeting webcast will begin promptly at 10:00 a.m., Eastern Daylight Time, on Friday, May 12, 2023. Access to the Annual Meeting Website will begin at 9:30 a.m. Eastern Daylight Time and we encourage you to access the Annual Meeting Website prior to the meeting start time.

For those unable to attend the virtual annual meeting, a recorded version of the webcast will be made available on our website.

&nbsp;&nbsp;&nbsp;**What if I have technical difficulties or trouble accessing the virtual meeting?**

If you encounter any technical difficulties accessing the Annual Meeting Website or during the virtual meeting, please call: 844-976-0738 (toll-free) or 303-562-9301 (international). Technical support will be available thirty minutes prior to the start time of the Annual Meeting.

&nbsp;&nbsp;&nbsp;**How can I ask a question during the Annual Meeting?**

As part of the Annual Meeting, we will hold a live question and answer session, during which we intend to answer questions submitted before or during the Annual Meeting in accordance with the Annual Meeting's Rules of Conduct (which will be available in the Investors section of our website and on the Annual Meeting Website) that are pertinent to the Company and the meeting matters, as time permits. Questions that are substantially similar may be grouped and answered once to avoid repetition and allow time for additional question topics. If there are any pertinent questions that cannot be answered during the Annual Meeting due to time constraints, we plan to respond directly to that stockholder after the Annual Meeting using the contact information provided.

You will be able to submit written questions prior to the Annual Meeting through www.proxyvote.com or during the Annual Meeting through the Annual Meeting Website. You will need the 16-digit control number found on your Notice of Internet Availability, your proxy card or the instructions that accompany your proxy materials in order to submit questions through these websites. If your shares are held in the name of a bank, broker or other holder of record, you should follow the instructions provided by your bank, broker or other holder of record to be able to submit questions.

**72**

**[**Table of Contents**](#toc)** 

Questions and Answers About Our Annual Meeting

&nbsp;&nbsp;**Can I change my vote?**

Yes. You can change your vote or revoke your proxy at any time before it is exercised at the Annual Meeting by taking any one of the following actions: (i) follow the instructions given for changing your vote via the internet or by telephone or deliver a valid written proxy with a later date; (ii) notify the Company Secretary in writing that you have revoked your proxy by mail to the Office of the Company Secretary, Colgate-Palmolive Company, 300 Park Avenue, 11th Floor, New York, New York 10022; or (iii) vote electronically during the Annual Meeting through the Annual Meeting Website.

&nbsp;&nbsp;**How many shares must be present to conduct the Annual Meeting?**

To carry on the business of the Annual Meeting, a minimum number of shares, constituting a quorum, must be present. The quorum for the Annual Meeting is a majority of the votes represented by the outstanding shares of our Common Stock. This majority may be present in person or by proxy. Abstentions and "broker non-votes" (which are explained below) are counted as present to determine whether there is a quorum for the Annual Meeting. Stockholders who attend the virtual meeting will be considered to be attending the meeting in person.

&nbsp;&nbsp;**What if I am a beneficial owner and do not give instructions to my broker?**

As a beneficial owner, in order to ensure your shares are voted in the way you would like, you must provide voting instructions to your broker by the deadline provided in the proxy materials you receive from your broker. If you do not provide voting instructions to your broker, whether your broker can vote your shares depends on the type of item being considered for vote. Under NYSE rules, if your broker holds shares in your name and delivers this Proxy Statement or a Notice of Internet Availability to you, the broker is entitled to vote your shares with respect to the ratification of the selection of the independent registered public accounting firm (Proposal 2) even if the broker does not receive voting instructions from you. The broker is not entitled to vote your shares with respect to the election of directors, the advisory vote on executive compensation, the advisory vote on the frequency of future advisory votes on executive compensation or the two stockholder proposals (Proposals 1, 3, 4, 5 or 6) without your instructions.

A "broker non-vote" occurs when your broker submits a proxy for your shares but does not indicate a vote for a particular proposal because the broker does not have authority to vote on that proposal and has not received voting instructions from you. "Broker non-votes" are not counted as votes for or against the proposal in question or as abstentions, nor are they counted to determine the number of votes present for the particular proposal.

&nbsp;&nbsp;**What vote is required to pass each of the proposals at the Annual Meeting?**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Proposals** | **Board Recommendation** | **Votes Required** | **Effect of Abstentions** | **Effect of Broker<br> Non-Votes** |
| Election of Directors | **FOR each nominee** | Majority of votes cast | None | None |
| Ratification of Selection of Independent Registered Public Accounting Firm | **FOR** | Majority of the shares represented at the meeting, either in person or by proxy, and entitled to vote on the proposal | Same as "AGAINST" | No Broker Non-Votes |
| Advisory Vote on Executive Compensation | **FOR** | Majority of the shares represented at the meeting, either in person or by proxy, and entitled to vote on the proposal | Same as "AGAINST" | None |
| Advisory Vote on Frequency of Future Advisory Votes on Executive Compensation | **ONE YEAR** | Majority of the shares represented at the meeting, either in person or by proxy, and entitled to vote on the proposal | Same as "AGAINST" the three voting frequencies proposed | None |
| Stockholder Proposals | **AGAINST** | Majority of the shares represented at the meeting, either in person or by proxy, and entitled to vote on the proposal | Same as "AGAINST" | None |

---

---

| | |
|:---|:---|
| 2023 Proxy Statement | **73** |

---

**[**Table of Contents**](#toc)** 

Questions and Answers About Our Annual Meeting

A majority of votes cast means that the number of shares voted for a nominee's election must exceed the number of votes cast against that nominee's election. When voting your proxy, the Proxy Committee will vote in accordance with the Board's recommendation for each proposal unless you instruct otherwise.

&nbsp;&nbsp;**Who nominates the directors?**

Nominations for directors may be made at a stockholders' meeting by the Board or by any of our stockholders who comply with the requirements of our by-laws. Proposals to nominate a director directly at next year's Annual Meeting must be received by the Company Secretary no earlier than January 13, 2024 and no later than February 12, 2024, as further described below under "How do I submit a stockholder proposal for consideration at next year's Annual Meeting?" To comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than Colgate nominees must provide notice that sets forth the information required by Rule 14a-19(b) under the Exchange Act no later than February 12, 2024, and otherwise comply with the requirements set forth in our by-laws.

In addition, stockholders who meet the eligibility requirements set forth in our by-laws may nominate directors for inclusion in our proxy statement. In order to include director nominees in our proxy statement for next year's Annual Meeting, nominations must be received by the Company Secretary no earlier than October 31, 2023 and no later than November 30, 2023 and must comply with the requirements of our by-laws.

The NGCR Committee will also consider director nominees recommended by stockholders in writing if such candidates meet our criteria for Board membership, as described under "Governance of the Company—The Board of Directors."

&nbsp;&nbsp;**How can I vote if I am an employee participating in the Savings & Investment Plan?**

If you are a Colgate employee who participates in the Savings & Investment Plan you will receive electronic notice or a Notice of Internet Availability with instructions on how to vote your shares. The notice also indicates the aggregate number of shares of Common Stock credited to your account under the Savings & Investment Plan as of March 13, 2023, the record date for voting at the meeting.

&nbsp;&nbsp;&nbsp;&nbsp;● You can direct the trustee how to vote your shares via the internet or by telephone.
 You can also direct the trustee how to vote by mail by requesting a proxy card and returning your completed proxy card to us.

**●** The deadline for submitting your vote is 11:59 p.m. (Eastern Daylight Time) on Wednesday, May 10,
 2022. If you do not indicate your vote to the trustee by that time, the trustee will vote your shares in the same proportion as it
 votes the shares of employees who indicate their votes by that time, unless inconsistent with the Employee Retirement Income Security
 Act of 1974 (ERISA).

&nbsp;&nbsp;**How can I vote if I am an employee participating in a stock ownership plan outside the United States?**

If you are a Colgate employee who participates in one of Colgate's employee stock ownership plans outside the United States, you will receive separate voting instructions electronically or from your local Human Resources Department.

&nbsp;&nbsp;**How do I submit a stockholder proposal for consideration at next year's Annual Meeting?**

A proposal submitted by any stockholder for consideration at next year's Annual Meeting (other than director nominations pursuant to our proxy access by-law) will be acted upon only if the following criteria are met:

&nbsp;&nbsp;&nbsp;&nbsp;**●** If you wish to submit a proposal for inclusion in our proxy statement for next year's Annual Meeting pursuant to Rule 14a-8 under the Exchange Act, the proposal must be received by the Company Secretary no later than November 30, 2023; or

**●** If you wish to present a proposal directly at next year's Annual Meeting without including it in our proxy statement, pursuant to our by-laws, the proposal must be received by the Company Secretary no earlier than January 13, 2024 and no later than February 12, 2024. Your proposal also must comply with certain information requirements set forth in our by-laws. These requirements apply to any matter that a stockholder wishes to raise at the Annual Meeting other than through inclusion in the proxy statement.

**74**

**[**Table of Contents**](#toc)** 

Questions and Answers About Our Annual Meeting

Proposals should be sent to the Company Secretary by mail to the Office of the Company Secretary, Colgate-Palmolive Company, 300 Park Avenue, 11th Floor, New York, New York 10022 or by email to stockholderproposals@colpal.com.

Please see "Who nominates the directors?" above for a description of the timing requirements for nominating a director pursuant to our by-laws.

&nbsp;&nbsp;**How are proxies solicited and what is the cost?**

We pay the cost of soliciting proxies for the meeting. Proxies may be solicited in person by Colgate employees, or by mail, telephone or electronic methods. In addition, we have retained Innisfree M&A Incorporated to solicit proxies by mail, telephone and electronic methods. We will pay a fee of approximately $30,000 to Innisfree M&A Incorporated plus expenses for these services.

&nbsp;&nbsp;**What is householding? Does Colgate use it?**

We have sent to registered stockholders who have requested a printed copy of proxy materials and have the same address and last name a single copy of this Proxy Statement and the 2022 Annual Report and one proxy card for each stockholder and, to all other registered stockholders who have not previously requested electronic delivery of proxy materials, a single envelope containing one Notice of Internet Availability for each stockholder.

If, now or in the future, you do not wish to participate in householding and prefer to receive separate copies of the Proxy Statement and Annual Report or your Notice of Internet Availability in a separate envelope, please call us at (855) 322-3551 or (212) 310-2575 or inform us in writing at: Colgate-Palmolive Company, Attention: Investor Relations, 300 Park Avenue, New York, New York 10022 or by sending an email to investor_relations@colpal.com. Or, if you are currently receiving separate copies of the Proxy Statement and Annual Report or Notice of Internet Availability at one address and would like to receive a single copy or a single envelope containing one Notice of Internet Availability for each stockholder, please contact us at the phone numbers, mailing address or email address listed in the previous sentence. We will respond promptly to such requests.

If your shares are held in the name of a bank, broker or other holder of record, you can request information about householding from such holder of record.

&nbsp;&nbsp;**Where can I find more information about Colgate?**

Our website address is www.colgatepalmolive.com. The information contained on our website is not included as a part of, or incorporated by reference into, this Proxy Statement. We make available, free of charge on our website, our annual reports on Form 10-K, our quarterly reports on Form 10-Q, our current reports on Form 8-K and amendments to such reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we have electronically filed such material with, or furnished it to, the SEC. Also available on our website are our Code of Conduct and corporate governance guidelines, the charters of the committees of the Board and reports under Section 16(a) of the Exchange Act of transactions in Company stock by our directors and executive officers. Hard copies of these materials are also available free of charge from our Investor Relations department by calling (855) 322-3551 or (212) 310-2575 or by sending an email to investor_relations@colpal.com. You may obtain a copy of our by-laws by writing to the Company Secretary at Office of the Company Secretary, Colgate-Palmolive Company, 300 Park Avenue, 11th Floor, New York, New York 10022.

---

| | |
|:---|:---|
| 2023 Proxy Statement | **75** |

---

**[**Table of Contents**](#toc)** 

This page intentionally left blank.

**[**Table of Contents**](#toc)** 

Annex A

Reconciliation of Non-GAAP Financial

Measures

---

| | | | |
|:---|:---|:---|:---|
| | **2020** | **2021** | **2022** |
| **Net Sales Growth—GAAP** | **5.0%** | **5.8%** | **3.0%** |
| Acquisitions and Divestments Impact | (1.6) | (0.1) | (0.5) |
| Foreign Exchange Impact | 3.8 | (1.3) | 4.5 |
| **Organic Sales Growth—Non-GAAP** | **7.2%** | **4.4%** | **7.0%** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **2019** | **2020** | **2021** | **2022** |
| **Diluted Earnings Per Share As Reported—GAAP** | **$2.75** | **$3.14** | **$2.55** | **$2.13** |
| Global Growth & Efficiency Program | 0.12 | (0.02) |  |  |
| Acquisition-Related Costs | 0.02 | 0.00 |  | 0.02 |
| Swiss Income Tax Reform | (0.04) |  |  |  |
| Value-Added Tax Matter in Brazil | (0.02) |  | (0.02) |  |
| Subsidiary and Operating Structure Initiatives |  | (0.08) |  |  |
| Loss on Early Extinguishment of Debt |  | 0.02 | 0.07 |  |
| Goodwill and Intangible Assets Impairment Charges |  |  | 0.61 | 0.74 |
| 2022 Global Productivity Initiative |  |  |  | 0.10 |
| Gain on the Sale of Land in Asia Pacific |  |  |  | (0.02) |
| **Base Business Earnings Per Share—Non-GAAP** | **$2.83** | **$3.06** | **$3.21** | **$2.97** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **(Dollars in millions)** | **(Dollars in millions)** | **(Dollars in millions)** | **(Dollars in millions)** |
| | **2019** | **2020** | **2021** | **2022** |
| <br>**Net Income Attributable to Colgate-Palmolive Company—GAAP** | $**2367** | $**2695** | $**2166** | $**1785** |
| Global Growth & Efficiency Program | 102 | (13) |  |  |
| Acquisition-Related Costs | 20 | 4 |  | 16 |
| Swiss Income Tax Reform | (29) |  |  |  |
| Value-Added Tax Matter in Brazil | (20) |  | (20) |  |
| Subsidiary and Operating Structure Initiatives |  | (71) |  |  |
| Loss on Early Extinguishment of Debt |  | 18 | 55 |  |
| Goodwill and Intangible Assets Impairment Charges |  |  | 518 | 620 |
| 2022 Global Productivity Initiative |  |  |  | 87 |
| Gain on the Sale of Land in Asia Pacific |  |  |  | (15) |
| **Base Business Net Income—Non-GAAP** | $**2440** | $**2633** | $**2719** | $**2493** |

---

---

| | | | |
|:---|:---|:---|:---|
| | **(Dollars in millions)** | **(Dollars in millions)** | **(Dollars in millions)** |
| | **2020** | **2021** | **2022** |
| <br>**Net Cash Provided by Operations—GAAP** | $**3719** | $**3325** | $**2556** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less: Capital Expenditures | (410) | (567) | (696) |
| **Free Cash Flow Before Dividends—Non-GAAP** | $**3309** | $**2758** | $**1860** |

---

**A-1**

**[**Table of Contents**](#toc)** 

This page intentionally left blank.

**[**Table of Contents**](#toc)** 

Annex B

Countries Excluded under CEO Pay Ratio

 *"De Minimis"* Exemption

---

| | |
|:---|:---|
| Country | **Number of<br> Employees** |
| Cameroon | 47 |
| Puerto Rico | 44 |
| El Salvador | 44 |
| Romania | 42 |
| Nicaragua | 41 |
| Kenya | 40 |
| Kazakhstan | 40 |
| Panama | 39 |
| Ukraine | 37 |
| Sweden | 37 |
| Uruguay | 36 |
| Bolivia | 33 |
| Paraguay | 31 |
| Norway | 28 |
| Honduras | 27 |
| Indonesia | 24 |
| South Korea | 23 |
| Tunisia | 22 |
| Singapore | 22 |
| Hungary | 22 |
| Austria | 20 |
| Senegal | 13 |
| Ghana | 12 |
| Finland | 12 |
| Reunion | 11 |
| Israel | 10 |
| Martinique | 9 |
| Zambia | 8 |
| Serbia | 8 |
| Tanzania | 7 |
| Slovenia | 7 |
| Mozambique | 7 |
| Latvia | 7 |
| Guadeloupe | 7 |
| Slovakia | 6 |
| Lebanon | 6 |
| French Polynesia | 6 |
| Croatia | 6 |
| Azerbaijan | 6 |
| New Caledonia | 5 |
| Belarus | 5 |
| Macedonia | 4 |
| Ivory Coast | 4 |
| Gabon | 4 |
| Trinidad | 3 |
| Malawi | 3 |
| Jamaica | 3 |
| Uzbekistan | 2 |
| Guyana | 2 |
| Georgia | 2 |
| Bulgaria | 2 |
| Brunei | 2 |
| Algeria | 2 |
| Bosnia | 1 |
| Bangladesh | 1 |

---

---

| | |
|:---|:---|
| 2023 Proxy Statement | **B-1** |

---

**[**Table of Contents**](#toc)** 

This page intentionally left blank.

**[**Table of Contents**](#toc)**![](cl4117791_def14ax87x1.jpg)

**[**Table of Contents**](#toc)**![](cl4117791_def14ax88x1.jpg)

---

| | |
|:---|:---|
| ![](cl4117791_def14ax88x2.jpg) | Colgate-Palmolive Company |
| ![](cl4117791_def14ax88x2.jpg) | 300 Park Avenue |
| ![](cl4117791_def14ax88x2.jpg) | New York, NY 10022 |
| ![](cl4117791_def14ax88x2.jpg) | (212) 310-2000 |
| ![](cl4117791_def14ax88x2.jpg) | www.colgatepalmolive.com |
| ![](cl4117791_def14ax88x2.jpg) |© 2023 Colgate-Palmolive Company |

---

**[**Table of Contents**](#toc)**![](cl4117791_def14ax89x1.jpg)

**[**Table of Contents**](#toc)**![](cl4117791_def14ax90x1.jpg)

### Attached PDF Documents

**Attachment 1:** `cl_courtesy-pdf.pdf`

![img-0.jpeg](img-0.jpeg)

# Colgate-Palmolive Company  
2023 Proxy Statement  
Notice of Annual Meeting  
of Stockholders

May 12, 2023

# Our Priorities

![img-1.jpeg](img-1.jpeg)

## Driving Organic Sales Growth

- Accelerating growth through science-led, core and premium innovation
- Pursuing higher-growth adjacent categories and segments
- Expanding in faster-growing channels and markets
- Maximizing growth in digital and eCommerce
- Investing to drive penetration in growing populations, including through our Bright Smiles, Bright Futures oral health education program

## Maximizing Efficiency in Our Income Statement

- Generating savings as part of our ongoing funding-the-growth cost-saving initiatives and our 2022 Global Productivity Initiative
- Driving our digital transformation and operating with a digital-first mindset in all aspects of our business
- Using advanced data analytics to identify opportunities that amplify growth and efficiencies
- Investing in technology to drive simplification, efficiency and standardization

## Deploying Cash Flow Effectively

- Capital spending to drive growth and productivity
- Making smart acquisitions that expand our categories, improve our market positions and/or add capabilities
- Continuing our record of paying cash dividends every year since 1895 and increasing dividends for 60 consecutive years
- Returning value to stockholders through ongoing share repurchases

## Demonstrating Our Purpose

- Committed to being a caring, innovative growth company reimagining a healthier future for all people, their pets and our planet
- Focused on implementing our global sustainability and social impact strategy with three key ambitions-Preserving Our Environment, Helping Millions of Homes and Driving Social Impact
- Dedicated to fostering diversity, equity and inclusion
- Committed to acting with compassion, integrity, honesty and high ethics in all situations
- Focused on excellence in corporate governance, an ongoing and steadfast commitment shared by the Board of Directors, management and all Colgate people

![img-2.jpeg](img-2.jpeg)

Learn more about our key priorities from the Annual Report, available in the Investors section of our website at www.colgatepalmolive.com

To learn about our 2025 Sustainability & Social Impact Strategy, see page 8 and the inside back cover of this Proxy Statement. Additional information about our sustainability and social impact initiatives and about our diversity, equity and inclusion initiatives is available in the Sustainability and Diversity, Equity and Inclusion sections of our website at www.colgatepalmolive.com

(The information on the Annual Report and Sustainability and Diversity, Equity and Inclusion web pages is not incorporated by reference into, and does not form part of, this Proxy Statement)

COLGATE-PALMOLIVE COMPANY

# Message from Our Chairman, President and CEO

March 29, 2023

Dear Fellow Colgate Stockholder:

You are cordially invited to attend our 2023 Annual Meeting of Stockholders on Friday, May 12, 2023 at 10:00 a.m. Eastern Daylight Time. The Annual Meeting will be a virtual meeting, conducted only via live webcast. You will be able to participate in the virtual meeting online, vote your shares electronically and submit your questions during the meeting by visiting: www.virtualshareholdermeeting.com/CL2023.

At the meeting, we will ask you to elect as directors the eleven nominees named in the Proxy Statement, to ratify the selection of our independent registered public accounting firm, to cast an advisory vote on executive compensation and to cast an advisory vote relating to the frequency of future stockholder advisory votes on executive compensation. In addition, two stockholder proposals will be offered for your consideration, if properly presented at the meeting. We will also review our progress during the past year and answer your questions.

This booklet includes the Notice of Annual Meeting and Proxy Statement. The Proxy Statement describes the business we will conduct at the meeting and provides information about Colgate that you should consider when you vote your shares.

The Proxy Statement includes a section highlighting our corporate governance practices. The Company and the Board of Directors have a longstanding commitment to the highest standards of corporate governance, and the Board of Directors reviews its governance practices on an ongoing basis to ensure that they promote stakeholder value. We invite you to review the governance section beginning on page 6 of the Proxy Statement to learn more about our continuing commitment to excellence in corporate governance.

It is important that your stock be represented at the meeting. Whether or not you plan to attend the virtual meeting, we hope that you will vote on the matters to be considered. You may vote your proxy via the internet or by telephone. If you received a printed copy of your proxy materials, you may also vote by mail by signing, dating and returning your proxy card in the envelope provided.

Very truly yours,

Noel R. Wallace
Chairman, President and Chief Executive Officer

![img-3.jpeg](img-3.jpeg)

“

As a stockholder you have an important role to play in Colgate’s future. Please take the time to vote in advance of this year’s meeting.”

# Letter to Stockholders from Our Directors

March 29, 2023

## Dear Fellow Colgate Stockholder:

We are honored to serve as your Board and want to thank you for placing your trust in us to oversee your Company and to represent you and your interests. We are pleased that Colgate continues to deliver strong progress against our growth strategy, even as we continued to navigate unprecedented uncertainty and difficult operating conditions during 2022 due to the effects of the war in Ukraine, the COVID-19 pandemic, inflation and rising interest rates.

We are pleased to have this opportunity to highlight for you a few key developments for Colgate in the past year.

### Board Refreshment

Board composition and refreshment remain a priority for us. Our current Board is a diverse, distinguished group with a wide array of experience, skills and other qualifications. All of our Board members are independent, other than Noel Wallace, Colgate's Chairman, President and CEO. We appointed a new independent Lead Director earlier this year, Lorrie Norrington, who succeeded Steve Sadove in that role. Lorrie is a highly effective director who brings extensive global corporate leadership, digital, eCommerce and ESG experience to the independent Lead Director role. She also has extensive experience serving on other public company boards.

We have also added four new independent directors since 2019. Our recently added directors bring varied professional experiences that allow them to contribute to the Board's oversight of Colgate's business strategy and support the future growth of Colgate's business, with a particular focus on skills and experiences that are crucial in today's environment, such as global enterprise leadership, cybersecurity, eCommerce and digital transformation and environmental and social responsibility. In undertaking our board refreshment process, we have sought to balance fresh perspectives, expertise in new capabilities and disciplines and the valuable insights into Colgate and its operations that directors develop over time.

### Executive Compensation Program Changes

Starting in 2021, the Personnel and Organization Committee determined that, in addition to financial goals, the annual incentive program should include a performance measure based on progress against strategic initiatives critical to the Company's growth strategy and continuing success, representing 20% of the annual bonus opportunity. In 2022, this strategic measure was tied to Colgate's performance against its enterprise-wide innovation, digital transformation and ESG goals. The Personnel and Organization Committee selected this strategic measure to further align compensation with Colgate's strategic priorities to build competitive advantage through digital and data capabilities, deliver innovation that drives category growth, foster a culture where everyone feels they belong and integrate sustainability into Colgate's business. The remaining 80% of the annual bonus opportunity continued to be determined by Colgate's achievement against organic sales growth and earnings-per-share goals.

The Personnel and Organization Committee also recently oversaw a review of our long-term incentive compensation structure and, with support from the other independent directors, determined to add an additional type of equity to the Company's long-term incentive program. Through 2022, we used two types of long-term incentives for officers, each weighted 50%: performance-based restricted stock units and stock options. Starting in 2023, performance-based restricted stock units will continue to comprise 50% of the long-term incentive program for officers, while stock options will comprise 30% and time-based restricted stock units will comprise 20%. We believe the new structure will better align with market standards and practice, while still focusing on growth and driving long-term performance.

Letter to Stockholders from Our Directors

## Responsiveness to Stockholders

We are committed to the highest standards of corporate governance, continuous improvement and being responsive to our stockholders. We believe it is important to engage with investors to better understand their priorities and, each year, members of management engage with a diverse group of our stockholders on topics important to our stockholders as well as the Company. Such topics include our business strategy and initiatives, executive compensation, Board composition and governance practices, as well as environmental and social topics such as human capital management, DE&I and sustainability. The Board discusses feedback from these engagement sessions with management on a regular basis.

Prior to Colgate's 2022 Annual Meeting, representatives of management and the Board engaged with certain stockholders to better understand their views and policies relating to a stockholder proposal received for the 2022 Annual Meeting on stockholder ratification of termination pay. Following that engagement, in April 2022, we adopted a policy that Colgate will not execute any new severance agreement with an executive officer that provides for cash severance benefits exceeding 2.99 times the sum of the executive officer's base salary plus target annual bonus opportunity, without seeking stockholder ratification of the agreement. During Colgate's regular annual stockholder engagement program in late 2022 and early 2023, stockholders indicated that they appreciated that we were proactive and responsive to feedback regarding that stockholder proposal.

Together with Colgate's management team, we remain committed to creating long-term value for you and to meeting the needs of all of our stakeholders. Despite the continued challenges the world faces, we believe that, by ensuring Colgate's strategies focus on all of our stakeholders, Colgate is well positioned to deliver sustainable, profitable growth over the long term.

Thank you for your trust and support and your continued investment in Colgate.

Very truly yours,

### The Members of Colgate's Board of Directors

John P. Bilbrey

John T. Cahill

Steve Cahillane

Lisa M. Edwards

C. Martin Harris

Martina Hund-Mejean

Kimberly A. Nelson

Lorrie M. Norrington

Michael B. Polk

Stephen I. Sadove

Noel R. Wallace

We are committed to the highest standards of corporate governance, continuous improvement and being responsive to our stockholders."

# Notice of Annual Meeting of Stockholders

Logistics

DATE AND TIME

Friday, May 12, 2023,
at 10:00 a.m.
Eastern Daylight Time

LIVE WEBCAST

www.virtualshareholder
meeting.com/CL2023

WHO CAN VOTE

Stockholders of record at
the close of business on
March 13, 2023 are
entitled to vote at the
Annual Meeting

Items to be Voted On

PROPOSAL 1 Elect as directors the eleven nominees identified in the Proxy Statement

PROPOSAL 2 Ratify selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2023

PROPOSAL 3 Advisory vote on executive compensation

PROPOSAL 4 Advisory vote on the frequency of future advisory votes on executive compensation

PROPOSALS 5-6 Stockholder proposals, if properly presented at the meeting

Board Recommendation

☑ FOR each director nominee

☑ FOR

☑ FOR

☑ FOR

☒ AGAINST

Stockholders will also consider and act upon such other business as may properly come before the meeting.

Because the Annual Meeting is virtual and being conducted only via live webcast, stockholders will not be able to physically attend the Annual Meeting. To attend the virtual meeting and vote during the meeting, go to www.virtualshareholdermeeting.com/CL2023. You will need the 16-digit control number found on your Notice of Internet Availability, your proxy card or the instructions that accompany your proxy materials to participate in the Annual Meeting.

Your vote is important. We encourage you to vote by proxy even if you plan to attend the virtual meeting. You may vote your proxy via the internet or by telephone by following the instructions included on your Notice of Internet Availability, your proxy card or the instructions that accompany your proxy materials. If you received a printed copy of your proxy materials, you may also vote by mail by signing, dating and returning your proxy card in the envelope provided. Voting now will not limit your right to change your vote or to attend the virtual meeting.

March 29, 2023

**Jennifer M. Daniels**
*Chief Legal Officer and Secretary*

Colgate-Palmolive Company
300 Park Avenue
New York, New York 10022

# Table of Contents

| Proxy Statement Summary | 2 |
| --- | --- |
| Governance of the Company | 6 |
| Our Corporate Governance Commitment | 6 |
| The Board of Directors | 11 |
| Director Independence | 19 |
| Certain Relationships and Related Transactions | 20 |
| Compensation Committee Interlocks and Insider Participation | 20 |
| Board Structure and Responsibilities | 20 |
| Stockholder Engagement | 25 |
| Communications to the Board of Directors | 26 |
| Compensation of Directors | 27 |
| Executive Compensation | 29 |
| Compensation Discussion and Analysis | 29 |
| P&O Committee Report | 43 |
| Summary Compensation Table | 44 |
| Grants of Plan-Based Awards | 46 |
| Outstanding Equity Awards at Fiscal Year-End | 47 |
| Option Exercises and Stock Vested | 48 |
| Retirement Plans | 49 |
| Deferred Compensation Plan | 51 |
| Supplemental Savings & Investment Plan | 51 |
| Executive Severance and Other Termination Benefits | 52 |
| CEO Pay Ratio | 56 |
| Pay Versus Performance | 57 |
| Stock Ownership | 60 |
| Stock Ownership of Directors and Executive Officers | 60 |
| Stock Ownership of Certain Beneficial Owners | 61 |
| Proposals Requiring Your Vote | 62 |
| Proposal 1: Election of Directors | 62 |
| Proposal 2: Ratification of Selection of Independent Registered Public Accounting Firm (includes Audit Committee Report) | 62 |
| Proposal 3: Advisory Vote on Executive Compensation | 65 |
| Proposal 4: Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation | 65 |
| Proposals 5-6: Stockholder Proposals | 66 |
| Other Matters | 70 |
| Questions and Answers About Our Annual Meeting | 71 |
| Annex A-Reconciliation of Non-GAAP Financial Measures | A-1 |
| Annex B-Countries Excluded Under CEO Pay Ratio “ De Minimis ” Exemption | B-1 |

# Proxy Statement Summary

This summary highlights information about Colgate-Palmolive Company (referred to in this Proxy Statement as "we," "us," "our," "Colgate" or the "Company") and our upcoming 2023 Annual Meeting of Stockholders (the "Annual Meeting") contained elsewhere in this Proxy Statement. This summary does not contain all of the information you should consider, and you should read the entire Proxy Statement carefully before voting.

## About Colgate

**Our Purpose:** We are a caring, innovative growth company reimagining a healthier future for all people, their pets and our planet. We seek to deliver sustainable, profitable growth through science-led, core and premium innovation and superior shareholder returns, as well as to provide Colgate people with an innovative and inclusive work environment. We do this by developing and selling products globally that make people's and their pets' lives healthier and more enjoyable and by embracing our sustainability and social impact and diversity, equity and inclusion ("DE&I") strategies across our organization.

**Our Products** are marketed in over 200 countries and territories throughout the world across four core categories.

| Oral Care | Personal Care | Home Care | Pet Nutrition | Worldwide 2022 Net Sales $18.0 Billion |
| --- | --- | --- | --- | --- |
| Key Brands Colgate elmex hello meridol Sorriso Tom's of Maine | Key Brands EltaMD Filorga Irish Spring Palmolive PCA Skin | Key Brands Protex Sanex Softsoap Speed Stick | Key Brands Ajax Axion Fabuloso Palmolive Soupline Suavitel | Key Brands Hill's Science Diet Hill's Prescription Diet |
|  |  | 17% of Net Sales | 21% of Net Sales |  |

**Living Our Values:** Our approximately 33,800 employees worldwide share a commitment to our three core corporate values: caring, global teamwork and continuous improvement. These values are reflected not only in the quality of our products and reputation, but also in our dedication to serving the communities where we live and work.

| CARING | GLOBAL TEAMWORK | CONTINUOUS IMPROVEMENT |
| --- | --- | --- |
| We care about people: Colgate people, consumers, customers, stockholders, business partners and people in the communities where we live and work. We are committed to acting with compassion, integrity, honesty and high ethics in all situations and to providing Colgate people with an innovative and inclusive work environment. | All Colgate people are part of a global team, committed to working and collaborating together across functions and countries. Only by sharing ideas, technologies and talents can we achieve and sustain profitable growth. | We are committed to getting better every day in all that we do, as individuals and as teams. We continue to drive a learning culture and transform our learning strategy to better meet our evolving business needs. We continue to embed new ways of working and leadership principles to, among other things, instill a growth mindset to drive innovation with focus, empowerment, experimentation and digitalization. |

## Roadmap of Voting Items

| Items to be Voted On | Board's Voting Recommendation | More Information |
| --- | --- | --- |
| PROPOSAL 1 Elect as directors the eleven nominees identified in the Proxy Statement | ☑ FOR each director nominee | Page 62 |
| PROPOSAL 2 Ratify selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2023 | ☑ FOR | Page 62 |
| PROPOSAL 3 Advisory vote on executive compensation | ☑ FOR | Page 65 |
| PROPOSAL 4 Advisory vote on the frequency of future advisory votes on executive compensation | ☑ FOR | Page 65 |
| PROPOSALS 5-6 Stockholder proposals, if properly presented at the meeting | ☒ AGAINST | Page 66 |

2

COLGATE-PALMOLIVE COMPANY

Proxy Statement Summary

## Director Nominees

The following table provides summary information about the eleven director nominees the Board has nominated for election at the Annual Meeting. Additional information about each nominee's background and experience can be found beginning on page 14.

| Name and Principal Occupation | Age | Years of Tenure | Committee Memberships |  |  |  | Other Current Public Company Boards |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  | AUD | FIN | NGCR | P&O |  |
| John P. Bilbrey Independent Former Chairman, President and Chief Executive Officer, The Hershey Company | 66 | 8 |  | ● | ● |  | Campbell Soup Company Elanco Animal Health Inc. Tapestry, Inc. |
| John T. Cahill Independent Vice Chairman, The Kraft Heinz Company | 65 | 18 | ● |  |  | ● | American Airlines Group Inc. The Kraft Heinz Company |
| Steve Cahillane 1 Independent Chairman, President and Chief Executive Officer, Kellogg Company | 57 | 0 |  |  |  |  | Kellogg Company |
| Lisa M. Edwards Independent Executive Chair, Diligent Institute | 55 | 4 |  | ● | ● |  |  |
| C. Martin Harris Independent Associate Vice President of the Health Enterprise and Chief Business Officer, Dell Medical School | 66 | 7 |  |  | ● | ● | Agiliti, Inc. MultiPlan Corporation Thermo Fisher Scientific Inc. |
| Martina Hund-Mejean Independent Former Chief Financial Officer, Mastercard Inc. | 62 | 3 | ● | ● |  |  | Prudential Financial, Inc. Shell plc |
| Kimberly A. Nelson Independent Former Senior Vice President, External Relations, General Mills, Inc. | 60 | 2 |  |  | ● | ● | Cummins Inc. Tate & Lyle PLC |
| Lorrie M. Norrington Independent, Lead Director Operating Partner, Lead Edge Capital LLC | 63 | 8 | ● |  | ● |  | Asana, Inc. Autodesk, Inc. HubSpot, Inc. |
| Michael B. Polk Independent Advisory Director, Berkshire Partners LLC and Chief Executive Officer, Implus LLC | 62 | 9 |  | ● |  | ● | Logitech International S.A. |
| Stephen I. Sadove Independent Founding Partner, JW Levin Management Partners LLC | 71 | 16 | ● |  |  | ● | Aramark Movado Group, Inc. Park Hotels & Resorts Inc. |
| Noel R. Wallace Chairman, President and Chief Executive Officer, Colgate-Palmolive Company | 58 | 4 |  |  |  |  |  |
| AUD Audit FIN Finance NGCR Nominating, Governance & Corporate Responsibility P&O Personnel & Organization ● Member ● Chair |  |  |  |  |  |  |  |

$^{1}$ Mr. Cahillane, who became a director in 2023, is expected to be appointed to committees in 2023.

## Director Nominee Highlights

### Strong Board Diversity

![img-4.jpeg](img-4.jpeg)

* Ms. Edwards, Ms. Hund-Mejean, Ms. Nelson and Ms. Norrington are our female director nominees. Dr. Harris and Ms. Nelson identify as African-American and Ms. Norrington identifies as LGBTQ+.

### Director Nominee Diversity, Experience, Skills and Qualifications

The Nominating, Governance and Corporate Responsibility Committee (the "NGCR Committee") seeks to compose a Board with members who have a broad range of experiences, skills, diversity and different perspectives. In addition to educational achievement and a strong moral and ethical character, the following skills and attributes were all considered by the Board in connection with this year's director nomination process:

![img-5.jpeg](img-5.jpeg)

2023 Proxy Statement 3

Proxy Statement Summary

# Governance Highlights

The Board believes that excellence in corporate governance accompanies and greatly aids our long-term business success and that we have consistently been at the forefront of excellent corporate governance. Reflecting its commitment to continuous improvement, the Board reviews its governance practices on an ongoing basis to ensure that they promote stakeholder value. The governance section beginning on page 6 describes our corporate governance framework and commitment, which includes the following highlights:

BOARD FOCUSED ON KEY STRATEGIC PRIORITIES

- ✓ Board plays major role in overseeing business strategy and performance, risk management, Company culture and succession planning
- ✓ Board and management focus on environmental, social and governance ("ESG") matters and cybersecurity, each of which we believe is crucial to our ongoing business success

FOCUS ON BOARD PERFORMANCE

- ✓ Board composition defined by strong leadership and experience
- ✓ Strong focus on diversity (45% of director nominees are female and/or members of underrepresented communities)
- ✓ Strong record of Board refreshment with four new independent directors since 2019
- ✓ 98% average attendance of incumbent directors at Board and committee meetings in 2022
- ✓ Mandatory retirement age of 72 provides a mechanism for regular Board refreshment
- ✓ Directorship limits and related policies prevent overboarding
- ✓ Annual Board and committee self-evaluations
- ✓ Regular independent director evaluations
- ✓ Regular review of committee charters, corporate governance guidelines, director qualifications and related policies

ALIGNMENT WITH STOCKHOLDER INTERESTS

- ✓ Substantial majority of director compensation paid in Colgate equity
- ✓ Robust stock ownership requirements for directors and officers
- ✓ Clawback, anti-hedging and anti-pledging policies
- ✓ Pay-for-performance philosophy
- ✓ Robust annual stockholder engagement program

BOARD INDEPENDENCE

- ✓ New independent Lead Director appointed as of March 1, 2023
- ✓ Strict director independence standards
- ✓ 10 out of 11 director nominees are independent (all except for the Chief Executive Officer)
- ✓ Board committees are 100% independent
- ✓ Independent Lead Director duties recently enhanced
- ✓ Executive sessions of independent directors are held at every regularly scheduled Board meeting

STOCKHOLDER RIGHTS

- ✓ Annual election of all directors
- ✓ Majority voting and director resignation policy for directors in uncontested elections
- ✓ Stockholders have ability to call special meetings (threshold reduced to 15% in 2021) and to act by written consent
- ✓ Stockholders have proxy access right

4

COLGATE-PALMOLIVE COMPANY

Proxy Statement Summary

## Executive Compensation Program Highlights

The key principles underlying our compensation philosophy are aligning pay and performance, driving strong business results and our strategic plan, focusing on long-term shareholder return, motivating and retaining critical talent and reflecting external market and competitive practices.

In 2022, the compensation of the Named Officers (as defined in the Compensation Discussion and Analysis, or “CD&A”) was designed so that approximately 75% to 90% of their target direct compensation (salary and target annual and long-term incentives) would be performance-based. Annual and long-term incentive award payments vary from target levels based on our business performance, and long-term incentive award payments and the value of equity awards also vary based on the performance of our common stock (“Common Stock”).

Our executive compensation program for 2021 received substantial stockholder support and was approved, on an advisory basis, by

**90.8%**

of stockholders voting on the proposal at the 2022 Annual Meeting of Stockholders.

## New ESG Component Added to Strategic Measure in 2022 Annual Incentive Program

Starting in 2021, the Board’s compensation committee, known as the Personnel and Organization Committee (the “P&O Committee”), determined that, in addition to financial goals, the annual incentive program should include a performance measure based on strategic initiatives, representing 20% of the annual bonus opportunity. For 2021, the strategic measure was tied to our enterprise-wide innovation and digital transformation progress in recognition of the critical importance of innovation and digital transformation to our growth strategy and continuing success and to further align compensation with our strategic priorities. In 2022, the P&O Committee determined that, in addition to performance measures tied to our enterprise-wide innovation and digital transformation progress, the strategic measure should also include performance measures tied to our sustainability and DE&I progress in recognition of the importance of ESG matters to our continuing success. See page 39 of the CD&A for further detail regarding how the P&O Committee measured achievement against the strategic measure. The remaining 80% of the annual bonus opportunity was determined by our achievement against our organic sales growth and earnings-per-share goals.

## Compensation Governance

Our key executive compensation practices include the following:

- ✓ High percentage of compensation is variable and is tied to annual and long-term performance
- ✓ Programs designed to compensate at approximately the median level if paid at target
- ✓ Multiple performance measures used
- ✓ Robust stock ownership guidelines
- ✓ Ability to claw back compensation
- ✓ Only perquisite is use of car and driver for CEO
- ✓ Double-trigger vesting of severance payments upon change in control
- ✓ No executive officer employment agreements
- ✓ No hedging or pledging of Colgate stock is permitted
- ✓ No backdating, springloading or repricing of stock options
- ✓ No tax gross-ups on perquisites or severance

Please see the CD&A beginning on page 29 for a detailed description of our executive compensation programs.

2023 Proxy Statement 5

# Governance of the Company

## Our Corporate Governance Commitment

We are a caring, innovative growth company reimagining a healthier future for all people, their pets and our planet. The Board believes that excellence in corporate governance accompanies and greatly aids our achievement of this purpose, as well as our long-term business success. Our key strategic business priorities are driving organic sales growth and long-term profitable growth through science-led, core and premium innovation, pursuing higher-growth adjacent categories and segments, expanding in faster-growing channels and markets and delivering margin expansion through operating leverage and efficiency. We also seek to maximize the impact of our ESG programs and lead in the development of human capital, including our sustainability and social impact and DE&I strategies. The Board has been at the center of these key priorities, helping to design and implement them across the organization, and seeing that they guide our operations.

The Board believes that we have consistently been at the forefront of excellent corporate governance. Reflecting its commitment to continuous improvement, the Board reviews its governance practices on an ongoing basis to ensure that they promote stakeholder value.

## Board Independence, Expertise and Accountability

### Strict Director Independence Standards

With the exception of Noel R. Wallace, our Chairman of the Board, President and Chief Executive Officer (the “CEO”), the Board is comprised entirely of independent directors. All members of the Audit Committee, the Finance Committee, the NGCR Committee and the P&O Committee are independent directors. The Board believes that an independent director should be free of any relationship with Colgate or our senior management that may in fact or in appearance impair the director’s ability to make independent judgments or compromise the director’s objectivity and loyalty to stockholders. Based on this principle, the Board adopted director independence standards that outline the types of relationships, both personal and professional, between directors and the Company, our senior management, other directors and third parties that, if present, would preclude a finding of independence. These standards, which are stricter than those required by the listing standards of the New York Stock Exchange (the “NYSE”), guide the Board’s annual affirmative determinations of independence. A copy of the standards is available on our website. For more information regarding our independence standards and the Board’s determinations of independence, see “Director Independence.”

### Lead Director/Executive Sessions

Lorrie M. Norrington is currently serving as our independent Lead Director, having succeeded Stephen I. Sadove in that role as of March 1, 2023. The independent directors of the Board meet in executive session, without any members of management present, at every regularly scheduled Board meeting. The Lead Director chairs these sessions. The Lead Director serves a three-year term and is selected by the independent directors following nomination by the NGCR Committee. For more information regarding the Board’s leadership structure and the responsibilities of the Lead Director, which were recently enhanced in connection with a review of external practices and in response to stockholder feedback, see “Board Structure and Responsibilities-Board Leadership Structure.”

### All Directors Elected Annually by Majority Vote

The Board is accountable to stockholders through the annual election of all directors by majority vote. We have never had a staggered board. Under our by-laws, in uncontested elections for directors, if a nominee for director who is an incumbent director is not re-elected by a majority of the votes cast, the by-laws require the director to promptly tender their resignation to the Board. The NGCR Committee will then consider the resignation and make a recommendation to the Board.

### Director Attendance at Annual Meetings

It is our policy that all members of the Board should attend our Annual Meeting of Stockholders, whether held virtually or in person, unless extraordinary circumstances prevent a director’s attendance. All of the ten directors who were elected to the Board at the 2022 Annual Meeting were in attendance.

### Proxy Access

Our by-laws permit a group of up to 20 stockholders who have owned at least three percent of our outstanding Common Stock continuously for at least three years to submit director nominees (up to the greater of two individuals or 20% of the Board) for inclusion in our proxy statement if the stockholder(s) and the nominee(s) satisfy the requirements specified in our by-laws.

6

![Colgate-Palmolive Company logo]() COLGATE-PALMOLIVE COMPANY

Governance of the Company

## Audit Committee Independence and Financial Literacy

All members of the Audit Committee are independent directors. The Board has also determined that all members of the Audit Committee are “audit committee financial experts,” as that term is defined under the rules of the Securities and Exchange Commission (the “SEC”), and that they meet the independence and financial literacy requirements of the NYSE.

## Board Experience and Diversity

As our present directors exemplify, we value the following attributes in Board members:

- enterprise leadership experience
- experience in one of more of the following areas: digital, technology and innovation; environmental and social responsibility; finance; our or a complementary industry; regulatory; and/or risk management and cybersecurity
- international experience
- corporate governance experience
- educational achievement
- strong moral and ethical character

A copy of our criteria for Board membership, entitled “Independent Board Candidate Qualifications,” is available on our website. We are strongly focused on diversity, and 45% of director nominees are female and/or members of underrepresented communities. For more information regarding the role of diversity in the selection of nominees for Board membership, see “The Board of Directors-Director Diversity, Experience, Skills and Qualifications.”

## Board Focused on Key Strategic Priorities

### Strategic Role of Board

The Board plays an essential role in developing, guiding and overseeing our business strategy. It was deeply involved in the development of our strategic plan and receives detailed briefings throughout the year on critical aspects of its implementation. These include reviews of the strategic choices we are making and the capabilities needed to deliver against our goals, as well as performance reviews of operating divisions, product categories and competitive and marketplace trends.

### Role of Board in Risk Management

The Board oversees our risk management process to ensure it is properly designed, well-functioning and consistent with our overall corporate strategy. Annually, the Board or a relevant committee reviews each of the top risk areas identified by management and receives reports more regularly for certain risk areas to ensure risks are being adequately managed. See “Board Structure and Responsibilities-Board Role in Risk Oversight” for more information about our risk management process.

### Oversight of Company Culture

The Board believes that our culture and our core corporate values of caring, global teamwork and continuous improvement are critical to our business success. It monitors the ongoing impact of those values and our culture in various ways, including by visiting our operations and reviewing the results of employee engagement surveys and related responsive actions.

### Succession Planning

The Board has extensive involvement in succession planning and people development, with special focus on CEO succession. It discusses potential successors to key executives, regularly interacts with key executives and potential successors and examines backgrounds, capabilities and appropriate developmental assignments. Regular reviews of professional training programs, benefit programs and career development processes assist the Board in guiding our people development initiatives.

### Cybersecurity

The Board is particularly focused on cybersecurity. Specific responsibility for cybersecurity oversight is delegated to the Audit Committee, and four directors have considerable experience in this area. Our Chief Information Security Officer provides a report to the Audit Committee on cybersecurity quarterly, or more frequently if circumstances warrant, including on topics related to information security, data privacy and cyber risks and mitigation strategies. In addition, outside experts periodically present to the Board on cybersecurity. Our dedicated information security organization, led by our Chief Information Security Officer and overseen by our Chief Information Officer, leverages various frameworks for managing cybersecurity risks, including the National Institute of Standards and Technology (NIST) framework. The information security organization seeks to employ cybersecurity best practices, including implementing new

2023 Proxy Statement 7

Governance of the Company

technologies to proactively identify and monitor new vulnerabilities and reduce risk, conducting due diligence of third-party vendors’ information security programs, maintaining security policies and standards and regularly updating and testing our response planning and protocols. The information security organization also works in partnership with our Internal Audit function to review cybersecurity-related internal controls with our external auditors and other third parties as part of the overall internal controls process. Additionally, employees are provided mandatory cybersecurity awareness education and training, including conducting phishing simulations and testing scenarios through tabletop exercises, to help ensure compliance with our cyber policies and procedures. We also have a cybersecurity insurance policy in place.

## ESG

ESG initiatives remain an important focus for us. As part of this focus, we have proactively engaged with investors to learn from their perspectives on ESG matters and to share our approach. Oversight of ESG issues has been and remains one of the Board’s key priorities, particularly through the NGCR Committee, which was reconstituted and renamed in 2020 to heighten the Board’s focus on sustainability (including climate change), social responsibility and corporate citizenship matters, and through the P&O Committee, which oversees human capital matters, including our DE&I strategy.

### Sustainability (Including Climate Change)

Sustainability is critically important to our overall business and growth strategy. Our 2025 Sustainability & Social Impact Strategy focuses on three key ambitions-preserving our environment by accelerating action on climate change and reducing our environmental footprint; helping millions of homes by empowering people to develop healthier habits; and driving social impact with a commitment to helping to ensure the wellbeing of all people and their pets. These ambitions are supported by actionable targets consistent with our continued commitment to building environmental and social consciousness into our decision-making. As discussed further in our 2022 Climate Transition & Net Zero Action Plan, these actionable targets include science-based near-term, long-term and Net Zero 2040 emissions targets across our operations and supply chain, which were approved by The Science Based Targets initiative in 2022. Please see the inside back cover of this Proxy Statement for highlights of our progress and the Sustainability section of our website for more information regarding our 2025 Sustainability & Social Impact Strategy.

The NGCR Committee oversees our 2025 Sustainability & Social Impact Strategy and receives regular updates from management on sustainability matters, risks and opportunities, including our efforts to accelerate action on climate change, reduce our environmental footprint and achieve our sustainability targets.

Our sustainability function is overseen by our Group President, Growth and Strategy, an executive officer who reports to our CEO. The management and implementation of our 2025 Sustainability & Social Impact Strategy is led on a day-to-day basis by our Chief Sustainability Officer. Our Chief Sustainability Officer also leads our sustainability steering committee, which is composed of members of senior management. The sustainability steering committee makes strategic decisions related to sustainability and works to integrate our strategy into our broader organization and meet our sustainability targets. Networks of senior leaders in each division and local champions support on-the-ground sustainability efforts, communications and reporting. To integrate sustainability tracking and disclosures into our business strategy, operations and employee review process, our global sustainability initiatives are among the individual objectives used to determine the compensation for many of our senior managers. In addition, to further emphasize the importance of executing on our sustainability strategy, the P&O Committee included a sustainability component in the strategic measure of our annual incentive program applicable to all executives starting in 2022. Additional information about our strategy and processes for identifying, assessing and managing climate-related risks and opportunities, including governance, metrics and targets, can be found in the Sustainability section of our website, including our annual Sustainability & Social Impact Report, our 2022 Climate Transition & Net Zero Action Plan and our reports aligned with the Task Force on Climate-related Financial Disclosures (TCFD) recommendations and Sustainability Accounting Standards Board (SASB). References to these reports and our website are for informational purposes only and neither the reports nor the other information on our website is incorporated by reference into this Proxy Statement.

### Human Capital (Including DE&I)

We believe our people are crucial to our ongoing business success and aim to recruit, develop and retain strong and diverse talent. We celebrate differences, promote an equitable and inclusive environment and value the contributions of all Colgate people. At Colgate, we are proud of our collaborative spirit - what we call The Power of WE. As a truly global company, we are working to ensure that our workforce reflects the diversity of the communities in which we live and work and that Colgate people around the world feel that Colgate is a place where they belong, can be their authentic selves, are treated with respect and have equal opportunity to impact the business and be recognized for it.

8

![Colgate-Palmolive Company logo]() COLGATE-PALMOLIVE COMPANY

Governance of the Company

As part of our commitment to continuous improvement, we continue to drive a learning culture and transform our learning strategy to better meet our evolving business needs. We provide our employees with learning experiences focused on building leadership skills and offer training programs that are closely aligned with our business strategy. Specifically, we continue to embed new ways of working and leadership principles to, among other things, instill a growth mindset to drive innovation with focus, empowerment, experimentation and digitalization. Colgate people are embracing data and analytics as part of their jobs, and we are scaling new capabilities worldwide. For example, in 2022 approximately 14,000 Colgate people completed a new Data Literacy & Analytics Academy course we created with training experts. We are also committed to listening to our employees and seeing how the Company is evolving and growing through regular employee engagement surveys.

We are also committed to providing all of our employees with an equitable and inclusive work environment, learning opportunities and promotion and growth opportunities. A vital piece of our DE&I strategy has been ensuring that our succession planning process incorporates the advancement of women and people of all cultures, including underrepresented communities. Our global DE&I strategy aims to further advance our commitment to become an even more diverse, equitable and inclusive company through its four pillars of People, Community, Supplier Diversity and Communication. As part of our commitment to transparency and progress in these efforts, we publish our latest EEO-1 reports on our website and publish an annual DE&I report. To further emphasize the importance of executing on our DE&I strategy, the P&O Committee included a DE&I component in the strategic measure of our annual incentive program starting in 2022. Additionally, starting in 2021, DE&I measures were among the individual objectives used to determine the compensation for our managers. The NGCR Committee and the P&O Committee receive regular updates on the implementation of our DE&I strategy and initiatives. For more information about our DE&I commitment and initiatives, including detail on the gender and racial/ethnic diversity of our organization and our most recent EEO-1 reports, please see the Diversity, Equity and Inclusion section of our website.

## Directors are Stockholders

### Director Compensation in Stock

On average, 78% of a non-employee director’s compensation was paid in Colgate equity in 2022. For more information regarding director compensation, see “Compensation of Directors.”

### Significant Levels of Director Stock Ownership

Board members own significant amounts of Colgate stock. Under our stock ownership guidelines, independent directors are required to own stock equal in value to at least five times their annual share grant. For more information on director stock ownership, see “Stock Ownership-Stock Ownership of Directors and Executive Officers.”

## Established Policies Guide Governance and Business Integrity

### Corporate Governance Guidelines

The corporate governance guidelines reflect the Board’s views and Company policy regarding significant corporate governance issues, which the Board believes are best practice. As part of its ongoing review of best practices in corporate governance, the Board periodically reviews and updates the guidelines. A copy of the guidelines, entitled “Board Guidelines on Significant Corporate Governance Issues,” is available on our website.

### Code of Conduct

The Board sponsors our Code of Conduct, which promotes the highest ethical standards in all of our business dealings. The Global Ethics and Compliance function, headed by a corporate officer who reports to the CEO and provides reports directly to the Audit Committee, oversees compliance with these standards and periodically reviews and updates the Code of Conduct in conjunction with our Global Legal Organization. The Code of Conduct applies to our directors and employees, including the CEO, the Chief Financial Officer and the Controller (who is our principal accounting officer), and satisfies the SEC’s requirements for a code of ethics for senior financial officers. The Code of Conduct is available on our website.

### Business Integrity Initiatives

The Board supports our efforts to effectively communicate our commitment to ethical business practices, which are led by our Global Ethics and Compliance function. To further this goal, all of our directors and employees worldwide are required to annually certify that they understand and comply with the Code of Conduct. In addition, all of our directors and employees worldwide participate in regular training programs regarding the Code of Conduct, and our salaried and clerical employees participate in additional periodic training programs regarding Colgate’s values, ethical leadership and the applicable laws and regulations that govern our business practices around the world.

2023 Proxy Statement 9

Governance of the Company

## Political Expenditures

As set forth in our Code of Conduct and our Political Contributions Policy, we have a longstanding policy against making direct or indirect contributions to any political party or candidate. In addition, each year, we advise our U.S. trade associations of this policy to prevent the use of Company dues or contributions for any such expenditures and request that such associations that receive at least $10,000 annually from us confirm their compliance with this policy. The Political Contributions Policy is available on our website.

## Restrictions on Hiring Audit Firm Employees

To bolster the independence of our independent registered public accounting firm and the integrity of our internal financial reporting and audit processes, we have a longstanding policy prohibiting us from hiring any partners or managers engaged in an audit of Colgate or any employees engaged in the corporate portion of an audit of Colgate from PricewaterhouseCoopers LLP, our independent registered public accounting firm, within five years of the end of their engagement without the approval of the Audit Committee.

## Hedging and Pledging Policies

To further ensure that the interests of our directors, officers and senior managers are aligned with those of our stockholders, our hedging policy prohibits our directors, officers and employees who receive stock-based compensation from engaging in transactions to hedge against declines in the value of our stock, as further described in the CD&A. The policy also strongly discourages all other employees from entering into such transactions. Further, to prevent forced sales of Colgate stock by our directors and officers, we prohibit our directors and officers from pledging Colgate stock.

## Clawback Policies

Our clawback policy permits us to recoup cash and equity-based incentive awards made to an officer or other executive subject to the policy if (i) the financial results on which such awards were based are subsequently restated or (ii) the officer or executive engaged in conduct that violates our Code of Conduct. In addition, our equity award agreements include non-competition, non-solicitation and non-interference restrictions in the event of an employee's departure from Colgate. Failure to comply with any of these requirements may result in forfeiture and/or cancellation of equity awards. We are monitoring regulatory developments regarding clawback requirements and will adopt any changes that may be necessary to comply with NYSE listing standards when effective.

## Direct Access to Management

### Management Participation at Board Meetings

Key senior managers regularly attend Board meetings. Topics are presented to the Board by the members of management who are most knowledgeable about the issue at hand irrespective of seniority. An open and informal environment allows dialogue to develop between directors and management, which often produces new ideas and areas of focus.

### Direct Access to Management

The Board's direct access to management continues outside the boardroom in discussions and working groups with corporate officers, division presidents and other employees, often without the CEO present. Directors are invited to and do contact senior managers directly with questions and suggestions.

## Ensuring Management Accountability

### Performance-Based Compensation

We have linked the pay of our managers and employees at all levels to Colgate's performance. As described in greater detail in the CD&A, the P&O Committee adheres to this pay-for-performance philosophy, and stock-based incentive awards are a significant component of senior management's overall compensation.

### CEO Evaluation Process

The Board's evaluation of the CEO is a formal annual process. The CEO is evaluated by the Board against the goals set each year, including both objective measures (such as earnings per share, organic sales growth and achievement of strategic initiatives) and subjective criteria (such as leadership and demonstration of our core values). As part of the overall evaluation process, the Board and the Lead Director meet informally with the CEO to give feedback on a regular basis.

## Board Practices Promote Effective Oversight

### Board Size

Designed to maximize board effectiveness, our by-laws fix the number of directors between seven and fifteen. The number of directors is currently fixed at eleven, and eleven directors have been nominated for election at the Annual Meeting.

10 ![Colgate-Palmolive Company logo]() COLGATE-PALMOLIVE COMPANY

Governance of the Company

## Board Retirement Age

Our by-laws mandate that no director may stand for re-election after their 72nd birthday, which provides a mechanism for regular Board refreshment.

## Directorship Limits

To ensure that directors are able to devote sufficient time to properly discharge their duties, our corporate governance guidelines provide that directors should not serve on more than three other public company boards. All directors are in compliance with this policy. Directors are also required to seek the approval of the NGCR Committee prior to joining any corporate board or assuming a leadership position (e.g., chair, lead director or committee chair) on a corporate board or upon a material change in their qualifications or status. In addition, the NGCR Committee conducts an annual review of director time commitments, with consideration given to public company board leadership positions and other director time commitments, to ensure they continue to have sufficient availability.

## Meeting Attendance

On average, each incumbent director attended 98% of the meetings of the Board and the committees on which he or she served in 2022. No incumbent director attended less than 75% of these meetings.

## Continuous Improvement Through Evaluation and Education

### Board Self-Evaluation Process

Each year, the Board evaluates its performance against criteria that it has determined are important to its success. One or more of the following topics may be considered during such evaluations: financial oversight, risk oversight, succession planning, executive compensation, strategic planning, corporate governance, oversight of sustainability issues (including climate change), ethics and compliance and Board composition and structure. The Board then considers the results of the evaluation and identifies steps to enhance its performance.

### Board Committee Evaluations

Self-evaluations of each of the Board's committees are also conducted annually. The results of these evaluations are reviewed with each committee, and further enhancements are agreed for each committee.

### Individual Director Evaluations

Complementing the Board and committee self-evaluations, the Board has also developed an individual director evaluation process to be used every three years. Using director effectiveness criteria selected by the Board following a review of external best practices, directors evaluate their peers and the resulting feedback is shared with individual directors by an external facilitator. This process, which the Board intends to conduct again in 2023, enables directors to provide valuable feedback to one another and identifies areas of strength and areas of focus for enhanced effectiveness.

### Ongoing Director Education

Outside experts periodically present to the Board on various subjects. During 2022, such subjects included cybersecurity, ESG reporting and executive compensation trends. From time to time, our directors also visit Colgate operations, deepening their understanding of our business. In 2022, they visited our Hill's business operations and science and technology center in Topeka, Kansas.

## The Board of Directors

The Board oversees our strategy, business, performance, assets, affairs, culture, values and financial integrity. In accordance with our longstanding practice, the Board is independent, consisting of a substantial majority of outside directors. Currently, the Board has eleven directors, with ten independent directors and one employee director, Noel R. Wallace, who is our President and CEO and Chairman of the Board.

During 2022, the independent directors met in executive session without Mr. Wallace or other members of management present at every regularly scheduled Board meeting.

The Board met **twelve** times during 2022. On average, the incumbent directors attended

**98%**

of the meetings of the Board and the committees on which they served in 2022.

## Director Diversity, Experience, Skills and Qualifications

The Board selects director candidates based on the recommendation of the NGCR Committee. The NGCR Committee identifies, screens and recruits potential candidates for membership on the Board of Directors, taking into account the needs of Colgate and the Board at the time as well as anticipated future needs. We have engaged a third-party international executive search firm to assist the NGCR Committee in identifying and evaluating potential director candidates.

2023 Proxy Statement 11

Governance of the Company

The NGCR Committee seeks to compose a Board with members who have a broad range of experiences and skills and different perspectives, with a particular emphasis on enterprise leadership experience; experience in digital, technology and innovation, environmental and social responsibility, finance, our or a complementary industry, regulatory and/or risk management and cybersecurity; international experience; corporate governance experience; diversity; educational achievement; and strong moral and ethical character. This variety and depth of experience enables the Board collectively to understand our global business and our consumers around the world and the directors individually to make significant contributions to the deliberations of the Board.

The Board has adopted a written statement, known as the Independent Board Candidate Qualifications and made available on our website, outlining the qualities sought in our directors. This statement, which is refreshed periodically and was most recently updated in January 2023, is used by the NGCR Committee in evaluating individual director candidates. It highlights the following skills and experiences, among others, as being important to creating an effective, well-rounded and diverse Board:

| Experience, Skill or Qualification | Rationale |
| --- | --- |
| Enterprise Leadership -Is or has been the Chief Executive Officer, Chief Operating Officer or other high level executive at a complex public corporation or held a comparable position in the nonprofit sector or government and has experience with strategy. | Directors who have served in these roles possess exceptional leadership qualities and demonstrate a practical understanding of how large organizations operate, including strategic planning. |
| Digital, Technology and Innovation -Has experience with eCommerce, digital marketing, data and analytics, information technology or digital transformation, or relevant innovation experience including with new technologies, product development or scientific research. | We are focused on maximizing growth in eCommerce, using digital marketing as a way of reaching today’s consumers and innovating to drive growth. Directors with experience in those fields are therefore able to provide insights that help us advance powerful commercial strategies in the rapidly evolving digital and eCommerce landscapes. In addition, directors with expertise in data and analytics, information technology or digital transformation, including enterprise software, artificial intelligence and machine learning, provide helpful oversight with respect to the use of technology to gain insights and drive efficiency of operations. |
| Environmental and Social Responsibility -Has experience with sustainability, social responsibility or human capital matters (including DE&I issues and initiatives). | Given the critical importance of sustainability and human capital matters to our culture, business and growth strategy, directors with experience with environmental and social responsibility issues strengthen the Board’s oversight of these matters, including the risks and opportunities associated with them. They also bring important perspectives to our business, including with respect to our 2025 Sustainability & Social Impact Strategy, DE&I strategy and initiatives such as our Bright Smiles, Bright Futures oral health education program. |
| Finance -Has a background in finance, including an understanding of accounting and financial reporting processes, complex financial transactions and/or strategic mergers and acquisitions. | We use a variety of financial metrics to measure our performance, and accurate financial reporting and accounting are critical to our success. Therefore, directors with financial experience, including an understanding of accounting and financial reporting processes, provide an essential oversight role. In addition, directors who have experience with strategic mergers and acquisitions provide helpful perspectives and oversight as we evaluate and implement strategic transactions. |
| Industry -Has experience in the fast-moving consumer goods industry or other complementary field, such as public health. | Directors with experience in the fast-moving consumer goods industry have experience with manufacturing, marketing and selling products and consumer engagement and therefore can provide valuable market and consumer insights, as well as contribute a broad understanding of industry trends. Directors with experience in complementary industries, such as public health, also bring important perspectives and knowledge to our business, including with respect to engagement with dental, veterinary and skin health professionals. |
| Regulatory -Has experience working in a highly regulated industry, such as pharmaceutical, healthcare or insurance. | Directors with experience in highly regulated industries bring valuable insights because our business requires compliance with a variety of regulatory requirements around the world. |
| Risk Management and Cybersecurity -Has experience with overseeing and managing risk management processes, including with respect to cybersecurity. | Directors with experience overseeing and managing risk management processes play a critical role in the Board’s oversight of our enterprise risk management process. Given our focus on digital transformation and increased use of data and analytics, experience in cybersecurity is increasingly important. |

12 ![Colgate-Palmolive Company logo]() COLGATE-PALMOLIVE COMPANY

Governance of the Company

| Experience, Skill or Qualification | Rationale |
| --- | --- |
| International -Has significant international experience, whether through managing international business operations or living and working outside the United States; an understanding of the language and culture of non-English speaking countries is also important. | Since approximately two-thirds of our net sales are generated outside the United States and we are focused on continuing to drive penetration in markets with growing populations, having directors with experience managing international operations is essential. Exposure to different cultural perspectives and practices is also important in helping us meet the needs of our global consumers in the over 200 countries and territories worldwide in which we compete. |
| Corporate Governance -Has sufficient applicable experience to understand and fulfill the legal and other responsibilities of an independent director of a U.S.-based public company. | Excellence in corporate governance accompanies and greatly aids our long-term business success, including by promoting transparency, accountability and promotion of stakeholder value. Having directors with experience serving as directors of other U.S. public companies helps ensure the Board deeply understands its roles and duties and we remain at the forefront of excellent corporate governance. |

The NGCR Committee expects each of our directors to have the personal qualities necessary to make a substantial contribution to the Board, including high moral and ethical standards, strong communication and interpersonal skills, a commitment to Colgate's success and the willingness and ability to devote sufficient time to discharge their duties. Prospective directors must also satisfy our director independence standards and should not currently be, or have been within the past three years, an officer or director of a competitor.

In addition, the NGCR Committee has a policy of promoting diversity on the Board, as it believes the Board should constantly be striving to achieve the diversity of the communities in which we operate, including with respect to race, ethnicity, gender, sexual orientation, gender identity and cultural background. The NGCR Committee implements this policy through its director recruitment efforts and assesses the effectiveness of the policy regularly through Board and committee self-evaluations. The NGCR Committee strives to consider a diverse slate of candidates for every director search.

The NGCR Committee will consider director candidates recommended by stockholders and others if such candidates meet our criteria for Board membership, evaluating them in the same manner in which the committee evaluates other candidates. Such recommendations should be made in writing to the NGCR Committee or the Company Secretary and should include a description of the qualifications of the proposed candidate. Any of our stockholders may also nominate a director at a stockholders' meeting, and eligible stockholders may also nominate directors for inclusion in our proxy statement, in each case in accordance with the requirements of our by-laws relating to stockholder nominations as described in 'Questions and Answers About Our Annual Meeting-Who nominates the directors?'

The table below provides a high-level summary of the particular skills and qualifications of each of the eleven director nominees approved by the NGCR Committee for election at the Annual Meeting. Biographical information and additional detail regarding the director nominees' particular skills and qualifications follows. The absence of a reference to a qualification for an individual director nominee does not mean that the nominee does not possess that qualification, but rather that it is not one of the specific qualifications for which the nominee has been proposed. All nominees except for Mr. Cahillane have been directors since last year's annual meeting. Mr. Cahillane, who joined the Board in February 2023, was recommended by a third-party international executive search firm.

|  | Enterprise Leadership | Digital Technology and Innovation | Environmental and Social Responsibility | Finance | Industry | Regulatory | Risk Management and Cybersecurity | International | Corporate Governance | Diversity* |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| John P. Bilbrey | ☑ |  |  | ☑ | ☑ |  |  | ☑ | ☑ |  |
| John T. Cahill | ☑ |  |  | ☑ | ☑ |  | ☑ | ☑ | ☑ |  |
| Steve Cahillane | ☑ |  |  | ☑ | ☑ |  |  | ☑ | ☑ |  |
| Lisa M. Edwards | ☑ | ☑ | ☑ | ☑ |  |  | ☑ |  | ☑ | ☑ |
| C. Martin Harris |  | ☑ | ☑ |  | ☑ | ☑ | ☑ |  | ☑ | ☑ |
| Martina Hund-Mejean | ☑ | ☑ |  | ☑ |  |  | ☑ | ☑ | ☑ | ☑ |
| Kimberly A. Nelson | ☑ |  | ☑ |  | ☑ |  |  | ☑ | ☑ | ☑ |
| Lorrie M. Norrington | ☑ | ☑ | ☑ | ☑ |  |  | ☑ | ☑ | ☑ | ☑ |
| Michael B. Polk | ☑ |  |  | ☑ | ☑ |  |  | ☑ | ☑ |  |
| Stephen I. Sadove | ☑ |  |  | ☑ | ☑ |  |  | ☑ | ☑ |  |
| Noel R. Wallace | ☑ |  | ☑ | ☑ | ☑ |  |  | ☑ | ☑ |  |

* Ms. Edwards, Ms. Hund-Mejean, Ms. Nelson and Ms. Norrington are our female director nominees. Dr. Harris and Ms. Nelson identify as African-American and Ms. Norrington identifies as LGBTQ+.

2023 Proxy Statement 13

Governance of the Company

# John P. Bilbrey

![img-0.jpeg](img-0.jpeg)

Age: 66

Director since 2015

Committees:

Finance (Chair), NGCR

Other Public Company

Directorships:

Campbell Soup Company
(since 2019)

Elanco Animal Health
Incorporated (since 2019)

Tapestry, Inc.
(since 2020)

Former (During Past 5 Years):

The Hershey Company
(until 2018)

# Independent

Mr. Bilbrey served as President and Chief Executive Officer of The Hershey Company ("Hershey"), a multinational consumer food company, from 2011 until his retirement in 2017. He also served as Chairman of the Board of Directors of Hershey from 2015 to 2017 and as Non-Executive Chairman from 2017 to 2018. Mr. Bilbrey joined Hershey as Senior Vice President, President Hershey International in 2003 and served as Senior Vice President, President Hershey North America from 2007 to 2010 and as Executive Vice President and Chief Operating Officer from 2010 to 2011. Prior to joining Hershey, Mr. Bilbrey held executive positions at Mission Foods and Danone Waters of North America, Inc., a division of Groupe Danone, and previously spent 22 years at The Procter & Gamble Company ("Procter & Gamble"). Mr. Bilbrey also serves on the Kansas State University Foundation Board of Directors.

# Skills and Qualifications:

# Enterprise Leadership

Extensive operational leadership experience through service as Chief Executive Officer and Chief Operating Officer of Hershey.

# Industry

In-depth knowledge of fast-moving consumer goods industry through experience at Hershey and Procter & Gamble and expertise in marketing through leadership roles at consumer-focused companies.

# Finance

Strong knowledge of business finance and financial statements through oversight of operating budgets and financial statements at Hershey and significant mergers and acquisitions and business integration experience throughout his career.

# International

Experience managing Hershey's international operations and living and working in foreign countries.

# Corporate Governance

Experience serving as a director of other U.S. public companies.

# John T. Cahill

![img-1.jpeg](img-1.jpeg)

Age: 65

Director since 2005

Committees:

Audit (Chair), P&O

Other Public Company

Directorships:

American Airlines

Group Inc. (since 2013)

The Kraft Heinz Company
(since 2015)

# Independent

Mr. Cahill has served as Vice Chairman of The Kraft Heinz Company, a multinational food and beverage company, since 2015 after serving as Chairman and Chief Executive Officer of Kraft Foods Group, Inc. ("Kraft") from 2014 until its merger with H.J. Heinz Holding Corporation in 2015. Mr. Cahill previously served as Executive Chairman of Kraft from 2012, when Kraft was spun off from Kraft Foods Inc. ("Kraft Foods"), until 2014, when he was elected Non-Executive Chairman. He served as Executive Chairman of Kraft Foods North America in 2012. Mr. Cahill was an Industrial Partner at Ripplewood Holdings LLC, a private equity firm, from 2008 through 2011. He previously served The Pepsi Bottling Group, Inc. ("PBG") in a variety of leadership positions culminating in Chairman and Chief Executive Officer. He also held multiple senior financial and operating leadership positions at PepsiCo Inc. ("PepsiCo").

# Skills and Qualifications:

# Finance

Strong knowledge of business finance and financial statements through service as Chief Financial Officer of PBG, Kentucky Fried Chicken and Pepsi-Cola North America and as Senior Vice President and Treasurer of PepsiCo and significant mergers and acquisitions and business integration experience throughout his career.

# Risk Management and Cybersecurity

Significant experience overseeing enterprise risk management through service as Chief Financial Officer at several companies.

# Enterprise Leadership

Extensive operational leadership experience through service as Chairman and Chief Executive Officer of Kraft and as Chairman and Chief Executive Officer of PBG.

# Industry

In-depth knowledge of fast-moving consumer goods industry through experience at Kraft and nearly 20-year career at PepsiCo and PBG.

# International

Experience managing international operations for PBG.

# Corporate Governance

Experience serving as a director of other U.S. public companies.

14

COLGATE-PALMOLIVE COMPANY

Governance of the Company

# Steve Cahillane

![img-0.jpeg](img-0.jpeg)

Age: 57

Director since

February 2023

Committees: None

Other Public Company

Directorships:

Kellogg Company

(since 2017)

# Independent

Mr. Cahillane has been President and Chief Executive Officer of Kellogg Company ("Kellogg"), a global snacks, cereal and frozen foods company, since 2017 and Chairman of the Board of Kellogg since 2018. Prior to joining Kellogg, from 2014 to 2017, Mr. Cahillane served as President and Chief Executive Officer of The Nature's Bounty Co. ("Nature's Bounty"). Mr. Cahillane previously spent seven years with The Coca-Cola Company ("Coca-Cola") culminating as Executive Vice President of Coca-Cola and President of Coca-Cola Americas. Prior to that, Mr. Cahillane served as President of various Coca-Cola operating groups.

# Skills and Qualifications:

# Enterprise Leadership

Extensive operational leadership experience through service as President and Chief Executive Officer of Kellogg and Nature's Bounty and as head of various operating groups at Coca-Cola.

# Industry

In-depth knowledge of fast-moving consumer goods and health and nutrition industries through experience at Kellogg, Nature's Bounty and Coca-Cola and expertise in marketing through leadership roles at consumer-focused companies.

# Finance

Strong knowledge of business finance and financial statements through oversight of operating budgets at various companies and operating budgets and financial statements at Kellogg and significant mergers and acquisitions and business integration experience throughout his career.

# International

Experience managing Kellogg's international operations.

# Corporate Governance

Experience serving as a director of another U.S. public company.

# Lisa M. Edwards

![img-1.jpeg](img-1.jpeg)

Age: 55

Director since 2019

Committees:

Finance, NGCR

Other Public Company

Directorships:

None

# Independent

Ms. Edwards has served as Executive Chair of Diligent Institute, a governance think tank owned by Diligent Corporation ("Diligent"), since November 2022. She previously served as President and Chief Operating Officer of Diligent, a governance software company, from 2020 to 2022. Prior to joining Diligent, she served as Executive Vice President, Strategic Business Operations, Customer and Partner Engagement of Salesforce.com, Inc. ("Salesforce"), an enterprise software company, from 2017 to 2020. She joined Salesforce in 2012 as Executive Vice President, Finance, Head of Global Corporate Services and Chief Procurement Officer. Ms. Edwards previously served in several senior management roles at Visa Inc. ("Visa"), including as Senior Vice President and Head of Global Business Development and IP Strategy. Prior to that, she was an entrepreneur after starting her career at Bain & Company.

# Skills and Qualifications:

# Digital, Technology and Innovation

Significant experience with information technology, including data and analytics, eCommerce and digital transformation through service at Diligent, Salesforce and other companies.

# Environmental and Social Responsibility

Certifications in and experience with sustainability and social responsibility matters through service at Diligent Institute and Diligent.

# Risk Management and Cybersecurity

Certifications in cybersecurity oversight and significant experience with cybersecurity through service at Diligent Institute, Diligent and other companies.

# Corporate Governance

Strong knowledge of corporate governance practices through service as Executive Chair of Diligent Institute and President and Chief Operating Officer of Diligent.

# Enterprise Leadership

Extensive operational leadership experience as President and Chief Operating Officer of Diligent and as head of various functions at Salesforce and Visa.

# Finance

Strong knowledge of business finance and financial statements through oversight of operating budgets at Diligent and through service as Executive Vice President, Finance at Salesforce and significant mergers and acquisitions and business integration experience throughout her career.

2023 Proxy Statement

15

Governance of the Company

### C. Martin Harris

![img-2.jpeg](img-2.jpeg)

Age: 66

Director since 2016

Committees:

NGCR, P&O

Other Public Company

Directorships:

Agiliti, Inc. (since 2022)

MultiPlan Corporation

(since 2021)

Thermo Fisher Scientific

Inc. (since 2012)

Former (During Past 5 Years):

Healthstream, Inc.

(until 2021)

Invacare Corporation

(until 2022)

### Independent

Dr. Harris has served as Associate Vice President of the Health Enterprise and Chief Business Officer of the Dell Medical School at The University of Texas at Austin since 2016. Dr. Harris previously served as Chief Information Officer and Chairman of the Information Technology Division of The Cleveland Clinic Foundation, a non-profit academic medical center, and a Staff Physician for The Cleveland Clinic Hospital and The Cleveland Clinic Foundation Department of General Internal Medicine from 1996 to 2016. Additionally, from 2000 to 2016, he was Executive Director of e-Cleveland Clinic, a series of e-health clinical programs offered over the internet. Prior to joining the Cleveland Clinic, Dr. Harris spent 14 years with the School of Medicine at the University of Pennsylvania.

#### Skills and Qualifications:

##### Digital, Technology and Innovation

Significant experience with information technology, including data, through service at the Dell Medical School, the Cleveland Clinic and the University of Pennsylvania.

##### Regulatory

Extensive leadership experience in healthcare, a highly regulated industry, through positions at the Dell Medical School and the Cleveland Clinic.

##### Risk Management and Cybersecurity

Significant experience with cybersecurity through service at the Dell Medical School and the Cleveland Clinic.

##### Environmental and Social Responsibility

Experience with social responsibility through expertise in the public health field.

##### Industry

In-depth knowledge of and expertise in the public health field, a complementary industry.

##### Corporate Governance

Experience serving as a director of other U.S. public companies.

### Martina Hund-Mejean

![img-3.jpeg](img-3.jpeg)

Age: 62

Director since 2020

Committees:

Audit, Finance

Other Public Company

Directorships:

Prudential Financial, Inc.

(since 2010)

Shell plc (since 2020)

### Independent

Ms. Hund-Mejean served as Chief Financial Officer of Mastercard Inc. ("Mastercard"), a technology company in the global payments industry, from 2007 until her retirement in 2019. Prior to joining Mastercard, Ms. Hund-Mejean served as Senior Vice President and Treasurer of Tyco International Ltd. ("Tyco") from 2002 to 2007 and Senior Vice President and Treasurer of Lucent Technologies Inc. ("Lucent") from 2000 to 2002. She previously held a series of finance positions of increasing responsibility at General Motors Company from 1988 to 2000. Ms. Hund-Mejean began her career as a credit analyst at Dow Chemical in Germany.

#### Skills and Qualifications:

##### Finance

Strong knowledge of business finance and financial statements through service as Chief Financial Officer of Mastercard, Senior Vice President and Treasurer of Tyco and Lucent and various positions at General Motors Company and significant mergers and acquisitions and business integration experience throughout her career.

##### Risk Management and Cybersecurity

Significant experience overseeing enterprise risk management and with cybersecurity through service as Chief Financial Officer of Mastercard.

##### Digital, Technology and Innovation

Significant experience with information technology, including data, as Chief Financial Officer of Mastercard.

##### International

Experience managing global functions for Mastercard, Tyco and Lucent, serving as a director of Shell, a public company incorporated and headquartered outside the U.S., and living and working in foreign countries (native of Germany).

##### Enterprise Leadership

Extensive operational leadership experience as Chief Financial Officer of Mastercard.

##### Corporate Governance

Experience serving as a director of other public companies.

16

[LOGO]

COLGATE-PALMOLIVE COMPANY

Governance of the Company

# Kimberly A. Nelson

# Independent

![img-4.jpeg](img-4.jpeg)

Age: 60

Director since 2021

Committees:

NGCR, P&O

Other Public Company

Directorships:

Cummins Inc.

(since 2020)

Tate & Lyle PLC

(since 2019)

Ms. Nelson served as Senior Vice President, External Relations of General Mills, Inc. ("General Mills"), a multinational food company, from 2010 until her retirement in 2018. In this global role, she led sustainability, consumer relations, corporate branding and communications, government affairs and public policy and external stakeholder relations for General Mills. Ms. Nelson also served as President of the General Mills Foundation from 2011 until 2018. Previously, she held several senior brand and general management roles during her nearly 30-year career at General Mills, including serving as President of the Snack Food Division from 2004 to 2010.

# Skills and Qualifications:

# Industry

In-depth knowledge of fast-moving consumer goods industry through experience at General Mills and expertise in marketing through leadership roles at General Mills.

# Environmental and Social Responsibility

Experience with sustainability and social responsibility through service as Senior Vice President, External Relations at General Mills and President of the General Mills Foundation.

# Enterprise Leadership

Extensive operational leadership experience through service as President of General Mills's Snack Food Division and other management positions at General Mills.

# International

Experience managing global functions for General Mills and serving as a director of Tate & Lyle, a public company incorporated and headquartered outside the U.S.

# Corporate Governance

Experience serving as a director of other public companies.

# Lorrie M. Norrington

# Independent, Lead Director

![img-5.jpeg](img-5.jpeg)

Age: 63

Director since 2015

Committees:

Audit, NGCR (Chair)

Other Public Company

Directorships:

Asana, Inc. (since 2020)

Autodesk, Inc.

(since 2011)

HubSpot, Inc.

(since 2013)

Former (During Past 5 Years):

Eventbrite, Inc.

(until 2020)

Ms. Norrington has served as an Operating Partner of Lead Edge Capital LLC, a growth equity investment firm, since 2012. Ms. Norrington previously served in several senior management roles at eBay from 2005 to 2010, including President of Global eBay Marketplaces, Chief Operating Officer of eBay Marketplaces, President of eBay International and CEO of Shopping.com. Prior to joining eBay, Ms. Norrington held senior positions at Intuit Inc. ("Intuit"). Prior to Intuit, she was a company officer and held a number of global operating roles, including CEO of GE FANUC, at General Electric Company ("General Electric") over an almost 20-year period.

# Skills and Qualifications:

# Digital, Technology and Innovation

Significant experience with information technology and software, including data and analytics, eCommerce, digital marketing and artificial intelligence through service at eBay and Intuit and Board advisory work for other technology companies.

# Risk Management and Cybersecurity

Certifications in cybersecurity oversight and significant experience with cybersecurity through service at and Board advisory work for various technology companies.

# Environmental and Social Responsibility

Experience with sustainability and social responsibility through chairing responsible committees at various U.S. public companies.

# Enterprise Leadership

Extensive operational leadership experience through service as President and Chief Operating Officer of eBay Marketplaces and as head of various operating divisions at General Electric.

# Finance

Strong knowledge of business finance and financial statements through oversight of operating budgets at various companies and significant mergers and acquisitions and business integration experience throughout her career.

# International

Experience managing international operations for eBay and global businesses for General Electric.

# Corporate Governance

Experience serving as a director of other U.S. public companies.

2023 Proxy Statement

17

Governance of the Company

# Michael B. Polk

![img-6.jpeg](img-6.jpeg)

Age: 62

Director since 2014

Committees:

Finance, P&O (Chair)

Other Public Company
Directorships:

Logitech International S.A.
(since 2019)

Former (During Past 5 Years):

Newell Brands Inc.
(until 2019)

# Independent

Mr. Polk has been an Advisory Director to Berkshire Partners LLC ("Berkshire"), a private investment firm, since 2020. He became the Chief Executive Officer of a Berkshire portfolio company, Implus LLC ("Implus"), a fitness and outdoor accessories provider, in 2020, where he also serves on the Board of Directors. Mr. Polk previously served as President and Chief Executive Officer of Newell Brands Inc. and its predecessor, Newell Rubbermaid Inc. (together, "Newell"), a multinational consumer goods company, from 2011 until 2019. Prior to Newell, Mr. Polk held a series of executive positions at Unilever, including President, Global Foods, Home and Personal Care, and at Kraft Foods, where he served as President, Asia Pacific Region, Kraft Foods International and President, Nabisco Biscuit & Snacks, Kraft Foods North America. He started his career at Procter & Gamble.

# Skills and Qualifications:

# Enterprise Leadership

Extensive operational leadership experience through service as Chief Executive Officer of Newell and Implus and as head of various operating divisions of Unilever and Kraft Foods.

# Industry

In-depth knowledge of fast-moving consumer goods industry through experience at Newell, Unilever, Kraft Foods and Procter & Gamble and expertise in marketing through leadership roles at consumer-focused companies.

# International

Experience managing Newell's, Unilever's and Kraft Foods' international operations and serving as a director of Logitech International, a public company incorporated and headquartered outside the U.S.

# Finance

Strong knowledge of business finance and financial statements through oversight of operating budgets at various companies and operating budgets and financial statements at Newell and significant mergers and acquisitions and business integration experience throughout his career.

# Corporate Governance

Experience serving as a director of other public companies.

# Stephen I. Sadove

![img-7.jpeg](img-7.jpeg)

Age: 71

Director since 2007

Committees:

Audit, P&O

Other Public Company
Directorships:

Aramark (since 2013)

Movado Group, Inc.
(since 2018)

Park Hotels & Resorts Inc.
(since 2017)

# Independent

Mr. Sadove has served as a founding partner of JW Levin Management Partners LLC, a private equity firm, since 2015 and as principal of Stephen Sadove and Associates, which provides consulting services to the retail industry, since 2013. Mr. Sadove served as Chairman and Chief Executive Officer of Saks Incorporated ("Saks") from 2007 until 2013. He joined Saks as Vice Chairman in 2002, served as Chief Operating Officer from 2004 to 2006 and was named Chief Executive Officer in 2006. Previously, Mr. Sadove worked for Bristol-Myers Squibb Company ("Bristol-Myers Squibb"), which he joined in 1991 as President of Clairol in the U.S. He later gained additional responsibility for the consumer businesses in Canada, Europe, the Middle East, Africa and Latin America. In 1996, he was named President of Bristol-Myers Squibb's worldwide beauty care business and was later named a senior vice president with additional responsibility for Mead Johnson Nutritionals. Mr. Sadove also serves as Chairman Emeritus of the Board of Hamilton College.

# Skills and Qualifications:

# Enterprise Leadership

Extensive operational leadership experience through service as Chief Executive Officer of Saks and as head of various operating divisions at Bristol-Myers Squibb.

# Industry

In-depth knowledge of fast-moving consumer goods industry through experience at Bristol-Myers Squibb and expertise in marketing through leadership roles at consumer-focused companies.

# Finance

Strong knowledge of business finance and financial statements through oversight of operating budgets at various companies and operating budgets and financial statements at Saks and significant mergers and acquisitions and business integration experience throughout his career.

# International

Experience managing Bristol-Myers Squibb's international operations.

# Corporate Governance

Experience serving as a director of other U.S. public companies.

18

[LOGO]

COLGATE-PALMOLIVE COMPANY

Governance of the Company

# Noel R. Wallace

![img-8.jpeg](img-8.jpeg)

Age: 58

Director since 2019

Committees:

None

Other Public Company

Directorships:

Former (During Past 5 Years):

Kellogg Company
(until 2018)

# Chairman

Mr. Wallace has been President and Chief Executive Officer of Colgate since 2019 and Chairman of the Board since 2020. He previously served as President and Chief Operating Officer of Colgate from 2018 until 2019, with responsibility for all of our operating units worldwide. Mr. Wallace began his career at Colgate in 1987 and progressed through a series of senior management roles around the world. Prior to being appointed President and Chief Operating Officer, he served as Chief Operating Officer, Global Innovation & Growth and Hill's Pet Nutrition from 2016 to 2018, as President, Colgate Latin America from 2013 to 2016 and as President, Colgate North America and Global Sustainability from 2010 to 2013.

# Skills and Qualifications:

# Enterprise Leadership

Extensive operational leadership experience through service as President and Chief Executive Officer and Chief Operating Officer of Colgate.

# Industry

In-depth knowledge of fast-moving consumer goods industry through 35-year career at Colgate and expertise in marketing through leadership roles at Colgate.

# International

Experience managing Colgate's international operations and living and working in foreign countries.

# Environmental and Social Responsibility

Experience with sustainability and social responsibility through service as President and Chief Executive Officer of Colgate and as President, Colgate North America and Global Sustainability.

# Finance

Strong knowledge of business finance and financial statements through oversight of operating budgets and financial statements at Colgate and significant mergers and acquisitions and business integration experience throughout his career at Colgate.

# Corporate Governance

Experience serving as a director of another U.S. public company.

# Director Independence

As described above, the Board has adopted director independence standards that are stricter than those required by the listing standards of the NYSE. Specifically, a director is not considered independent if the director has any relationship with Colgate or our senior management or with another director or any other person that in the Board's judgment may impair the director's ability to make independent judgments. Such relationships could include voting arrangements or personal, economic or professional ties between a director and an officer of Colgate, another Colgate director or a significant stockholder of Colgate. Relationships and transactions (direct or indirect) that would preclude independence include:

- current or former employment with Colgate;
- affiliation with Colgate's advisors;
- compensation from Colgate (other than director fees);
- material business relationships with Colgate;
- loans between directors and Colgate or our senior management;
- material investments with Colgate or our officers;
- joint investments with Colgate's officers or other directors;
- leadership roles in charitable organizations that receive significant support from Colgate;
- affiliation or employment with a present or former Colgate auditor; and
- service on interlocking boards of directors or compensation committees.

A copy of the complete independence standards is available on our website.

In making its determination regarding the independence of each non-employee director, the Board considers any transactions, relationships or arrangements as required by our director independence standards. Based on these standards, the Board has determined that each current director, other than Mr. Wallace, who is our Chairman, President and CEO, is independent as there were no transactions, relationships or arrangements of the types described in our director independence standards.

2023 Proxy Statement 19

Governance of the Company

## Certain Relationships and Related Transactions

We have a longstanding policy prohibiting our directors, officers and employees from entering into transactions that present actual or potential conflicts of interest. This policy is reflected in our Code of Conduct, Business Practices Guidelines and Director Independence Standards. In addition, the Board has adopted a written policy regarding related person transactions which supplements these policies by establishing additional procedures for monitoring and reviewing and, if appropriate, approving, these types of transactions. The policy covers any “related person transaction,” as defined under SEC rules, which generally includes any transaction, arrangement or relationship involving more than $120,000 in which we or any of our subsidiaries was, is or will be a participant and in which a “related person” had, has or will have a direct or indirect material interest. “Related persons” means directors and executive officers and their immediate family members, and stockholders owning five percent or more of our outstanding stock.

Our Corporate Legal Department, together with the Controller’s Department, is responsible for monitoring compliance with these policies and procedures. In the rare instance where a related person transaction is determined to provide a material benefit to Colgate and our stockholders, the transaction must be submitted to the independent directors of the Board for their review. Only the independent directors of the Board may approve the transaction in accordance with the procedures for review and approval described in the policy. In the course of its review of related person transactions, the independent directors of the Board will consider all of the relevant facts and circumstances that are available to them, including but not limited to: (i) the benefits to Colgate; (ii) in a transaction involving a director, the impact on the director’s independence; (iii) the availability of other sources for comparable products or services; (iv) the terms of the transaction; and (v) whether the transaction is proposed to be on terms more favorable to Colgate than terms that could have been reached with an unrelated third party.

Based on our review of Company transactions, there were no transactions considered to be a related person transaction during 2022.

## Compensation Committee Interlocks and Insider Participation

During 2022, the following directors were members of the P&O Committee: Dr. Harris, Ms. Nelson and Messrs. Cahill, Polk and Sadove. None of the members of the P&O Committee has been an officer of Colgate and none was an employee of Colgate during 2022, and none had any relationship with us or any of our subsidiaries during 2022 that would be required to be disclosed as a related person transaction. None of our executive officers has served on the board of directors or compensation committee of another company at any time during which an executive officer of such other company served on our Board or the P&O Committee.

## Board Structure and Responsibilities

### Board Leadership Structure

The NGCR Committee regularly reviews Board leadership trends and has determined that combining the positions of Chairman and Chief Executive Officer is best for us. **Our current Board leadership structure consists of:**

Chairman, President and CEO

Independent Lead Director

Ms. Norrington has served as the independent Lead Director since March 1, 2023, succeeding Stephen I. Sadove in that role. Ms. Norrington was appointed by the independent directors to serve a three-year term as Lead Director following nomination by the NGCR Committee.

**Our Board structure ensures robust, independent oversight.** Our active and independent Board, with our robust Lead Director role and independent committee chairs and committees, ensures that the Board, and not the Chairman alone, determines the Board’s focus. The Chairman is guided by these strong independent leaders and having our CEO serve as Chairman creates a bridge to management that helps provide the Board with the management support it needs. Having a unified leadership structure is particularly beneficial at this time given the dynamic consumer and retail landscape and rapidly evolving environment in which we compete. Based on these considerations, the Board believes that this is the best leadership structure for us at this time and that, operating under this structure, the Board will continue to effectively guide Colgate and represent the interests of our stakeholders. The Board believes its programs for overseeing risk, as described under “Board Role in Risk Oversight,” would be effective under a variety of leadership structures and therefore do not materially affect its choice of structure.

20 ![Colgate-Palmolive Company logo]() COLGATE-PALMOLIVE COMPANY

Governance of the Company

**Board Effectiveness**

The Board works very effectively together

**Board Committees**

The Board's committees are composed solely of, and chaired by, independent directors

**Board Independence**

10 of 11 director nominees

are independent

**Executive Sessions**

The independent directors meet at each regularly scheduled Board meeting in separate executive sessions without any members of management present, which are chaired by the independent Lead Director

**We have an independent lead director with significant authority and clear duties.** We have long been committed to having an independent lead director, having first established a lead independent director position in 2003. In 2021, the Board enhanced the duties of the Lead Director set forth in our corporate governance guidelines in connection with a review of external practices and in response to stockholder feedback. In many cases, the expanded responsibilities simply formalized activities that the Lead Director already had been performing. The Board further enhanced the Lead Director's duties in January 2023. The role of the Lead Director includes the following responsibilities:

![img-9.jpeg](img-9.jpeg)

**Board Leadership**

- Preside at the executive sessions of the independent directors that occur at every regularly scheduled Board meeting, any other executive session of the independent directors and any other meeting of the Board at which the Chairman is not present
- Serve as interim Chairman if the Chairman is unable to perform their duties
- Establish agendas for the executive sessions of the independent directors in consultation with the other directors
- Call meetings of the independent directors
- Authorize the retention of outside advisors and consultants who report directly to the independent directors on Board issues

**Communicating with Management**

- After each executive session of the independent directors, provide feedback to and apprise the Chairman/CEO of the views expressed, suggestions made and decisions reached during the session
- Meet regularly with the Chairman/CEO between meetings, including acting as a sounding board to the CEO and providing strategic counsel
- Serve as primary liaison between the independent directors and the Chairman/CEO and management (although all independent directors are encouraged to communicate freely with the Chairman/CEO and other members of management at any time)

2023 Proxy Statement 21

Governance of the Company

## Board Culture

- Together with the Chairman, facilitate the efficient and effective functioning and performance of the Board
- Encourage and facilitate active and candid participation of all directors, including by fostering an environment of open dialogue and constructive feedback among the independent directors

## Board Information, Agendas and Schedules

- Review and approve information to be sent to the Board and provide feedback on quality, quantity and timeliness of information flow from management
- Participate in setting, and ultimately approve, proposed Board meeting agendas
- Solicit the other independent directors for advice on agenda items for Board meetings to help facilitate Board focus on key issues and topics of interest to the Board
- Review and approve meeting schedules to help ensure there is sufficient time for discussion of all agenda items
- Ensure Board meeting agendas provide the Board with the ability to periodically review and provide input on the Company's long-term strategy and to monitor management's execution of the long-term strategy

## Performance Evaluations, Succession Planning, Recruitment and Development

- Together with the P&O Committee, lead the annual performance evaluation of the Chairman/CEO, distinguishing as necessary between performance as Chairman and performance as CEO
- Together with the P&O Committee, lead the CEO succession planning process and participate in talent retention and development of senior management
- Provide guidance on Board succession and development
- In coordination with the NGCR Committee, interview Board candidates

## Stakeholder Engagement

- Be available, as deemed appropriate by the Board, for consultation and direct communication with stockholders or other key constituents

## Other

- Facilitate the effective functioning of Board committees, as appropriate
- Perform such other duties as the Board may specify from time to time

22

COLGATE-PALMOLIVE COMPANY

Governance of the Company

## Committees of the Board of Directors

The Board has four standing committees: the Audit Committee, the Finance Committee, the NGCR Committee and the P&O Committee. A summary of the responsibilities of these committees is set forth below. The committee charters are available on our website.

### Committee Membership

| Director | Audit | Finance | Nominating, Governance and Corporate Responsibility | Personnel and Organization |
| --- | --- | --- | --- | --- |
| John P. Bilbrey Independent | ☐ | ☑ | ☑ | ☐ |
| John T. Cahill Independent | ☑ | ☐ | ☐ | ☑ |
| Steve Cahillane 1 Independent | ☐ | ☐ | ☐ | ☐ |
| Lisa M. Edwards Independent | ☐ | ☑ | ☑ | ☐ |
| C. Martin Harris Independent | ☐ | ☐ | ☑ | ☑ |
| Martina Hund-Mejean Independent | ☑ | ☑ | ☐ | ☐ |
| Kimberly A. Nelson Independent | ☐ | ☐ | ☑ | ☑ |
| Lorrie M. Norrington Independent, Lead Director | ☑ | ☐ | ☑ | ☐ |
| Michael B. Polk Independent | ☐ | ☑ | ☐ | ☑ |
| Stephen I. Sadove Independent | ☑ | ☐ | ☐ | ☑ |
| Noel R. Wallace Chairman of the Board | ☐ | ☐ | ☐ | ☐ |
| Number of meetings held in 2022 | 7 | 5 | 4 | 5 |

$^{1}$ Mr. Cahillane, who became a director in 2023, is expected to be appointed to committees in 2023.

☑ Member ☑ Chair

### Audit Committee

**7 MEETINGS**
in 2022

#### Members

John T. Cahill (Chair)
Martina Hund-Mejean

Lorrie M. Norrington
Stephen I. Sadove

**All members of the Audit Committee are independent directors and audit committee financial experts.**

#### Role and Responsibilities

- Assists the Board in its oversight of management's fulfillment of its financial reporting and disclosure responsibilities and its maintenance of an appropriate internal control system.
- Appoints the independent registered public accounting firm and oversees the activities of our Internal Audit function and the Global Ethics and Compliance function.
- Assists the Board in its oversight of our enterprise risk management process, including cybersecurity.
- The Board has determined that all members of the Audit Committee are "independent," as required by the Securities Exchange Act of 1934, as amended (the "Exchange Act"), the listing standards of the NYSE and our own, stricter director independence standards, and are "audit committee financial experts" as that term is defined under SEC rules.

### Finance Committee

**5 MEETINGS**
in 2022

#### Members

John P. Bilbrey (Chair)
Lisa M. Edwards

Martina Hund-Mejean
Michael B. Polk

**All members of the Finance Committee are independent directors.**

#### Role and Responsibilities

- Oversees our financial policies and practices, reviews our budgets and makes recommendations to the Board on financial and strategic matters, including major strategic investments, acquisitions, divestitures and other transactions.
- Oversees our capital structure, our productivity initiatives and our Finance, Treasury, Tax and related functions.

2023 Proxy Statement 23

Governance of the Company

## Nominating, Governance and Corporate Responsibility Committee

**4 MEETINGS**
in 2022

### Members

Lorrie M. Norrington (Chair) C. Martin Harris
John P. Bilbrey Kimberly A. Nelson
Lisa M. Edwards

**All members of the NGCR Committee are independent directors.**

### Role and Responsibilities

- Recommends nominees for the Board, develops and implements formal Board self-evaluation procedures and oversees director education.
- Makes recommendations to the Board regarding Board and committee structure, corporate governance and director compensation.
- Oversees our sustainability (including climate change), social responsibility and corporate citizenship matters.

### Director Compensation

The NGCR Committee's director compensation recommendation process is described in greater detail on page 27. The NGCR Committee does not delegate any of its authority in making director compensation recommendations.

## Personnel and Organization Committee

**5 MEETINGS**
in 2022

### Members

Michael B. Polk (Chair) Kimberly A. Nelson
John T. Cahill Stephen I. Sadove
C. Martin Harris

**All members of the P&O Committee are independent directors.**

### Role and Responsibilities

- Appointed by the Board to act on its behalf with respect to overseeing personnel and organizational matters, including the compensation of our executives, succession planning and our human capital management and DE&I initiatives.
- Recommends and approves, with the participation and concurrence of the other independent directors of the Board, the performance goals and compensation of the CEO.
- Reviews and approves the performance goals and compensation recommended by our Global Human Resources function and CEO for our other executive officers in accordance with the compensation programs described in the CD&A.

### Compensation Consultants

The P&O Committee periodically retains the services of outside compensation consultants to provide it with objective, third-party advice on the appropriateness of our compensation of the CEO and other senior executives. The P&O Committee has adopted a written policy regarding its selection and use of outside compensation consultants, a copy of which is available on our website. The policy contains the following key principles:

- The P&O Committee selects all outside compensation consultants that provide advice to it, and directly retains and compensates such consultants, who report to and are solely responsible to the committee.
- Such consultants may not provide any other services to Colgate unless these are expressly approved by the P&O Committee in advance. The P&O Committee will approve such other services only if it concludes that providing them will not impair the ability of the consultant to provide objective and independent advice to the committee.

The P&O Committee has retained Frederic W. Cook & Co., Inc. ("FW Cook") to advise it with respect to the CEO's compensation and such other matters as the P&O Committee may direct. Neither FW Cook nor any of its affiliates provides any other services to Colgate. FW Cook works directly with the P&O Committee and its chair and meets with the P&O Committee in executive session. The P&O Committee conducted an assessment of whether the work of FW Cook during 2022 generated any conflict of interest, within the meaning of SEC rules, and concluded it did not.

### Compensation Data

During 2022 and early 2023, our Global Human Resources function purchased executive compensation survey data from Mercer Human Resources Consulting, Aon, WTW and Equilar and used Aon to provide change-in-control and similar calculations for this Proxy Statement. These providers were chosen because they are the leading providers in their fields and have global capabilities and/or consumer products industry experience.

24 COLGATE-PALMOLIVE COMPANY

Governance of the Company

## Board Role in Risk Oversight

We have established a systematic and thorough risk management process, which is designed to identify, assess, prioritize and mitigate risks that threaten achievement of our strategic and operating objectives.

![img-0.jpeg](img-0.jpeg)

## Stockholder Engagement

We believe it is important to engage with investors to better understand their priorities and therefore have developed a robust annual stockholder engagement program. Each year, we engage with a significant and diverse group of our stockholders on topics important to our stockholders as well as the Company. Such topics may include our business strategy and initiatives, executive compensation, Board composition and governance practices, as well as environmental and social topics such as human capital management, DE&I and sustainability. To the extent we receive stockholder proposals in connection with a given year's annual meeting of stockholders, we also typically include a discussion of those proposal topics in our engagements for the following year. In addition, our Investor Relations team, together with members of senior management, regularly meet with investors and participate in investor conferences and presentations.

Feedback received through management's discussions with investors, as well as engagement with proxy advisory firms that represent the interests of a wide array of stockholders, is reported to and discussed with the Board. Our Lead Director is also available, as deemed appropriate by the Board, for consultation and direct communication with stockholders, and all stockholders may contact any of our directors using the process described below under "Communications to the Board of Directors."

2023 Proxy Statement 25

Governance of the Company

## Recent Engagement Highlights

Prior to our 2022 Annual Meeting of Stockholders, representatives of management and the Board engaged with certain stockholders to better understand their views and policies relating to the stockholder proposal we received for the 2022 Annual Meeting of Stockholders on stockholder ratification of termination pay. Following that engagement, in April 2022, the Board adopted a policy that we will not execute any new severance agreement with an executive officer that provides for cash severance benefits exceeding 2.99 times the sum of the executive officer’s base salary plus target annual bonus opportunity, without seeking stockholder ratification of the agreement.

In addition, since our 2022 Annual Meeting of Stockholders, representatives of our Global Human Resources, Investor Relations, Global Legal and Sustainability functions have reached out to a variety of institutional investors, including index, actively managed and public pension funds, based in and outside the United States, representing approximately 40% of our Common Stock. Discussions with those investors centered around our business strategy and our ESG focus, including our sustainability priorities and progress, driving social impact, DE&I, corporate governance and compensation. We also discussed with some of these investors their views regarding the stockholder ratification of termination pay stockholder proposal discussed in the prior paragraph and found that they appreciated that we were proactive and responsive to feedback.

## Communications to the Board of Directors

Stockholders and other interested parties are encouraged to communicate directly with our independent directors by sending an email to directors@colpal.com or by writing to Directors, c/o Office of the Chief Legal Officer, Colgate-Palmolive Company, 300 Park Avenue, 11th Floor, New York, New York 10022. Stockholders and other interested parties may also communicate with individual independent directors and committee chairs by writing to them at the above mailing address. Such communications are handled in accordance with the procedures described on our website.

Significant concerns and questions relating to accounting, internal accounting controls or auditing matters are promptly brought to the attention of the Audit Committee chair and handled in accordance with the procedures established by the Audit Committee. Under these procedures, our Global Ethics and Compliance function, in conjunction with our Internal Audit and Corporate Legal departments, addresses these concerns in accordance with the directions of the Audit Committee chair. The Audit Committee chair approves recommendations regarding the handling of each matter, oversees any investigations and approves the disposition of each matter. The Audit Committee chair may, in their discretion, engage outside counsel and other independent advisors. The Audit Committee receives quarterly updates regarding other concerns or questions relating to accounting, internal accounting controls or auditing matters.

Concerns relating to accounting, internal accounting controls or auditing matters may also be reported to the Global Ethics and Compliance function by telephone and email as follows: 24-hour EthicsLine: (800) 778-6080 (toll-free from the United States, Canada and Puerto Rico) or (212) 310-2330 (collect from all other locations) and email: ethics@colpal.com.

We strictly prohibit retaliation against any individual who reports in good faith to the Company or the directors information concerning potential violations, or who participates in good faith in any investigation or proceeding by the Company or a government agency. Concerns may be submitted to the Company or the directors on an anonymous basis through their postal address or through the 24-hour EthicsLine numbers maintained by the Global Ethics and Compliance function. If requested, we will keep information submitted confidential, subject to the need to conduct an effective investigation and take appropriate action or as otherwise required by applicable law.

26 ![Colgate-Palmolive Company logo]() COLGATE-PALMOLIVE COMPANY

Governance of the Company

## Compensation of Directors

Compensation for the non-employee directors is set by the Board at the recommendation of the NGCR Committee. The NGCR Committee seeks to set director compensation levels to ensure non-employee directors are paid competitively for their time commitment and responsibilities. A market competitive compensation package is important because it enables us to attract and retain highly qualified directors who are critical to our long-term success. The substantial majority of the compensation paid to the non-employee directors is in the form of fixed-value annual grants of Colgate equity pursuant to the stockholder-approved Colgate-Palmolive Company 2019 Incentive Compensation Plan (the “2019 Plan”), which helps foster commonality of interest between our directors and our stockholders.

In making recommendations to the Board regarding director compensation, the NGCR Committee annually reviews information provided by the Global Human Resources function regarding recent trends in director compensation and comparison data regarding peer company practices in the compensation comparison group discussed in the CD&A. The Global Human Resources function purchases subscriptions from the National Association of Corporate Directors, Aon and Equilar, from which they receive such comparison data. Based on its review of the information provided by the Global Human Resources function, the NGCR Committee determines whether to recommend to the Board any changes in the director compensation program. Based on the 2022 review, the NGCR Committee and the Board determined not to make any changes to the director compensation program.

In 2022, non-employee director compensation consisted of the following, as applicable:

| Annual Share Grant | Shares of Common Stock equal in value to $180,000 |
| --- | --- |
| Annual Retainer | $75,000 |
| Stock Option Grant | Options to purchase shares of Common Stock equal in value to $45,000 |
| Lead Director Retainer | $20,000 |
| Committee Chair Retainers | $10,000 for the chair of each committee |
| Expenses and Benefits | Reimbursement of travel and related expenses incurred in attending meetings; life and travel/accident insurance; and Charitable Matching Gifts Program available to U.S. employees as described below |

Mr. Wallace received no compensation for serving on the Board in 2022.

## Deferral of Compensation

Under the 2019 Plan, directors may elect to defer all or a part of their annual stock compensation. Deferred stock compensation is credited to a stock unit account, the value of which reflects changes in the market price of our Common Stock and dividends paid. No interest is paid on deferred balances. The directors also may elect to receive cash in lieu of up to 25% of the shares of our Common Stock granted and not deferred under the 2019 Plan.

Directors may elect to defer all or a part of their cash compensation under the Colgate-Palmolive Company Restated and Amended Deferred Compensation Plan for Non-Employee Directors. As with the 2019 Plan, deferred fees are credited to a stock unit account, the value of which reflects changes in the market price of our Common Stock and dividends paid. No interest is paid on deferred balances. Under both plans, distributions are made in shares of our Common Stock in annual installments or by lump sum in accordance with the distribution election made by the director.

The tables included below under “Director Compensation” and in “Stock Ownership-Stock Ownership of Directors and Executive Officers” include information concerning directors who have elected to defer their fees.

## Director Compensation Governance Features

Under our stock ownership guidelines, independent directors are required to own stock equal in value to at least five times their annual share grant. Directors have five years from the date of their initial election to achieve required ownership levels. Compliance with these guidelines is evaluated on an annual basis. All of the directors are in compliance with this policy. For more information on director stock ownership, see “Stock Ownership-Stock Ownership of Directors and Executive Officers.” Directors are also prohibited from engaging in transactions to hedge against declines in the value of our stock and from pledging Colgate stock, as further described in the CD&A. During 2022, all of the directors were in compliance with both the anti-hedging and anti-pledging policies.

2023 Proxy Statement 27

Governance of the Company

## Director Compensation

The following table shows the compensation earned by each non-employee director in 2022.

| Name (a) | Fees Earned or Paid in Cash ($) (1) (b) | Stock Awards ($) (2) (c) | Option Awards ($) (3) (d) | All Other Compensation ($) (4) (g) | Total ($) (h) |
| --- | --- | --- | --- | --- | --- |
| John P. Bilbrey | 85,000 (5) | 179,961 (3) | 44,988 | 8,715 | 318,664 |
| John T. Cahill | 85,000 | 179,961 | 44,988 | 450 | 310,399 |
| Lisa M. Edwards | 120,000 (5) | 134,990 (6) | 44,988 | 260 | 300,238 |
| C. Martin Harris | 75,000 | 179,961 (3) | 44,988 | 715 | 300,664 |
| Martina Hund-Mejean | 75,000 | 179,961 (3) | 44,988 | 8,450 | 308,399 |
| Kimberly A. Nelson | 75,000 | 179,961 (3) | 44,988 | 8,347 | 308,296 |
| Lorrie M. Norrington | 85,000 (5) | 179,961 (3) | 44,988 | 450 | 310,399 |
| Michael B. Polk | 85,000 | 179,961 | 44,988 | 8,450 | 318,399 |
| Stephen I. Sadove | 95,000 | 179,961 | 44,988 | 9,056 | 329,005 |

### NOTES TO THE DIRECTOR COMPENSATION TABLE

$^{(1)}$ Consists of an annual retainer and lead director and committee chair retainers, as described above.

$^{(2)}$ This column reflects the aggregate grant date fair value of stock awards granted to each non-employee director in 2022. The grant date fair value of stock awards granted to each non-employee director in 2022 was $77.67 per share, based on the fair market value of our Common Stock on the date of grant.

$^{(3)}$ This column reflects the aggregate grant date fair value of stock option awards granted to each non-employee director in 2022. The key terms of such stock options are as follows: (i) the exercise price is equal to the closing price of our Common Stock on the date of grant; (ii) the term is eight years; and (iii) they vest in equal annual installments over three years.

The grant date fair value of stock options granted to each non-employee director in 2022 was $14.41 per option. The estimated value of options is calculated using the Black-Scholes-Merton option pricing model (the “Black-Scholes model”). For a description of the assumptions used to calculate the amounts shown in this column, see Note 8 (“Capital Stock and Stock-Based Compensation Plans”) to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022.

The aggregate number of stock options outstanding for each non-employee director as of December 31, 2022 was as follows: Mr. Bilbrey-27,090; Mr. Cahill-27,090; Ms. Edwards-14,363; Dr. Harris-23,521; Ms. Hund-Mejean-10,195; Ms. Nelson-6,131; Ms. Norrington-27,090; Mr. Polk-27,090; and Mr. Sadove-27,090.

$^{(4)}$ The amounts shown consist of (i) the value of Company-paid life insurance premiums and (ii) matching charitable donations contributed by Colgate in the director’s name pursuant to the Charitable Matching Gifts Program, which is available to all directors and to U.S. employees who are actively employed on a full-time basis. Under the Charitable Matching Gifts Program, we match an individual’s contributions of up to $8,000 per year that are made to eligible institutions on a 1:1 basis. We do not match certain gifts, such as contributions to organizations that are not tax-exempt, dues to alumni or similar groups, tuition payments, contributions to school funds or associations that are not used exclusively to support educational purposes of the institution and any gift for which the donor receives a substantial benefit.

$^{(5)}$ Mr. Bilbrey and Ms. Norrington each elected to defer the cash retainer they earned in 2022 and Mr. Bilbrey, Dr. Harris and Mses. Hund-Mejean, Nelson and Norrington each elected to defer the share grant they earned in 2022 pursuant to the procedure described above.

$^{(6)}$ Ms. Edwards elected to receive 25% of her annual share grant in cash in 2022 to satisfy tax obligations pursuant to the procedure described above.

28

![Colgate-Palmolive Company logo]() COLGATE-PALMOLIVE COMPANY

# Executive Compensation

## Compensation Discussion and Analysis

### Executive Summary

#### Pay for Performance Overview

The key principles underlying our compensation philosophy are aligning pay and performance, driving strong business results and our strategic plan, focusing on long-term shareholder return, motivating and retaining critical talent and reflecting external market and competitive practices. Annual and long-term incentive award payments vary based on our business performance, and long-term incentive award payments and the value of equity awards also vary based on the performance of our common stock (“Common Stock”). Reflecting these principles, target direct compensation (salary and target annual and long-term incentives) for the executive officers listed in the Summary Compensation Table of this Proxy Statement (the “Named Officers”) is designed to be weighted more heavily towards performance-based compensation than fixed compensation. For 2022, 89% of the target direct compensation of our Chairman, President and Chief Executive Officer (“CEO”) and 75% of the average target direct compensation of our other Named Officers was performance-based, as the following charts demonstrate.

#### TARGET PERFORMANCE-BASED COMPENSATION

![img-1.jpeg](img-1.jpeg)

#### 2022 Performance at a Glance

We continued to face a difficult operating environment in 2022. Global macroeconomic, geopolitical and market conditions attributable to the war in Ukraine, COVID-19, inflation, rising interest rates and foreign exchange headwinds caused significant challenges and we continued to experience significant increases in raw material and logistics costs. Despite these challenges, we remained focused on serving the needs of our customers and consumers by delivering products that make people’s and their pets’ lives healthier and more enjoyable and on sustaining growth through science-led, core and premium innovation, revenue growth management, digital transformation and investing behind our strategic priorities.

The strong resilience, dedication, creativity and agility of our people and our ability to execute on our business strategy in the difficult environment are positively reflected in our 2022 results. We delivered strong organic sales growth (a non-GAAP financial measure, defined as net sales excluding foreign exchange, acquisitions and divestments) and solid performance on adjusted earnings per share (a non-GAAP financial measure, referred to herein as “Base Business Earnings Per Share”) in 2022 and Free Cash Flow Productivity (a non-GAAP financial measure, defined below) over a three-year period, as demonstrated below.

#### OPERATING RESULTS$^{1}$

![img-2.jpeg](img-2.jpeg)

$^{1}$ Please see Annex A for reconciliations of organic sales growth to net sales growth calculated in accordance with GAAP, of Base Business Earnings Per Share to Diluted earnings per share calculated in accordance with GAAP and of free cash flow before dividends to Net cash provided by operations calculated in accordance with GAAP.

$^{2}$ “Free Cash Flow Productivity” is defined as free cash flow before dividends as a percentage of net income including non-controlling interests as reported in our audited financial results, which for 2020-2022 was 109.4%. The P&O Committee (as defined below) reduced our 2020-2022 Free Cash Flow Productivity results for compensation purposes to 94.7%, as described on page 42.

Given our focus on growth, we were especially pleased with our 2022 organic sales growth, which was above our target long-term range. Our organic sales growth was broad based, as we delivered organic sales growth across all four of our categories and in nearly every division. Our Base Business Earnings Per Share for 2022 was in line with our publicly

2023 Proxy Statement 29

Executive Compensation

announced goal. That goal represented a decline relative to 2021, due to the significant raw material and logistics cost inflation and foreign exchange headwinds we faced.

Our stock price was impacted by the difficult market conditions in 2022, along with the cost and foreign exchange headwinds mentioned above, which created a significant impact on the cumulative total shareholder returns on our Common Stock for the one-year, five-year and ten-year periods ended December 31, 2022. Despite these challenging conditions, we maintained our strong balance sheet and the Board of Directors authorized an increase in the quarterly cash dividend, effective in the second quarter of 2022. This was our 60th consecutive year of dividend increases and our 128th consecutive year paying a dividend, as part of our commitment to, and strong record of, returning value to shareholders.

# RETURN TO SHAREHOLDERS

![img-3.jpeg](img-3.jpeg)

Going forward, we remain focused on delivering long-term shareholder return and building long-term business success through excellence in corporate governance and the design and implementation of our key strategic business priorities-driving organic sales growth and long-term profitable growth through science-led, core and premium innovation, pursuing higher-growth adjacent categories and segments, expanding in faster-growing channels and markets and delivering margin expansion through operating leverage and efficiency. We also continue to seek to maximize the impact of our environmental, social and governance (“ESG”) programs and lead in the development of human capital, including our sustainability and social impact and diversity, equity and inclusion (“DE&I”) strategies. We intend to continue our practice of tying compensation to achievement of both annual and long-term business goals to help further those priorities.

This Compensation Discussion and Analysis (“CD&A”) discusses the compensation of the Named Officers, namely:

Noel R. Wallace

Chairman, President and Chief Executive Officer

Stanley J. Sutula III

Chief Financial Officer

Jennifer M. Daniels

Chief Legal Officer and Secretary

Prabha Parameswaran

Group President, Growth and Strategy

Panagiotis Tsourapas

Group President, Europe and Developing Markets

The Personnel and Organization Committee of the Board (the “P&O Committee”) annually analyzes the relationship between pay and performance for our Named Officers. The analysis includes a review of the relationship between the compensation paid to our CEO and our other Named Officers and Company performance relative to the Comparison Group (as defined below) over the past three years. The review shows a strong link between Company pay and Company performance over time in terms of various key operating measures. During the three-year period from 2020 to 2022, our adjusted net income growth, adjusted earnings-per-share growth, total shareholder return, net sales growth, organic sales growth, return on sales, operating cash flow as a percentage of sales, return on invested capital and CEO total direct compensation relative to the Comparison Group are as shown to the right.

COLGATE 2020-2022 PERFORMANCE RELATIVE TO COMPARISON GROUP* (%)

![img-4.jpeg](img-4.jpeg)

* Adjusted net income growth, adjusted earnings-per-share growth and organic sales growth reflect the adjustments described in Annex A to Colgate’s net income, earnings per share and net sales growth, respectively, and comparable adjustments to peer companies’ net income, earnings per share and net sales growth. See page 32 for an explanation regarding the components of “total direct compensation” or “TDC.”

30 COLGATE-PALMOLIVE COMPANY

Executive Compensation

## 2022 Compensation Program Highlights

### New ESG Component Added to Strategic Measure in 2022 Annual Incentive Program

Starting in 2021, the P&O Committee determined that, in addition to financial goals, the annual incentive program should include a performance measure based on strategic initiatives, representing 20% of the annual bonus opportunity. For 2021, the strategic measure was tied to our enterprise-wide innovation and digital transformation progress in recognition of the critical importance of innovation and digital transformation to our growth strategy and continuing success and to further align compensation with our strategic priorities. In 2022, the P&O Committee determined that, in addition to performance measures tied to our enterprise-wide innovation and digital transformation progress, the strategic measure should also include performance measures tied to our sustainability and DE&I progress in recognition of the importance of ESG matters to our continuing success. See “Compensation Components-Annual Incentives” below for further detail regarding how the P&O Committee measured achievement against the strategic measure. The remaining 80% of the annual bonus opportunity was determined by our achievement against our organic sales growth and earnings-per-share goals.

### Performance Measures

The P&O Committee selected the following performance measures in 2022 to assess the performance of the Named Officers in 2022 and in the three-year performance period commencing in 2022:

| Pay Component | CEO 2022 Target Compensation Mix | Other Named Officer Average 2022 Target Compensation Mix | Performance Measures | Performance Period | Form of Payment |
| --- | --- | --- | --- | --- | --- |
| Annual incentive | 18% | 21% | Base Business Earnings Per Share Organic sales growth Strategic initiatives | One year (2022) | Cash bonus |
| Long-term incentive* | 71% | 54% | Organic sales growth relative to the Comparison Group Base Business Net Income (defined below) growth relative to the Comparison Group Free Cash Flow Productivity Total shareholder return relative to the Comparison Group (modifier) | Three years (2022-2024) | PBRSUs (vesting in 2025, if earned) |

* Percentages shown include the target value of the performance-based restricted stock unit (“PBRSU”) awards for the 2022-2024 performance cycle pursuant to our Growth Performance Plan and the target value of stock option awards based on salary grade guidelines.

The performance measures in the annual and long-term incentive programs were selected to drive our growth strategy and focus on sustainable value creation.

### Annual Incentive Awards

| Measure | Target | 2022 Results | Outcome | Comparison vs. Comparison Group* |
| --- | --- | --- | --- | --- |
| Base Business Earnings Per Share | $2.92-$3.02 | $2.97 | 134.7% of the assigned award opportunities for each of the Named Officers. | Annual bonuses for the Named Officers (other than Mr. Wallace) were paid at approximately the 55th to the 80th percentile of annual bonuses for similar jobs in the Comparison Group. Mr. Wallace’s award represented a payout at approximately the 55th percentile of annual bonuses for CEOs in the Comparison Group. |
| Organic Sales Growth | 5.0% | 7.0% |  |  |
| Strategic Initiatives | See below description |  |  |  |

* Based on the most recent data available.

In determining the extent to which the strategic measure was achieved, the P&O Committee considered achievement against our enterprise-wide innovation, digital transformation and ESG goals. Following this evaluation, the P&O Committee determined that the strategic measure should pay out at 140% of target, based on our strong performance against those goals as described under “Compensation Components-Annual Incentives” below.

2023 Proxy Statement 31

Executive Compensation

## Long-Term Incentive Awards

### 2022-2024 Long-Term Incentive Awards Performance Cycle (Growth Performance Plan)

| Measure | Target | Status |
| --- | --- | --- |
| Relative Organic Sales Growth | Performance at the 50th percentile of the Comparison Group | If PBRSUs were to vest solely based on performance achieved through December 31, 2022, payout would be between the threshold and target levels. Performance over the remaining two years of the performance period will determine the actual number of shares earned, if any. PBRSUs will vest, if earned, in 2025. |
| Relative Base Business Net Income Growth | Performance at the 50th percentile of the Comparison Group |  |
| Free Cash Flow Productivity | 95% |  |
| Total Shareholder Return Modifier | The number of PBRSUs may increase or decrease by up to 25% based on our total shareholder return relative to the Comparison Group |  |

### Stock Options

In 2022, the P&O Committee approved annual stock option awards for the Named Officers. These awards are made based on guidelines set for each salary grade, which are established annually based on a review of market data and share usage.

### CEO Total Direct Compensation*

![img-5.jpeg](img-5.jpeg)

↑ 9% vs. 2021

Primarily due to increases in his annual cash bonus opportunity, stock option award and target PBRSU award, reflecting the P&O Committee's intent to maintain his target direct compensation near the median relative to the Comparison Group as described on page 35.

* For purposes of this CD&A, Mr. Wallace's total direct compensation for each year includes his year-end salary and the amounts shown in the Summary Compensation Table in the columns "Option Awards," "Non-Equity Incentive Plan Compensation" and "All Other Compensation" and the PBRSU award granted in such year, consistent with the way the P&O Committee analyzes his compensation. The actual value of the payout from his PBRSU awards for the Growth Performance Plan's 2021-2023 and 2022-2024 performance cycles granted in 2021 and 2022, respectively, will depend upon achievement of the performance goals as well as the price of our Common Stock at the time of vesting in 2024 and 2025, respectively.

## Additional Compensation Program Highlights

Highlighted below are compensation practices we have implemented to drive Company performance and to align the interests of our executives with our stockholders.

### What We Do

- ✓ **Pay for Performance.** Our executive compensation is tied to performance with clearly articulated financial and other strategic goals. Each year, the P&O Committee conducts a comprehensive review of executive compensation prior to making compensation decisions to ensure pay and performance are aligned.
- ✓ **Competitive Compensation Programs.** We regularly benchmark our compensation programs and design the programs to compensate employees at approximately the median level, with above-median payouts for superior performance and below-median payouts for performance below expectations.
- ✓ **Robust Stock Ownership Guidelines.** We maintain stringent stock ownership guidelines for members of senior management, requiring the CEO to own Colgate stock equal in value to eight times his annual salary and the other Named Officers to hold Colgate stock in amounts equal to four times their annual salaries.
- ✓ **Ability to "Claw Back" Compensation.** Our clawback policy permits recoupment of cash and equity-based incentive awards made to an officer or other executive subject to the policy if the financial results on which such awards were based are subsequently restated or the officer or executive engaged in conduct that violates our Code of Conduct.
- ✓ **Perquisites are Insignificant.** Executive perquisites are limited to the use of a Company car and driver for the CEO.

### What We Don't Do

- ✗ **Incentives Do Not Encourage Excessive Risk-Taking.** Our incentive programs do not contain features that may encourage excessive risk-taking, such as multi-year guaranteed bonuses or high pay opportunities relative to peer companies. In addition, we utilize multiple performance measures for annual and long-term incentives.
- ✗ **No Executive Officer Employment Agreements.** We do not have employment agreements with our Named Officers, meaning they are not entitled to minimum base salaries, guaranteed bonuses or guaranteed levels of equity or other incentives.
- ✗ **No Hedging or Pledging of Colgate Stock is Permitted.** Our hedging policy prohibits our directors, officers and employees who receive stock-based compensation from engaging in transactions that hedge against declines in the value of Colgate stock, strengthening the alignment between stockholders and directors and executives. Further, our pledging policy prohibits our directors and officers from pledging Colgate stock to prevent forced sales of Colgate stock by our directors and officers.
- ✗ **No Backdating, Springloading or Repricing of Stock Options.** We make annual equity awards at the same predetermined times each year. Equity awards, including stock options, are never backdated or issued with below-market exercise prices. Repricing of stock options without stockholder approval is expressly prohibited.
- ✗ **No Single Trigger Severance Payments Under Our Severance Plan.** Severance payments under the Colgate-Palmolive Company Executive Severance Plan (the "Severance Plan") are payable only if an executive's employment is terminated or an executive terminates their employment as a result of an "adverse change in conditions of employment" (as defined in the Severance Plan) following a change in control.
- ✗ **No Tax Gross-Ups on Perquisites or Severance.** Perquisites are limited to the use of a Company car and driver for the CEO, as previously noted, and any personal income taxes due as a result of that perquisite are the CEO's responsibility. In addition, the Severance Plan does not provide for tax gross-ups on severance payments.

32 COLGATE-PALMOLIVE COMPANY

Executive Compensation

## Compensation Philosophy

We believe that people are the most important driver of our business success and, accordingly, view compensation as an important tool to motivate leaders at all levels of the organization. Outlined below are the principles underlying our executive compensation programs and examples of specific program features used to implement those principles.

|  | Base salary | Annual incentives | Long-term incentives |
| --- | --- | --- | --- |
| ALIGN PAY AND PERFORMANCE |  |  |  |
| Multiple performance measures are used to ensure a focus on overall Company performance. |  | ● | ● |
| Payouts vary based upon the degree to which performance measures are achieved. |  | ● | ● |
| We do not guarantee minimum base salaries, bonuses or levels of equity or other incentives for our Named Officers, through employment agreements or otherwise. | ● | ● | ● |
| DRIVE STRONG BUSINESS RESULTS AND OUR STRATEGIC PLAN |  |  |  |
| Selecting performance measures, such as organic sales growth, net income growth, earnings per share and free cash flow productivity, that are key metrics for investors fosters profitable growth and increases shareholder value. |  | ● | ● |
| Using performance measures tied to our annual and long-term goals, the achievement of which the Named Officers have the ability to influence, motivates the Named Officers to achieve strong and sustained business results. |  | ● | ● |
| Using performance measures tied to our strategy, such as innovation, digital transformation and ESG initiatives, helps align compensation with and drive our strategic growth priorities. |  | ● |  |
| Using measures in the long-term incentive award program that emphasize our performance relative to peers focuses the Named Officers on achieving peer-leading performance. |  |  | ● |
| FOCUS ON LONG-TERM SHAREHOLDER RETURN |  |  |  |
| Our long-term incentive award program has a three-year performance period, driving a focus on long-term results. |  |  | ● |
| A significant portion of the Named Officers' total compensation is paid in equity (approximately 50-65% in 2022), aligning the interests of the Named Officers with those of stockholders. |  |  | ● |
| The Named Officers' payout through the long-term incentive award program varies based on our three-year total shareholder return compared to the Comparison Group, directly tying a portion of the Named Officers' compensation opportunity to relative shareholder return. |  |  | ● |
| Our use of stock options, which provide value only to the extent that our stock price appreciates, provides an effective link to changes in shareholder value that aligns the interests of stockholders and executives. |  |  | ● |
| Stock ownership guidelines require that executives own significant levels of stock, further strengthening the focus on long-term shareholder return. |  |  | ● |
| MOTIVATE AND RETAIN CRITICAL TALENT AND REFLECT EXTERNAL MARKET AND COMPETITIVE PRACTICES |  |  |  |
| We regularly benchmark our compensation programs and design the programs to compensate executives at the median level, with above-median payouts for superior performance and below-median payouts for performance below expectations. |  | ● | ● |
| Using components that measure performance against both financial results and key strategic initiatives aligns with market practice. |  | ● |  |
| To promote equal pay and fairness, our policy is to compensate each individual at a level commensurate with their role, work location, individual performance and experience, irrespective of gender, race, ethnicity or any other category protected by law. | ● | ● | ● |
| Individual performance influences salary increases and stock option awards, motivating the Named Officers to perform at the highest levels. | ● |  | ● |
| We reward executives for strong performance, including by increasing payouts under the long-term incentive award program when we outperform our peers and decreasing payouts when we underperform our peers. |  | ● | ● |

2023 Proxy Statement 33

Executive Compensation

The P&O Committee devotes substantial time and attention throughout each year to executive compensation matters to ensure that compensation is aligned with our performance and the best interests of stockholders. Our compensation programs reflect our strategic initiatives and balance achievement of short-term results with long-term strategic objectives. As discussed in more detail below, the P&O Committee's well-balanced and disciplined approach includes regular reviews with its independent compensation consultant and careful benchmarking to ensure that our compensation is effective in motivating and retaining critical talent, is supported by underlying performance and is reasonable relative to our peers. In reviewing and approving compensation for the Named Officers, the P&O Committee considers all material components of compensation as well as comprehensive information regarding market practices. The purpose of these materials is to bring together all of the elements of actual and potential future compensation of the Named Officers, so that the P&O Committee may review individual elements of compensation, including compensation mix, as well as the aggregate amount of total compensation.

This CD&A discusses the compensation paid to the Named Officers. The compensation programs described, however, apply more broadly to our other officers and senior managers, with changes as appropriate to reflect different salary grade levels and job responsibilities. We believe that this approach helps to align Colgate people into one global team sharply focused on our performance objectives and key strategic initiatives.

## Compensation-Setting Process

### Role of the P&O Committee

The P&O Committee oversees our executive compensation programs. The P&O Committee does not delegate any of its responsibilities regarding the consideration and determination of executive compensation.

The P&O Committee:

- Recommends and approves, with the participation and concurrence of the other independent directors, the CEO's performance goals and compensation; the CEO does not play any role in setting his own compensation;
- Reviews and approves the performance goals and compensation recommended by our Global Human Resources function and the CEO for our other executive officers;
- References tally sheets that summarize all material components of compensation in reviewing and approving compensation for executive officers; and
- Approves the peer group companies that are used as a reference point in designing our compensation programs and in setting compensation levels and that our performance is reviewed against for purposes of making awards that are based on relative performance measures.

### Role of the Independent Compensation Consultant

The P&O Committee has engaged Frederic W. Cook & Co., Inc. ("FW Cook") as its independent compensation consultant. FW Cook is actively involved in advising the P&O Committee on compensation decisions.

FW Cook, as the P&O Committee's independent compensation consultant:

- Regularly reviews our executive compensation programs with the P&O Committee;
- Advises the P&O Committee on the setting of target compensation levels, the design of our variable incentive plans and the setting of performance goals;
- Helps the P&O Committee ensure there is a strong positive relationship between earned compensation and performance, as measured by operating results and changes in shareholder value;
- Provides observations and recommendations about the peer group companies that are used as a reference point in designing our compensation programs and in setting compensation levels and that our performance is reviewed against for purposes of making awards that are based on relative performance measures; and
- Informs the P&O Committee of emerging trends and best practices in executive compensation design and related regulatory developments.

34 COLGATE-PALMOLIVE COMPANY

Executive Compensation

## 2022 CEO Compensation Review

In 2022, the P&O Committee worked with FW Cook to determine the appropriate target level of direct compensation for Mr. Wallace based on his individual performance, including his leadership, and overall Company performance. Following this review, which also took into account our compensation philosophy, competitive data from the Comparison Group and market trends, the P&O Committee determined in March 2022 to maintain Mr. Wallace's overall target direct compensation (salary and annual and long-term incentives) for 2022 near the median of the Comparison Group, with the potential for above-median compensation based on superior performance and below-median compensation if performance fell below expectations. The P&O Committee also continued to have the variable portion of Mr. Wallace's target direct compensation represent a larger portion of his compensation as compared with the other Named Officers, to ensure his compensation is strongly tied to Company performance. In making these determinations, the P&O Committee worked together with the other independent directors of the Board.

In light of those considerations, in March 2022 the P&O Committee determined to increase Mr. Wallace's salary, annual bonus opportunity and long-term equity incentive target. The P&O Committee determined that a salary increase of 3.7% and an increase in assigned annual bonus award opportunity from 160% to 175% of base salary were warranted as a result of Mr. Wallace's leadership, market trends and consistent with its intent to maintain his target direct compensation near the median relative to the Comparison Group. The P&O Committee also determined to increase the long-term equity incentive portion of Mr. Wallace's target direct compensation from $9,000,000 to $9,500,000 in order to maintain his target direct compensation near the median of the Comparison Group and consistent with the P&O Committee's intent to link a significant part of his compensation to the achievement of multi-year performance goals and our absolute and relative stock price performance.

## Comparison Group

We use comparative compensation data from a group of other leading companies, referred to in this CD&A as the 'Comparison Group,' as a point of reference in designing our compensation programs and in setting compensation levels. The P&O Committee does not use this comparative data as the determinative factor in setting compensation levels but rather as a single component in its effort to verify that our compensation programs are reasonable and competitive in light of compensation levels at similarly situated companies. The P&O Committee also reviews our performance against the Comparison Group for purposes of making awards that are based on relative performance measures, including the long-term incentive awards granted under the Growth Performance Plan.

The Comparison Group is selected to include companies of similar size and complexity to us (including our substantial international operations) and to represent both the market for executive talent in which we compete as well as our peer companies from a performance and investment perspective. It is comprised primarily of fast-moving consumer goods companies with product portfolios consisting of globally recognized brands that are similarly situated to us in terms of overall size or performance against relevant measures. Our 2022 revenues and market capitalization as of December 31, 2022 were at the 38th and 53rd percentiles, respectively, of the Comparison Group.

The companies comprising the Comparison Group are approved by the P&O Committee after taking into account observations and recommendations of management and FW Cook.

For 2022, the P&O Committee determined not to make any changes to the Comparison Group, so it remained unchanged from 2021 and consisted of the following 15 companies:

### COMPARISON GROUP

| • Campbell Soup Company | • General Mills, Inc. | • Mondélez International, Inc. |
| --- | --- | --- |
| • The Clorox Company | • Johnson & Johnson | • PepsiCo, Inc. |
| • The Coca-Cola Company | • Kellogg Company | • The Procter & Gamble Company |
| • Conagra Brands, Inc. | • Kimberly-Clark Corporation | • Reckitt Benckiser Group PLC |
| • The Estée Lauder Companies Inc. | • The Kraft Heinz Company | • Unilever PLC |

Compensation data are collected for these companies for all of our three primary compensation components (base salary, annual incentive pay and long-term incentive pay), both individually and in the aggregate, as well as for indirect compensation elements such as perquisites and retirement benefits.

2023 Proxy Statement 35

## Executive Compensation

Our adjusted net income growth, adjusted earnings-per-share growth, total shareholder return, net sales growth, organic sales growth, return on sales, operating cash flow as a percentage of sales, return on invested capital and CEO total direct compensation relative to the Comparison Group during the three-year period from 2020 to 2022 were as follows:

**COLGATE 2020-2022 PERFORMANCE RELATIVE TO COMPARISON GROUP\***

![img-0.jpeg](img-0.jpeg)

\* Adjusted net income growth, adjusted earnings-per-share growth and organic sales growth reflect the adjustments described in Annex A to Colgate's net income, earnings per share and net sales growth, respectively, and comparable adjustments to peer companies' net income, earnings per share and net sales growth.

## Compensation Components

### Compensation Mix

Our executive compensation programs consist of the following three primary components:

| Base salary | Annual incentives | Long-term incentives |
| --- | --- | --- |
|  | Payable in the form of cash bonuses | Payable in the form of stock options and PBRSUs |

In allocating target compensation among these three components, the P&O Committee seeks to provide reasonable and competitive levels of fixed compensation (i.e., salary), while emphasizing performance-based compensation that varies based on overall Company or business unit performance and/or the performance of our Common Stock. Accordingly, as the following chart illustrates, base salaries for the Named Officers other than Mr. Wallace represented approximately 25% of the three compensation components noted above, and incentive compensation, consisting of annual and long-term, represented approximately 75% at target, while the base salary for Mr. Wallace represented 11% of the three components noted above and incentive compensation represented 89% at target. The target compensation mix for Mr. Wallace reflects the P&O Committee's belief that a larger portion of his compensation should be variable and tied to our financial and stock price performance.

**NAMED OFFICERS' TARGET COMPENSATION MIX**

![img-1.jpeg](img-1.jpeg)

36 ![Colgate-Palmolive Company logo]() COLGATE-PALMOLIVE COMPANY

Executive Compensation

The target mix between annual incentive pay and long-term incentives is determined based on competitive practice and our desire to focus, first, on long-term performance and shareholder value and, second, on annual performance. Within the long-term incentive category, the Named Officers are eligible to receive a mix of stock options and PBRSUs because the two types of awards serve different but complementary purposes. Stock options provide value only to the extent that our stock price appreciates, thereby providing an effective link to changes in shareholder value that aligns the interests of stockholders and executives. PBRSUs provide value based on both our long-term performance relative to our objectives and an increase in shareholder value, creating a strong link between compensation and the achievement of our long-term financial goals and our performance relative to peers. Our compensation philosophy and competitive practice also drive determinations about total target compensation levels for the Named Officers.

In addition to the three primary components of compensation discussed above, we provide Mr. Wallace with the use of a Company car and driver, the value of which is included in note 6 to the Summary Compensation Table. Any personal income taxes due as a result of this perquisite are Mr. Wallace's responsibility. We do not provide any other perquisites to our Named Officers.

The compensation and benefits payable to the Named Officers in the event of retirement, severance and change in control are described on pages 49 to 50 and 52 to 56. Our retirement programs are designed to provide our long-serving, retiring employees with competitive retirement benefits based on prevailing market practice. The Named Officers participate in the same retirement programs that are available to other U.S. employees, with supplemental benefits provided to make up for benefits under certain plans that cannot be provided as a result of the application of certain limits under the Internal Revenue Code of 1986, as amended. Ms. Parameswaran and Messrs. Tsourapas and Wallace, who participate in the Colgate-Palmolive Company Employees' Retirement Income Plan (the "Retirement Plan"), receive pension benefits determined under the PRA formula as described in "Retirement Plans." Ms. Daniels and Mr. Sutula are not participants in the Retirement Plan and instead participate only in our defined contribution plans. Our severance program is designed to provide participants with reasonable compensation if their employment is terminated in the event of a change in control or at the Company's convenience. The potential payments and benefits under these various programs did not influence the decisions discussed in the balance of this CD&A regarding the setting of salary, annual incentives and long-term incentives for the Named Officers since these programs serve very different purposes.

## Base Salary

Base salaries for the Named Officers and all other employees are based on established salary ranges for each grade level. The CEO's salary is set independently by the P&O Committee, without the involvement of the CEO. The P&O Committee reviews salaries for the other Named Officers based on recommendations from the Global Human Resources function and the CEO in accordance with the established salary ranges and the guidelines described below.

Since base salaries are designed to provide a reasonable, competitive level of fixed compensation, the mid-point of each salary range is based on the median pay level for similar jobs at companies in the Comparison Group. Salaries above the median are available for key contributors to our success. Setting salaries in the median range or above mitigates pressure that might otherwise exist to support short-term focused or higher-risk business strategies if fixed compensation were set materially below market rates.

Decisions regarding where in the range a particular individual's salary should be and whether their salary should be increased during the year are based on the following factors:

- Our annual salary budget guidelines;
- Company or business unit performance, as applicable;
- Assumption of new responsibilities;
- Data from the Comparison Group; and
- Individual performance, elements of which include:
  - the individual's ability to translate our key priorities into specific strategies applicable to their function, to communicate those strategies clearly and effectively and, working with their team, to deliver results against those strategies to help us achieve our performance objectives and strategic initiatives; and
  - other performance measures, such as the successful launch of innovative new products, increases in market share of Colgate products, geographic expansion and increases in productivity.

The Named Officers are experienced executives and key contributors to our success. In 2022, salaries for the Named Officers other than Mr. Wallace ranged between approximately the 60th and 80th percentiles of salaries for similar jobs in the Comparison Group, based on the most recent data available to us. Mr. Wallace's salary is near the median for CEOs in the Comparison Group.

2023 Proxy Statement 37

Executive Compensation

## Annual Incentives

### Award Opportunities

Annual incentive awards are awarded under a stockholder-approved plan. Cash bonuses are designed to reward performance over a one-year period against one or more pre-established performance measures set by the P&O Committee at the beginning of the year. Awards are determined by the P&O Committee based on achievement against the designated goals early in the following year when our audited financial results are available. In addition, the P&O Committee has discretion to adjust calculated awards upward or downward, subject to award limits established by the P&O Committee at the time the performance measures were set.

Executives, including the Named Officers, are each assigned a bonus award opportunity, which is based on salary grade level, expressed as a percentage of year-end base salary and generally set at or below the median of the Comparison Group. Assigned award opportunities are established for each Named Officer to ensure that the portion of annual cash compensation (i.e., salary plus cash bonus) that is based on performance increases with the level of responsibility. This ensures that the executives who are most responsible for managing Colgate and establishing our strategic plan are held most accountable to stockholders. For 2022, the Named Officers’ assigned award opportunities and award maximums, which are equal to 200% of the assigned award opportunities, were as follows:

|  | Assigned Award Opportunity | Maximum Award Opportunity |
| --- | --- | --- |
| Noel R. Wallace | 175% of base salary | 350% of base salary |
| Stanley J. Sutula III | 100% of base salary | 200% of base salary |
| Jennifer M. Daniels | 80% of base salary | 160% of base salary |
| Prabha Parameswaran | 80% of base salary | 160% of base salary |
| Panagiotis Tsourapas | 80% of base salary | 160% of base salary |

The annual cash bonuses for 2022 for the Named Officers were subject to a 10% downward adjustment if certain key global ethics and compliance objectives were not met. These ethics and compliance objectives were achieved in 2022 and therefore no downward adjustment was applied.

### Performance Measures and Bonus Payouts

#### Financial Measures (80%)

80% of the 2022 cash bonuses for the Named Officers were based on financial performance measures, namely Base Business Earnings Per Share and organic sales growth, in each case as reported in our 2022 financial results. The organic sales growth measure was selected to drive our growth strategy and reflect the underlying momentum of our business. The earnings-per-share measure was selected to create a strong focus on our overall profit goal and its underlying drivers of sales, cost control and financial efficiency.

The earnings-per-share measure is adjusted for the effects of the following, as applicable: restructuring charges, charges for certain litigation and tax matters, acquisition-related costs, gains and losses from certain divestitures and certain other unusual, non-recurring items. The purpose of the adjustments is to ensure that the measurement of performance reflects factors that management can directly control and that payout levels are not impacted by factors unrelated to the ongoing operation of the business. These adjustments are consistent with the presentation in our public filings in which the impact of these items is discussed separately.

The P&O Committee typically establishes annual bonus targets in March. However, in March 2022, the P&O Committee, in consultation with FW Cook, determined to delay setting the annual bonus targets in light of the uncertainty at that time regarding the impact of the war in Ukraine and the associated volatility. Significant uncertainty remained in April 2022, leading the P&O Committee to set the 2022 earnings-per-share target as a range, rather than a single number. The P&O Committee established the target range consistent with our publicly announced guidance for 2022 and based on our 2022 plan to sustain net and organic sales growth through science-led, core and premium innovation, digital transformation and investing behind our strategic priorities while continuing to manage through the cost environment. Given the economic and market conditions at the time the targets for the annual bonus award were set, the target goals were designed to be challenging but achievable, with payout levels intended to encourage strong, focused performance in a difficult operating environment characterized by significant raw material and logistics cost inflation and foreign exchange headwinds. As a result, the 2022 earnings-per-share target range was set below the 2021 earnings-per-share target and outcome, consistent with our publicly announced earnings-per-share goal for 2022, while the maximum was set at a higher level relative to target than our historical practice. We take into account the budget for our share repurchase program when setting our earnings-per-share targets, and no decisions about share repurchase plans are tied to an attempt to influence compensation results.

38 ![Colgate-Palmolive Company logo]() COLGATE-PALMOLIVE COMPANY

Executive Compensation

In 2022, the performance required to receive threshold, target and maximum payouts for each of the two financial components, and the payout relative to the Comparison Group that overall performance at each level would represent for the Named Officers, were as follows:

|  | Weight | Threshold | Target | Maximum |
| --- | --- | --- | --- | --- |
| Base Business Earnings Per Share | 40% | $2.62 | $2.92 - $3.02 | $3.42 |
| Organic Sales Growth | 40% | 2.0% | 5.0% | 8.0% |
| Strategic Initiatives | 20% | See discussion below |  |  |
| Payout Relative to the Comparison Group |  | Below 10th percentile | 21st to 58th percentile | 70th to above 90th percentile |

If Base Business Earnings Per Share was less than $2.62 or organic sales growth was less than 2.0%, no annual bonus would be paid with respect to that component. To the extent performance on either performance measure fell between two applicable values, the applicable payout percentage would be interpolated on a linear basis.

### Strategic Initiatives (20%)

The remaining 20% of the 2022 annual cash bonuses for the Named Officers was determined based on our progress on certain strategic initiatives, measured by considering our performance during 2022 against our enterprise-wide innovation, digital transformation and ESG goals. The strategic measure was selected to further align compensation with our strategic priorities to build competitive advantage through digital and data capabilities, deliver innovation that drives category growth, foster a culture where everyone feels they belong and integrate sustainability into our business.

The strategic measure was payable at 25% for threshold performance, 100% for target performance and 200% for maximum performance, as determined by the P&O Committee. However, in the event our performance on either of the two financial performance measures discussed above was below the threshold level, the strategic measure would be capped at 100%.

The chart below shows the performance considered by the P&O Committee during its assessment of our 2022 performance against the strategic goals.

| Goal | Measure | Assessment |
| --- | --- | --- |
| Innovation | Our revenue from new products | Exceeded our goals by 26% |
|  | Our incremental net sales coming from innovation | Exceeded our goals by 6% |
| Digital Transformation | Our year-over-year growth in net sales from eCommerce | Fell below internal goals but outpaced the industry average forecasts for 2022 by double digits |
| DE&I | Our progress in building a culture of inclusion and belonging | Exceeded our goals, improving our internal score year over year and achieving top quartile of the market benchmark |
| Sustainability | Our progress towards making all our packaging recyclable, reusable or compostable | Was in line with our 2022 goal of 86.4% percent |

Based on our strong performance against our enterprise-wide innovation, digital transformation and ESG goals detailed above, the P&O Committee determined that the strategic measure should pay out at 140% of target.

Based on strategic measure performance of 140%, Base Business Earnings Per Share of $2.97 and organic sales growth of 7.0%, the P&O Committee approved bonus awards for the Named Officers at 134.7% of their assigned award opportunities. The annual cash bonus for Mr. Wallace equaled 236% of his year-end salary, for Mr. Sutula equaled 135% of his year-end salary and for Mses. Daniels and Parameswaran and Mr. Tsourapas equaled 108% of their respective year-end salaries.

2023 Proxy Statement 39

Executive Compensation

## Long-term Incentives

### Overview

Our long-term incentive compensation is designed to focus the Named Officers and other Colgate executives on increasing shareholder value and to incentivize their contribution to our long-term growth and performance. We use two types of long-term incentives for the Named Officers, both granted in the form of equity: stock options and PBRSUs (weighted equally). Stock options and PBRSUs are used to balance and support the key principles discussed on page 33. Because their value is solely dependent on appreciation in stock price, stock options strongly support the objectives of ensuring that pay is aligned with changes in shareholder value and creating commonality of interest between the Named Officers and stockholders. The use of PBRSUs ensures that the amount of long-term incentive compensation granted is tied directly to both increases in shareholder value and the achievement of critically important multi-year performance objectives. Due to the multi-year earning and/or vesting requirements, all of our long-term incentives support the goal of retaining the Named Officers and other key executives.

Consistent with our longstanding practice of encouraging stock ownership throughout the organization to reward employees for the long-term value they create and to align management and stockholder interests, long-term equity grants are the largest component of target direct compensation for the Named Officers. Following a review of the practices of the Comparison Group, long-term incentives are generally targeted at the median of the Comparison Group, with above-median awards available based on superior performance and below-median awards available based on performance below expectations.

In 2022, our annual stock option and restricted stock unit utilization for all awards was 0.63% of outstanding stock, placing us at the 76th percentile of the Comparison Group based on available market data. Because we use a mix of long-term incentives that is weighted more heavily toward stock options than full-value awards as compared with the companies in the Comparison Group, our utilization rate will generally be above the median of the Comparison Group.

### Equity Grant Process and Policies

We make annual equity awards at the same predetermined times each year, at regularly scheduled P&O Committee meetings in the first and third quarters. Equity awards for new hires or newly promoted employees or special awards for recognition or retention purposes are generally made on a monthly basis. The grant date of any award is no earlier than the date on which such award is approved, and the grant price of any award is never less than the closing price of our Common Stock on the date of grant. All awards are granted under a stockholder-approved plan.

### Stock Options

#### Overview

The number of stock options granted to individual executives is determined based on guidelines set for each salary grade level. Established annually, the stock option guidelines are determined based on a review of market data and share usage. Actual awards may vary from such guidelines based on a qualitative assessment of factors similar to those used to determine salary, including each individual's performance, the performance of the business unit or function for which they are responsible and the assumption of new job responsibilities. (See discussion of salary on page 37.) As with other compensation decisions, in the case of the CEO, the P&O Committee makes such assessment with the participation and concurrence of the other independent directors of the Board and considering advice from its independent consultant, FW Cook. In the case of the other Named Officers, the P&O Committee reviews and approves awards taking into account the recommendations of the Global Human Resources function and the CEO.

#### Stock Option Grants

During 2022, the stock option grants to the Named Officers were at our guideline award level. See column (j) of the Grants of Plan-Based Awards Table for the number of stock options granted to the Named Officers in 2022. Mr. Wallace's award for 2022 was 322,910 options, consistent with the pre-established guideline.

#### Stock Option Terms

For all of the Named Officers, the stock options vest in equal annual installments over three years, the exercise price of the stock options is equal to the closing price of our Common Stock on the date of grant and the term of the stock options is eight years. Unvested stock options are forfeited if the recipient terminates their employment, other than through retirement, death or disability. For more information regarding the effect of various types of termination of employment on the vesting of outstanding equity awards, including stock options, see page 54.

### Performance-Based Restricted Stock Unit Awards

#### Awards

Under our long-term incentive program, the Growth Performance Plan, executives, including the Named Officers, receive PBRSUs at the beginning of each three-year performance cycle.

40 ![Colgate-Palmolive Company logo]() COLGATE-PALMOLIVE COMPANY

Executive Compensation

Each year, at the beginning of a three-year performance cycle, the P&O Committee approves a set of performance goals and a target award expressed in dollars, which is converted into PBRSUs by dividing the dollar value by the closing price of our Common Stock on the grant date. The number of PBRSUs that are earned and vest at the end of the performance period will be determined based on our performance against the pre-established performance goals. The PBRSUs will vest, to the extent earned, following the conclusion of the three-year performance period when actual performance is known and certified by the P&O Committee and shares of Common Stock are delivered in respect of the earned PBRSUs following vesting. In addition, the P&O Committee has discretion to adjust earned awards upward or downward, subject to award limits established by the P&O Committee at the time the performance measures were set.

For the 2022-2024 performance cycle, Mr. Wallace's target award was 64,328 PBRSUs and the target award for each of the other Named Officers ranged from 12,459 PBRSUs to 15,066 PBRSUs. All such target awards were granted in March 2022. Depending upon performance against the pre-established measures discussed below, including the modifier based on total shareholder return relative to peers, the number of PBRSUs that can be earned ranges from zero, if performance falls below a certain level, to a maximum of 250% of the target number of PBRSUs. The actual value of the payout from the PBRSUs will be determined in 2025 and will depend upon achievement of the performance goals as well as the price of our Common Stock at the time of vesting.

### Performance Measures

The performance measures used for the 2022-2024 performance cycle are described below.

| Performance Measure | Weight | Threshold | Target | Maximum |
| --- | --- | --- | --- | --- |
| Average organic sales growth relative to the Comparison Group over the three-year performance period | 50% | 25th Percentile | 50th Percentile | Highest Percentile |
| Average Base Business Net Income growth relative to the Comparison Group over the three-year performance period* | 30% | 25th Percentile | 50th Percentile | Highest Percentile |
| Average Free Cash Flow Productivity over the three-year performance period | 20% | 75% | 95% | 110% |

* We adjust net income in our audited financial statements for the effects of the following, as applicable: restructuring charges, charges for certain litigation and tax matters, acquisition-related costs, gains and losses from certain divestitures and certain other unusual, non-recurring items. For purposes of this Proxy Statement, this is referred to as 'Base Business Net Income.' Comparable adjustments are also made to net income of the companies in the Comparison Group for purposes of determining relative performance.

If performance on any of the performance measures is below the threshold level, no PBRSUs would be earned with respect to that component. To the extent performance on any of the performance measures falls between two applicable values, the applicable payout percentage would be interpolated on a linear basis.

These measures were chosen based on our view that together they will drive sustainable profitable growth while reflecting the underlying momentum and strong fundamentals of our business and our ability to generate cash to satisfy current and future obligations, reinvest in business-building activities and return value to stockholders. The measures are primarily based on our performance relative to peers to ensure focus on delivering peer-leading performance, no matter the marketplace conditions.

The Growth Performance Plan also includes a total shareholder return modifier to further link awards to the shareholder experience and hold management accountable for outperforming peers. The number of PBRSUs earned following completion of the 2022-2024 performance cycle may increase or decrease by up to 25% based on our total shareholder return, defined as stock price appreciation plus dividends paid, relative to the Comparison Group over the same three-year period, as follows:

| Company's TSR Relative to Comparison Group | Award Modifier |
| --- | --- |
| ≥75 th percentile | +25% |
| 60 th percentile | +15% |
| 50 th percentile | 0 |
| 40 th percentile | -15% |
| ≤25 th percentile | -25% |

2023 Proxy Statement 41

Executive Compensation

To the extent our total shareholder return relative to the Comparison Group falls between two applicable values, the total shareholder return modifier would be interpolated on a linear basis. In addition, in the event our total shareholder return over the performance period is negative, no participant would be eligible to earn more than the target number of PBRSUs, even if our performance on the other performance measures would otherwise entitle them to a higher payout.

### Performance Cycles Status

The status of our just completed and in-progress performance cycles are described below.

| Performance Period and Measures | Performance Levels | Status |
| --- | --- | --- |
| 2020-2022 |  |  |
| 50% relative organic sales growth | RESULT: 44th 25th percentile \| 50th percentile \| Highest percentile | Results were certified in February 2023 Relative organic sales growth was at the 44th percentile, relative Base Business Net Income growth was at the 32nd percentile and Free Cash Flow Productivity was 94.7% (following the reduction described below) Total shareholder return was at the 36th percentile relative to the Comparison Group, which decreased the payout by 18% based on the total shareholder return modifier Based on the above performance, the PBRSUs paid out at 73.7% of target |
| 30% relative Base Business Net Income growth | RESULT: 32nd 25th percentile \| 50th percentile \| Highest percentile |  |
| 20% Free Cash Flow Productivity | RESULT: 94.7%* 75% \| 90% \| 105% |  |
| 2021-2023 |  |  |
| 50% relative organic sales growth | 25th percentile \| 50th percentile \| Highest percentile | Based on performance achieved through December 31, 2022, payout would be between the threshold and target levels. Performance over the remaining year of the performance period will determine the actual number of shares earned, if any Results will be certified in February 2024, including applying the total shareholder return modifier |
| 30% relative Base Business Net Income growth | 25th percentile \| 50th percentile \| Highest percentile |  |
| 20% Free Cash Flow Productivity | 75% \| 95% \| 110% |  |
| 2022-2024 |  |  |
| 50% relative organic sales growth | 25th percentile \| 50th percentile \| Highest percentile | Based on performance achieved through December 31, 2022, payout would be between the threshold and target levels. Performance over the remaining two years of the performance period will determine the actual number of shares earned, if any Results will be certified in February 2025, including applying the total shareholder return modifier |
| 30% relative Base Business Net Income growth | 25th percentile \| 50th percentile \| Highest percentile |  |
| 20% Free Cash Flow Productivity | 75% \| 95% \| 110% |  |

* Free Cash Flow Productivity for 2020-2022 was 109.4%. However, in each of 2022 and 2021, our Free Cash Flow Productivity was impacted by goodwill and intangible assets impairment charges related to the Filorga skin health business. These non-cash charges had the effect of reducing the Company's 2022 and 2021 GAAP net income (the denominator used to calculate Free Cash Flow Productivity) but did not impact free cash flow before dividends (the numerator), thus resulting in higher Free Cash Flow Productivity than the Company would otherwise have achieved in 2022 and 2021. Therefore, the P&O Committee adjusted net income for the goodwill and intangible assets impairment charges related to the Filorga skin health business in order to eliminate the distortion the charges caused to the Free Cash Flow Productivity measure, resulting in Free Cash Flow Productivity for 2022 of 71.9%, for 2021 of 96.5%, and for the 2020-2022 performance period of 94.7%.

### PBRSU Terms

To the extent earned, the PBRSUs granted under the Growth Performance Plan vest upon certification of the performance results in February of the year following completion of the performance period (in 2025 for the 2022-2024 performance cycle) and are distributed as shares of Common Stock as soon as administratively practicable thereafter. Awards are forfeited if the recipient terminates their employment, other than through retirement, death or disability, prior to the end of the performance period. If a recipient retires, dies or becomes disabled during the performance period (provided they remained employed for at least the first six months of the performance period), they are eligible to earn PBRSUs on a pro rata basis at the conclusion of the performance period reflecting the proportion of the performance period for which they were employed. For more information regarding the effect of various types of termination on the vesting of outstanding equity awards, including PBRSUs, see page 54. Recipients of PBRSUs do not have voting rights or the right to receive dividends until they are distributed as shares of Common Stock.

42 COLGATE-PALMOLIVE COMPANY

Executive Compensation

## Compensation Governance Features

### Stock Ownership Guidelines

To further align the interests of our officers with those of our stockholders and ensure a long-term perspective, the Board has established minimum stock ownership guidelines for members of senior management. The CEO is required to own Colgate stock equal in value to eight times his annual salary, and the other Named Officers must hold Colgate stock in amounts equal to four times their annual salaries. Other senior managers are subject to ownership requirements of one or two times their annual salaries. Executives have five years from their initial promotion into an eligible position to achieve required ownership levels and neither unexercised stock options nor unearned PBRSUs are counted for purposes of determining whether the ownership requirements have been met. Compliance with these guidelines is evaluated on an annual basis. All of the Named Officers are in compliance with this policy.

### Hedging and Pledging of Company Stock

The Board has adopted a policy that prohibits our directors, officers and employees who receive stock-based compensation from purchasing any financial instrument that is designed to hedge against or offset any decrease in the value of Colgate's stock, such as short sales and put and call options. The policy also strongly discourages all other employees from entering into such transactions. In addition, we prohibit our directors and officers from pledging Colgate stock. During 2022, all of the Named Officers were in compliance with both the anti-hedging and anti-pledging policies.

### Clawback Policies

The Board has adopted a policy that permits us to recoup cash and equity-based incentive awards made to an officer or other executive subject to the policy if (i) the financial results on which such awards were based are subsequently restated or (ii) the officer or executive engaged in conduct that violates our Code of Conduct. In addition, our equity award agreements include non-competition, non-solicitation and non-interference restrictions in the event of an employee's departure from Colgate. Failure to comply with any of these requirements may result in forfeiture and/or cancellation of equity awards. We are monitoring regulatory developments regarding clawback requirements and will adopt any changes that may be necessary to comply with New York Stock Exchange listing standards when effective.

### Advisory Vote on Executive Compensation

Our executive compensation program received substantial stockholder support and was approved, on an advisory basis, by 90.8% of stockholders voting on the proposal at the 2022 Annual Meeting of Stockholders. The P&O Committee believes that this strong result reflects the stockholders' support for the compensation decisions made by the P&O Committee for our Named Officers. See pages 25 to 26 for information regarding our stockholder engagement efforts on compensation and other matters.

## Conclusion

In summary, the P&O Committee believes in aligning pay and performance. Thus, its approach to executive compensation is guided by the principle that executives should have the potential for increased compensation when performance objectives are exceeded, provided that compensation decreases if performance objectives are not met.

## P&O Committee Report

The P&O Committee has reviewed and discussed with management the foregoing Compensation Discussion and Analysis and, based on such review and discussion, recommended to the Board of Directors that the Compensation Discussion and Analysis be included in our Annual Report on Form 10-K for the year ended December 31, 2022 and this Proxy Statement.

*The foregoing P&O Committee report has been submitted by the members of the P&O Committee: Michael B. Polk (Chair), John T. Cahill, C. Martin Harris, Kimberly A. Nelson and Stephen I. Sadove.*

2023 Proxy Statement 43

Executive Compensation

## Summary Compensation Table

The following table shows the compensation of our Chief Executive Officer, Chief Financial Officer and three other most highly compensated executive officers (the “Named Officers”) for 2022, 2021 and 2020, as applicable.

| Name and Principal Position (a) | Year (b) | Salary ($) (c) | Bonus ($) (1) (d) | Stock Awards ($) (2) (e) | Option Awards ($) (3) (f) | Non-Equity Incentive Plan Compensation ($) (4) (g) | Change in Pension Value and Nonqualified Deferred Compensation Earnings ($) (5) (h) | All Other Compensation ($) (6) (i) | Total ($) (j) |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | Noel R. Wallace | 2022 | 1,387,500 | - | 4,364,655 | 4,750,006 | 3,300,150 | 31,939 | 628,156 | 14,462,406 |
| Chairman, President and Chief Executive Officer | 2021 | 1,337,500 | - | 6,403,522 | 4,500,006 | 2,613,600 | 29,102 | 574,421 | 15,458,151 |  |  |
|  | 2020 | 1,287,500 | - | 4,391,284 | 4,250,008 | 4,097,600 | 32,585 | 305,141 | 14,364,118 |  |  |
| Stanley J. Sutula III | 2022 | 905,018 | 589,199 (7) | 1,022,228 | 1,112,503 | 1,232,694 | - | 138,685 | 5,000,327 |  |  |
| Chief Financial Officer | 2021 | 868,488 | 877,908 (7) | 983,698 | 1,060,005 | 952,494 | - | 78,717 | 4,821,310 |  |  |
|  | 2020 | 130,769 | 100,000 (7) | 2,254,184 | 1,179,008 | - | - | 8,500 | 3,672,461 |  |  |
| Jennifer M. Daniels | 2022 | 835,748 | - | 845,343 | 920,008 | 910,820 | - | 138,252 | 3,650,171 |  |  |
| Chief Legal Officer and Secretary | 2021 | 800,475 | - | 1,356,976 | 831,250 | 683,783 | - | 139,232 | 3,811,716 |  |  |
|  | 2020 | 766,368 | - | 904,184 | 787,502 | 1,075,620 | - | 95,512 | 3,629,186 |  |  |
| Prabha Parameswaran | 2022 | 876,475 | - | 845,343 | 920,008 | 953,999 | 7,655 | 196,010 | 3,799,490 |  |  |
| Group President, Growth and Strategy | 2021 | 800,475 | - | 1,356,976 | 831,250 | 683,783 | 6,790 | 167,850 | 3,847,124 |  |  |
|  | 2020 | 744,117 | - | 904,184 | 787,502 | 1,075,620 | 8,239 | 387,724 | 3,907,386 |  |  |
| Panagiotis Tsourapas | 2022 | 876,475 | - | 845,343 | 920,008 | 953,999 | 2,215 | 196,333 | 3,794,373 |  |  |
| Group President, Europe and Developing Markets | 2021 | 800,475 | - | 1,356,976 | 831,250 | 683,783 | 1,964 | 188,508 | 3,862,956 |  |  |
|  | 2020 | 751,617 | - | 904,184 | 787,502 | 1,075,620 | 2,384 | 126,516 | 3,647,823 |  |  |

### NOTES TO THE SUMMARY COMPENSATION TABLE

$^{(1)}$ **Bonus.** Except as described in note 7 below, cash bonuses are awarded based on specific pre-established performance measures and therefore are reported in column (g) under Non-Equity Incentive Plan Compensation.

$^{(2)}$ **Stock Awards.** The amounts reported in this column reflect the aggregate grant date fair value of performance-based restricted stock units (“PBRSUs”) granted to each Named Officer in the years reported pursuant to our Growth Performance Plan under the stockholder-approved 2019 Plan. These PBRSUs may be earned and, if earned, will vest in shares of Common Stock to the extent the pre-established performance measures are met over the three-year performance cycle starting in the year of grant. Since these awards are subject to future performance conditions, the aggregate values at the grant date reflected in this column for those awards were based on the probable outcome of those conditions at the grant date, consistent with applicable accounting guidance. For a description of how the aggregate grant date fair value of the PBRSUs was calculated, see Note 8 (“Capital Stock and Stock-Based Compensation Plans”) to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022. The below table provides the aggregate value of the PBRSUs for the 2022-2024 performance cycle at the grant date at the threshold, target and maximum performance levels. The actual value of the PBRSUs at the time of payout will depend upon achievement of the performance measures as well as the price of our Common Stock at the time of vesting. For more information regarding these awards and the program under which they were made, including the terms and conditions and applicable performance measures, see pages 40 to 42 of the CD&A and the Grants of Plan-Based Awards Table.

| Named Officer | 2022-2024 PBRSUs |  |  |
| --- | --- | --- | --- |
|  | Value at Threshold Level ($) (a) | Value at Target Level (Reported in Column (e) above) ($) (a) | Value at Maximum Level ($) (a) |
| Noel R. Wallace | 436,479 | 4,364,655 | 8,729,310 |
| Stanley J. Sutula III | 102,250 | 1,022,228 | 2,044,456 |
| Jennifer M. Daniels | 84,541 | 845,343 | 1,690,686 |
| Prabha Parameswaran | 84,541 | 845,343 | 1,690,686 |
| Panagiotis Tsourapas | 84,541 | 845,343 | 1,690,686 |

$^{(a)}$ The amount of shares earned at the conclusion of the 2022-2024 performance cycle may increase or decrease by up to 25% based on our total shareholder return relative to the Comparison Group.

Since Mr. Sutula joined Colgate in November 2020, he did not receive PBRSUs pursuant to the Growth Performance Plan for the 2020-2022 performance cycle. The amounts reported in this column for Mr. Sutula for 2020 instead reflect the aggregate grant date fair value of restricted stock unit awards granted to him in 2020 under the stockholder-approved 2019 Plan to compensate him for awards from his former employer that he forfeited upon joining Colgate. The value of these restricted stock unit awards is based on the fair market value (which is the closing stock price) of our Common Stock on the date of grant.

44

![Colgate-Palmolive Company logo]() COLGATE-PALMOLIVE COMPANY

Executive Compensation

The amounts reported in this column for 2021 also reflect the aggregate grant date fair value of performance-based restricted stock unit awards made to each Named Officer (other than Mr. Sutula) pursuant to our legacy Long-Term Global Growth Program under the stockholder-approved 2019 Plan in 2021 with respect to the 2018-2020 performance cycle based on pre-established performance measures. The value of these restricted stock unit awards is based on the fair market value (which is the closing stock price) of our Common Stock on the date of grant. No amounts are shown for 2020 under the legacy Long-Term Global Growth Program for the performance cycle ending in 2019, because none were earned. 2018-2020 represented the final performance cycle under the Long-Term Global Growth Program, so there were no awards granted under that program in 2022.

(i) Option Awards. This column reflects the aggregate grant date fair value of stock option awards granted to each Named Officer in the years reported under the stockholder-approved 2019 Plan. The estimated value of stock options is calculated using the Black-Scholes model. For a description of the assumptions used to calculate the amounts, see Note 8 ("Capital Stock and Stock-Based Compensation Plans") to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022. For more information regarding these awards, including their terms and conditions, see page 40 of the CD&A and the Grants of Plan-Based Awards Table.
(ii) Non-Equity Incentive Plan Compensation. This column reflects the cash bonuses earned by the Named Officers under the stockholder-approved 2019 Plan based on one or more pre-established performance measures, as discussed more fully on pages 38 to 39 of the CD&A. These bonuses were awarded and paid after audited financial results for the years for which performance was measured were known early in the following year. See the Grants of Plan-Based Awards Table for more information regarding 2022 bonuses.
(iii) Change in Pension Value. This column reflects (i) for Ms. Parameswaran and Messrs. Tsourapas and Wallace, the aggregate change in the actuarial present value of their accumulated benefit under the Colgate-Palmolive Company Employees' Retirement Income Plan (the "Retirement Plan") and the Colgate-Palmolive Company Supplemental Salaried Employees' Retirement Plan (the "Supplemental Retirement Plan") from December 31, 2021 to December 31, 2022, December 31, 2020 to December 31, 2021 and December 31, 2019 to December 31, 2020, as applicable, reflecting additional interest credited to their plan accounts as described beginning on page 49 and (ii) for Mr. Wallace, above-market interest earned during those periods ($6,046 in 2022) under the Colgate-Palmolive Company Supplemental Savings and Investment Plan (the "Supplemental Savings & Investment Plan"), as described on page 51. None of the Named Officers except Mr. Wallace earned above-market interest under the Supplemental Savings & Investment Plan. Ms. Daniels and Mr. Sutula are not participants in the Retirement Plan or Supplemental Retirement Plan and instead participate only in our defined contribution plans so no amounts are shown for either of them in this column.
(iv) All Other Compensation. The amounts shown in this column are paid pursuant to programs available either to all U.S. employees generally or to a broad group of management employees, except as specifically noted in the footnotes below. The dollar amounts paid under each such program and the value of perquisites and other personal benefits granted to the Named Officers in 2022 were:

| Named Officer | Company Contributions to Savings & Investment 401(k) Plan ($) (a) | Company Allocations to Supplemental Savings & Investment Plan ($) (b) | Value of Company-Paid Life Insurance Premiums ($) | Perquisites and Other Personal Benefits ($) (c) |
| --- | --- | --- | --- | --- |
| Noel R. Wallace | 35,837 | 491,193 | 2,754 | 98,372 |
| Stanley J. Sutula III | 28,213 | 108,687 | 1,785 | - |
| Jennifer M. Daniels | 32,788 | 103,247 | 2,217 | - |
| Prabha Parameswaran | 35,838 | 158,272 | 1,900 | - |
| Panagiotis Tsourapas | 35,838 | 158,272 | 2,223 | - |

(a) This column reflects Company contributions to the Named Officers' accounts under the Colgate-Palmolive Company Employees Savings and Investment Plan (the "Savings & Investment Plan"), a broad-based employee stock ownership and 401(k) plan available generally to all U.S. employees. Profit-sharing contributions are made in the form of shares of Common Stock. Company matching contributions and retirement contributions are invested in the same form as employees' own contributions to the Savings & Investment Plan. The amounts shown represent the value of such contributions at the time of allocation to the Named Officers' accounts.

(b) This column reflects Company allocations to the Supplemental Savings & Investment Plan, a plan available to U.S. employees who are not able to receive the full Company matching or retirement contributions under the Savings & Investment Plan due to Internal Revenue Service ("IRS") or Savings & Investment Plan rules. Amounts allocated by Colgate to the Named Officers' and other employees' accounts under this plan are equal only to the amount of the Company matching and/or retirement contributions that cannot be made to the Savings & Investment Plan due to these IRS or Savings & Investment Plan rules.

(c) This column consists of the incremental cost to Colgate of the personal use of a car and driver by Mr. Wallace, valued as a proportionate amount of the cost of the annual lease, driver and related operating expenses. Any income taxes due as a result of this perquisite are the responsibility of Mr. Wallace.

(7) Mr. Sutula was appointed Chief Financial Officer effective November 9, 2020. In connection with his hiring, he received a one-time sign-on bonus of $100,000 in 2020 to compensate him for certain retirement and other benefits he relinquished upon his departure from his former employer, Pitney Bowes. In addition, in March 2021 he received cash payments of (i) $492,600, equal to the actual 2020 annual bonus he would have received from Pitney Bowes had he remained in his prior role and (ii) $385,308, equal to the value of the restricted stock units he would have received under the Pitney Bowes long-term incentive compensation program for the Pitney Bowes 2018-2020 performance cycle had he remained in his prior role, and in March 2022, he received a cash payment of $589,199, equal to the value of the restricted stock units he would have received under the Pitney Bowes long-term incentive compensation program for the Pitney Bowes 2019-2021 performance cycle had he remained in his prior role. These compensatory arrangements were negotiated at arm's length at a level appropriate to attract external talent.

2023 Proxy Statement 45

Executive Compensation

## Grants of Plan-Based Awards

The following table shows information in accordance with SEC requirements about the non-equity incentive awards, stock options and PBRSUs that are reflected in the Summary Compensation Table for 2022 and that were granted to the Named Officers either during, or with respect to services rendered in, 2022.

| Name (a) | Grant Date (b) | Estimated Possible Payouts Under Non-Equity Incentive Plan Awards (1) |  |  | Estimated Possible Payouts Under Equity Incentive Plan Awards (2) |  |  | All Other Stock Awards: Number of Shares of Stock or Units (#) (i) | All Other Option Awards: Number of Securities Underlying Options (#) (3) (j) | Exercise or Base Price of Option Awards ($/Sh) (k) | Grant Date Fair Value of Stock and Option Awards ($) (4) (l) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | Threshold ($) (c) | Target ($) (d) | Maximum ($) (e) | Threshold (#) (f) | Target (#) (g) | Maximum (#) (h) |  |  |  |  |
| Noel R. Wallace | 3/10/22 |  |  |  | 6,433 | 64,328 | 128,656 |  |  |  | 4,364,655 |
|  | 9/9/22 |  |  |  |  |  |  |  | 322,910 | 78.03 | 4,750,006 |
|  | 2/16/23 | 122,500 | 2,450,000 | 4,900,000 |  |  |  |  |  |  |  |
| Stanley J. Sutula III | 3/10/22 |  |  |  | 1,507 | 15,066 | 30,132 |  |  |  | 1,022,228 |
|  | 9/9/22 |  |  |  |  |  |  |  | 75,629 | 78.03 | 1,112,503 |
|  | 2/16/23 | 45,757 | 915,140 | 1,830,280 |  |  |  |  |  |  |  |
| Jennifer M. Daniels | 3/10/22 |  |  |  | 1,246 | 12,459 | 24,918 |  |  |  | 845,343 |
|  | 9/9/22 |  |  |  |  |  |  |  | 62,543 | 78.03 | 920,008 |
|  | 2/16/23 | 33,809 | 676,184 | 1,352,368 |  |  |  |  |  |  |  |
| Prabha Parameswaran | 3/10/22 |  |  |  | 1,246 | 12,459 | 24,918 |  |  |  | 845,343 |
|  | 9/9/22 |  |  |  |  |  |  |  | 62,543 | 78.03 | 920,008 |
|  | 2/16/23 | 35,412 | 708,240 | 1,416,480 |  |  |  |  |  |  |  |
| Panagiotis Tsourapas | 3/10/22 |  |  |  | 1,246 | 12,459 | 24,918 |  |  |  | 845,343 |
|  | 9/9/22 |  |  |  |  |  |  |  | 62,543 | 78.03 | 920,008 |
|  | 2/16/23 | 35,412 | 708,240 | 1,416,480 |  |  |  |  |  |  |  |

### NOTES TO THE GRANTS OF PLAN-BASED AWARDS TABLE

$^{(1)}$ The amounts shown represent the threshold, target and maximum payouts for annual performance-based cash bonuses under the stockholder-approved 2019 Plan with respect to services rendered in 2022. The threshold amounts represent the potential payout if performance against the pre-established performance measures is at the lowest level resulting in an award being paid, while the target and maximum amounts represent the potential payout if performance against the pre-established performance measures is at target and maximum levels, respectively. The actual amounts awarded are reported in column (g) of the Summary Compensation Table. See pages 38 to 39 of the CD&A for a description of our annual incentive program, including the above-mentioned performance measures.

$^{(2)}$ The amounts shown represent the number of shares the Named Officers are eligible to earn at the threshold, target and maximum levels in connection with the target PBRSUs granted to the Named Officers in March 2022 under the Growth Performance Plan pursuant to the stockholder-approved 2019 Plan for the 2022-2024 performance cycle. The threshold amounts represent the number of shares that would be earned if performance against the pre-established performance measures is at the lowest level resulting in an award being paid, while the target and maximum amounts represent the number of shares that would be earned if performance against the pre-established performance measures is at target and maximum levels, respectively. The awards are also subject to a relative total shareholder return modifier. The aggregate grant date fair value of such awards is included in column (e) of the Summary Compensation Table. As described in more detail on pages 40 to 42 of the CD&A, these PBRSUs provide the Named Officers with an opportunity to earn shares of Common Stock, the amount of which will be determined based on our performance against pre-established performance measures over the three-year performance period from January 1, 2022 to December 31, 2024. Target award opportunities were expressed in dollars and converted into the target number of PBRSUs based on the price of our Common Stock on the date of grant.

$^{(3)}$ The amounts shown represent annual stock option awards granted in September 2022 under the stockholder-approved 2019 Plan. The aggregate grant date fair value of such awards is included in column (f) of the Summary Compensation Table. The key terms of our stock options are as follows: (i) the exercise price is equal to the closing price of our Common Stock on the date of grant; (ii) the term is eight years; and (iii) they vest in equal annual installments over three years.

$^{(4)}$ This column shows the grant date fair value of: (i) the unearned PBRSUs granted to the Named Officers in March 2022 under the Growth Performance Plan for the 2022-2024 performance cycle calculated in accordance with accounting guidance and (ii) the stock option awards shown in column (j) of this table calculated using the Black-Scholes model. For a description of the assumptions used to calculate these amounts, see Note 8 ('Capital Stock and Stock-Based Compensation Plans') to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022.

46 ![Colgate-Palmolive Company Logo]() COLGATE-PALMOLIVE COMPANY

Executive Compensation

## Outstanding Equity Awards at Fiscal Year-End

The following table contains information about stock options and PBRSUs and other restricted stock units held by the Named Officers as of December 31, 2022.

| Name (a) | Option Grant Date | Option Awards (1)(3) |  |  |  | Stock Awards (1) |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | Number of Securities Underlying Unexercised Options (#) Exercisable (b) | Number of Securities Underlying Unexercised Options (#) (3) Unexercisable (c) | Option Exercise Price ($) (e) | Option Expiration Date (f) | Number of Shares or Units of Stock That Have Not Vested (#) (4)(5) (g) | Market Value of Shares or Units of Stock That Have Not Vested ($) (6) (h) | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#) (7) (i) | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) (6) (j) |  |  |
|  |  | Noel R. Wallace | 9/25/17 | 98,627 | - | 73.00 | 9/25/23 | 73,516 | 5,792,326 | 124,113 | 9,778,863 |
| 9/13/18 | 105,486 |  | - | 68.16 | 9/13/24 |  |  |  |  |  |  |
| 9/12/19 | 322,042 |  | - | 72.29 | 9/12/27 |  |  |  |  |  |  |
| 9/10/20 | 251,628 |  | 125,815 | 76.41 | 9/10/28 |  |  |  |  |  |  |
| 9/10/21 | 135,013 |  | 270,028 | 77.04 | 9/10/29 |  |  |  |  |  |  |
| 9/9/22 | - |  | 322,910 | 78.03 | 9/9/30 |  |  |  |  |  |  |
| Stanley J. Sutula III | 11/9/20 | 65,228 | 32,615 | 81.78 | 11/9/28 | 21,399 | 1,686,027 | 29,149 | 2,296,650 |  |  |
|  | 9/10/21 | 31,803 | 63,607 | 77.04 | 9/10/29 |  |  |  |  |  |  |
|  | 9/9/22 | - | 75,629 | 78.03 | 9/9/30 |  |  |  |  |  |  |
| Jennifer M. Daniels | 9/25/17 | 49,407 | - | 73.00 | 9/25/23 | 16,223 | 1,278,210 | 24,085 | 1,897,657 |  |  |
|  | 9/13/18 | 65,433 | - | 68.16 | 9/13/24 |  |  |  |  |  |  |
|  | 9/12/19 | 66,250 | - | 72.29 | 9/12/27 |  |  |  |  |  |  |
|  | 9/10/20 | 46,625 | 23,313 | 76.41 | 9/10/28 |  |  |  |  |  |  |
|  | 9/10/21 | 24,940 | 49,880 | 77.04 | 9/10/29 |  |  |  |  |  |  |
|  | 9/9/22 | - | 62,543 | 78.03 | 9/9/30 |  |  |  |  |  |  |
| Prabha Parameswaran | 9/25/17 | 64,373 | - | 73.00 | 9/25/23 | 16,190 | 1,275,610 | 24,085 | 1,897,657 |  |  |
|  | 9/13/18 | 56,836 | - | 68.16 | 9/13/24 |  |  |  |  |  |  |
|  | 9/12/19 | 66,794 | - | 72.29 | 9/12/27 |  |  |  |  |  |  |
|  | 9/10/20 | 46,625 | 23,313 | 76.41 | 9/10/28 |  |  |  |  |  |  |
|  | 9/10/21 | 24,940 | 49,880 | 77.04 | 9/10/29 |  |  |  |  |  |  |
|  | 9/9/22 | - | 62,543 | 78.03 | 9/9/30 |  |  |  |  |  |  |
| Panagiotis Tsourapas | 9/25/17 | 68,698 | - | 73.00 | 9/25/23 | 16,223 | 1,278,210 | 24,085 | 1,897,657 |  |  |
|  | 9/13/18 | 65,433 | - | 68.16 | 9/13/24 |  |  |  |  |  |  |
|  | 9/12/19 | 66,794 | - | 72.29 | 9/12/27 |  |  |  |  |  |  |
|  | 9/10/20 | 46,625 | 23,313 | 76.41 | 9/10/28 |  |  |  |  |  |  |
|  | 9/10/21 | 24,940 | 49,880 | 77.04 | 9/10/29 |  |  |  |  |  |  |
|  | 9/9/22 | - | 62,543 | 78.03 | 9/9/30 |  |  |  |  |  |  |

### NOTES TO THE OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END TABLE

(1) For information regarding the treatment of these awards in the event of termination of employment under various circumstances including retirement, see 'Executive Severance and Other Termination Benefits-Equity Awards.'

(2) The following table contains information about the aggregate value of stock options held by each of the Named Officers as of December 31, 2022. The values shown are calculated based on the difference between the closing price of our Common Stock on December 31, 2022 and the applicable exercise prices.

| Named Officer | Value of Unexercised In-the-Money Options at Fiscal Year-End |  |
| --- | --- | --- |
|  | Exercisable ($) | Unexercisable ($) |
| Noel R. Wallace | 4,620,787 | 1,017,400 |
| Stanley J. Sutula III | 55,655 | 168,790 |
| Jennifer M. Daniels | 1,566,857 | 190,308 |
| Prabha Parameswaran | 1,565,660 | 190,308 |
| Panagiotis Tsourapas | 1,682,088 | 190,308 |

(3) The stock option awards shown in this column vest as follows:

| Named Officer | 9/9/23 | 9/10/23 | 11/9/23 | 9/9/24 | 9/10/24 | 9/9/25 |
| --- | --- | --- | --- | --- | --- | --- |
| Noel R. Wallace | 107,636 | 260,829 | - | 107,637 | 135,014 | 107,637 |
| Stanley J. Sutula III | 25,209 | 31,803 | 32,615 | 25,210 | 31,804 | 25,210 |
| Jennifer M. Daniels | 20,847 | 48,253 | - | 20,848 | 24,940 | 20,848 |
| Prabha Parameswaran | 20,847 | 48,253 | - | 20,848 | 24,940 | 20,848 |
| Panagiotis Tsourapas | 20,847 | 48,253 | - | 20,848 | 24,940 | 20,848 |

2023 Proxy Statement 47

Executive Compensation

(4) The amounts shown in this column and in note 5 below also include, where applicable, dividend equivalents in the form of additional restricted stock units that have accrued during the applicable vesting period, rounded down to the nearest whole number. Any accrued fractional restricted stock units are settled in cash and therefore are not included in the amounts shown.
(5) The earned PBRSUs and restricted stock units shown in this column will vest as follows:

| Named Officer | PBRSUs | Restricted Stock Units |  |  |
| --- | --- | --- | --- | --- |
|  | 2/16/23 | 2/15/23 | 11/9/23 | 2/18/24 |
| Noel R. Wallace | 45,461 | - | - | 28,055 |
| Stanley J. Sutula III | - | 17,669 | 3,730 | - |
| Jennifer M. Daniels | 9,361 | - | - | 6,862 |
| Prabha Parameswaran | 9,361 | - | - | 6,829 |
| Panagiotis Tsourapas | 9,361 | - | - | 6,862 |

(6) The market value of earned PBRSUs and restricted stock units that have not vested is calculated based on the closing price of our Common Stock on December 31, 2022.

(7) The PBRSUs shown in this column were granted under our Growth Performance Plan and will vest, subject to achievement of the applicable performance criteria, in February 2024 and February 2025, as shown in the below table. The amounts shown in this column (and in column (j)) reflect the number of shares each of the Named Officers will earn if the target level of performance is achieved.

| Named Officer | Unearned PBRSUs Under the Growth Performance Plan - Target Level |  |
| --- | --- | --- |
|  | 2021-2023 Cycle (Vesting in 2024) | 2022-2024 Cycle (Vesting in 2025) |
| Noel R. Wallace | 59,785 | 64,328 |
| Stanley J. Sutula III | 14,083 | 15,066 |
| Jennifer M. Daniels | 11,626 | 12,459 |
| Prabha Parameswaran | 11,626 | 12,459 |
| Panagiotis Tsourapas | 11,626 | 12,459 |

(8) The market value of unearned PBRSUs that have not vested is calculated based on the closing price of our Common Stock on December 31, 2022.

## Option Exercises and Stock Vested

The following table contains information about the number of shares acquired and value realized (including, in the case of restricted stock units, dividend equivalents in the form of additional restricted stock units that accrued during the vesting period) during 2022 upon the exercise or vesting of equity awards previously granted to each of the Named Officers.

| Name (a) | Option Awards |  | Stock Awards |  |
| --- | --- | --- | --- | --- |
|  | Number of Shares Acquired on Exercise ($) (b) | Value Realized on Exercise ($) (1) (c) | Number of Shares Acquired on Vesting ($) (d) | Value Realized on Vesting ($) (2) (e) |
| Noel R. Wallace | 101,665 | 745,271 | 73,562 | 5,822,432 |
| Stanley J. Sutula III | - | - | 3,730 | 274,106 |
| Jennifer M. Daniels | 65,283 | 607,161 | 16,797 | 1,329,483 |
| Prabha Parameswaran | 48,778 | 283,257 | 12,450 | 985,418 |
| Panagiotis Tsourapas | 60,976 | 530,869 | 14,332 | 1,134,378 |

# NOTES TO THE OPTION EXERCISES AND STOCK VESTED TABLE

(1) The aggregate dollar amount realized upon the exercise of stock options is calculated based on the difference between the fair market value of our Common Stock on the exercise date and the exercise price of the stock option.
(2) The aggregate dollar amount realized upon the vesting of PBRSUs and restricted stock units is calculated based on the closing price of our Common Stock on the vesting date of each award. The aggregate dollar amount realized upon the vesting of PBRSUs and restricted stock units includes the value of any accrued fractional restricted stock units settled in cash.

48

[LOGO]

COLGATE-PALMOLIVE COMPANY

Executive Compensation

## Retirement Plans

Ms. Parameswaran and Messrs. Tsourapas and Wallace are participants in and will receive retirement benefits under the Retirement Plan, a broad-based, tax-qualified retirement plan available generally to all U.S. employees who were eligible for the plan as of August 31, 2010, and the Supplemental Retirement Plan, a non-qualified supplemental plan available to employees whose benefits under the Retirement Plan are subject to certain IRS limits. The Supplemental Retirement Plan provides for payment of the portion of the Retirement Plan benefit that exceeds IRS and Retirement Plan limits. Our retirement programs, including these plans, are generally designed to provide our long-serving, retiring employees with competitive replacement income based on prevailing market practice. Employees hired after June 1, 2010 are not eligible to participate in the Retirement Plan. Ms. Daniels and Mr. Sutula, who joined Colgate in 2014 and 2020, respectively, are not participants in either the Retirement Plan or the Supplemental Retirement Plan.

All Named Officers participate in the Savings & Investment Plan, a defined contribution plan sponsored by Colgate generally available to all U.S. employees, as well as the Supplemental Savings & Investment Plan, a plan available to U.S. employees whose benefits under the Savings & Investment Plan are otherwise limited due to IRS or Savings & Investment Plan rules.

Ms. Parameswaran's and Messrs. Tsourapas's and Wallace's Retirement Plan benefits are determined in accordance with the Personal Retirement Account ('PRA') formula. Under the PRA formula, the benefit is payable upon the employee's departure from Colgate at any age and the value is equal to the employee's vested account balance. Total annual retirement benefits payable under the Retirement Plan and the Supplemental Retirement Plan are subject to a maximum of 70% of the sum of an individual's base salary at retirement plus cash-based incentive compensation awarded for services rendered in the calendar year immediately preceding retirement. Under the standard form of retirement benefit for a married participant, the employee receives a monthly retirement benefit for life and, upon the employee's death, their spouse is entitled to receive a monthly benefit for life equal to 50% of the employee's benefit. For approximately 200 employees, including the Named Officers who participate in the Retirement Plan, the employee's spouse is entitled to receive an additional monthly amount equal to 25% of the employee's normal monthly retirement benefit for life if the employee dies during retirement or while in active service after attaining early retirement eligibility. However, this benefit is not available to the extent it would cause the total retirement benefit payable to the employee's spouse to exceed 100% of the employee's normal retirement benefit and is not available if a participant elects a lump sum form of payment under the Retirement Plan.

If the participant in question is a 'specified employee' under Section 409A of the Internal Revenue Code of 1986, as amended (the 'Internal Revenue Code'), there may be a six-month delay in the commencement of Supplemental Retirement Plan distributions, if triggered by the participant's termination or retirement.

Ms. Parameswaran and Messrs. Tsourapas and Wallace each accrued benefits under the PRA formula until December 31, 2013. PRA formula benefits are determined as follows: On July 1, 1989, an account was established for each eligible person employed on June 30, 1989, with an opening balance equal to the greater of (i) the value of the pension then accrued under the formula that existed prior to July 1, 1989 and (ii) an amount equal to the sum of the monthly pay-based credits that would have been made to the employee's account had the PRA formula always been in effect. For employees who were hired or became eligible to participate in the Retirement Plan between July 1, 1989 and June 1, 2010, monthly pay-based credits accumulated in a PRA account established in the employee's name. Through August 31, 2010, these credits equaled a percentage of the employee's monthly recognized earnings determined in accordance with the following schedule:

| Years of Service | Up to 1/48 of Social Security Wage Base | Over 1/48 of Social Security Wage Base |
| --- | --- | --- |
| 0-9 | 2.50% | 3.75% |
| 10-14 | 3.00% | 4.50% |
| 15-19 | 4.00% | 6.00% |
| 20-24 | 5.35% | 8.00% |
| 25 or more | 7.50% | 11.25% |

'Recognized earnings' for a particular year were set on February 1 each year prior to 2022, and consisted of the higher of (i) the compensation earned by an employee during the previous year and (ii) their annual salary as of January 1 of the year in question plus the annual bonus paid to the employee in the previous year. Recognized earnings did not include the value of equity compensation.

2023 Proxy Statement 49

## Executive Compensation

The PRA formula was amended effective September 1, 2010 to provide for monthly pay-based credits equal to a percentage of the employee's monthly recognized earnings determined in accordance with the following schedule:

| Years of Service | Basic Retirement Contributions |
| --- | --- |
| 0-9 | 2.00% |
| 10 or more | 2.50% |

In addition, eligible employees received additional allocations to their PRA accounts in September 2010 and September 2011 of 0.25% of their projected PRA balance as of August 31, 2010 for each full year of vesting service through August 31, 2010, up to a combined maximum of 15% based on 30 years of service.

The Retirement Plan was amended effective January 1, 2014 to provide that no additional pay-based credits will be made to PRA accounts after December 31, 2013. This change also applied to the Supplemental Retirement Plan.

Employees who accrued benefits under the PRA formula receive monthly credits for interest in their accounts. Interest credits continue after December 31, 2013. The interest crediting rate for 2022 was 2.82%, which was determined in accordance with the Retirement Plan rules and applicable IRS guidance.

For employees retiring under the PRA formula, benefits earned under the Supplemental Retirement Plan through December 31, 2004 will follow the form of payment elected under the Retirement Plan, and benefits earned after December 31, 2004 will be paid in a lump sum. However, employees may request to have their full retirement benefit under the Supplemental Retirement Plan paid in a lump sum. Such requests may be accepted or denied.

## Pension Benefits

The following table shows the actuarial present value of each Named Officer's total accumulated benefit as of December 31, 2022 under the terms of the Retirement Plan and the Supplemental Retirement Plan. As described above, Ms. Daniels and Mr. Sutula are not participants in the Retirement Plan or the Supplemental Retirement Plan and therefore do not appear in the following table.

| Name (a) | Plan Name (b) | Number of Years Credited Service (#) (1) (c) | Present Value of Accumulated Benefit ($) (2) (d) | Payments During Last Fiscal Year ($) (e) |
| --- | --- | --- | --- | --- |
| Noel R. Wallace | Retirement Plan | 26.25 | 495,442 | - |
|  | Supplemental Retirement Plan | 26.25 | 436,691 | - |
|  |  |  | 932,133 | - |
| Prabha Parameswaran | Retirement Plan | 16.17 | 245,633 | - |
|  | Supplemental Retirement Plan | 16.17 | 29,940 | - |
|  |  |  | 275,573 | - |
| Panagiotis Tsourapas | Retirement Plan | 3.58 | 38,571 | - |
|  | Supplemental Retirement Plan | 3.58 | 41,149 | - |
|  |  |  | 79,720 | - |

### NOTES TO THE PENSION BENEFITS TABLE

$^{(1)}$ For Mr. Wallace, the years in this column represent the actual years worked by him for Colgate as of December 31, 2013. For Ms. Parameswaran and Mr. Tsourapas, the years in this column represent the years worked by them for Colgate as of December 31, 2013 during which they were eligible to participate in the Retirement Plan and Supplemental Retirement Plan described above. As noted above, the Retirement Plan and Supplemental Retirement Plan do not take into account service after December 31, 2013.

$^{(2)}$ The amounts shown reflect the value as of December 31, 2022 of the applicable Named Officers' benefits under the PRA formula under the Retirement Plan and Supplemental Retirement Plan described above.

As noted above, Ms. Parameswaran and Messrs. Tsourapas and Wallace are eligible to receive their full benefit (including benefits under both the Retirement Plan and the Supplemental Retirement Plan) in a lump sum under the PRA formula.

50 ![Colgate-Palmolive Company logo]() COLGATE-PALMOLIVE COMPANY

Executive Compensation

## Deferred Compensation Plan

Prior to 2021, eligible employees, including the Named Officers, were able to elect annually to defer a portion of their salary and/or cash bonus under the Colgate-Palmolive Company Deferred Compensation Plan (the “Deferred Compensation Plan”). Under this plan, participants could defer up to 75% of their salary and/or 100% of their cash bonus payable in the following calendar year. At the option of the participant, these amounts could be deferred to a specific date, at least five years from when the compensation was otherwise payable, or until retirement. Effective October 28, 2021, the Deferred Compensation Plan was amended to prohibit new participation and freeze future deferral elections. Prior deferral elections were unaffected by the amendment.

Interest on deferred amounts is credited to the participant’s account at the end of each calendar year and compounded annually. Interest accrues at a fixed rate equal to 120% of the Applicable Federal Rate (“AFR”) published by the IRS for the year of deferral. Mid- or long-term AFRs are used based on the length of the deferral period elected. Once established at the time of deferral, the same rate remains in effect throughout the entire deferral period.

At the time of deferral, a participant indicated whether they wished to receive the amount deferred in either a lump sum or up to ten annual installments. If the participant in question is a “specified employee” under Section 409A of the Internal Revenue Code, there may be a six-month delay in the commencement of distributions, if triggered by the participant’s termination or retirement. Changes to deferral elections and early withdrawals from deferred accounts are only permitted in extreme cases, such as unforeseen financial hardship that is demonstrated to the P&O Committee. Of the Named Officers, only Mr. Wallace had previously elected to participate in the Deferred Compensation Plan, and information about earnings on his prior deferrals is included in the Nonqualified Deferred Compensation Table.

## Supplemental Savings & Investment Plan

Employees, including the Named Officers, whose earnings exceed IRS limitations on compensation that may be recognized under the Savings & Investment Plan or whose benefits under the Savings & Investment Plan are otherwise limited due to IRS or Savings & Investment Plan rules, are entitled to receive a supplemental contribution under the Supplemental Savings & Investment Plan. The supplemental contribution is equal to the amount of the Company’s matching contributions and/or retirement contributions that cannot be made under the Savings & Investment Plan due to certain IRS or Savings & Investment Plan rules. Under the Savings & Investment Plan, we match a portion of employee contributions up to 6% of the employee’s eligible earnings and provide retirement contributions based on a percentage of eligible earnings as such earnings are paid to the employee, subject to a maximum amount of eligible earnings under applicable IRS regulations ($330,000 for 2023 and $305,000 for 2022). Eligible earnings include compensation paid in cash but do not include the value of equity compensation. The supplemental contributions are allocated to the Supplemental Savings & Investment Plan.

Interest is credited under the Supplemental Savings & Investment Plan as follows:

- Contributions allocated to the plan through December 31, 2002 realize investment results based on the performance of our Common Stock.
- Contributions allocated to the plan from January 1, 2003 through December 31, 2009 for matching contributions were credited with interest at annual interest rates calculated on the same basis as under the Deferred Compensation Plan described above. Effective October 1, 2010, the interest crediting rate was adjusted so that these contributions are credited with interest at the rate of 6.01%.
- Contributions allocated to the plan in December 2010 for 2010 matching contributions are credited with interest at the rate of 6.01%.
- Contributions allocated to the plan for retirement contributions beginning on September 1, 2010, and for matching contributions beginning on January 1, 2011, are credited with the same interest rate that applies under the Retirement Plan as described on page 50.

Amounts allocated to the Supplemental Savings & Investment Plan are distributed upon the participant’s departure from Colgate. If the participant in question is a “specified employee” under Section 409A of the Internal Revenue Code, there may be a six-month delay in the commencement of distributions, if triggered by the participant’s termination or retirement.

2023 Proxy Statement 51

Executive Compensation

## Nonqualified Deferred Compensation

The following table shows information about the amount of contributions, earnings and balances for each Named Officer under the Supplemental Savings & Investment Plan and, in the case of Mr. Wallace, the Deferred Compensation Plan as of December 31, 2022.

| Name (a) | Aggregate Balance at Beginning of Last Fiscal Year ($) | Executive Contributions in Last Fiscal Year ($) (b) | Registrant Contributions in Last Fiscal Year ($) (1) (c) | Aggregate Earnings in Last Fiscal Year ($) (2) (d) | Aggregate Withdrawals/ Distributions ($) (e) | Aggregate Balance at Last Fiscal Year End ($) (1) (f) |
| --- | --- | --- | --- | --- | --- | --- |
| Noel R. Wallace | 2,232,891 | - | 491,193 | 77,183 | - | 2,801,267 |
| Stanley J. Sutula III | 45,463 | - | 108,687 | 3,176 | - | 157,326 |
| Jennifer M. Daniels | 417,685 | - | 103,247 | 13,607 | - | 534,539 |
| Prabha Parameswaran | 700,278 | - | 158,272 | 22,618 | - | 881,168 |
| Panagiotis Tsourapas | 905,682 | - | 158,272 | 28,485 | - | 1,092,439 |

### NOTES TO THE NONQUALIFIED DEFERRED COMPENSATION TABLE

$^{(1)}$ These amounts represent Company contributions under the Supplemental Savings & Investment Plan for 2022, which were allocated to the Supplemental Savings & Investment Plan. These contributions are also included in compensation reported for each Named Officer in column (i) of the Summary Compensation Table.

$^{(2)}$ These amounts represent the interest credited to each Named Officer during 2022 and the impact of investment results based on the performance of our Common Stock, as applicable, for amounts allocated under the Supplemental Savings & Investment Plan and, in the case of Mr. Wallace, deferred under the Deferred Compensation Plan. For further information regarding the calculation of interest earnings on these amounts, see page 51.

$^{(3)}$ To the extent that an executive was a “Named Officer” for a reported year, these amounts, other than the portion attributable to accrued earnings, were reported in previous proxy statements as compensation in the year of the executive’s deferral (under the Deferred Compensation Plan) or the Company’s contribution (under the Supplemental Savings & Investment Plan), as applicable.

## Executive Severance and Other Termination Benefits

The P&O Committee periodically reviews the appropriateness of the payment and benefit levels provided under the plans and programs described in this section, based on competitive market information and emerging best practices and governance trends. In particular, the Colgate-Palmolive Company Executive Severance Plan (the “Severance Plan”) is subject to approval periodically by the Board. The most recent approval was in September 2018.

### Severance Plan

The Severance Plan is designed to provide participants with reasonable compensation if their employment is terminated following a change in control of the Company. Individual employees are assigned a particular severance level up to the maximum allowed under the plan (24 months) based on grade level and years of service.

Approximately 125 senior executives participate in the Severance Program, including the Named Officers. In addition to the Severance Plan, we have incorporated other arrangements relating to a change in control into our compensation and benefit plans, as described below.

Under the Severance Plan, if at any time within two years of a “change in control” of the Company, we terminate a Named Officer’s employment for any reason other than for cause, or a Named Officer terminates employment due to an adverse change in his or her conditions of employment, such as a diminution in his or her position, authority or responsibilities, or a salary reduction (each a “Qualified Termination”), such Named Officer is entitled to receive a lump sum amount equal to (i) either 18 or 24 months of compensation (defined as base salary as of the termination date plus the average of his or her last three years’ annual bonus awards) plus (ii) the present value of additional retirement program benefits he or she would have received had he or she remained employed until the end of the severance period, or age 65, if earlier. The Named Officers are also entitled to receive the continuation of medical, dental and life insurance benefits during the severance period. No severance payments are required if a Named Officer is terminated for “cause,” which is defined as the felony conviction of the Named Officer for a crime having a detrimental effect on our reputation, business or financial condition, the Named Officer’s willful engagement in any malfeasance, dishonesty, fraud or gross misconduct having a material detrimental effect on our reputation, business or financial condition or the Named Officer’s willful and deliberate failure to materially perform his or her employment duties.

52 ![Colgate-Palmolive Company logo]() COLGATE-PALMOLIVE COMPANY

Executive Compensation

Generally under the plan, a "change in control" is deemed to occur if: (i) any person, entity or group acquires 30% or more of the outstanding shares of our Common Stock or voting securities (other than securities acquired directly from the Company); (ii) a majority of the board of directors as of the effective date of the Severance Plan is replaced (unless any subsequent board member is approved by at least a majority of the original incumbent board, who shall thereafter be considered an incumbent board member); (iii) a reorganization, merger, consolidation or sale or other disposition of all or substantially all of the Company's assets is consummated (other than under specific circumstances); or (iv) a complete liquidation or dissolution of the Company is approved by our stockholders.

If an outside accounting firm were to determine that a payment under the Severance Plan would cause a Named Officer to exceed the statutory limit and subject him or her to the so-called "golden parachute" tax under Section 4999 of the Internal Revenue Code, then the Named Officer would either (i) receive all payments and pay the tax or (ii) receive a reduced amount such that the tax does not apply, whichever approach yields the best after-tax outcome for the Named Officer.

In addition to the foregoing severance benefit, the Severance Plan provides for a payment within 30 days after the change in control, whether or not the Named Officer remains employed, of a pro-rated bonus for the year in which the change in control occurs. The pro-rated bonus paid may be used to offset any other bonus awarded for such year.

## Other Change-in-Control Arrangements

Other arrangements relating to a change in control in our compensation and benefit plans are as follows.

- **Equity Awards.** We generally have a "double trigger" vesting policy upon a change in control, meaning that unvested equity awards only vest upon a change in control if (i) there is also a Qualified Termination or (ii) the acquirer fails to assume or replace the outstanding awards. The following provides further detail about the treatment of various equity awards upon a change in control (assuming that outstanding awards are assumed or replaced by the acquirer):
  - Stock options held by employees that are not yet exercisable become exercisable upon a change in control and a Qualified Termination; and
  - Unvested restricted stock units are considered earned in full and non-forfeitable (i) in the case of performance-based awards for which the performance goals have been satisfied (i.e., restricted stock units granted under our legacy Long-Term Global Growth Program), upon a change in control and (ii) in the case of all other awards (including PBRSUs granted under our Growth Performance Plan), upon a change in control and a Qualified Termination. Upon a change in control and a Qualified Termination, performance-based awards for which the performance goals have not yet been satisfied are deemed earned at the greater of the target level or the level of performance achieved to that point.
- **Deferred Compensation Balances.** Under the Severance Plan, participating employees are also entitled to receive within 30 days following a change in control all amounts previously deferred by the employee under the Deferred Compensation Plan. They are also entitled to receive amounts held in the employee's Supplemental Savings & Investment Plan account as soon as practicable following a change in control. For more information regarding the Deferred Compensation Plan and the Supplemental Savings & Investment Plan, see page 51.
- **Letter of Credit for Unfunded Retirement Plan.** With respect to the Supplemental Retirement Plan, which is an unfunded plan, we have arranged for a letter of credit that requires the issuing bank to fund the accrued benefits payable under this plan if we refuse to pay these benefits after a change in control. Funding would be made by payments to a trust, the assets of which would be subject to the claims of our creditors if we were to become insolvent.

## Termination for Company Convenience

If we terminate the employment of a Named Officer at the Company's convenience, we will pay in a lump sum an amount equal to between 12 and 24 months of the Named Officer's base salary and continue to pay certain medical and dental insurance benefits for either 12 or 18 months. Mr. Sutula and Ms. Daniels are also entitled to receive the continuation of life insurance benefits for 12 months following termination, while the other Named Officers, who each have at least 10 years of service with Colgate and are at least 55 years old, are eligible to receive retiree life insurance benefits. We are not required to make these payments if we terminate a Named Officer's employment for "cause" (as defined above) or if the Named Officer voluntarily terminates his or her employment.

## Deferred Compensation and Retirement Benefits

For information about the pension benefits payable to the Named Officers upon their retirement and deferred compensation balances, see pages 49 to 52. In addition to the post-retirement welfare benefits available to U.S. employees generally, approximately 600 employees, including the Named Officers, who have at least 10 years of service at retirement, qualify for a post-retirement life insurance benefit. Named Officers are eligible to receive a retiree life insurance benefit up to a maximum of $750,000 in lieu of our regular life insurance benefit for retirees.

2023 Proxy Statement 53

Executive Compensation

## Equity Awards

The treatment, in general, of previously granted equity awards in the case of the termination of employment under the following circumstances is as follows:

| Nature of Termination | Stock Options | Unearned PBRSUs | Unvested Restricted Stock Units |
| --- | --- | --- | --- |
| Change in Control (1) | Double-trigger vesting | Double-trigger vesting | Double-trigger vesting (2) |
| Termination for Cause | Forfeited | Forfeited | Forfeited |
| Termination for Company Convenience | Vested stock options (including those that vest during the severance period) are exercisable for shorter of remainder of option term or three months; remaining unvested stock options are forfeited (3)(4) | Forfeited | Normal vesting continues through the severance period; remaining unvested are forfeited (3)(4) |
| Retirement | Fully vest; exercisable for shorter of remainder of option term or three years (4) | Pro rata vesting at the end of the performance period with payout subject to actual performance (3) | Normal vesting continues (4) |
| Death or Disability | Fully vest; exercisable for shorter of remainder of option term or three years | Pro rata vesting at the end of the performance period with payout subject to actual performance (3) | Normal vesting continues |
| Resignation | Vested stock options are exercisable for shorter of remainder of option term or three months; unvested stock options are forfeited | Forfeited | Forfeited |

$^{(1)}$ See 'Other Change-In-Control Arrangements-Equity Awards' above for a full description of the treatment of equity awards following a change in control of the Company.

$^{(2)}$ Except for performance-based awards granted under our legacy Long-Term Global Growth Program for which the performance goals have been satisfied.

$^{(3)}$ If the employee becomes retirement-eligible during the severance period, stock options and restricted stock units instead receive retirement treatment.

$^{(4)}$ Except for special retention awards that are subject to continued employment.

$^{(5)}$ As long as the recipient was employed for at least the first six months of the performance period.

The treatments described above assume that employees comply with the terms and conditions of the applicable equity award agreements, including non-competition, non-solicitation and non-interference restrictions, in each case following termination of employment. Failure to comply with any of these requirements may result in forfeiture and/or cancellation of those equity awards.

## Potential Payments Upon Termination or Change in Control

The following table sets forth the estimated incremental payments and benefits that would be payable to each Named Officer upon termination of their employment or a change in control of the Company, assuming that the triggering event occurred at year-end 2022. These amounts would be incremental to the compensation and benefit entitlements described previously in this Proxy Statement that are not contingent upon a termination or change in control.

| Name | Change In Control |  | Involuntary Termination |  | Resignation ($) | Death ($) (4) | Disability ($) (4) | Retirement ($) (5) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Without Qualified Termination ($) (1) | With Qualified Termination ($) (1) | With Cause ($) | Without Cause ($) (1) |  |  |  |  |
| Noel R. Wallace | - | 5,057,428 | - | 2,872,819 | - | - | - | - |
| Stanley J. Sutula III | - | 3,050,214 | - | 953,334 | - | - | - | - |
| Jennifer M. Daniels | - | 2,722,348 | - | 883,856 | - | - | - | - |
| Prabha Parameswaran | - | 2,504,589 | - | 1,364,188 | - | - | - | - |
| Panagiotis Tsourapas | - | 3,816,355 | - | 1,364,188 | - | - | - | - |

### NOTES TO THE POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE IN CONTROL TABLE

$^{(1)}$ **Change in Control without Qualified Termination.** As shown in this column, if there is a change in control but there is no Qualified Termination of the Named Officer's employment, the Named Officer would not be entitled to receive any incremental payment or benefit. However, the vesting or distribution of certain existing compensation reported previously in this Proxy Statement would be accelerated as follows:

- **Equity Awards.** The vesting of certain previously earned but unvested performance-based restricted stock units would be accelerated as described under 'Other Change-in-Control Arrangements-Equity Awards' above. All such awards were reported as compensation in the proxy statement for the year of grant, to the extent the executive was a 'Named Officer' for that year. The estimated value as of year-end 2022 of the previously granted awards that would be accelerated for the applicable Named Officers is as follows: Mr. Wallace-$2,210,453; Ms. Daniels-$540,657; Ms. Parameswaran-$538,057; and Mr. Tsourapas-$540,657. For all of the applicable Named Officers, these amounts reflect the value of previously granted and earned performance-based restricted stock units under our legacy Long-Term Global Growth Program that they were already entitled to receive in accordance with their original vesting schedule because they were eligible for retirement but would be accelerated upon a change in control. The estimated value of restricted stock units that would be accelerated was calculated based on the closing

54 ![Colgate-Palmolive Company logo]() COLGATE-PALMOLIVE COMPANY

Executive Compensation

price of our Common Stock on December 31, 2022. Assuming that all other outstanding equity awards were assumed or replaced upon the change in control, no other outstanding equity awards would be accelerated.

- • **Cash Bonus.** If the change in control occurs at year-end, as assumed in the table above, the Named Officers would be entitled to receive their annual cash bonus for the year in which the change in control occurs (reported as of year-end 2022 in column (g) of the Summary Compensation Table).
- • **Deferred Compensation Balances.** The Named Officers would be entitled to receive any amounts previously deferred by or allocated to them under the Deferred Compensation Plan or Supplemental Savings & Investment Plan (reported as of year-end 2022 in column (f) of the Nonqualified Deferred Compensation Table).

(2) **Change in Control with Qualified Termination.** This column consists of the following benefits under the Severance Plan described beginning on page 52: (i) severance payments; (ii) the value of benefits under our retirement programs during the severance period; and (iii) the value of the continuation of medical and dental (and, for Mr. Sutula and Ms. Daniels, life) insurance benefits during the severance period. The value of retirement benefits was calculated based on the difference between the present value of additional retirement program benefits that the Named Officer would have received had he or she remained employed until the end of the severance period, or age 65, if earlier, and the present value of retirement benefits payable at the change-in-control date without assuming future service. The additional medical, dental and life insurance benefits were valued based on the aggregate premiums paid by us for the applicable severance period.

In addition to the amounts shown in this column, the vesting or distribution of certain existing compensation reported previously in this Proxy Statement would be accelerated as follows:

- • **Equity Awards.** The vesting of previously earned but unvested restricted stock units and unearned PBRSUs would be accelerated as described under "Other Change-in-Control Arrangements-Equity Awards" above. All such awards were reported as compensation in the proxy statement for the year of grant, to the extent the executive was a "Named Officer" for that year. The estimated value as of year-end 2022 of the previously granted awards that would be accelerated for the applicable Named Officers is as follows: Mr. Wallace-$11,989,317; Mr. Sutula-$3,982,677; Ms. Daniels-$2,438,314; Ms. Parameswaran-$2,435,714; and Mr. Tsourapas-$2,438,314. The amounts shown in the preceding sentence include the following values of previously granted and earned restricted stock units under our legacy Long-Term Global Growth Program that they were already entitled to receive in accordance with their original vesting schedule because they were eligible for retirement but would be accelerated upon a Qualified Termination: Mr. Wallace-$2,210,453; Ms. Daniels-$540,657; Ms. Parameswaran-$538,057; and Mr. Tsourapas-$540,657. For the assumptions used to calculate the value of the restricted stock units, see note 1 above. The estimated value of PBRSUs that would be considered earned in full and accelerated was calculated based on (i) the greater of target level and the level of performance achieved through December 31, 2022 and (ii) the closing price of our Common Stock on December 31, 2022.
- • **Cash Bonus and PBRSU Award.** If the triggering event occurs at year-end, as assumed in the table above, the Named Officers would be entitled to receive their annual cash bonus for the year in which the triggering event occurs (reported as of year-end 2022 in column (g) of the Summary Compensation Table) and their earned PBRSUs for the Growth Performance Plan three-year performance cycle ending such year, if any (reported in note 5 to the Outstanding Equity Awards at Fiscal Year-End Table).
- • **Retirement Accruals and Deferred Compensation Balances.** The Named Officers would be entitled to receive their accrued retirement benefits (reported in the Pension Benefits Table) and any amounts previously deferred by or allocated to them under the Deferred Compensation Plan or Supplemental Savings & Investment Plan (reported as of year-end 2022 in column (f) of the Nonqualified Deferred Compensation Table). The Named Officers would also be entitled to receive the balance in their accounts under the Savings & Investment Plan, including the Company contributions to the accounts, as further described in note 5 below.

(3) **Involuntary Termination without Cause.** This column shows the severance payment and the value of the continuation of medical and dental (and, for Mr. Sutula and Ms. Daniels, life) insurance benefits during the severance period. For the assumptions used to calculate the additional insurance benefits, see note 2 above.

In addition to the amounts shown in this column, the vesting or distribution of certain existing compensation reported previously in this Proxy Statement would continue or be accelerated as follows:

- • **Equity Awards.** Certain earned but unvested restricted stock units would be allowed to vest in accordance with their original vesting schedule and certain unvested stock options would become exercisable for a period of three months or until the end of the original term, whichever is shorter, in each case only if they would have otherwise vested before the end of the severance period. All such awards were reported as compensation in the proxy statement for the year of grant, to the extent the executive was a "Named Officer" for that year. For Mr. Sutula the estimated value as of year-end 2022 of previously granted restricted stock units that would continue to vest is $1,686,027. Mr. Sutula's stock option award received in November 2020 in connection with his hiring would also be subject to acceleration, but no amount is included here because the award was out of the money as of year-end 2022. No other amounts are shown for any of the Named Officers because, as employees eligible for retirement, they were already entitled to have their previously granted and earned restricted stock units continue to vest and stock options accelerate (other than special retention awards that are subject to continued employment). Since the Named Officers are retirement-eligible, their PBRSUs under the Growth Performance Plan would be treated as described in note 5 below.
- • **Cash Bonus.** If the triggering event occurs at year-end, as assumed in the table above, each Named Officer would also be entitled to receive their annual cash bonus for the year in which the triggering event occurs (reported in column (g) of the Summary Compensation Table).
- • **Deferred Compensation Balances.** The Named Officers would be entitled to receive any amounts previously deferred by or allocated to them under the Deferred Compensation Plan and Supplemental Savings & Investment Plan (reported as of year-end 2022 in column (f) of the Nonqualified Deferred Compensation Table).

(4) **Death and Disability.** As shown in these columns, the Named Officers would not be entitled to receive any incremental payment or benefit upon death or disability. However, the vesting or distribution of certain existing compensation reported previously in this Proxy Statement would continue or be accelerated as follows:

- • **Equity Awards.** Earned but unvested restricted stock units would continue to vest in accordance with their original vesting schedule and all outstanding stock options would be exercisable for a period of three years or until the end of the original term, whichever is shorter. All such awards were reported as compensation in the proxy statement for the year of grant, to the extent the executive was a "Named Officer" for that year. For Mr. Sutula the estimated value as of year-end 2022 of previously granted restricted stock units that would continue to vest is $1,686,027. Mr. Sutula's stock option award received in November 2020 in connection with his hiring would also be subject to acceleration, but no amount is included here because the award was out of the money as of year-end 2022. No other amounts are shown for any of the Named Officers because, as employees eligible for retirement, they were already entitled to have their previously granted and earned restricted stock units continue to vest and stock options accelerate (other than special retention awards that are subject to continued employment). If the triggering event occurs at year-end, as assumed in the table above, each Named Officer's earned PBRSUs for the Growth Performance Plan three-year performance cycle ending such year, if any (reported in note 5 to the Outstanding Equity Awards at Fiscal Year-End Table) would vest in accordance with their original vesting schedule. The Named Officers would also be entitled to vest at the conclusion of each in-progress Growth Performance Plan three-year performance cycle in a prorated amount of the PBRSUs earned reflecting the proportion of the performance period for which they were employed. No amounts are shown for those PBRSUs because they remain subject to performance requirements even after the triggering event.

2023 Proxy Statement 55

# Executive Compensation

- • **Cash Bonus.** If the triggering event occurs at year-end, as assumed in the table above, each Named Officer would also be entitled to receive their annual cash bonus for the year in which the triggering event occurs (reported in column (g) of the Summary Compensation Table).
- (i) **Retirement.** As shown in this column, the Named Officers would not be entitled to receive any incremental payment or benefit upon retirement. However, the vesting or distribution of certain existing compensation reported previously in this Proxy Statement would continue or be accelerated as follows:
  - • **Equity Awards.** Earned but unvested restricted stock units, except those subject to continued employment, would continue to vest in accordance with their original vesting schedule and all outstanding stock options, except those subject to continued employment, would be exercisable for a period of three years or until the end of the original term, whichever is shorter. All such awards were reported as compensation in the proxy statement for the year of grant, to the extent the executive was a "Named Officer" for that year. If the triggering event occurs at year-end, as assumed in the table above, each Named Officer's earned PBRSUs for the Growth Performance Plan three-year performance cycle ending such year, if any (reported in note 5 to the Outstanding Equity Awards at Fiscal Year-End Table) would vest in accordance with their original vesting schedule. The Named Officers would also be entitled to vest at the conclusion of each in-progress Growth Performance Plan three-year performance cycle in a prorated amount of the PBRSUs earned reflecting the proportion of the performance period for which they were employed. No amounts are shown for those PBRSUs because they remain subject to performance requirements even after the triggering event.
  - • **Retirement Accruals.** Each Named Officer would be entitled to receive their retirement benefits under the Retirement Plan and Supplemental Retirement Plan, if any, as described on pages 49 to 50. Each Named Officer would also be entitled to receive the balance in their account under the Savings & Investment Plan, including the Company contributions made pursuant to the Company match, profit-sharing and retirement program under the Savings & Investment Plan, as well as investment gains and losses thereon. As of year-end 2022, the balance, which remains subject to future investment gains and losses, in each Named Officer's Savings & Investment Plan account from these sources was as follows: Mr. Wallace-$2,174,386; Mr. Sutula-$44,777; Ms. Daniels-$260,010; Ms. Parameswaran-$981,720; and Mr. Tsourapas-$606,782. The annual contributions by the Company to these accounts are reported in note 6 to the Summary Compensation Table.
  - • **Cash Bonus.** If the triggering event occurs at year-end, as assumed in the table above, each Named Officer would also be entitled to receive their annual cash bonus for the year in which the triggering event occurs (reported in column (g) of the Summary Compensation Table).
  - • **Deferred Compensation Balances.** The Named Officers would be entitled to receive any amounts previously deferred by or allocated to them under the Deferred Compensation Plan and Supplemental Savings & Investment Plan (reported as of year-end 2022 in column (f) of the Nonqualified Deferred Compensation Table) in accordance with the distribution schedule they elected.

## CEO Pay Ratio

Our products are marketed in over 200 countries and territories throughout the world with approximately two-thirds of our net sales generated outside the United States and approximately 45% of net sales coming from emerging markets. Consistent with our global presence, we have a dispersed workforce, with over 85% of our employees based outside the United States in over 100 countries. To attract and retain talent, we seek to pay competitively in each jurisdiction consistent with market practice, resulting in compensation levels that vary from country to country. Our workforce also covers a broad range of functions, from manufacturing employees to management personnel, and includes both employees who are compensated on a salaried basis and those who are compensated on an hourly basis.

For 2022, the median of the annual total compensation of all employees (other than our CEO, Noel Wallace) was $39,370 and the annual total compensation of the CEO, as reported in the Summary Compensation Table on page 44, was $14,462,406. Based on this information, for 2022 the CEO's annual total compensation was 367 times that of the median of the annual total compensation of all employees. This amount is a reasonable estimate calculated in a manner consistent with Item 402(u) of Regulation S-K.

The above-referenced pay ratio may not be comparable to pay ratios disclosed by other companies, including the companies in the Comparison Group (as defined in the CD&A). Pay ratios at different companies may vary due to differences in workforce composition, including geographic breadth, types of work performed and the relative percentages of salaried versus hourly compensated workers.

## Methodology for Determining the Median Employee and Annual Total Compensation

For purposes of calculating the above-referenced 2022 pay ratio, we used the same median employee that was identified in 2020, as we determined that there have been no changes to the employee population or employee compensation arrangements in 2022 (including the compensation arrangements of the previously identified median employee) that we believe would result in a significant change to our pay ratio.

We used the following methodology, material assumptions, adjustments and estimates to identify the median of the annual total compensation of all employees. As described above, all determinations were made in 2020 except the annual total compensation of the median employee, which was calculated for 2022 based on the median employee identified in 2020.

### Determination of Employee Population in 2020

We determined that, as of October 1, 2020, we had approximately 35,300 employees (including approximately 1,500 temporary employees) working for Colgate-Palmolive Company or its consolidated subsidiaries, of which approximately 5,100 were based in the United States and the remaining approximately 30,200 were based outside the United States.

As permitted by SEC rules, we chose to exclude from this population approximately 900 employees in 55 countries, representing approximately 2.5% of our total employees. All employees from each of these countries, which are identified in

56 COLGATE-PALMOLIVE COMPANY

Executive Compensation

Annex B to this Proxy Statement along with the number of employees based in each such country, were excluded. As a result, our employee population used for determining the median employee was approximately 34,400, consisting of approximately 5,100 employees based in the United States and approximately 29,300 employees based outside the United States.

## Statistical Sampling

We elected to use statistical sampling to identify the median employee and conducted a simple random sample of 2,000 employees worldwide, which was determined to be the appropriate sample size for the size and complexity of our employee population based on advice from an external consultant.

## Compensation Measure

We selected base salary or comparable wages for the 12-month period ended September 30, 2020 as the measure of compensation that could be consistently applied across the sample population. In making this determination, the compensation of all permanent employees included in the sample who were hired in 2020 but were not employed for the entire measurement period was annualized, but no cost-of-living adjustments were made. Using this methodology, the median employee was identified as a full-time, salaried employee located in China.

## Annual Total Compensation of Median Employee

The elements of the median employee's annual total compensation for 2022 were calculated in accordance with the requirements of Item 402(c)(2)(x) of Regulation S-K, resulting in annual total compensation of $39,370. For purposes of this disclosure, Chinese renminbi were converted to U.S. dollars using a 12-month average exchange rate from January 1, 2022 through December 31, 2022.

## Pay Versus Performance

As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item 402(v) of Regulation S-K, we are providing the following information about the relationship between the 'total compensation' and 'compensation actually paid' to our Named Officers and certain financial performance of the Company. This disclosure has been prepared in accordance with Item 402(v) of Regulation S-K and does not necessarily reflect value actually realized by the Named Officers. The P&O Committee evaluates compensation decisions in light of Company or individual performance and does not use 'compensation actually paid' as a basis for making compensation decisions. For information concerning our compensation philosophy and how we align executive compensation with our performance, see the CD&A.

| Year (a) | Summary Compensation Table Total for CEO ($) (1) (b) | Compensation Actually Paid to CEO ($) (2) (c) | Average Summary Compensation Table Total for Non-CEO Named Officers ($) (3) (d) | Average Compensation Actually Paid to Non-CEO Named Officers ($) (4) (e) | Value of Initial Fixed $100 Investment Based On: |  | Net Income ($ in millions) (h) | Company-Selected Measure: Organic Sales Growth (%) (5) (i) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  | Total Shareholder Return ($) (f) | Peer Group Total Shareholder Return ($) (5) (g) |  |  |
| 2022 | 14,462,406 | 11,047,446 | 4,061,090 | 3,453,780 | 122.8 | 126.7 | 1,967 | 7.0 |
| 2021 | 15,458,151 | 18,008,793 | 4,085,777 | 4,559,072 | 129.8 | 125.3 | 2,338 | 4.4 |
| 2020 | 14,364,118 | 22,765,213 | 4,024,886 | 5,573,106 | 127.2 | 110.7 | 2,860 | 7.2 |

### NOTES TO THE PAY VERSUS PERFORMANCE TABLE

$^{(1)}$ The dollar amounts reported in column (b) are the amounts of total compensation reported for Noel R. Wallace (who was our Chairman, President and Chief Executive Officer for all years presented) in the 'Total' column of the Summary Compensation Table.

$^{(2)}$ The dollar amounts reported in column (c) represent the amount of compensation actually paid to Mr. Wallace, as computed in accordance with Item 402(v) of Regulation S-K ('CAP'). The dollar amounts do not reflect the actual amount of compensation earned by or paid to Mr. Wallace during the applicable year. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to Mr. Wallace's total compensation for each year to determine the CAP:

| Year | Reported Summary Compensation Table Total for CEO ($) | (Subtract): Reported Value of Equity Awards ($) (a) | Add: Equity Award Adjustments ($) (b) | (Subtract): Reported Change in the Actuarial Present Value of Pension Benefits ($) (c) | Add: Pension Benefit Adjustments ($) (d) | CAP for CEO ($) |
| --- | --- | --- | --- | --- | --- | --- |
| 2022 | 14,462,406 | (9,114,661) | 5,725,594 | (25,893) | - | 11,047,446 |
| 2021 | 15,458,151 | (10,903,528) | 13,477,139 | (22,969) | - | 18,008,793 |
| 2020 | 14,364,118 | (8,641,292) | 17,070,257 | (27,870) | - | 22,765,213 |

$^{(a)}$ The reported value of equity awards represents the grant date fair value of equity awards as reported in the 'Stock Awards' and 'Option Awards' columns in the Summary Compensation Table for each applicable year.

2023 Proxy Statement 57

## Executive Compensation

$^{(b)}$ The amounts added (or subtracted, as applicable) in calculating the equity award adjustments for the CEO for each applicable year are as follows:

| Year | Year End Fair Value of Equity Awards Granted During the Year ($) | Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years ($) | Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year ($) | Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year ($) | Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year ($) | Value of Dividends or other Earnings Paid on Equity Awards not Otherwise Reflected in Fair Value or Total Compensation ($) | Total Equity Award Adjustments ($) |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 2022 | 9,656,022 | (1,253,543) | - | (2,725,632) | - | 48,747 | 5,725,594 |
| 2021 | 13,417,733 | 296,498 | 105,132 | (382,562) | - | 40,338 | 13,477,139 |
| 2020 | 11,443,463 | 4,540,148 | - | 1,059,193 | - | 27,453 | 17,070,257 |

$^{(c)}$ The amounts in this column represent the change in pension value amounts reported in the 'Change in Pension and Nonqualified Deferred Compensation' column of the Summary Compensation Table for each applicable year.

$^{(d)}$ No values are shown in this column for pension benefit adjustments because (i) there are no service costs for services rendered during the applicable years because the Retirement Plan and Supplemental Retirement Plan were both frozen prior to 2020 and (ii) there are no prior service costs because no additional benefits were granted in a plan amendment during the applicable years.

$^{(3)}$ The dollar amounts reported in column (d) represent the average of the amounts reported for our Named Officers as a group (excluding Mr. Wallace) in the 'Total' column of the Summary Compensation Table for each applicable year. The Named Officers included for purposes of calculating the average amounts in each applicable year are as follows: (i) for each of 2022 and 2021, Stanley J. Sutula III, Jennifer M. Daniels, Prabha Parameswaran and Panagiotis Tsourapas; and (ii) for 2020, Henning I. Jakobsen, Stanley J. Sutula III, Jennifer M. Daniels, Prabha Parameswaran and Panagiotis Tsourapas.

$^{(4)}$ The dollar amounts reported in column (e) represent the average amount of CAP for the Named Officers as a group (excluding Mr. Wallace), as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual average amount of compensation earned by or paid to the Named Officers as a group (excluding Mr. Wallace) during the applicable year. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to the average total compensation of the Named Officers as a group (excluding Mr. Wallace) for each year to determine the CAP, using the same methodology described above in note 2:

| Year | Average Reported Summary Compensation Table Total for non-CEO Named Officers ($) | (Subtract): Average Reported Value of Equity Awards ($) | Add: Average Equity Award Adjustments ($) (a) | (Subtract): Average Reported Change in the Actuarial Present Value of Pension Benefits ($) | Add: Average Pension Benefit Adjustments ($) | Average CAP for non-CEO Named Officers ($) |
| --- | --- | --- | --- | --- | --- | --- |
| 2022 | 4,061,090 | (1,857,696) | 1,252,854 | (2,468) | - | 3,453,780 |
| 2021 | 4,085,777 | (2,152,095) | 2,627,579 | (2,189) | - | 4,559,072 |
| 2020 | 4,024,886 | (2,057,487) | 3,607,832 | (2,125) | - | 5,573,106 |

$^{(a)}$ The amounts added (or subtracted, as applicable) in calculating the total average equity award adjustments for each applicable year are as follows:

| Year | Year End Fair Value of Equity Awards Granted During the Year ($) | Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years ($) | Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year ($) | Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year ($) | Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year ($) | Value of Dividends or other Earnings Paid on Equity Awards not Otherwise Reflected in Fair Value or Total Compensation ($) | Total Equity Award Adjustments |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 2022 | 1,968,034 | (285,769) | - | (448,213) | - | 18,802 | 1,252,854 |
| 2021 | 2,651,509 | 49,886 | 19,907 | (114,020) | - | 20,297 | 2,627,579 |
| 2020 | 2,538,288 | 785,601 | - | 269,390 | - | 14,553 | 3,607,832 |

$^{(5)}$ Represents the weighted peer group total shareholder return, weighted according to the respective companies' stock market capitalization at the beginning of each period for which a return is indicated. The peer company index used for this purpose, which is the peer company index used by us for purposes of Item 201(e) of Regulation S-K, is comprised of the following companies: Campbell Soup Company, The Clorox Company, The Coca-Cola Company, ConAgra Brands, Inc., The Estée Lauder Companies, Inc., General Mills, Inc., Johnson & Johnson, Kellogg Company, Kimberly-Clark Corporation, The Kraft Heinz Company, Mondélez International, Inc., PepsiCo, Inc., The Procter & Gamble Company, Reckitt Benckiser Group plc and Unilever PLC.

$^{(6)}$ Organic sales growth is a non-GAAP financial measure defined as net sales excluding foreign exchange, acquisitions and divestments. Please see Annex A for a reconciliation of organic sales growth to net sales growth calculated in accordance with GAAP.

58 ![Colgate-Palmolive Company logo]() COLGATE-PALMOLIVE COMPANY

Executive Compensation

# Tabular List of Financial Performance Measures Used to Link CAP For the Most Recently Completed Fiscal Year To Company Performance

The following table lists the financial performance metrics that, in our assessment, represent the most important financial performance measures we use to link CAP for our Named Officers for 2022 to Company performance.

- Adjusted Earnings Per Share
- Free Cash Flow Productivity
- Organic Sales Growth (Company-Selected Measure)
- Relative Adjusted Net Income Growth
- Relative Organic Sales Growth
- Relative Total Shareholder Return

## Analysis of the Information Presented in the Pay versus Performance Table

As described in more detail in the CD&A beginning on page 29, the key principles underlying our compensation philosophy are aligning pay and performance, driving strong business results and our strategic plan, focusing on long-term shareholder return, motivating and retaining critical talent and reflecting external market and competitive practices.

In accordance with Item 402(v) of Regulation S-K, we are providing the following graphs showing the relationships over the past three years of CAP as compared to our total shareholder return, net income and organic sales growth, as well as the relationship between total shareholder return and peer group total shareholder return. Since a significant portion of the Named Officers' compensation is comprised of equity awards (71% of Mr. Wallace's target direct compensation and 54% of the average target direct compensation of our other Named Officers for 2022, as described in more detail in the CD&A), the CAP of our CEO and other Named Officers is higher when our stock price is higher, and lower when our stock price is lower, demonstrating the clear alignment of interests of our CEO and other Named Officers and our stockholders.

![img-0.jpeg](img-0.jpeg)

![img-1.jpeg](img-1.jpeg)

![img-2.jpeg](img-2.jpeg)

2023 Proxy Statement

59

# Stock Ownership

## Stock Ownership of Directors and Executive Officers

Our directors and executive officers own significant amounts of Colgate stock. Under our stock ownership guidelines, non-employee directors are required to own stock equal in value to at least five times their annual share grant, and executive officers are required to own stock equal in value to between two and eight times their salary, depending on their position.

The following table shows the beneficial ownership of Common Stock of each director, each of the Named Officers and the directors and executive officers (including the Named Officers) as a group. “Beneficial ownership” as used here means more than “ownership” as that term is commonly used. For example, a person “beneficially” owns Common Stock not only if they hold it directly, but also if they have (or share) the power to vote or sell the stock indirectly (for example, through a relationship, a position as a director or trustee, or a contract or understanding). Beneficial ownership also includes shares a person has the right to acquire within 60 days, for example, through the exercise of a stock option.

| Name of Beneficial Owner | Common Stock |  |  |  |
| --- | --- | --- | --- | --- |
|  | Amount and Nature of Beneficial Ownership (1)(3) |  |  |  |
|  | Directly Owned | Exercisable Options (5) | Common Stock Units | Held by Savings & Investment Plan Trustee (4) |
| Noel R. Wallace (5) | 270,719 | 912,796 | - | 50,677 |
| Stanley J. Sutula III (5) | 14,484 | 97,031 | - | 78 |
| Jennifer M. Daniels (6) | 45,822 | 252,655 | - | 1,070 |
| Prabha Parameswaran (6)(7) | 26,252 | 259,568 | - | 4,685 |
| Panagiotis Tsourapas (6)(8) | 61,686 | 272,490 | - | 4,279 |
| John P. Bilbrey (9) | 5,902 | 23,804 | 24,782 (10) | - |
| John T. Cahill (11) | 30,213 | 18,101 | 24,384 (10) | - |
| Steve Cahillane (12)(13) | - | - | - | - |
| Lisa M. Edwards (13) | 6,876 | 11,077 | 120 (10) | - |
| C. Martin Harris | 14,650 | 14,532 | 2,360 (10) | - |
| Martina Hund-Mejean (13) | 1,622 | 6,909 | 4,622 (10) | - |
| Kimberly A. Nelson (13)(14) | 3,214 | 3,046 | 2,360 (10) | - |
| Lorrie M. Norrington | 889 | 18,101 | 26,780 (10) | - |
| Michael B. Polk | 23,583 | 18,101 | - | - |
| Stephen I. Sadove (15) | 22,220 | 23,804 | 11,866 (10) | - |
| All directors and executive officers as a group (18 persons) | 541,615 | 2,151,742 | 97,274 | 86,231 |

### NOTES TO THE STOCK OWNERSHIP OF DIRECTORS AND EXECUTIVE OFFICERS TABLE

$^{(1)}$ Information about Common Stock holdings is as of March 13, 2023, the record date for the Annual Meeting. Unless stated otherwise in these notes, each person named in the table owns his or her shares directly and has sole voting and investment power over such shares.

$^{(2)}$ Each person named in the table beneficially owns less than 0.25% of the outstanding Common Stock. The directors and executive officers as a group beneficially own 0.35% of the outstanding Common Stock.

$^{(3)}$ This column consists of options that are exercisable on or before May 12, 2023, which is 60 days after March 13, 2023. As of March 13, 2023, a total of 22,662,530 options were outstanding under the 2019 Plan and the predecessors to the 2019 Plan and 22,088,403 shares were available for future grants under the 2019 Plan.

$^{(4)}$ Consists of Common Stock credited to or otherwise beneficially owned by executive officers under our Savings & Investment Plan. Under this plan, we issue Common Stock to a trustee acting on behalf of the plan. Employees who participate in the Savings & Investment Plan, including the Named Officers, have voting power over the shares allocated to their accounts under the plan, subject to the right of the plan trustee to vote such shares if a participant fails to do so. Participants have no investment power over such shares until they are distributed or diversified at the participant’s election in accordance with the terms of the plan.

$^{(5)}$ Mr. Wallace’s holdings include 335 shares of Common Stock owned by the Noel R. Wallace 2012 GST Trust and 52,000 shares of Common Stock owned by the N.R.W. Irrevocable Trust.

$^{(6)}$ Executive officers have five years from the date of their initial hiring or promotion into an eligible position to achieve required ownership levels.

$^{(7)}$ Ms. Parameswaran’s holdings include 20,698 shares of Common Stock owned by the Prabha Parameswaran Mitra Revocable Trust.

$^{(8)}$ Mr. Tsourapas’s holdings include 53,059 shares of Common Stock owned by the Panagiotis Tsourapas Revocable Living Trust and 3,226 shares of Common Stock owned by his spouse, 822 of which are held through our Savings & Investment Plan.

$^{(9)}$ Mr. Bilbrey’s holdings include 4,719 shares of Common Stock owned by the John P. Bilbrey Revocable Trust.

$^{(10)}$ Consists of Common Stock units credited to one or more of the following accounts: (i) a deferred account for amounts granted under the 2019 Plan and any predecessor plans or (ii) a deferred account under the Restated and Amended Deferred Compensation Plan for Non-Employee Directors. In each case, the holder of Common Stock units has no voting or investment power over such units.

60

![Colgate-Palmolive Company logo]() COLGATE-PALMOLIVE COMPANY

Stock Ownership

(11) Mr. Cahill's holdings include 30,213 shares of Common Stock owned by the John Tobin Cahill Revocable Trust.
(12) In accordance with the 2019 Plan, Mr. Cahillane, who was first elected to the Board effective February 1, 2023, will receive grants in 2023 of shares of Common Stock equal in value to $165,000 and options to purchase shares of Common Stock equal in value to $41,250 on May 15, 2023.
(13) Mr. Cahillane was first elected to the Board effective February 1, 2023, Ms. Edwards was first elected to the Board effective March 1, 2019, Ms. Hund-Mejean was first elected to the Board effective March 11, 2020 and Ms. Nelson was first elected to the Board effective March 11, 2021. Directors have five years from the date of their initial election to meet our stock ownership guidelines.
(14) Ms. Nelson's holdings include 1,799 shares of Common Stock owned by the Kimberly A. Nelson 2011 Revocable Trust, 215 shares of Common Stock owned by her spouse and 575 shares of Common Stock owned by the Stafford B Nelson 2015 Irrevocable Family Trust.
(15) Mr. Sadove's holdings include 9,220 shares of Common Stock owned by the Stephen I. Sadove Revocable Trust and 13,000 shares of Common Stock owned by the Sadove Family Delaware Dynasty Trust.

## Stock Ownership of Certain Beneficial Owners

The following table sets forth information regarding persons or groups known to us to be beneficial owners of more than 5% of our outstanding Common Stock as of December 31, 2022.

| Name and Address of Beneficial Owner | Number of Shares Beneficially Owned as of December 31, 2022 | Percent of Common Stock Outstanding as of December 31, 2022 |
| --- | --- | --- |
| The Vanguard Group 100 Vanguard Blvd. Malvern, PA 19355 | 80,375,011 (1) | 9.6% |
| BlackRock, Inc. 55 East 52nd Street New York, NY 10055 | 68,041,416 (2) | 8.1% |
| State Street Corporation (3) State Street Financial Center One Lincoln Street Boston, MA 02111 | 49,899,351 (4) | 6.0% |

# NOTES TO THE STOCK OWNERSHIP OF CERTAIN BENEFICIAL OWNERS TABLE

(1) On a Schedule 13G/A filed with the SEC by The Vanguard Group ("Vanguard") on February 9, 2023, Vanguard reported that, as of December 31, 2022, it beneficially owned 80,375,011 shares of Common Stock with shared voting power over 1,201,151 shares of Common Stock, sole dispositive power over 76,804,816 shares of Common Stock and shared dispositive power over 3,570,195 shares of Common Stock.
(2) On a Schedule 13G/A filed with the SEC by BlackRock, Inc. ("BlackRock") on February 3, 2023, BlackRock reported that, as of December 31, 2022, it beneficially owned 68,041,416 shares of Common Stock with sole voting power over 59,783,771 shares of Common Stock and sole dispositive power over 68,041,416 shares of Common Stock.
(3) State Street Bank and Trust Company, a subsidiary of State Street Corporation ("State Street"), is the trustee of the Colgate-Palmolive Company Employee Stock Ownership Trust (the "Trustee").
(4) On a Schedule 13G/A filed with the SEC by State Street on February 6, 2023, State Street reported that, as of December 31, 2022, it beneficially owned 49,899,351 shares of Common Stock with shared voting power over 45,191,754 shares of Common Stock and shared dispositive power over 49,614,512 shares of Common Stock.

For information regarding the voting of shares allocated to the Colgate-Palmolive Company Employee Stock Ownership Plan participants, please see "Questions and Answers About Our Annual Meeting-How can I vote if I am an employee participating in the Savings & Investment Plan?" The Trustee will vote unallocated shares in the same proportion in which allocated shares are voted.

2023 Proxy Statement 61

# Proposals Requiring Your Vote

The following six proposals will be presented at the meeting for your vote. When voting by internet or telephone, you will be instructed how to vote for or against or abstain from voting on these proposals. If you received a printed copy of your proxy materials, space is provided on the proxy card to vote for or against or abstain from voting on each of the proposals.

## Proposal 1

### Election of Directors

The Board has nominated eleven people for election as directors at the Annual Meeting. All nominees are currently serving as Colgate directors and all nominees except for Mr. Cahillane were elected at the 2022 Annual Meeting. Mr. Cahillane was elected by the Board effective February 1, 2023. If elected, each nominee will hold office until the next Annual Meeting or until his or her successor is elected and qualified.

The nominees are John P. Bilbrey, John T. Cahill, Steve Cahillane, Lisa M. Edwards, C. Martin Harris, Martina Hund-Mejean, Kimberly A. Nelson, Lorrie M. Norrington, Michael B. Polk, Stephen I. Sadove and Noel R. Wallace. Biographical information regarding the nominees and information regarding the skills and qualifications of the nominees appears on pages 14 to 19 of this Proxy Statement.

The Board of Directors recommends a vote **FOR** each of the nominees for director listed above.

## Proposal 2

### Ratification of Selection of Independent Registered Public Accounting Firm

We ask that you ratify the Audit Committee's selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2023. PricewaterhouseCoopers LLP has audited the accounts of the Company since May 2002. The members of the Audit Committee and the Board believe that the continued retention of PricewaterhouseCoopers LLP as our independent registered public accounting firm is in the best interests of Colgate and our stockholders.

The Board of Directors recommends a vote **FOR** the ratification of the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2023.

## Audit Committee Report

The Audit Committee is composed of four independent directors. The Board of Directors has determined that it would be desirable for all Audit Committee members to be 'audit committee financial experts' as that term is defined under SEC rules. The Board has conducted an inquiry into the qualifications and experience of each member of the Audit Committee, and has determined that they each meet the SEC's criteria for audit committee financial experts.

### Role and Responsibilities

The Audit Committee assists the Board of Directors in its oversight of our financial statements and reporting processes, including our internal control over financial reporting and our Internal Audit function. The Audit Committee is also directly responsible for the appointment, compensation, retention and oversight of the independent registered public accounting firm, including review of their qualifications, independence and performance and approval of their fees. In addition, the Audit Committee oversees our Global Ethics and Compliance function, enterprise risk management process, including cybersecurity, and compliance with legal and regulatory requirements. For more information about oversight of the Global Ethics and Compliance function, including procedures for investigating complaints related to accounting, internal accounting controls or auditing matters, see 'Governance of the Company-Communications to the Board of Directors.' A copy of the charter of the Audit Committee, which describes these and other responsibilities of the committee, is available on our website at www.colgatepalmolive.com.

Management has the direct and primary responsibility for the financial statements and the reporting processes, including establishing and maintaining adequate internal control over financial reporting. The independent registered public accounting firm is responsible for auditing the annual financial statements prepared by management and expressing an opinion as to whether those financial statements present fairly, in all material respects, the financial position of the Company and our subsidiaries and the results of our operations and our cash flows in conformity with accounting principles generally accepted in the United States of America. The independent registered public accounting firm is also responsible for auditing the effectiveness of our internal control over financial reporting.

62 ![Colgate-Palmolive Company logo]() COLGATE-PALMOLIVE COMPANY

Proposals Requiring Your Vote

## Selection of Independent Registered Public Accounting Firm

The Audit Committee appointed PricewaterhouseCoopers LLP (“PwC”) to audit our financial statements as of and for the year ended December 31, 2022 and the effectiveness of our internal control over financial reporting as of December 31, 2022. PwC has served as our independent registered public accounting firm continuously since May 2002. The Audit Committee considered several factors in selecting PwC as our independent registered public accounting firm, including the firm’s independence and internal quality controls, the qualifications and experience of the lead audit partner and overall depth of talent, their experience with our industry (including any potential conflicts arising from representation of our direct competitors) and their capability and expertise in handling the breadth and complexity of our global operations along with the firm’s familiarity with our business, accounting policies and internal control over financial reporting. In determining whether to reappoint PwC as our independent registered public accounting firm for the year ending December 31, 2023, the Audit Committee again took those factors into consideration along with its evaluation of the past performance of PwC. The Audit Committee determined that the continued retention of PwC as our independent registered public accounting firm is in the Company’s best interests. The Audit Committee periodically considers whether there should be a regular rotation of the independent registered public accounting firm in order to assure continuing auditor independence.

PwC’s lead audit partner rotates every five years pursuant to the requirement mandated by the Sarbanes-Oxley Act of 2002. The process for selecting the new lead audit partner involves an assessment of many factors, including the candidates’ independence, objectivity, broad-based business judgment, multinational and industry experience, commitment to serving the Company, ability to leverage the resources of the firm and commitment to continuous improvement and robust dialogue with the Audit Committee. The selection process also involves discussions with management and the Audit Committee regarding each of the candidates and a meeting between the Audit Committee chair and the final candidate for the role.

## Review and Recommendation Regarding Financial Statements

The Audit Committee met seven times in 2022, including to review and discuss each quarterly earnings release prior to its announcement and each of our quarterly and annual financial statements. The Audit Committee reviewed and discussed the scope of and plans for the internal and external audits with management and the independent registered public accounting firm together and separately. The Audit Committee also met with management and the independent registered public accounting firm together and separately to review and discuss the audited financial statements, including the critical audit matter reported on by the independent registered public accounting firm, and matters related to the design and operating effectiveness of our internal control over financial reporting. These discussions and reviews included the reasonableness of significant estimates and judgments, significant accounting policies (including critical accounting policies), significant unusual transactions, the independent registered public accounting firm’s assessment of the quality, not just acceptability, of our accounting principles, risk assessment and such other matters as are required to be discussed with the Audit Committee under the standards of the Public Company Accounting Oversight Board (United States) (the “PCAOB”).

The Audit Committee has received the written disclosures of the independent registered public accounting firm as required by the applicable requirements of the PCAOB, and has discussed with the independent registered public accounting firm, and received a letter from them confirming, their independence from management and the Company. In addition, the Audit Committee has reviewed and approved our policy with regard to the hiring of former employees of the independent registered public accounting firm. In evaluating the independent registered public accounting firm’s independence, the Audit Committee considered whether the firm’s provision of any non-audit services impaired or compromised the firm’s independence and the Audit Committee concluded that the provision of those services did not. Those services, along with the fees paid to the independent registered public accounting firm and the Audit Committee’s pre-approval policy for services that may be performed by the independent registered public accounting firm, are described below.

Based upon the review and discussions described in this report, the Audit Committee recommended to the Board of Directors that the audited financial statements as of and for the year ended December 31, 2022 be accepted and included in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC.

*The foregoing report has been submitted by the members of the Audit Committee: John T. Cahill (Chair), Martina Hund-Mejean, Lorrie M. Norrington and Stephen I. Sadove.*

2023 Proxy Statement 63

Proposals Requiring Your Vote

## Fees of Independent Accounting Firm

The Audit Committee approves the fees billed or expected to be billed by PricewaterhouseCoopers LLP for their services. Such fees for services rendered to Colgate during 2022 and 2021 are set forth below. The Audit Committee has concluded that the provision to Colgate of the non-audit services by PricewaterhouseCoopers LLP described below did not and does not impair or compromise their independence. All such services were pre-approved by the Audit Committee in accordance with the pre-approval policy described below.

### PRICEWATERHOUSECOOPERS LLP FEES

(in millions)

|  | 2022 ($) | 2021 ($) |
| --- | --- | --- |
| Audit Fees | 13.0 | 11.9 |
| Audit-Related Fees | 0.4 | 0.3 |
| Tax Fees | 1.4 | 2.5 |
| All Other Fees | - | - |
| Total | 14.8 | 14.7 |

### Audit Fees

These amounts represent fees billed or expected to be billed by PricewaterhouseCoopers LLP for professional services rendered for the audits of our annual financial statements for the years ended December 31, 2022 and 2021 and the effectiveness of our internal control over financial reporting as of December 31, 2022 and 2021, the reviews of the financial statements included in our Quarterly Reports on Form 10-Q, and services related to statutory and regulatory filings and engagements for such fiscal years.

### Audit-Related Fees

These amounts represent fees billed or expected to be billed by PricewaterhouseCoopers LLP for professional services rendered that were reasonably related to the performance of the audits or the reviews of our financial statements in 2022 and 2021 (but which are not included under “Audit Fees” above). Audit-Related fees consist primarily of certain agreed-upon-procedures engagements.

### Tax Fees

These amounts represent fees billed or expected to be billed by PricewaterhouseCoopers LLP for professional services rendered relating to tax compliance, tax advice and tax planning in various tax jurisdictions around the world. Specifically, these fees were associated with assistance in tax return filings, tax audits and refund claims, as well as advice on interpretation of and compliance with tax laws and tax valuation services.

### All Other Fees

None.

## Audit Committee Pre-Approval Policy

The Audit Committee has adopted a policy for the pre-approval of all audit and permitted non-audit services that may be performed by our independent registered public accounting firm. Under this policy, each year, at the time it engages the independent registered public accounting firm, the Audit Committee pre-approves the audit engagement terms and fees and also pre-approves detailed types of audit-related and permitted tax services, subject to certain dollar limits, that may be performed during the year. All other permitted non-audit services are required to be pre-approved by the Audit Committee on an engagement-by-engagement basis. The Audit Committee may delegate its authority to pre-approve services to one or more of its members, whose activities are reported to the Audit Committee at each regularly scheduled meeting.

## Independent Accounting Firm Attendance at Annual Meeting

Representatives of PricewaterhouseCoopers LLP are expected to attend the Annual Meeting. They will have the opportunity to make a statement if they desire to do so and will be available to respond to appropriate questions.

64 ![Colgate-Palmolive Company logo]() COLGATE-PALMOLIVE COMPANY

Proposals Requiring Your Vote

### Proposal 3

#### Advisory Vote on Executive Compensation

We ask that you indicate your support for the executive compensation, as described in this Proxy Statement, of our executive officers named in the Summary Compensation Table appearing on page 44. We are providing stockholders with this vote pursuant to Section 14A of the Exchange Act.

The Board is asking you to cast a non-binding advisory vote on the following resolution:

“RESOLVED, that the compensation of our executive officers named in the Summary Compensation Table, as disclosed in the Proxy Statement, including the Compensation Discussion and Analysis, compensation tables and narrative discussion, is hereby APPROVED.”

The Compensation Discussion and Analysis, beginning on page 29, describes our executive compensation programs and the compensation decisions made by the Personnel and Organization Committee and the Board of Directors for 2022 with respect to the Chief Executive Officer and the other officers named in the Summary Compensation Table (referred to as the “Named Officers”). As described in detail in the Compensation Discussion and Analysis and highlighted in the section captioned “Executive Summary,” the key principles underlying the Personnel and Organization Committee’s compensation philosophy are aligning pay and performance, driving strong business results and our strategic plan, focusing on long-term shareholder return, motivating and retaining critical talent and reflecting external market and competitive practices. Annual and long-term incentive award payments vary based on our business performance, and long-term incentive award payments and the value of equity awards also vary based on the performance of our Common Stock.

The Board is asking you to support this proposal. Because your vote is advisory, it will not be binding on the Board. However, the Board and the Personnel and Organization Committee will review the voting results in their entirety and take them into consideration when making future decisions regarding executive compensation.

The Board of Directors recommends a vote **FOR** the executive compensation of our Named Officers, as described in this Proxy Statement.

### Proposal 4

#### Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation

We ask that you indicate how frequently we should hold future stockholder advisory votes on executive compensation, such as Proposal 3. By voting on this Proposal 4, you may indicate whether you would prefer an advisory vote on named executive officer compensation once every one, two or three years. Alternatively, you may abstain from voting. Consistent with Section 14A of the Exchange Act, we intend to provide stockholders with a non-binding advisory vote on the frequency of future stockholder advisory votes on executive compensation every six years.

The Board has determined that an annual stockholder advisory vote on executive compensation continues to be the most appropriate for the Company and therefore recommends that stockholders vote in favor of holding a stockholder advisory vote on executive compensation every year.

The Company has held a stockholder advisory vote on executive compensation every year since 2010, consistent with the advisory votes of the stockholders at the Company’s 2011 and 2017 Annual Meetings of Stockholders. The Board has found that such vote provides a clear and simple means for stockholders to provide direct feedback to the Company regarding its compensation philosophy, policies and practices as disclosed in the proxy statement, consistent with the Company’s practice of seeking input from, and engaging in discussions with, the Company’s stockholders on executive compensation and other matters.

While the Board is making a recommendation with respect to this proposal, stockholders are not voting to approve or disapprove the Board’s recommendation. Instead, stockholders are being asked to specify one of the four choices for this proposal indicated on the proxy card: one year, two years, three years or abstain. Since you have several voting choices, it is possible that no single choice will receive a majority vote. In addition, because your vote is advisory, it will not be binding on the Board, whether or not a particular frequency receives a majority vote. However, the Board will review the voting results in their entirety and take them into consideration when making future decisions regarding the frequency of advisory votes on executive compensation.

The Board of Directors recommends a vote **FOR** the option of once every **ONE YEAR** as the frequency with which stockholders will be provided an advisory vote on executive compensation.

2023 Proxy Statement 65

Proposals Requiring Your Vote

### Stockholder Proposal

John Chevedden, 2215 Nelson Avenue, No. 205, Redondo Beach, California 90278, owner of at least 100 shares of Common Stock, has informed us that he intends to offer the following resolution for consideration at the Annual Meeting.

#### Proposal 5-Independent Board Chairman

![img-0.jpeg](img-0.jpeg)

Shareholders request that the Board of Directors adopt an enduring policy, and amend the governing documents as necessary in order that 2 separate people hold the office of the Chairman and the office of the CEO as follows:

Selection of the Chairman of the Board the Board requires the separation of the offices of the Chairman of the Board and the Chief Executive Officer.

Whenever possible, the Chairman of the Board shall be an Independent Director.

The Board has the discretion to select a Temporary Chairman of the Board who is not an Independent Director to serve while the Board is seeking an Independent Chairman of the Board. This policy could be phased in when there is a contract renewal for our current CEO or for the next CEO transition.

This proposal topic has built up momentum at Colgate-Palmolive. Year after year it has progressed form 37% to 46% to 47% support. The 47% support likely means close to 55% support form the shares that have access to independent proxy voting advice and are not forced to rely on the biased opinion of management. Colgate-Palmolive should support the vote of a majority of shareholders who have full access to the pro and con arguments.

Colgate-Palmolive is Exhibit A in why the Lead Director role is an empty suit compared to an independent Board Chairman. Our Lead Director, Mr. Stephen Sadove, attracts negative shareholder votes. Mr. Sadove received the most negative shareholder votes in 2020 and 2021 and the second highest negative votes in 2022.

Mr. Sadove's negative votes were up to 35-times the number of negative votes of other CL directors. Mr. Sadove violates the most important attribute of a Lead Director - independence. As director tenure goes up director independence goes down. Mr. Sadove has 16-years tenure. Mr. Sadove's long tenure makes him a prime candidate to retire.

With the current CEO serving as Chair this means giving up a substantial check and balance safeguard that can only occur with an independent Board Chairman.

A lead director is no substitute for an independent board chairman. A lead director cannot call a special shareholder meeting and cannot even call a special meeting of the board. A lead director can delegate most of his lead director duties to the CEO office and then simply rubber-stamp it. There is no way shareholders can be sure of what goes on.

This is proposal is especially important due to our lackluster stock price since 2017 when it was $76.

Please vote yes:

#### Independent Board Chairman-Proposal 5

### Company Response

Your Board of Directors recommends a vote **AGAINST** this stockholder proposal for the following reasons:

**The Board is truly independent and has an experienced and highly effective independent Lead Director with significant authority and clear duties to ensure proper checks and balances.**

Lorrie M. Norrington has served as the independent Lead Director since March 1, 2023, succeeding Stephen I. Sadove in that role. Ms. Norrington joined the Board in 2015 and has been the Chair of the Nominating, Governance and Corporate Responsibility Committee since 2021. Ms. Norrington is a highly effective director who brings extensive global corporate leadership, digital, eCommerce and ESG experience to the independent Lead Director role. She also has extensive experience serving on other public company boards.

The duties of the independent Lead Director are comprehensive and are clearly delineated in our corporate governance guidelines, entitled 'Board Guidelines on Significant Corporate Governance Issues.' In 2021, the Board enhanced these duties in connection with a review of external practices and in response to stockholder feedback.

66

![Colgate-Palmolive Company logo]() COLGATE-PALMOLIVE COMPANY

Proposals Requiring Your Vote

In many cases, the expanded responsibilities simply formalized activities that the independent Lead Director already had been performing. The Board further enhanced the independent Lead Director's duties in January 2023 in response to feedback from the proponent of this stockholder proposal. The role of the Lead Director includes the following responsibilities:

Board Leadership

- Preside at the executive sessions of the independent directors that occur at every regularly scheduled Board meeting, any other executive session of the independent directors and any other meeting of the Board at which the Chairman is not present
- Serve as interim Chairman if the Chairman is unable to perform their duties
- Establish agendas for the executive sessions of the independent directors in consultation with the other directors
- Call meetings of the independent directors
- Authorize the retention of outside advisors and consultants who report directly to the independent directors on Board issues

Communicating with Management

- After each executive session of the independent directors, provide feedback to and apprise the Chairman/CEO of the views expressed, suggestions made and decisions reached during the session
- Meet regularly with the Chairman/CEO between meetings, including acting as a sounding board to the CEO and providing strategic counsel
- Serve as primary liaison between the independent directors and the Chairman/CEO and management (although all independent directors are encouraged to communicate freely with the Chairman/CEO and other members of management at any time)

Board Culture

- Together with the Chairman, facilitate the efficient and effective functioning and performance of the Board
- Encourage and facilitate active and candid participation of all directors, including by fostering an environment of open dialogue and constructive feedback among the independent directors

Board Information, Agendas and Schedules

- Review and approve information to be sent to the Board and provide feedback on quality, quantity and timeliness of information flow from management
- Participate in setting, and ultimately approve, proposed Board meeting agendas
- Solicit the other independent directors for advice on agenda items for Board meetings to help facilitate Board focus on key issues and topics of interest to the Board
- Review and approve meeting schedules to help ensure there is sufficient time for discussion of all agenda items
- Ensure Board meeting agendas provide the Board with the ability to periodically review and provide input on the Company's long-term strategy and to monitor management's execution of the long-term strategy

Performance Evaluations, Succession Planning, Recruitment and Development

- Together with the Personnel and Organization Committee, lead the annual performance evaluation of the Chairman/CEO, distinguishing as necessary between performance as Chairman and performance as CEO
- Together with the Personnel and Organization Committee, lead the CEO succession planning process and participate in talent retention and development of senior management
- Provide guidance on Board succession and development
- In coordination with the Nominating, Governance and Corporate Responsibility Committee, interview Board candidates

Stakeholder Engagement

- Be available, as deemed appropriate by the Board, for consultation and direct communication with stockholders or other key constituents

Other

- Facilitate the effective functioning of Board committees, as appropriate
- Perform such other duties as the Board may specify from time to time

2023 Proxy Statement 67

Proposals Requiring Your Vote

With the exception of Noel R. Wallace, the Chairman, President and CEO, the Board is composed entirely of independent directors, and the Board's meeting practices and leadership structure encourage independence. As described above, the independent directors meet at each regularly scheduled Board meeting in separate executive sessions without any members of management present. These sessions are chaired by the independent Lead Director. The independent Lead Director serves a three-year term and is selected by and from the independent directors following nomination by the Nominating, Governance and Corporate Responsibility Committee.

Further, all of the members (including the chairs) of the Audit Committee, the Finance Committee, the Nominating, Governance and Corporate Responsibility Committee and the Board's compensation committee (known as the Personnel and Organization Committee) are independent directors. This, when coupled with the independent composition of the Board as described above, ensures that independent directors guide all critical matters, such as the integrity of our financial statements, oversight of the enterprise risk management process, cybersecurity and ESG initiatives, CEO and senior management compensation, succession planning and talent development and selection of directors.

# **The Board and Colgate are committed to the highest standards of corporate governance and are accountable and responsive to stockholders.**

Our corporate governance practices and policies are described in the section of this Proxy Statement entitled 'Governance of the Company.' As discussed in that section, we have had a longstanding commitment to the highest standards of corporate governance, including a policy requiring the annual election of all directors by majority vote. Reflecting the Board's commitment to continuous improvement, the Board reviews its governance practices on an ongoing basis to ensure that they promote stakeholder value and effective functioning of the Board. As a result of this review, the Board has made a number of enhancements over the years. For example, in 2021 the Board reduced the ownership threshold required to call a special stockholder meeting from 25% to 15% in response to stockholder feedback in connection with a stockholder proposal received on the topic. In 2016, the Board adopted proxy access, allowing eligible stockholders to nominate directors for inclusion in our proxy statement if they satisfy the requirements specified in our by-laws. These actions demonstrate the Board's accountability and responsiveness to stockholders, and the proxy access right, together with the requirement that all directors be elected annually by majority vote, helps to ensure that the Board remains accountable to stockholders.

# **Requiring an independent Chairman and the separation of the Chairman and CEO roles is not in the best interests of stockholders.**

Our active and independent Board, with our robust independent Lead Director role and independent committee chairs and committees, ensures that the Board, and not the Chairman alone, determines the Board's focus. The Chairman is guided by these strong independent leaders and having our CEO serve as Chairman creates a bridge to management that helps provide the Board with the management support it needs. Having a unified leadership structure is particularly beneficial at this time given the dynamic consumer and retail landscape and rapidly evolving environment in which we compete. Under the leadership of Mr. Wallace as Chairman and CEO during the past three years, and overseen by our strong independent Board, we have delivered strong performance, as illustrated by the following chart:

**COLGATE 2020-2022 PERFORMANCE RELATIVE TO COMPARISON GROUP\***

![img-1.jpeg](img-1.jpeg)

\* Adjusted earnings-per-share growth and organic sales growth reflect the adjustments described in Annex A to Colgate's earnings per share and net sales growth, respectively, and comparable adjustments to peer companies' earnings per share and net sales growth.

68 ![Colgate-Palmolive Company logo]() COLGATE-PALMOLIVE COMPANY

Proposals Requiring Your Vote

Based on these considerations, the Board believes that this is the best leadership structure for us at this time and that, operating under this structure, the Board will continue to effectively guide Colgate and represent the interests of our stakeholders. A requirement that the Chairman be an independent director, as the proposal requests, would reduce the Board's ability to act in the best interests of the Company and to respond to the changing needs of the Board and the Company.

Given its in-depth knowledge of Colgate's business and experience, the Board is uniquely positioned to evaluate the optimal leadership structure for the Company at any particular time, and, based on the effective governance practices described above, stockholders can be confident the Board is composed of the right people to make that determination. The Board believes that retaining the flexibility to determine the best Board leadership structure based on the circumstances in effect from time to time best protects the interests of the stockholders.

For these reasons, the Board of Directors recommends a vote **AGAINST** this proposal.

## Proposal 6 Stockholder Proposal

Kenneth Steiner, 14 Stoner Avenue, 2M, Great Neck, New York 11021, owner of at least 500 shares of Common Stock, has informed us that he intends to offer the following resolution for consideration at the Annual Meeting.

### Proposal 6-Executives To Retain Significant Stock

![img-2.jpeg](img-2.jpeg)

Shareholders urge that our executive pay committee adopt a policy requiring senior executives to retain a significant percentage of stock acquired through equity pay programs until reaching normal retirement age and to report to shareholders regarding the policy in our Company's next annual meeting proxy. For the purpose of this policy, normal retirement age would be an age of at least 60 and be determined by our executive pay committee. Shareholders recommend a share retention percentage requirement of 33% of net after-tax shares.

This single unified policy shall prohibit hedging transactions for shares subject to this policy which are not sales but reduce the risk of loss to the executive. Otherwise our directors might be able to avoid the impact of this proposal. This policy shall supplement any other share ownership requirements that have been established for senior executives, and should be implemented without violating current company contractual obligations or the terms of any current pay or benefit plan.

Requiring senior executives to hold a significant portion of stock obtained through executive pay plans would focus our executives on our company's long-term success. A Conference Board Task Force report stated that hold-to-retirement requirements give executives 'an ever-growing incentive to focus on long-term stock price performance.

Please vote yes:

### Executives To Retain Significant Stock-Proposal 6

## Company Response

Your Board of Directors recommends a vote **AGAINST** this stockholder proposal for the following reasons:

### Senior executives are already required to hold significant amounts of Colgate stock.

Our robust stock ownership guidelines already require members of senior management to hold significant amounts of Colgate stock. The CEO is required to own Colgate stock equal in value to eight times his annual salary, and the other Named Officers must hold Colgate stock equal in value to four times their annual salaries. Other senior managers are subject to ownership requirements of one or two times their annual salaries. Executives have five years from their initial promotion into an eligible position to achieve required ownership levels and neither unexercised stock options nor unearned performance-based restricted stock units are counted for purposes of determining whether the ownership requirements have been met. All of the executives who are subject to our rigorous stock ownership guidelines are in compliance with them and many of our senior executives own Colgate stock at levels far in excess of these requirements. For example, Noel R. Wallace, our Chairman, President and CEO, currently holds Colgate stock equal in value to 18 times his annual salary. All of the other Named Officers, each of whom have been Named Officers for less than five years, either already hold Colgate stock equal in value to more than four times their annual salary or are on track to do so within the required five-year period. We also prohibit executives from pledging Colgate stock and from purchasing any financial instrument that is designed to hedge against or offset any decrease in the value of Colgate's stock, such as short sales and put and call options. As a result, our policies already ensure that executives' interests are aligned with those of our stockholders. Our Board also believes that these policies compare favorably with those of our peer companies and that implementation of the policy requested by this proposal could have an adverse impact on our ability to recruit and retain executive talent because it is not market practice.

2023 Proxy Statement 69

Proposals Requiring Your Vote

# **The proposal is unnecessary because our executive compensation program already effectively incentivizes management to increase shareholder value.**

Long-term equity grants are the largest component of target direct compensation for the Named Officers. Our long-term incentive compensation is designed to focus the Named Officers and other Colgate executives on increasing shareholder value and to incentivize their contribution to our long-term growth and performance. As discussed in greater detail in the CD&A, we use two types of long-term incentives for officers, both granted in the form of equity: stock options and performance-based restricted stock units. Our stock options provide value only to the extent that our stock price appreciates, thereby providing an effective link to changes in shareholder value that aligns the interests of stockholders and executives. Our use of performance-based restricted stock units, which pay out only upon achievement of our long-term financial performance goals over a three-year period, ensures that the amount of long-term incentive compensation executives receive is tied directly to both increases in shareholder value and the achievement of critically important multi-year performance objectives. The multi-year earning and/or vesting requirements in all of our long-term incentives provides an additional mechanism to reward long-term value creation. Our Board believes that these existing compensation components already align our executive compensation to long-term shareholder value and that requiring executives to hold stock acquired through our executive compensation program until retirement, regardless of the value of their existing stock ownership, would not provide additional benefit.

For these reasons, the Board of Directors recommends a vote **AGAINST** this proposal.

## Other Matters

As of the date of this Proxy Statement’s printing, we do not intend to submit any matters to the meeting other than those set forth herein, and we know of no additional matters that will be presented by others. However, if any other business should come before the meeting and you have voted by proxy, the directors named on the voting website and your proxy card as the Proxy Committee (the “Proxy Committee”) have discretionary authority to vote your shares with respect to such matters in accordance with their best judgment.

By order of the Board of Directors.

*Chief Legal Officer and Secretary*

70 ![Colgate-Palmolive Company logo]() COLGATE-PALMOLIVE COMPANY

# Questions and Answers About Our Annual Meeting

## Who receives this Proxy Statement?

Beginning March 29, 2023, we are mailing a printed copy of this Proxy Statement, a proxy card and our 2022 Annual Report to stockholders who have requested a printed copy, and a Notice of Internet Availability to all other stockholders who have not consented to electronic delivery. The Annual Report being made available on the internet and mailed with the Proxy Statement is not part of the proxy-soliciting material.

## Who is entitled to vote at the Annual Meeting?

We have one class of voting stock outstanding: Common Stock. If you were a record owner of our Common Stock on March 13, 2023, the record date for voting at the Annual Meeting, you are entitled to vote at the meeting. At the close of business on March 13, 2023, there were 832,137,632 shares of Common Stock outstanding and entitled to vote. Each share of Common Stock has one vote.

## How can I vote my shares?

You can vote your shares in two ways: either by proxy or electronically during the virtual Annual Meeting. If you choose to vote by proxy, you may do so using the internet, the telephone or, if you received a printed copy of your proxy materials, the mail. Each of these procedures is more fully explained below. Even if you plan to attend the virtual meeting, the Board recommends that you vote by proxy.

## How can I vote my shares by proxy?

You may vote your proxy by internet, telephone or, if you received a printed copy of your proxy materials, by mail, each as more fully explained below. In each case, the deadline for voting is 11:59 p.m. (Eastern Daylight Time) on Thursday, May 11, 2023, unless you are a Colgate employee participating in the Savings & Investment Plan or another Colgate employee stock ownership plan, in which case the deadline for voting is 11:59 p.m. (Eastern Daylight Time) on Wednesday, May 10, 2023. When you vote your proxy, you can specify whether you wish to vote “FOR” or “AGAINST” or “ABSTAIN” from voting on each nominee for director, the ratification of the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2023 and, if properly presented at the meeting, two stockholder proposals. In addition, you can cast non-binding advisory votes on executive compensation and on whether you wish to hold future advisory votes on executive compensation every year, every two years or every three years, or abstain from voting. We will vote your shares as you direct.

If any other matters are properly presented for consideration at the Annual Meeting, the Proxy Committee will have discretion to vote for you on those matters. At the time this Proxy Statement was printed, we knew of no other matters to be raised at the Annual Meeting.

VOTE BY
INTERNET

To vote your shares via the internet, go to the voting website, www.proxyvote.com. Internet voting is available 24 hours a day, seven days a week. You will have the opportunity to confirm that your instructions have been properly recorded. The internet voting procedures are designed to authenticate stockholders through individual control numbers. If you received a proxy card in the mail and choose to vote via the internet, you do not need to return your proxy card.

VOTE BY
TELEPHONE

If you reside in the United States, Canada or Puerto Rico, you can vote your shares by telephone by calling the toll-free number provided on the voting website (www.proxyvote.com) and on the proxy card. Telephone voting is available 24 hours a day, seven days a week. Easy-to-follow voice prompts allow you to vote your shares and confirm that your instructions have been properly recorded. The telephone voting procedures are designed to authenticate stockholders through individual control numbers. If you received a proxy card in the mail and choose to vote by telephone, you do not need to return your proxy card.

VOTE BY
MAIL

If you received a printed copy of your proxy materials, you can vote your shares by completing and mailing the enclosed proxy card to us so that we receive it by the deadline. If you received a Notice of Internet Availability, you can request a printed copy of your proxy materials by following the instructions contained in the notice. If you sign and return your proxy card but do not specify how to vote, we will vote your shares in favor of each of the Board’s nominees for director, the ratification of the selection of the independent registered public accounting firm, the advisory vote on executive compensation and the advisory vote on holding future advisory votes on executive compensation every year, and against the two stockholder proposals.

2023 Proxy Statement 71

Questions and Answers About Our Annual Meeting

## How can I vote my shares during the Annual Meeting?

As described in more detail below under 'How can I participate in the Annual Meeting?', this year's Annual Meeting will be a virtual meeting, conducted on the following website: www.virtualshareholdermeeting.com/CL2023 (the 'Annual Meeting Website'). If you would like to vote at the Annual Meeting, please follow the instructions that will be available on the Annual Meeting Website during the Annual Meeting. If your shares are held in the name of a bank, broker or other holder of record, you should follow the instructions provided by your bank, broker or other holder of record to be able to vote electronically at the meeting. Voting by proxy, whether by internet, telephone or mail, will not limit your right to vote electronically at the Annual Meeting. However, if you vote by proxy and also participate in the meeting, there is no need to vote electronically at the meeting unless you would like to change your vote.

## How can I participate in the Annual Meeting?

Participation in the Annual Meeting is limited to holders of Common Stock on March 13, 2023, the record date for voting at the Annual Meeting.

The Annual Meeting will be a virtual meeting, conducted only via live webcast through the Annual Meeting Website. You will have the same rights and opportunities to participate as you would have at a physical annual meeting, including voting your shares electronically and submitting questions during the meeting. To participate in the Annual Meeting, you will need the 16-digit control number found on your Notice of Internet Availability, your proxy card or the instructions that accompany your proxy materials. If you do not have your 16-digit control number, you will still be able to attend the meeting as a guest but will not be able to vote your shares electronically or submit questions during the meeting. If your shares are held in the name of a bank, broker or other holder of record, you should follow the instructions provided by your bank, broker or other holder of record to be able to participate in the meeting.

The meeting webcast will begin promptly at 10:00 a.m., Eastern Daylight Time, on Friday, May 12, 2023. Access to the Annual Meeting Website will begin at 9:30 a.m. Eastern Daylight Time and we encourage you to access the Annual Meeting Website prior to the meeting start time.

For those unable to attend the virtual annual meeting, a recorded version of the webcast will be made available on our website.

## What if I have technical difficulties or trouble accessing the virtual meeting?

If you encounter any technical difficulties accessing the Annual Meeting Website or during the virtual meeting, please call: 844-976-0738 (toll-free) or 303-562-9301 (international). Technical support will be available thirty minutes prior to the start time of the Annual Meeting.

## How can I ask a question during the Annual Meeting?

As part of the Annual Meeting, we will hold a live question and answer session, during which we intend to answer questions submitted before or during the Annual Meeting in accordance with the Annual Meeting's Rules of Conduct (which will be available in the Investors section of our website and on the Annual Meeting Website) that are pertinent to the Company and the meeting matters, as time permits. Questions that are substantially similar may be grouped and answered once to avoid repetition and allow time for additional question topics. If there are any pertinent questions that cannot be answered during the Annual Meeting due to time constraints, we plan to respond directly to that stockholder after the Annual Meeting using the contact information provided.

You will be able to submit written questions prior to the Annual Meeting through www.proxyvote.com or during the Annual Meeting through the Annual Meeting Website. You will need the 16-digit control number found on your Notice of Internet Availability, your proxy card or the instructions that accompany your proxy materials in order to submit questions through these websites. If your shares are held in the name of a bank, broker or other holder of record, you should follow the instructions provided by your bank, broker or other holder of record to be able to submit questions.

72

![Colgate-Palmolive Company logo]() COLGATE-PALMOLIVE COMPANY

Questions and Answers About Our Annual Meeting

## Can I change my vote?

Yes. You can change your vote or revoke your proxy at any time before it is exercised at the Annual Meeting by taking any one of the following actions: (i) follow the instructions given for changing your vote via the internet or by telephone or deliver a valid written proxy with a later date; (ii) notify the Company Secretary in writing that you have revoked your proxy by mail to the Office of the Company Secretary, Colgate-Palmolive Company, 300 Park Avenue, 11th Floor, New York, New York 10022; or (iii) vote electronically during the Annual Meeting through the Annual Meeting Website.

## How many shares must be present to conduct the Annual Meeting?

To carry on the business of the Annual Meeting, a minimum number of shares, constituting a quorum, must be present. The quorum for the Annual Meeting is a majority of the votes represented by the outstanding shares of our Common Stock. This majority may be present in person or by proxy. Abstentions and “broker non-votes” (which are explained below) are counted as present to determine whether there is a quorum for the Annual Meeting. Stockholders who attend the virtual meeting will be considered to be attending the meeting in person.

## What if I am a beneficial owner and do not give instructions to my broker?

As a beneficial owner, in order to ensure your shares are voted in the way you would like, you must provide voting instructions to your broker by the deadline provided in the proxy materials you receive from your broker. If you do not provide voting instructions to your broker, whether your broker can vote your shares depends on the type of item being considered for vote. Under NYSE rules, if your broker holds shares in your name and delivers this Proxy Statement or a Notice of Internet Availability to you, the broker is entitled to vote your shares with respect to the ratification of the selection of the independent registered public accounting firm (Proposal 2) even if the broker does not receive voting instructions from you. The broker is not entitled to vote your shares with respect to the election of directors, the advisory vote on executive compensation, the advisory vote on the frequency of future advisory votes on executive compensation or the two stockholder proposals (Proposals 1, 3, 4, 5 or 6) without your instructions.

A “broker non-vote” occurs when your broker submits a proxy for your shares but does not indicate a vote for a particular proposal because the broker does not have authority to vote on that proposal and has not received voting instructions from you. “Broker non-votes” are not counted as votes for or against the proposal in question or as abstentions, nor are they counted to determine the number of votes present for the particular proposal.

## What vote is required to pass each of the proposals at the Annual Meeting?

| Proposals | Board Recommendation | Votes Required | Effect of Abstentions | Effect of Broker Non-Votes |
| --- | --- | --- | --- | --- |
| Election of Directors | FOR each nominee | Majority of votes cast | None | None |
| Ratification of Selection of Independent Registered Public Accounting Firm | FOR | Majority of the shares represented at the meeting, either in person or by proxy, and entitled to vote on the proposal | Same as “AGAINST” | No Broker Non-Votes |
| Advisory Vote on Executive Compensation | FOR | Majority of the shares represented at the meeting, either in person or by proxy, and entitled to vote on the proposal | Same as “AGAINST” | None |
| Advisory Vote on Frequency of Future Advisory Votes on Executive Compensation | ONE YEAR | Majority of the shares represented at the meeting, either in person or by proxy, and entitled to vote on the proposal | Same as “AGAINST” the three voting frequencies proposed | None |
| Stockholder Proposals | AGAINST | Majority of the shares represented at the meeting, either in person or by proxy, and entitled to vote on the proposal | Same as “AGAINST” | None |

2023 Proxy Statement 73

Questions and Answers About Our Annual Meeting

A majority of votes cast means that the number of shares voted for a nominee's election must exceed the number of votes cast against that nominee's election. When voting your proxy, the Proxy Committee will vote in accordance with the Board's recommendation for each proposal unless you instruct otherwise.

### Who nominates the directors?

Nominations for directors may be made at a stockholders' meeting by the Board or by any of our stockholders who comply with the requirements of our by-laws. Proposals to nominate a director directly at next year's Annual Meeting must be received by the Company Secretary no earlier than January 13, 2024 and no later than February 12, 2024, as further described below under "How do I submit a stockholder proposal for consideration at next year's Annual Meeting?" To comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than Colgate nominees must provide notice that sets forth the information required by Rule 14a-19(b) under the Exchange Act no later than February 12, 2024, and otherwise comply with the requirements set forth in our by-laws.

In addition, stockholders who meet the eligibility requirements set forth in our by-laws may nominate directors for inclusion in our proxy statement. In order to include director nominees in our proxy statement for next year's Annual Meeting, nominations must be received by the Company Secretary no earlier than October 31, 2023 and no later than November 30, 2023 and must comply with the requirements of our by-laws.

The NGCR Committee will also consider director nominees recommended by stockholders in writing if such candidates meet our criteria for Board membership, as described under "Governance of the Company-The Board of Directors."

### How can I vote if I am an employee participating in the Savings & Investment Plan?

If you are a Colgate employee who participates in the Savings & Investment Plan you will receive electronic notice or a Notice of Internet Availability with instructions on how to vote your shares. The notice also indicates the aggregate number of shares of Common Stock credited to your account under the Savings & Investment Plan as of March 13, 2023, the record date for voting at the meeting.

- You can direct the trustee how to vote your shares via the internet or by telephone. You can also direct the trustee how to vote by mail by requesting a proxy card and returning your completed proxy card to us.
- The deadline for submitting your vote is 11:59 p.m. (Eastern Daylight Time) on Wednesday, May 10, 2022. If you do not indicate your vote to the trustee by that time, the trustee will vote your shares in the same proportion as it votes the shares of employees who indicate their votes by that time, unless inconsistent with the Employee Retirement Income Security Act of 1974 (ERISA).

### How can I vote if I am an employee participating in a stock ownership plan outside the United States?

If you are a Colgate employee who participates in one of Colgate's employee stock ownership plans outside the United States, you will receive separate voting instructions electronically or from your local Human Resources Department.

### How do I submit a stockholder proposal for consideration at next year's Annual Meeting?

A proposal submitted by any stockholder for consideration at next year's Annual Meeting (other than director nominations pursuant to our proxy access by-law) will be acted upon only if the following criteria are met:

- If you wish to submit a proposal for inclusion in our proxy statement for next year's Annual Meeting pursuant to Rule 14a-8 under the Exchange Act, the proposal must be received by the Company Secretary no later than November 30, 2023; or
- If you wish to present a proposal directly at next year's Annual Meeting without including it in our proxy statement, pursuant to our by-laws, the proposal must be received by the Company Secretary no earlier than January 13, 2024 and no later than February 12, 2024. Your proposal also must comply with certain information requirements set forth in our by-laws. These requirements apply to any matter that a stockholder wishes to raise at the Annual Meeting other than through inclusion in the proxy statement.

74

COLGATE-PALMOLIVE COMPANY

Questions and Answers About Our Annual Meeting

Proposals should be sent to the Company Secretary by mail to the Office of the Company Secretary, Colgate-Palmolive Company, 300 Park Avenue, 11th Floor, New York, New York 10022 or by email to stockholderproposals@colpal.com.

Please see “Who nominates the directors?” above for a description of the timing requirements for nominating a director pursuant to our by-laws.

### How are proxies solicited and what is the cost?

We pay the cost of soliciting proxies for the meeting. Proxies may be solicited in person by Colgate employees, or by mail, telephone or electronic methods. In addition, we have retained Innisfree M&A Incorporated to solicit proxies by mail, telephone and electronic methods. We will pay a fee of approximately $30,000 to Innisfree M&A Incorporated plus expenses for these services.

### What is householding? Does Colgate use it?

We have sent to registered stockholders who have requested a printed copy of proxy materials and have the same address and last name a single copy of this Proxy Statement and the 2022 Annual Report and one proxy card for each stockholder and, to all other registered stockholders who have not previously requested electronic delivery of proxy materials, a single envelope containing one Notice of Internet Availability for each stockholder.

If, now or in the future, you do not wish to participate in householding and prefer to receive separate copies of the Proxy Statement and Annual Report or your Notice of Internet Availability in a separate envelope, please call us at (855) 322-3551 or (212) 310-2575 or inform us in writing at: Colgate-Palmolive Company, Attention: Investor Relations, 300 Park Avenue, New York, New York 10022 or by sending an email to investor_relations@colpal.com. Or, if you are currently receiving separate copies of the Proxy Statement and Annual Report or Notice of Internet Availability at one address and would like to receive a single copy or a single envelope containing one Notice of Internet Availability for each stockholder, please contact us at the phone numbers, mailing address or email address listed in the previous sentence. We will respond promptly to such requests.

If your shares are held in the name of a bank, broker or other holder of record, you can request information about householding from such holder of record.

### Where can I find more information about Colgate?

Our website address is www.colgatepalmolive.com. The information contained on our website is not included as a part of, or incorporated by reference into, this Proxy Statement. We make available, free of charge on our website, our annual reports on Form 10-K, our quarterly reports on Form 10-Q, our current reports on Form 8-K and amendments to such reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we have electronically filed such material with, or furnished it to, the SEC. Also available on our website are our Code of Conduct and corporate governance guidelines, the charters of the committees of the Board and reports under Section 16(a) of the Exchange Act of transactions in Company stock by our directors and executive officers. Hard copies of these materials are also available free of charge from our Investor Relations department by calling (855) 322-3551 or (212) 310-2575 or by sending an email to investor_relations@colpal.com. You may obtain a copy of our by-laws by writing to the Company Secretary at Office of the Company Secretary, Colgate-Palmolive Company, 300 Park Avenue, 11th Floor, New York, New York 10022.

2023 Proxy Statement 75

## Reconciliation of Non-GAAP Financial Measures

|  | 2020 | 2021 | 2022 |
| --- | --- | --- | --- |
| Net Sales Growth-GAAP | 5.0% | 5.8% | 3.0% |
| Acquisitions and Divestments Impact | (1.6) | (0.1) | (0.5) |
| Foreign Exchange Impact | 3.8 | (1.3) | 4.5 |
| Organic Sales Growth-Non-GAAP | 7.2% | 4.4% | 7.0% |

|  | 2019 | 2020 | 2021 | 2022 |
| --- | --- | --- | --- | --- |
| Diluted Earnings Per Share As Reported-GAAP | $2.75 | $3.14 | $2.55 | $2.13 |
| Global Growth & Efficiency Program | 0.12 | (0.02) | - | - |
| Acquisition-Related Costs | 0.02 | 0.00 | - | 0.02 |
| Swiss Income Tax Reform | (0.04) | - | - | - |
| Value-Added Tax Matter in Brazil | (0.02) | - | (0.02) | - |
| Subsidiary and Operating Structure Initiatives | - | (0.08) | - | - |
| Loss on Early Extinguishment of Debt | - | 0.02 | 0.07 | - |
| Goodwill and Intangible Assets Impairment Charges | - | - | 0.61 | 0.74 |
| 2022 Global Productivity Initiative | - | - | - | 0.10 |
| Gain on the Sale of Land in Asia Pacific | - | - | - | (0.02) |
| Base Business Earnings Per Share-Non-GAAP | $2.83 | $3.06 | $3.21 | $2.97 |

|  | (Dollars in millions) |  |  |  |
| --- | --- | --- | --- | --- |
|  | 2019 | 2020 | 2021 | 2022 |
| Net Income Attributable to Colgate-Palmolive Company-GAAP | $2,367 | $2,695 | $2,166 | $1,785 |
| Global Growth & Efficiency Program | 102 | (13) | - | - |
| Acquisition-Related Costs | 20 | 4 | - | 16 |
| Swiss Income Tax Reform | (29) | - | - | - |
| Value-Added Tax Matter in Brazil | (20) | - | (20) | - |
| Subsidiary and Operating Structure Initiatives | - | (71) | - | - |
| Loss on Early Extinguishment of Debt | - | 18 | 55 | - |
| Goodwill and Intangible Assets Impairment Charges | - | - | 518 | 620 |
| 2022 Global Productivity Initiative | - | - | - | 87 |
| Gain on the Sale of Land in Asia Pacific | - | - | - | (15) |
| Base Business Net Income-Non-GAAP | $2,440 | $2,633 | $2,719 | $2,493 |

|  | (Dollars in millions) |  |  |
| --- | --- | --- | --- |
|  | 2020 | 2021 | 2022 |
| Net Cash Provided by Operations-GAAP | $3,719 | $3,325 | $2,556 |
| Less: Capital Expenditures | (410) | (567) | (696) |
| Free Cash Flow Before Dividends-Non-GAAP | $3,309 | $2,758 | $1,860 |

A-1 ![Colgate-Palmolive Company logo]() **COLGATE-PALMOLIVE COMPANY**

# Annex B
## Countries Excluded under CEO Pay Ratio
### “De Minimis” Exemption

| Country | Number of Employees |
| --- | --- |
| Cameroon | 47 |
| Puerto Rico | 44 |
| El Salvador | 44 |
| Romania | 42 |
| Nicaragua | 41 |
| Kenya | 40 |
| Kazakhstan | 40 |
| Panama | 39 |
| Ukraine | 37 |
| Sweden | 37 |
| Uruguay | 36 |
| Bolivia | 33 |
| Paraguay | 31 |
| Norway | 28 |
| Honduras | 27 |
| Indonesia | 24 |
| South Korea | 23 |
| Tunisia | 22 |
| Singapore | 22 |
| Hungary | 22 |
| Austria | 20 |
| Senegal | 13 |
| Ghana | 12 |
| Finland | 12 |
| Reunion | 11 |
| Israel | 10 |
| Martinique | 9 |
| Zambia | 8 |
| Serbia | 8 |
| Tanzania | 7 |
| Slovenia | 7 |
| Mozambique | 7 |
| Latvia | 7 |
| Guadeloupe | 7 |
| Slovakia | 6 |
| Lebanon | 6 |
| French Polynesia | 6 |
| Croatia | 6 |
| Azerbaijan | 6 |
| New Caledonia | 5 |
| Belarus | 5 |
| Macedonia | 4 |
| Ivory Coast | 4 |
| Gabon | 4 |
| Trinidad | 3 |
| Malawi | 3 |
| Jamaica | 3 |
| Uzbekistan | 2 |
| Guyana | 2 |
| Georgia | 2 |
| Bulgaria | 2 |
| Brunei | 2 |
| Algeria | 2 |
| Bosnia | 1 |
| Bangladesh | 1 |

2023 Proxy Statement B-1

![img-0.jpeg](img-0.jpeg)

# 2025 Sustainability & Social Impact Strategy

We are pleased to report excellent progress in 2022 on our 2025 Sustainability & Social Impact Strategy. Our continued commitment to building environmental and social consciousness into every decision earned us recognition in 2022 on the Dow Jones Sustainability Indices for the sixth consecutive year and as a U.S. EPA ENERGY STAR® Partner of the Year for the 12th consecutive year. We were also named to both the CDP Water A List and CDP Climate A List. In addition to the highlights below, more about our 2025 Sustainability & Social Impact Strategy progress is available in the Sustainability section of our website at www.colgatepalmolive.com/sustainability.

## Driving Social Impact

We are committed to helping to ensure the wellbeing of all people and their pets, building a culture of inclusivity and creating meaningful opportunities for all people to succeed inside and outside Colgate.

## Helping Millions Of Homes

We are empowering people to develop healthier habits by choosing sustainable products that improve their lives and homes from oral and personal care to home care and pet nutrition.

## Preserving Our Environment

We are accelerating action on climate change and reducing our environmental footprint, including by working with our partners and operations to eliminate waste, decrease plastic usage, save water and conserve natural resources.

Colgate Bright Smiles, Bright Futures is our flagship oral health and wellbeing initiative. Since the program was established in 1991, we have reached over

**1.6B**

children and their families in places that are convenient for them in more than 100 countries.

We are making good progress in the advancement of women and Blacks in the organization with representation at the senior leadership level increasing in 2022 to 36% for women and 11% for Blacks.

Since 2002, Hill's Food, Shelter & Love program has provided more than

**$305M**

in pet food to more than 1,000 pet shelters and helped more than 13 million pets find their new homes across North America.

Since introducing our first-of-its-kind recyclable toothpaste tube in 2019, as of December 31, 2022, we have transitioned over

**40%**

of our toothpaste SKUs globally to recyclable tubes; and in India, in 2022, we launched Colgate RecyClean, our first 100% recycled plastic handle toothbrush with plant-based bristles.

We are taking steps in our efforts to combat climate change by committing to achieve Net Zero carbon emissions across our operations and our supply chain by 2040. In 2022, our Net Zero targets were approved by the Science Based Targets initiative.

We were the

**1st**

large multinational company in our sector to receive approval.

As of December 31, 2022, we have achieved

**32**

TRUE Zero Waste certifications in 19 countries across five continents, more than any other company.

Our sustainability and social impact ambitions and targets are forward-looking statements (as such term is defined in the Private Securities Litigation Reform Act of 1995 or by the SEC in its rules, regulations and releases). These statements are made on the basis of our views and expectations as of this time and we undertake no obligation to update these statements whether as a result of new information, future events or otherwise, except as required by law or by the rules and regulations of the SEC. We caution investors that such forward-looking statements are not guarantees of future performance and that actual events or results may differ materially from those statements. For a description of certain factors that could cause our future events or results to differ materially from those expressed in any forward-looking statement, please refer to our filings with the SEC, including, without limitation, information under the captions "Risk Factors" and "Cautionary Statement on Forward-Looking Statements" included in our Annual Report on Form 10-K for the year ended December 31, 2022.

![img-1.jpeg](img-1.jpeg)

![img-2.jpeg](img-2.jpeg)

Colgate-Palmolive Company

300 Park Avenue

New York, NY 10022

(212) 310-2000

www.colgatepalmolive.com

© 2023 Colgate-Palmolive Company